Drug;Gene;Genotype;Alleles;Outcome;Variation;Effect;Entity
NICOTINE;CYP2A6;rs1801272;AA + AT;TOXICITY;DECREASED-RISK;OTHER;TOBACCO USE DISORDER 
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
TACROLIMUS;CYP3A4;rs2740574;T;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
ARIPIPRAZOLE;CYP2D6;CYP2D6 ultrarapid metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799930;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE REACTIONS 
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
ETHANOL;CHRNA5;rs615470;T;TOXICITY, OTHER;DECREASED-LIKELIHOOD;DISEASE;ALCOHOL ABUSE 
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING, DIARRHEA, GASTROINTESTINAL TOXICITY
PEGINTERFERON ALFA-2A, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1041983;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED AUC24 
GEFITINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING, DIARRHEA, GASTROINTESTINAL TOXICITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, STEVENS-JOHNSON SYNDROME 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;HEMORRHAGE 
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR3B;rs2276307;G;TOXICITY;INCREASED-RISK;DISEASE;MYALGIA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-LIKELIHOODPK;PK;ACHIEVING OPTIMAL TROUGH LEVEL 
NORTRIPTYLINE;UST;rs2500535;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;IMPROVEMENT OF DEPRESSION SYMPTOMS 
TACROLIMUS;CYP3A4;rs1851426;G;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BLEEDING 
OSIMERTINIB;IL6;rs1800796;CG + GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
RISPERIDONE;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
TAMOXIFEN;CYP2D6;CYP2D6*6;*6/*6;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*5;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-SEVERITY;OTHER;INTERSTITIAL INFLAMMATORY CELL INFILTRATION 
RISPERIDONE;HTR2A;rs6313;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
OXAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;DECREASED-PK;PK;S-OXAZEPAM GLUCURONIDATION IN HUMAN LIVER MICROSOMES 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
OXAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;DECREASED-PK;PK;OXAZEPAM ORAL CLEARANCE 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERCHOLESTEROLEMIA 
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED-RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
TACROLIMUS;PPARA;rs4823613;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ACUTE CELLULAR REJECTION 
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY, INFECTIOUS DISEASE, STOMATITIS, 
NITROUS OXIDE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-;SIDE_EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;STROKE, MYOCARDIAL INFARCTION, DEATH, 
RISPERIDONE;DRD3;rs167771;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS 
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TARDIVE DYSKINESIA 
FLUCLOXACILLIN;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
FLUCLOXACILLIN;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
AMOXICILLIN;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CISPLATIN, PACLITAXEL;GGT1;rs5751901;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA 
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
BUSULFAN;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*9;*1/*1 + *1/*5 + *1/*9;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;UTERINE DISORDER, LEIOMYOMA, ENDOMETRIAL HYPERPLASIA, POLYPS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
CAPECITABINE, FLUOROURACIL;ABCC11;rs17822471;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TARDIVE DYSKINESIA 
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5 + *10/*10 + *5/*10;LADME-PK;PK;PK;DIFFERENCES IN THE FLUVOXAMINE PLASMA LEVEL AT 50 MG/DAY 
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IDO1;rs9657182;CC;TOXICITY;INCREASED-;SIDE_EFFECT;DEPRESSION 
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;rs3129763;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID 
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID 
NITROUS OXIDE;MTHFR;rs1801131;GG;TOXICITY;INCREASED-;SIDE_EFFECT;PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS 
CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;DECREASED-PK;PK;AUC 
METHADONE;CYP3A4;rs3735451;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SIDE EFFECTS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
CARBOPLATIN, PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*10;TOXICITY;RISK-;SIDE_EFFECT;TARDIVE DYSKINESIA 
ANTIDEPRESSANTS;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
ASPARAGINASE;ATL2;rs59569490;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
AZATHIOPRINE, MERCAPTOPURINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCREATITIS 
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME-PK;INCREASED-EFFICACY;EFFICACY;MAXIMAL PLATELET AGGREGATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS (ST) AFTER 1 YEAR 
ESCITALOPRAM;CYP2C19;rs4986893;A;DOSAGE, LADME-PK;INCREASED-PK;PK;SERUM CONCENTRATION 
PLATINUM COMPOUNDS;RETN;rs1862513;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, RECURRENCE FREE SURVIVAL 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4 + *1/*4;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, RECURRENCE FREE SURVIVAL 
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
PRIMAQUINE;MAOA;rs1137070;CC + CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;DECREASED-PK;PK;AUC 
PRIMAQUINE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
PRIMAQUINE;CYP2D6;CYP2D6*4;*4;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
ESCITALOPRAM;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;DECREASED-PK;PK;SERUM CONCENTRATION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;CONCENTRATION/DOSE RATIO 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED-PK;PK;CONCENTRATION/DOSE RATIO 
TENOFOVIR;ABCC10;rs2125739;C;TOXICITY;INCREASED-;SIDE_EFFECT;KIDNEY TUBULAR DYSFUNCTION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME-PK;INCREASED-PK;PK;BLOOD CONCENTRATION/DOSAGE RATIO 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;CONCENTRATION/DOSE RATIO 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAEMATOLOGICAL TOXICITY OR HEPATOTOXICITY 
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
TACROLIMUS;CYP3A4;rs2687116;A;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VOMITING 
ESCITALOPRAM;CYP2C19;rs4244285;A;DOSAGE, LADME-PK;INCREASED-PK;PK;SERUM CONCENTRATION 
;IFNL4;rs11322783;TT/TT;OTHER;INCREASED-;OTHER;SPONTANEOUS HCV CLEARANCE 
MERCAPTOPURINE;SLC22A1;rs72552763;del;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;INFECTIOUS DISEASE 
CARBOPLATIN, CISPLATIN;;rs6856089;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME-PK;DECREASED-PK;PK;6-MMPN LEVELS 
;SOD1;rs36232792;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;OTHER;DECREASED-LIKELIHOOD;OTHER;OPIOID-RELATED DISORDERS 
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BONE MARROW TOXICITY 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVERALL ADRS 
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;OTHER;INCREASED-LIKELIHOOD;OTHER;DECREASED GLOMERULAR FILTRATION RATE 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED-LIKELIHOOD;OTHER;DISCONTINUATION, TREATMENT MODIFICATION 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED-LIKELIHOOD;OTHER;DISCONTINUATION, TREATMENT MODIFICATION 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED-;SIDE_EFFECT;HEMATOLOGICAL INDICES 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CYCLOSPORINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED-PK;PK;PLASMA LEVELS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 
CISPLATIN, PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ESCITALOPRAM;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;DECREASED-PK;PK;SERUM CONCENTRATION 
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
SUFENTANIL;ADRB1;rs1801253;GG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
TENOFOVIR;ABCC10;rs9349256;G;TOXICITY;INCREASED-;SIDE_EFFECT;KIDNEY TUBULAR DYSFUNCTION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MORTALITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
IMATINIB;ABCB1;rs1045642;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
IMATINIB;NR1I2;rs3814055;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;rs6295;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
FLUOROURACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;DECREASED-PK;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
METHOTREXATE;MTRR;rs1801394;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS 
CLOPIDOGREL, ROSUVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;OTHER;INCREASED-;OTHER;P2Y12 REACTION UNIT(PRU) VALUES 
METHADONE;CYP3A4;rs4646437;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SIDE EFFECTS 
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME-PK;INCREASED-PK;PK;AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*14;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TARDIVE DYSKINESIA 
AZATHIOPRINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
LAMOTRIGINE;HLA-C;HLA-C*07:18;*07:18;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
LAMOTRIGINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
RIVAROXABAN;ABCB1;rs4148738;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
LAMOTRIGINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
RIVAROXABAN;ABCB1;rs1045642;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;THROMBOEMBOLISM 
TAMOXIFEN;CYP2D6;CYP2D6*10;*10;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ENDOMETRIAL HYPERPLASIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CLOPIDOGREL RESISTANCE 
METHOTREXATE;MTHFD1;rs2236225;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
METHADONE;CYP3A4;rs2242480;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SIDE EFFECTS 
CARBOPLATIN, CISPLATIN;CD274;rs2297136;AG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BLEEDING EVENTS 
CARBOPLATIN, CISPLATIN;CD274;rs822336;CC + CG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CARBOPLATIN, CISPLATIN;CD274;rs2282055;GT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
HYDROMORPHONE, MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PRURITUS 
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*2;*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, SEVERE CUTANEOUS ADVERSE REACTIONS, STEVENS-JOHNSON SYNDROME, 
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*1/*2 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATION, MYELOSUPPRESSION 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*8, TPMT*9, TPMT*12, TPMT*24;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATION, MYELOSUPPRESSION 
DOXORUBICIN;CBR1;rs3787728;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:04;*04:04;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DOXORUBICIN;CBR1;rs1005695;CG + GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*1/*5 + *5/*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATION, STATIN-RELATED MYOPATHY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;OTHER;INCREASED-;OTHER;PLATELET REACTIVITY BY P2Y12 REACTION UNITS 
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
OLANZAPINE, QUETIAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED-RISK;DISEASE;DIZZINESS 
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOEMBOLISM 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CAPECITABINE, PLATINUM;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ONDANSETRON;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED-;OTHER;PERCENTAGE OF DAYS ABSTINENT AND LOWER NUMBER OF DRINKS PER DRINKING DAY 
CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6;*5/*6;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;EFFICACY;EFFICACY;WORSE PROGNOSES 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;EFFICACY;INCREASED-EFFICACY;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) 
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs1042927;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL PROBABILITY 
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;TREMOR, DIARRHEA 
AMOXICILLIN, CLAVULANATE;HLA-B;HLA-B*15:18;*15:18;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28 + *28/*37;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ASTHENIA, DIARRHEA, NEUTROPENIA, 
CAPECITABINE, PACLITAXEL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
AZATHIOPRINE, MERCAPTOPURINE;PTPN2;rs11664064;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) (P=0.00004) AND OVERALL SURVIVAL (OS) (P=0.034) 
METHOTREXATE;MTHFD1;rs2236225;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
TAMOXIFEN;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;ABCB1;rs1045642;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;GSTP1;rs1695;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
MERCAPTOPURINE, METHOTREXATE;TPMT;rs1142345;C;TOXICITY;INCREASED-;SIDE_EFFECT;GI TOXICITY 
METHOTREXATE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED-RISK;DISEASE;MUCOSITIS 
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
AMOXICILLIN, CLAVULANATE;ERAP1, ERAP2;rs1363907;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CYCLOPHOSPHAMIDE;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE 
AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE;TYMS;rs3786362;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;TYMS;rs699517;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;ENOSF1, TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;ENOSF1, TYMS;rs2790;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
;NME1, NME1-NME2;rs2302254;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, RECURRENCE FREE SURVIVAL 
IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
RIVAROXABAN;SUSD3;rs76292544;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
;CYP3A5, ZSCAN25;rs776746;CC;;;SIDE_EFFECT;DRUG TOXICITY 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
METHOTREXATE;SLCO1B1;rs4149081;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GI TOXICITY 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA, DRUG HYPERSENSITIVITY 
ASPIRIN;FCER1G;rs11587213;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA 
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;INCREASED-PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
;MS4A2;rs569108;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA 
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;CHANCE OF POSITIVE RESPONSE TO PACLITAXEL 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;rs536560;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
;FCER1G;rs11587213;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;OTHER;ATOPY IN PATIENTS WITH ASPIRIN-INTOLERANT CHRONIC URTICARIA 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
CISPLATIN, RADIOTHERAPY;EPHX1;rs1051740;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY 
CISPLATIN, RADIOTHERAPY;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
CISPLATIN, RADIOTHERAPY;ERCC2;rs1799793;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
GEMCITABINE, PLATINUM COMPOUNDS;CDA;rs2072671;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;NAUSEA 
;CYP2A6;CYP2A6*4;*4/*4;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;rs4646450;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED-;SIDE_EFFECT;NEUTROPENIA 
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED-;DISEASE;GASTRIC PH 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, OTHER;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CARBOPLATIN, GEMCITABINE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;THROMBOCYTOPENIA 
METHOTREXATE;SLCO1B1;rs4149056;C;OTHER, LADME-PK;DECREASED-PK;PK;CLEARANCE 
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;CHRONIC KIDNEY FAILURE 
SUCCINYLCHOLINE, VOLATILE ANESTHETICS;RYR1;rs193922752;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MALIGNANT HYPERTHERMIA 
EGFR INHIBITORS;EGFR;rs2227983;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;EXANTHEMA 
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs12806698;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;NAUSEA 
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs11030918;C;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;NAUSEA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
VERAPAMIL;ADRB1;rs1801252;AA + AG;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
HEROIN;DRD2;rs12364283;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEROIN DEPENDENCE 
REPAGLINIDE;CYP2C8;CYP2C8*3;*3;LADME-PK;DECREASED-PK;PK;REPAGLINIDE AUC 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAEMATOPOIETIC TOXICITY 
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
TACROLIMUS;CYP3A7;rs2257401;C;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
PHENYTOIN;CYP2C19;rs4986893;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;DOSAGE, EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE 
TACROLIMUS;CYP3A4;rs4646437;G;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME-PK;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ASPARAGINASE;SOD2;rs4880;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
;CYP1A2;rs762551;AC + CC;OTHER;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
TRASTUZUMAB;ERBB2;rs1136201;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
BETA BLOCKING AGENTS;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
PACLITAXEL;FZD3;rs7001034;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;SENSORY PERIPHERAL NEUROPATHY 
CAPECITABINE, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RISK-;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
CLOZAPINE;HLA-DRB1;HLA-DRB1*04:02;*04:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS 
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;rs12979860;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEPATOCELLULAR CARCINOMA 
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLYBURIDE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;OTHER;INCREASED-RISK;DISEASE;HYPOGLYCEMIA 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5/*5;DOSAGE, EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE 
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;NOS3;rs1799983;T;OTHER;INCREASED-RISK;OTHER;IN-STENT RESTENOSIS 
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ANTHRACYCLINES AND RELATED SUBSTANCES, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ASPIRIN, CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
TACROLIMUS;CYP3A4;rs6956344;C;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, RECURRENCE FREE SURVIVAL 
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
PACLITAXEL;ABCB1;rs1045642;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE CONTROL RATE AND LOWER OVERALL SURVIVAL RATE 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;LADME-PK;DECREASED-PK;PK;CLOPIDOGREL ACTIVE METABOLITE LEVEL 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-LIKELIHOODPK;PK;ACHIEVING TARGET CONCENTRATIONS 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;POST-TREATMENT ADP-STIMULATED PLATELET AGGREGATION 
PACLITAXEL;CYP3A5;rs776746;C;TOXICITY;DECREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HOT FLASHES 
INFLIXIMAB;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
INFLIXIMAB;HLA-DPB1;HLA-DPB1*10:01;*10:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
INFLIXIMAB;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED-RISK;DISEASE;ASPIRIN-INDUCED ASTHMA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*6;*6/*6;DOSAGE, EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;DOSAGE, EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE AND REQUIRED HIGHER DOSE 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;CPT1A, IGHMBP2;rs12283870;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED BLOOD LEVELS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATION 
TACROLIMUS;CYP3A4;rs2242480;C;LADME-PK;PK;PK;TACROLIMUS CONCENTRATION TO DOSE RATIO (C/D RATIO) 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;OTHER;INCREASED-;OTHER;CREATININE CLEARANCE 
FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*4 + *5 + *10 + *21 + *36;LADME-PK;INCREASED-PK;PK;AGE-RELATED DECLINE IN FLECAINIDE CLEARANCE PATIENTS TREATED WITH ORAL FLECAINIDE FOR SUPRAVENTRICULAR TACHYARRHYTHMIAS 
TRANILAST;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME-PK;INCREASED-PK;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION 
FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME-PK;DECREASED-PK;PK;ORAL CLEARANCE (CL/F) OF FLECAINIDE IN PATIENTS WITH SUPRAVENTRICULAR TACHYARRHYTHMIA 
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
ANTITHYROID PREPARATIONS;HLA-DQA1;HLA-DQA1*01:03;*01:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
ANTITHYROID PREPARATIONS;HLA-DQB1;HLA-DQB1*06:01;*06:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY, LEUKOPENIA, TOXIC LIVER DISEASE, 
CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;3 YEAR EVENT FREE SURVIVAL 
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
OPIOIDS;OPRM1;rs548646;T;TOXICITY;DECREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;TROUGH CONCENTRATIONS 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10;LADME-PK;INCREASED-PK;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT 
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;TOXICITY;INCREASED-RISK;DISEASE;ACUTE CELLULAR REJECTION 
RHODAMINE 123;ABCB1;rs1045642;GG;LADME-PK;INCREASED-PK;PK;EFFLUX OF RHODAMINE FROM CD56+ NATURAL KILLER CELLS 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;;SIDE_EFFECT;NEUTROPENIA, THROMBOCYTOPENIA 
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs2768759;AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
LAMOTRIGINE;HLA-A;HLA-A*68:01;*68:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;PAIN 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
CARBAMAZEPINE;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
TETANUS ANTITOXIN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ACETAMINOPHEN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
INFLIXIMAB;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
PHENYTOIN;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
NEVIRAPINE;HLA-B;HLA-B*14:02;*14:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
PHENYTOIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME, 
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CLINDAMYCIN;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
LAMOTRIGINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
INFLIXIMAB;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
OXCARBAZEPINE;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6;*3/*4 + *4/*6;LADME-PK;INCREASED-PK;PK;S-MIRTAZAPINE PLASMA LEVELS IN NON-SMOKERS AT DAY 14 OF TREATMENT 
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
CLINDAMYCIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ISONIAZID;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;LADME-PK;INCREASED-PK;PK;SERUM CONCENTRATIONS OF S(+)-MIRTAZAPINE,  MIRTAZAPINE S(+)/R(-) RATIOS AND S(+)-N-DESMETHYLMIRTAZAPINE 
OPIOIDS;OPRM1;rs609148;A;TOXICITY;DECREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1 + *1/*18;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATIONS 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
NEVIRAPINE;HLA-C;HLA-C*08:02;*08:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
INFLIXIMAB;HLA-C;HLA-C*12:03;*12:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED-RISK;DISEASE;ASPIRIN-INDUCED ASTHMA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
PHENYTOIN;HLA-C;HLA-C*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
TACROLIMUS;CYP2J2;rs890293;AA + AC;TOXICITY;INCREASED-RISK;DISEASE;NAUSEA, VOMITING 
CARBAMAZEPINE;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
ABACAVIR;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
FLUPIRTINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATITIS 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:02;*01:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
HYDRALAZINE;HLA-DRB1;HLA-DRB1*04:01;*04:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LUPUS ERYTHEMATOSUS DUE TO HYDRALAZINE 
OXCARBAZEPINE;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
ABACAVIR;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERSENSITIVITY 
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4969170;AA;TOXICITY;DECREASED-RISK;DISEASE;THROMBOCYTOPENIA 
PRAVASTATIN;LDLR;rs2738466;G;EFFICACY;INCREASED-RISK;DISEASE;CORONARY DISEASE 
LAMOTRIGINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
FLUPIRTINE;HLA-DRB1;HLA-DRB1*16:01;*16:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
THALIDOMIDE;GSTT1;rs4630;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY 
MINOCYCLINE;HLA-B;HLA-B*35:02;*35:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROTHROMBIN TIME (PT) AT INDUCTION 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;DECREASED-;SIDE_EFFECT;WEIGHT GAIN 
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;INCREASED-RISK;DISEASE;KIDNEY DISORDER 
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;INCREASED-RISK;DISEASE;KIDNEY DISORDER 
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME-PK;INCREASED-EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE, OVER-ANTICOAGULATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CAFFEINE;CYP1A2;CYP1A2 low activity;;OTHER;INCREASED-;OTHER;INTAKE 
HMG COA REDUCTASE INHIBITORS;GNB3;rs5443;CT + TT;EFFICACY;DECREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
;HMGCR;rs3846662;AA;OTHER;DECREASED-;OTHER;HMGCRV_1 EXPRESSION AND AN INCREASE IN THE EXPRESSION OF THE FULL-LENGTH TRANSCRIPT 
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;LADME-PK;;DISEASE;HYPERBILIRUBINEMIA 
ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PRIMARY GRAFT FAILURE 
METHOTREXATE;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
CAFFEINE;ADORA2A;rs35320474;T/del + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;BRONCHOPULMONARY DYSPLASIA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;EFFICACY;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;EFFICACY;EFFICACY;HIGHER MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY 
;DHFR;rs70991108;del/del;OTHER;INCREASED-;OTHER;SERUM AND RED BLOOD CELL FOLATE CONCENTRATIONS 
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED-;DISEASE;NEUTROPENIA 
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;DEPRESSION 
FLUOXETINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ANXIETY DISORDERS 
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME-PK;DECREASED-PK;PK;METABOLISM 
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3823010;A;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE, COCAINE DEPENDENCE, OPIOID-RELATED DISORDERS, 
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs495491;G;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE, COCAINE DEPENDENCE, OPIOID-RELATED DISORDERS, 
INTERFERON BETA-1A, INTERFERON BETA-1B;HLA-DQA1;rs9272105;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;ANTI-IFN-BETA ANTIBODIES 
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37;*37/*37;LADME-PK;DECREASED-PK;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE) 
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
EGFR INHIBITORS;EGFR;rs2227983;A;EFFICACY;EFFICACY;EFFICACY;CYTOTOXICITY 
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4961252;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;ANTI-IFN-BETA ANTIBODIES 
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PEGASPARGASE;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CNS RELAPSE, HEMATOLOGIC RELAPSE 
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
GEMCITABINE;RRM1;rs9937;G;TOXICITY;DECREASED-RISK;DISEASE;NEUTROPENIA 
;ACE;rs1799752;del/del;OTHER;INCREASED-SEVERITY;OTHER;COVID-19 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;PD;DECREASED-LIKELIHOOD;OTHER;TIME TO THERAPEUTIC INR 
ETHANOL;OPRM1;rs1381376;T;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
PEGASPARGASE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
PEGASPARGASE;HLA-DQB1;HLA-DQB1*02:02;*02:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
PEGASPARGASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
METHOTREXATE;DHFR, MSH3;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
METHOTREXATE;ENOSF1, TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED-LIKELIHOOD;OTHER;COVID-19 
CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED-SEVERITY;OTHER;COVID-19 
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT EMERGENT MANIA 
;ACE;rs1799752;del;OTHER;INCREASED-LIKELIHOOD;OTHER;COVID-19 
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;;rs1050450;A;OTHER;INCREASED-RISK;OTHER;IN-STENT RESTENOSIS 
;ACE;rs1799752;del/del;OTHER;INCREASED-RISK;OTHER;DEATH 
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT EMERGENT MANIA 
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED-;SIDE_EFFECT;HEMORRHAGE 
LEFLUNOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
ANAKINRA, CANAKINUMAB, RILONACEPT, TOCILIZUMAB;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME-PK;INCREASED-PK;PK; APPARENT TERMINAL ELIMINATION HALF-LIFE 
FLUCLOXACILLIN;HLA-B;HLA-B*57:03;*57:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CISPLATIN;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B + *3C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
PREDNISONE, TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY;INCREASED-RISK;OTHER;REMAINING ON STEROIDS AT 1 YEAR AFTER TRANSPLANTATION 
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ATAZANAVIR;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *1/*1;LADME-PK;INCREASED-PK;PK;ORAL CLEARANCE (CL) OF ATAZANAVIR 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
EGFR INHIBITORS;EGFR;rs712829;T;TOXICITY;EFFICACY;EFFICACY;CYTOTOXICITY 
ANTINEOPLASTIC AGENTS;TYMS;rs11280056;TTA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-A;HLA-A*24:07;*24:07;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*3A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LOW LEUKOCYTE COUNTS 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*1;EFFICACY;INCREASED-EFFICACY;EFFICACY;TREATMENT DURATION 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*4;*4;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED-RISK;DISEASE;HYPERBILIRUBINEMIA 
ATORVASTATIN, PRAVASTATIN;APOE;rs429358;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN C-REACTIVE PROTEIN (CRP) 
CLOZAPINE;GSTM1;GSTM1 non-null, GSTM1 null;null/null;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;THROMBOTIC DISEASE, SUDDEN CARDIAC DEATH, MYOCARDIAL INFARCTION, 
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*7;*4/*7;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY, LADME-PK;DECREASED-EFFICACY;EFFICACY;METABOLISM OF TRAMADOL AND DECREASED RESPONSE TO TRAMADOL 
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*12:02;*12:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED-;OTHER;INTRAGASTRIC PH 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;LADME-PK;INCREASED-PK;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
CARBAMAZEPINE;HLA-DQA1;HLA-DQA1*03:02;*03:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION INHIBITION 
EFAVIRENZ;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
EFAVIRENZ;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*11;*4/*11;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CYCLOSPORINE;ABCB1;rs1128503;AA;DOSAGE, LADME-PK;INCREASED-PK;PK;TROUGH BLOOD CONCENTRATION 
;TMPRSS2;rs383510;CC;OTHER;INCREASED-LIKELIHOOD;OTHER;COVID-19 
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME-PK;INCREASED-PK;PK;APPARENT TERMINAL ELIMINATION HALF-LIFE 
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
CYCLOSPORINE;ABCB1;rs2032582;AA;DOSAGE, LADME-PK;INCREASED-PK;PK;TROUGH BLOOD CONCENTRATION 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME-PK;INCREASED-PK;PK;MEAN SERUM CONCENTRATIONS OF SERTRALINE AND N-DESMETHYL SERTRALINE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE, EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
METHADONE;CYP3A4;rs2246709;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SIDE EFFECTS 
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED-PK;PK;FLUVOXAMINE PLASMA CONCENTRATIONS 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*2/*2 + *2/*4;LADME-PK;INCREASED-PK;PK;AREA UNDER THE TIME-PLASMA CONCENTRATION CURVE (AUC(0-24)) 
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED-RISK;DISEASE;CORONARY DISEASE 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
METHAZOLAMIDE;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE;CYP2D6;CYP2D6*1;*1/*1;EFFICACY, LADME-PK;PK;PK;INHIBITION OF METABOLISM 
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
METHADONE;CYP3A4;rs2242480;T;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS 
DOCETAXEL, THALIDOMIDE;RPL13, SNORD68, SPG7;rs12960;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE 
PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED-RISK;DISEASE;DEPRESSION 
METHADONE;CYP3A4;rs4646440;A;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ADVERSE CARDIOVASCULAR EVENTS 
CARBAMAZEPINE;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
ETHANOL, OPIOIDS;OPRM1;rs511435;T;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE, OPIOID-RELATED DISORDERS 
DOCETAXEL, THALIDOMIDE;NAT2;rs1799931;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED-PK;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION 
DOCETAXEL, THALIDOMIDE;CYP4B1;rs4646487;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*07:02;*07:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:02;*07:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY 
SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;GSTM1 null;null/null;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
OLANZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;FATIGUE 
FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
METHOTREXATE;DHFR;rs3045983;GGGAGCTGG/del + del/del;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
OPIOIDS;OPRM1;rs589046;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE, R-5-HYDROXYOMEPRAZOLE AND S-5-HYDROXYOMEPRAZOLE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;DECREASED-;SIDE_EFFECT;LEUKOCYTES AND NEUTROPHILS 
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO (DEFINED AS RATIO OF OMEPRAZOLE TO ITS METABOLITES) OF 5-HYDROXYOMEPRAZOLE AND R-5-HYDROXYOMEPRAZOLE 
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED-PK;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT 
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
PACLITAXEL;CYP3A4;CYP3A4*1, CYP3A4*8, CYP3A4*20;*1/*8 + *1/*20;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES, TREATMENT MODIFICATION 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CARBAMAZEPINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
DOCETAXEL;VEGFA;rs144854329;del/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*3/*3 + *3/*2 + *2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;DECREASED-PK;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN 
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;TOXICITY;DECREASED-;SIDE_EFFECT;ADVERSE EFFECT BURDEN 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*3, NUDT15*6;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3 + *2/*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;DECREASED-RISK;DISEASE;ASPIRIN-INDUCED ASTHMA 
CARBOPLATIN, CISPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
METHAMPHETAMINE;DAOA;rs947267;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*36;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED-PK;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE, OMEPRAZOLE SULFONE, R-OMEPRAZOLE AND S-OMEPRAZOLE 
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;;OTHER;HIGHER STABLE DOSE LEVELS 
METHAMPHETAMINE;OPRM1;rs2075572;C;TOXICITY;DECREASED-RISK;OTHER;METHAMPHETAMINE DEPENDENCE 
ACETAMINOPHEN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
ACETAMINOPHEN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
ACETAMINOPHEN;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED-PK;PK;AREA UNDER CURVE (AUC) OF OMEPRAZOLE RACEMATE, OMEPRAZOLE SULFONE, R-OMEPRAZOLE AND S-OMEPRAZOLE 
ACETAMINOPHEN;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
CARBAMAZEPINE, LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA, THROMBOCYTOPENIA 
METHADONE;CYP3A4;rs2246709;A;OTHER;DECREASED-SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;CLOPI-H4 CONCENTRATIONS AFTER 300 OR 900 MG CLOPIDOGREL LOADING DOSE 
ATORVASTATIN, PRAVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL 
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ATENOLOL, HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VERAPAMIL;GRK5;rs2230345;AT + TT;OTHER;DECREASED-RISK;OTHER;ADVERSE CARDIOVASCULAR OUTCOMES 
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS 
METHAMPHETAMINE;BDNF;rs6265;CC;TOXICITY;DECREASED-SEVERITY;OTHER;METHAMPHETAMINE DEPENDENCE 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;DELAYED GRAFT FUNCTION 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTICHOLINERGIC AGENTS;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED-PK;PK;SERUM ANTICHOLINERGIC ACTIVITY 
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED-PK;PK;FORMATION OF METABOLITES 
AZATHIOPRINE;NUDT15;NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*2 + *3 + *5 + *6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, DRUG TOXICITY 
;GSTT1;GSTT1 non-null, GSTT1 null;;OTHER;INCREASED-LIKELIHOOD;OTHER;ASTHMA 
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
;GSTM1;GSTM1 non-null, GSTM1 null;;OTHER;INCREASED-LIKELIHOOD;OTHER;ASTHMA 
METHAMPHETAMINE;DAOA;rs2391191;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
IRINOTECAN;HLA-DQB3;rs2859101;C;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
CYCLOSPORINE, METHOTREXATE;MTHFR;rs3737967;GG;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
ANTIDEPRESSANTS;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATIONS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs55633228;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
SULFASALAZINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCYTOPENIA, THROMBOCYTOPENIA 
CYCLOSPORINE, METHOTREXATE;MTHFR;rs2274976;CC;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
;G6PD;rs1050828;T;;INCREASED-;OTHER;PROTECTION AGAINST SEVERE MALARIA 
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs117101815;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;NEPHROTOXICITY 
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;JAUNDICE 
PRAVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) 
CAPECITABINE, FLUOROURACIL;DPYD;DPYD low activity;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, TREATMENT MODIFICATION 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
CISPLATIN, RADIOTHERAPY;GSTM1;GSTM1 non-null, GSTM1 null;null/null;EFFICACY;DECREASED-LIKELIHOOD;OTHER;DEATH, RECURRENCE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED-;OTHER;USE 
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED-;OTHER;USE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;DECREASED-PK;PK;C/D RATIO 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;ACUTE CELLULAR REJECTION 
IRINOTECAN;DPYD;rs1042482;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
PAZOPANIB;UGT1A1;UGT1A1*6, UGT1A1*28, UGT1A1*37;*28 + *37 + *6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
METHADONE;CYP3A4;rs4646440;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SIDE EFFECTS 
WARFARIN;VKORC1;rs9923231;CC;OTHER;INCREASED-LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY 
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PPP2R5D;rs3805945;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;STROKE 
ATAZANAVIR / RITONAVIR, LAMIVUDINE, ZIDOVUDINE;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;HYPERBILIRUBINEMIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CCNK;rs77769901;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBAMAZEPINE;SCN1A;rs3812718;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DISCONTINUATION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE 
;CHRNB2;rs2072661;GG;;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
ROSIGLITAZONE;PLIN1;rs894160;CT + TT;TOXICITY;DECREASED-;SIDE_EFFECT;WEIGHT GAIN 
PLATINUM;;rs836554;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CYCLOSPORINE, METHOTREXATE;ABCC1;rs17264736;GG + GT;EFFICACY;DECREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
METHADONE;CYP2B6;CYP2B6*6;*6;TOXICITY;INCREASED-SEVERITY;DISEASE;PAIN 
OXCARBAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
;LRP5;rs3736228;T;;INCREASED-RISK;OTHER;OSTEOPOROTIC FRACTURE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs118129530;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME-PK;INCREASED-PK;PK;AUC OF CITALOPRAM 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148013902;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
DRUGS USED IN NICOTINE DEPENDENCE;COMT;rs4680;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
VALGANCICLOVIR;ABCC4;rs11568658;AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs145623321;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CYCLOSPORINE, METHOTREXATE;NFATC1;rs1017860;CC;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP2C8;rs117458836;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
PRASUGREL;PEAR1;rs822442;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;DELAYED GRAFT FUNCTION 
CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*15:21;*15:21;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
NICOTINE;COMT;rs4680;G;TOXICITY, OTHER;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;;SIDE_EFFECT;DRUG TOXICITY 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
RISPERIDONE;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *4/*5 + *4/*6;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN PSYCHOTIC SYMPTOMS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA, STEVENS-JOHNSON SYNDROME 
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME-PK;DECREASED-PK;PK;BOSENTAN METABOLISM IN VITRO 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;LADME-PK;DECREASED-PK;PK;BOSENTAN METABOLISM IN VITRO 
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-;SIDE_EFFECT;DRUG TOXICITY 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-;SIDE_EFFECT;NEUTROPENIA 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
ATORVASTATIN;TNF;rs1800629;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;BONE MARROW DENSITY IN THE LUMBAR SPINE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
LAMOTRIGINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G/TT + GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT FAILURE IN JAPANESE PATIENTS WITH WITH CHRONIC GENOTYPE 1 HCV INFECTION 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (SVR RATE) TO HCV TRIPLE THERAPY (TELAPREVIR (TVR), PEG-INTERFERON (PEG-IFN) PLUS RIBAVIRIN (RBV) COMBINATION THERAPY) 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA, SEVERE CUTANEOUS ADVERSE REACTIONS, STEVENS-JOHNSON SYNDROME, 
FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED-RISK;OTHER;RECURRENCE 
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT BASED ON HAM-D SCORE PERCENTAGE REDUCTION 
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA, SEVERE CUTANEOUS ADVERSE REACTIONS 
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE 
METHOTREXATE;SLCO1B1;rs11045879;T;OTHER, LADME-PK;INCREASED-PK;PK;CLEARANCE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*17/*17;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*11;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR  BUT NOT MINOR HEMORRHAGE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR BUT NOT MINOR HEMORRHAGE 
CODEINE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;PAIN 
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;TOXICITY;INCREASED-SEVERITY;OTHER;TUBULAR VACUOLAR DEGENERATION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH LEVELS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-SEVERITY;DISEASE;INTERSTITIAL FIBROSIS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;CONCENTRATION/DOSE RATIO 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED-PK;PK;C/D RATIO 
CLOPIDOGREL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY AFTER 9MONTH OF TREATMENT 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;TOXICITY;INCREASED-RISKPK;PK;ACUTE REJECTION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DELAYED GRAFT FUNCTION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME-PK;INCREASED-PK;PK;BLOOD CONCENTRATIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
ACE INHIBITORS, PLAIN;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA, COUGH 
CODEINE, TRAMADOL;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY, TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
;KCNE1;rs727957;T;OTHER;INCREASED-;OTHER;QT INTERVAL 
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
OXCARBAZEPINE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN SYSTOLIC BLOOD PRESSURE 
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MUCOSITIS 
PERINDOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ACEI-RELATED COUGH 
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
;RGS2;rs34717272;TC/del + del/del;OTHER;INCREASED-RISK;DISEASE;HYPERTENSION 
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*14:05;*14:05;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs74743371;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-RISK;DISEASE;STOMATITIS 
LAMOTRIGINE;HLA-A;HLA-A*30:01;*30:01;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;DECREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
OXCARBAZEPINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
OXCARBAZEPINE;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
OXCARBAZEPINE;HLA-B;HLA-B*15:19;*15:19;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
OXCARBAZEPINE;HLA-B;HLA-B*48:04;*48:04;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
RALOXIFENE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;EFFICACY;INCREASED-EFFICACY;EFFICACY;BONE MINERAL DENSITY 
ASPIRIN;HLA-DQB1;HLA-DQB1*03:02;*03:02;EFFICACY, TOXICITY;DECREASED-SEVERITY;DISEASE;ASPIRIN-INDUCED ASTHMA 
OXCARBAZEPINE;HLA-B;HLA-B*27:09;*27:09;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
NEVIRAPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED-RISK;OTHER;DISEASE RECURRENCE 
NEVIRAPINE;HLA-B;HLA-B*58:02;*58:02;TOXICITY;DECREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;EFFICACY;EFFICACY;HIGHER MEAN BASELINE HCV RNA LEVEL AND STEEPER 1ST PHASE HCV RNA DECLINE IN GENOTYPE 2 AND 3 HCV INFECTED PATIENTS 
PRASUGREL;PEAR1;rs3737224;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
NEVIRAPINE;HLA-C;HLA-C*02:10;*02:10;TOXICITY;DECREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
CYCLOSPORINE, METHOTREXATE;ABCC1;rs4781712;AA + AG;EFFICACY;DECREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
OLANZAPINE;ABCB1;rs4728709;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASTHENIA 
BUPROPION;CYP2B6;rs3211371;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53AIP1;rs118088833;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ASPIRIN, SULFASALAZINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5;*3 + *4;DOSAGE, TOXICITY;INCREASED-LIKELIHOOD;DISEASE;BRAIN NEOPLASMS 
PRASUGREL;PEAR1;rs41273215;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO IMPROVE (BASED ON MEAN REDUCTIONS FROM BASELINE IN HRSD) 
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED-RISK;OTHER;DISEASE RECURRENCE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GNL3;rs112242273;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE;;OTHER;SIGNIFICANTLY HIGHER TRAMADOL CONSUMPTION IN CHINESE GASTRIC CANCER PATIENTS RECOVERING FROM GASTRECTOMY 
PRASUGREL;PEAR1;rs822441;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY, LADME-PK;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED-RISK;DISEASE;CARCINOMA, SQUAMOUS CELL 
CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;COMPLETE REMISSION 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;NON-RESPONSE 
CAFFEINE;CYP1A2;CYP1A2 high activity;;TOXICITY;INCREASED-RISK;DISEASE;ABORTION, SPONTANEOUS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;NON-RESPONSE 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;NON-RESPONSE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TOP2A;rs181501757;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
LAMOTRIGINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION AFTER SECOND TREATMENT SWITCH 
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;DECREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;IMPROVED SECOND TREATMENT SWITCH RESPONSE 
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9402944;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;NON-REMISSION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;OAS1;rs2660;AG;TOXICITY;DECREASED-RISK;DISEASE;ANEMIA 
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;NON-RESPONSE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
;VDR;rs731236;A;;INCREASED-RISK;DISEASE;ASTHMA 
OLANZAPINE;ABCB1;rs3842;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIAC RHYTHM DISEASE 
IRINOTECAN;UGT1A1;rs10929302;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs112783657;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;DECREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
HEROIN;OPRM1;rs1799971;AG;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CYCLOSPORINE, METHOTREXATE;NFATC1;rs8090560;GG;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA AND VOMITING 
RISPERIDONE;LEP;rs7799039;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;AG;TOXICITY;DECREASED-RISK;DISEASE;ANEMIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NOS1;rs149212925;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CYCLOSPORINE, METHOTREXATE;DHFR;rs34965641;GG;EFFICACY;DECREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
ETRAVIRINE;CYP2C19;rs4244285;AA + AG;LADME-PK;DECREASED-PK;PK;ETRAVIRINE CLEARANCE 
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL 
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVEL, IN A GENE-DOSE-DEPENDENT MANNER, 
FLUOROURACIL;MTHFR;rs1801131;TT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT BASED ON CHANGE OF HAM-D SCORE AFTER ANTIDEPRESSANT MEDICATION 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs58695150;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
PEMETREXED;GGH;rs11545078;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METFORMIN;SLC22A1;rs72552763;GAT/del;OTHER, LADME-PK;DECREASED-EFFICACY;EFFICACY;TROUGH METFORMIN STEADY-STATE CONCENTRATION 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;DEHYDRATION 
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;DPYD;DPYD low activity;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;;SIDE_EFFECT;DRUG TOXICITY 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs150688309;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
TAMOXIFEN;CYP2D6;CYP2D6*2;*2;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;TOXICITY;DECREASED-;SIDE_EFFECT;HOT FLASHES 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CORONARY RESTENOSIS 
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS, DRUG TOXICITY, HEADACHE, NAUSEA
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;TOXICITY;INCREASED-RISK;DISEASE;LEUKOPENIA 
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
ETHANOL;OPRM1;rs1799971;G;;INCREASED-;OTHER;ALCOHOL RESPONSE, CONSUMPTION, AND PREFERENCE 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED-PK;PK;VENLAFAXINE LEVELS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299293;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
EXEMESTANE;;rs934635;AA;TOXICITY;;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9389568;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;FOXO1;rs144991623;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
PRASUGREL;PEAR1;rs12407843;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
DIGOXIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SUDDEN CARDIAC DEATH 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PRASUGREL;PEAR1;rs77235035;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;INCREASED-PK;PK;VENLAFAXINE LEVELS 
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME-PK;INCREASED-PK;PK;VENLAFAXINE LEVELS 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION INHIBITION 
DIGOXIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SUDDEN CARDIAC DEATH 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE 
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;RISK-;DISEASE;NEUTROPENIA 
DIGOXIN;ABCB1;rs1128503;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SUDDEN CARDIAC DEATH 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED-PK;PK;CMAX AND AUC OF THIOL METABOLITE 
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED-RISK;DISEASE;HAND-FOOT SYNDROME 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALL AND MINOR HEMORRHAGE 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs8110364;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
OLANZAPINE;ABCB1;rs10248420;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
FLUOROURACIL;DPYD;rs56293913;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PC20 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117341846;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENT 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;EFFICACY;EFFICACY;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE 
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;IRS1;rs115457081;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;EFFICACY;EFFICACY;EFFICACY;SIGNIFICANTLY DELAYED TIME TO INHIBITION OF PLATELET AGGREGATION (IPA) 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT FAILURE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs142244113;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ASPIRIN, CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;EFFICACY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS 
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN 
DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED-PK;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs79430272;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;TOXICITY;INCREASED-;DISEASE;WEIGHT GAIN 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53;rs4968187;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
CISPLATIN;ERCC1;rs3212986;AA;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;NEPHROTOXICITY 
PALBOCICLIB;ABCG2;rs2231137;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117951771;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT FAILURE 
EXEMESTANE;;rs934635;AA;TOXICITY;;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF MUSCULOSKELETAL ADVERSE EVENTS (MSAES) IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS 
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DECREASED HEMOCRIT LEVELS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148235907;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
METHAMPHETAMINE;DAOA;rs3916965;C;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
;UGT1A1;rs34993780;G;OTHER;INCREASED-LIKELIHOOD;OTHER;GILBERT SYNDROME, CRIGLER-NAJJAR SYNDROME 
CYCLOPHOSPHAMIDE;CYP2C9;CYP2C9 poor metabolizer;*2 + *3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED-PK;PK;DESIPRAMINE/2-HYDROXY-DESIPRAMINE RATIO 
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;INCREASED-PK;PK;THE INTRINSIC METABOLIC ACTIVITY (V(MAX)/K(M)) 
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;INCREASED-PK;PK;THE MEAN MAXIMAL ELIMINATION RATES (V(MAX)) 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
PALBOCICLIB;SULT2A1;rs182420;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION, DISCONTINUATION 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED-PK;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299313;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
PRIMAQUINE;G6PD;G6PD deficiency;;OTHER;INCREASED-;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS 
SULFANILAMIDE;G6PD;G6PD deficiency;;OTHER;INCREASED-;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS 
CHLORAMPHENICOL;G6PD;G6PD deficiency;;OTHER;INCREASED-;OTHER;REDUCTIONS IN GLUTATHIONE LEVELS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
CODEINE, MORPHINE, TRAMADOL;UGT2B7;rs73823859;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PAIN 
CISPLATIN, DOCETAXEL;ALDH2;rs671;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299314;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;LADME-PK;DECREASED-PK;PK;IN VITRO INTRINSIC CLEARANCE OF S-WARFARIN WITH THE CDNA-EXPRESSED R150H PROTEIN 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;G;TOXICITY;INCREASED-RISK;DISEASE;HEART FAILURE 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
CISPLATIN;ERCC2;rs13181;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL 
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME 
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;rs10836235;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIAC DAMAGE 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
EXEMESTANE;UGT2B17;UGT2B17 deficiency;;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;FATIGUE 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;TOXICITY;INCREASED-;SIDE_EFFECT;BLEEDING TIME 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
VALPROIC ACID;XBP1;rs2269577;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROPHYLACTIC TREATMENT RESPONSE 
ACE INHIBITORS, PLAIN;ACE;rs1799752;del;TOXICITY;INCREASED-;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE 
PACLITAXEL;CYP1B1;rs1056836;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
DOCETAXEL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;DOSAGE, LADME-PK;DECREASED-PK;PK;UNBOUND ORAL CLEARANCE OF S-WARFARIN AND LOWER R- TO S-WARFARIN PLASMA CONCENTRATION RATIO 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;ADR 
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;ADP-INDUCED PLATELET AGGREGATION (PA) 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED-;OTHER;HYDROCHLOROTHIAZIDE INDUCED POTASSIUM EXCRETION 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VENOUS THROMBOEMBOLISM 
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED-EFFICACY;EFFICACY;BONE MINERAL DENSITY RESPONSE 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED-PK;PK;PAROXETINE SERUM CONCENTRATION 
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CAPECITABINE;ANK3;rs143414470;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14;*10/*10 + *5/*10;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;OTHER;INCREASED-RISK;DISEASE;RESPIRATORY TRACT INFECTIONS 
NEVIRAPINE;CCHCR1;rs130072;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH 
NEVIRAPINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;INCREASED-RISK;DISEASE;EXANTHEMA 
RITONAVIR;APOC3;rs5128;G;TOXICITY;INCREASED-;SIDE_EFFECT;TRIGLYCERIDE LEVELS 
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY, LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
METFORMIN;BDNF;rs6265;C;EFFICACY;INCREASED-LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME-PK;INCREASED-PK;PK;PLASMA EFAVIRENZ LEVELS 
LUMIRACOXIB;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;INCREASED-PK;PK;TROUGH ( R , S )-METHADONE PLASMA CONCENTRATIONS 
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*12;*12;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278293;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;BIOPSY-PROVEN ACUTE REJECTION 
MITOXANTRONE;ABCB1;rs2032582;AA;OTHER;INCREASED-;OTHER;SENSITIVITY IN VITRO 
LUMIRACOXIB;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;LADME-PK;INCREASED-RISK;OTHER;OVERANTICOAGULATION 
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;LADME-PK;INCREASED-RISK;OTHER;OVERANTICOAGULATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PROLONGED QTC 
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;INCREASED-PK;PK;(S)-METHADONE PLASMA LEVELS 
TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED-;SIDE_EFFECT;SEDATION 
CLOPIDOGREL;ABCB1;rs1045642;A;OTHER;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
NEVIRAPINE;HLA-C;rs9461684;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH 
ASPIRIN;IL1B;rs1143627;A;TOXICITY;;DISEASE;PEPTIC ULCER DISEASE 
PACLITAXEL;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
PHENYTOIN;EPHX1;rs2234922;G;TOXICITY;INCREASED-RISK;DISEASE;DISORDER OF FACIAL SKELETON 
PHENYTOIN;EPHX1;rs1051740;T;TOXICITY;INCREASED-RISK;DISEASE;DISORDER OF FACIAL SKELETON 
NEVIRAPINE;TCF19;rs2073724;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
CARBOPLATIN, PACLITAXEL;NRG3;rs1649942;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BEING OVERANTICOAGULATED 
;SLCO1B1;rs4149056;C;LADME-PK;INCREASED-PK;PK;STEROL/BILE ACID METABOLITES 
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED-PK;PK;PLASMA EFAVIRENZ LEVELS 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;NON-RESPONSIVENESS 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED-;DISEASE;ANXIETY DISORDERS 
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1208;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03;*05:01 + *05:02 + *05:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*5 + *10/*10 + *5/*10;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS 
NEMONAPRIDE;ANKK1;rs1800497;A;TOXICITY;INCREASED-;SIDE_EFFECT;PROLACTIN CONCENTRATIONS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
METHOTREXATE;SLC19A1;rs1051266;TT;OTHER, LADME-PK;INCREASED-PK;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
FLUVOXAMINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED-PK;PK;AREAS UNDER THE SERUM CONCENTRATION-TIME CURVE 
METHOTREXATE;GGH;rs3758149;AA;LADME-PK;DECREASED-PK;PK;METHOTREXATE POLYGLUTAMATE (MTXPG3-5) LEVELS 
RISPERIDONE;DRD2;rs1799978;C;TOXICITY;INCREASED-RISK;DISEASE;HYPERPROLACTINEMIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH, MYOCARDIAL INFARCTION, STROKE, 
RISPERIDONE;ANKK1;rs1800497;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;HYPERPROLACTINEMIA 
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;G;OTHER;INCREASED-;OTHER;INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY 
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;TREATMENT INTERRUPTION 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY; ADP-INDUCED ON TREATMENT PLATELET AGGREGATION (OTPR) 
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;G;LADME-PK;DECREASED-PK;PK;DOSE-NORMALIZED  CMAX AND DOSE-NORMALIZED  AUC0TO12 H 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;RELATIVE INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) 
INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
ANASTROZOLE;ABCB1;rs1045642;AA;OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;ARTHRALGIA 
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED-;OTHER;EVENT-FREE SURVIVAL 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HAVING INR ABOVE TARGET RANGE IN WEEK 1 
;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;OTHER;SUBSTANCE-RELATED DISORDERS 
MERCAPTOPURINE;ITPA;rs1127354;AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;FEBRILE NEUTROPENIA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, NEPHROTOXICITY 
FLECAINIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;SYSTEMIC EXPOSURE (AUC) AND LOWER ORAL CLEARANCE OF FLECAINIDE 
ETHANOL;ALDH2;rs671;GG;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
DIDANOSINE;XDH;rs1429376;AA;TOXICITY;INCREASED-RISK;DISEASE;HYPERTENSION, PORTAL 
DAUNORUBICIN;SZRD1;rs6603859;T;OTHER, LADME-PK;DECREASED-PK;PK;IC50 
DIDANOSINE;NT5C2;rs11598702;CC + CT;TOXICITY;INCREASED-RISK;DISEASE;HYPERTENSION, PORTAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
DIDANOSINE;XDH;rs1594160;AA;TOXICITY;INCREASED-RISK;DISEASE;HYPERTENSION, PORTAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*6;*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
DAUNORUBICIN;;rs7929521;GG;OTHER, LADME-PK;INCREASED-PK;PK;IC50 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
AZACITIDINE;TYMS;rs11280056;del/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DAUNORUBICIN;MAN1B1;rs3750518;T;OTHER, LADME-PK;INCREASED-PK;PK;IC50 
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME-PK;DECREASED-PK;PK;MEAN OXYMORPHONE/OXYCODONE RATIOS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
DIDANOSINE;NT5C2;rs11191561;CG + GG;TOXICITY;INCREASED-RISK;DISEASE;HYPERTENSION, PORTAL 
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;HLA-DQA1*01:02;*01:02;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
IGURATIMOD;CYP2C19;rs4244285;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
PHENYTOIN;HLA-C;HLA-C*14:02;*14:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
PHENYTOIN;HLA-B;HLA-B*56:02;*56:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
NICOTINE;CYP2A6;rs1801272;AT + TT;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
OLANZAPINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*6;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;HYPOTENSIVE DISORDER 
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED-PK;PK;STEADY-STATE PLASMA CONCENTRATIONS OF DESIPRAMINE/DAILY DOSE OF DESIPRAMINE/BODY WEIGHT 
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;FATIGUE 
;NAT1;NAT1*4, NAT1*11B;*11B/*4;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*3C;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
OLANZAPINE;GSTM3;rs1799735;CCT/CCT;LADME-PK;DECREASED-PK;PK;AREA UNDER THE CURVE 
OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED-PK;PK;AREA UNDER THE CURVE 
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
ANASTROZOLE;CYP19A1;rs727479;AA;EFFICACY;INCREASED-;OTHER;RECURRENCE FREE SURVIVAL 
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;LADME-PK;DECREASED-PK;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS 
FLUVASTATIN;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;LDL-C REDUCTION 
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME-PK;DECREASED-PK;PK;SERUM CONCENTRATIONS OF OXYMORPHONE AND NOROXYMORPHONE AND OXYMORPHONE/OXYCODONE RATIOS 
EFAVIRENZ;CYP2B6;CYP2B6*18;*18/*18;LADME-PK;INCREASED-PK;PK;PLASMA EFAVIRENZ LEVELS 
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO2;rs1143684;C;EFFICACY;EFFICACY;EFFICACY;WORSE PROGNOSIS (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) IN PATIENTS WHO WERE ER-VE/PR-VE NEGATIVE 
PIOGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2 + *2/*2;LADME-PK;DECREASED-PK;PK;M-III, PIOGLITAZONE AUC0-48 RATIO AND M-III, M-IV AUC0-48 RATIO IN HEALTHY AFRICAN-AMERICAN VOLUNTEERS, 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
DICLOFENAC;UGT2B7;rs7668258;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED-RISK;DISEASE;HEMORRHAGE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED-RISK;OTHER;NON-FATAL MYOCARDIAL INFARCTION,STROKE, REVASCULARIZATION OR DEATH 
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2;LADME-PK;INCREASED-PK;PK;R-IBUPROFEN METABOLISM 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ANEMIA 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;;SIDE_EFFECT;HIGHER COMPOSITE HAR OUTCOME (CARDIAC DEATH, NON FATAL MYOCARDIAL INFARCTION AND STENT THROMBOSIS) UP TO 12 MONTHS' FOLLOW UP 
;IRS1;rs1801123;C;OTHER;;OTHER;LYMPH NODE INVOLVEMENT 
ESTRADIOL;;rs1864729;A;OTHER;INCREASED-;OTHER;PLASMA LEVEL 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEDIAN SURVIVAL TIME 
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE, STROKE 
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE (RR) 
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOMYOPATHIES 
;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED-PK;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM 
DICLOFENAC;ABCC2;rs717620;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUCCESSFUL RHYTHM CONTROL 
CARBIMAZOLE, METHIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED-EFFICACY;EFFICACY;SURVIVAL TIME 
HYDRALAZINE;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;EFFICACY;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION 
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED-EFFICACY;EFFICACY;BETTER CLINICAL RESPONSE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;DECREASED-PK;PK;UNBOUND ORAL CLEARANCE FOR S-WARFARIN 
RIFAMPIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;EFFICACY;EFFICACY;MORE FREQUENT HIGH PLATELET REACTIVITY IN JAPANESE PATIENTS IN A STEADY STATE RECEIVING DUAL ANTIPLATELET THERAPY AFTER CORONARY STENT IMPLANTATION 
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED-EFFICACY;EFFICACY;HAM-D SCORE CHANGES IN FLUVOXAMINE-TREATED PATIENTS COMPARED TO PAROXETINE-TREATED PATIENTS 
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED-;OTHER;WAKEFULNESS ACTIVITY LEVEL 
;IGFBP3;rs2854744;T;OTHER;;OTHER;TUMOR SIZE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS 
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS 
NEVIRAPINE;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS-BULLOUS LESIONS 
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;LADME-PK;INCREASED-PK;PK;PAROXETINE PLASMA CONCENTRATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
;GSTM3;rs36120609;TC/TC + TC/TCCTC;OTHER;INCREASED-LIKELIHOOD;OTHER;METASTATIC NEOPLASM 
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME-PK;INCREASED-PK;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;OTHER;;SIDE_EFFECT;REQUIREMENT FOR EARLIER DOSE REDUCTION OF RIBAVIRIN 
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;AGRANULOCYTOSIS 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH PLATELET REACTIVITY 
;IFNL3;rs8099917;TT;;INCREASED-;OTHER;BASELINE VIRAL LOAD 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *6/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;LADME-PK;INCREASED-PK;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY 
DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;LADME-PK;INCREASED-PK;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;LADME-PK;INCREASED-PK;PK;PAROXETINE PLASMA CONCENTRATION 
HEPARIN;HLA-DRB3;HLA-DRB3*01:01;*01:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEPARIN-INDUCED THROMBOCYTOPENIA 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;TOXICITY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-REMISSION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;DECREASED-PK;PK;RACEMIC, S-IBUPROFEN AND R-IBUPROFEN METABOLISM, WITH INCREASE OF AUC(0-INFINITY) AND REDUCTION OF CLEARANCE 
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME-PK;INCREASED-PK;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;INCREASED-PK;PK;EXPOSURE (AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC)) AND DECREASED ORAL CLEARANCE 
EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;INCREASED-PK;PK;PLASMA 4BETA-OHC/CHOL RATIO 
TAMOXIFEN;CYP2D6;CYP2D6 low activity;;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY 
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10;*4 + *10 + *9;LADME-PK;DECREASED-PK;PK;PLASMA AND URINARY RATIO OF METABOLITES TRANS-3'-HYDROXYCOTININE TO COTININE (3HC/COT) 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
LUMIRACOXIB;HLA-DQA1;HLA-DQA1*01:01, HLA-DQA1*01:02;*01:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;INCREASED-PK;PK;PAROXETINE LEVELS 
IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;OTHER;DECREASED-;OTHER;INOS EXPRESSION 
IRINOTECAN;UGT1A6;rs2070959;A;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;LADME-PK;INCREASED-PK;PK;R-IBUPROFEN METABOLISM 
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
IMATINIB;EGFR;rs2072454;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIORBITAL EDEMA 
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;SIDE EFFECTS 
KETOPROFEN, TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEDATION 
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;INHIBITORY EFFECT ON CYCLOOXYGENASE 1 ACTIVITY 
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;INCREASED-PK;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE 
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME-PK;INCREASED-PK;PK;PIROXICAM'S AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE AND DECREASED ORAL CLEARANCE 
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*114;*10/*10;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CITALOPRAM, ESCITALOPRAM;CYP2D6;rs1065852;A;OTHER;;OTHER;PLASMA CONCENTRATION OF S-DIDESMETHYL-CITALOPRAM 
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK-;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED-PK;PK;CLEARANCE OF S(+) MIRTAZAPINE 
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
;CYP2D6;CYP2D6*2xN;*2xN;OTHER;INCREASED-RISK;DISEASE;SUICIDE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;EFFICACY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED-;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;DECREASED-PK;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;OTHER;DECREASED-SEVERITY;DISEASE;DEPRESSION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
IRINOTECAN;UGT1A9;rs11692021;C;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
METOPROLOL;ADRB2;rs1042714;CG;TOXICITY;INCREASED-;SIDE_EFFECT;TRIGLYCERIDES 
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA 
TAMOXIFEN;IGF1R;rs2016347;GG;EFFICACY;INCREASED-RISK;DISEASE;RECURRENCE 
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
;CYP2D6;CYP2D6*1xN;*1xN;OTHER;INCREASED-RISK;DISEASE;SUICIDE 
ALLOPURINOL;HLA-B;HLA-B*48:01;*48:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
PACLITAXEL;CYP2C8;rs10509681;C;TOXICITY;INCREASED-RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VOMITING 
PAZOPANIB;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASTHENIA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATIONS 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-;SIDE_EFFECT;INTOLERANCE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
QUETIAPINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*2 + *2/*2 + *2/*4;LADME-PK;INCREASED-SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA 
CAFFEINE;ADORA2A;rs35060421;TTTTTTT/TTTTTTT;TOXICITY;INCREASED-;SIDE_EFFECT;ANXIETY 
ALLOPURINOL;HLA-DRB1;HLA-DRB1*14:01;*14:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
ALLOPURINOL;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ZONISAMIDE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;;DISEASE;STEVENS-JOHNSON SYNDROME 
PHENOBARBITAL;HLA-B;HLA-B*51:01;*51:01;TOXICITY;;DISEASE;STEVENS-JOHNSON SYNDROME 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME-PK;DECREASED-PK;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION AND HIGHER MEAN METABOLIC RATIO 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED-SEVERITY;OTHER;PAIN 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;TROUGH CONCENTRATIONS 
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;;SIDE_EFFECT;EXANTHEMA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED-PK;PK;TIME TO ACHIEVE THERAPEUTIC WINDOW 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-;SIDE_EFFECT;DEATH 
METHOTREXATE;ABCC2;rs3740065;AG + GG;LADME-PK;INCREASED-PK;PK;PLASMA LEVEL 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
METOPROLOL;ADRB2;rs1042714;CC;TOXICITY;DECREASED-;SIDE_EFFECT;TOTAL CHOLESTEROL 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
METHOTREXATE;ABCC4;rs9516519;GG + GT;LADME-PK;DECREASED-PK;PK;PLASMA LEVEL 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;NUDT15;rs746071566;del;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED-PK;PK;TROUGH CONCENTRATIONS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED-PK;PK;S-CIT SERUM CONCENTRATIONS 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED-PK;PK;MEAN ESCITALOPRAM CONCENTRATION 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE WHEN MEASURED BY THE GERIATRIC DEPRESSION SCALE AT DAY 7 AND DAY 28 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;LOWER FINAL DAILY DOSE, DECREASED DOSING COMPLIANCE AND LOWER PLASMA LEVELS AT DAY 28 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;DOSAGE, LADME-PK;DECREASED-PK;PK;SERUM CONCENTRATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE 
MIRTAZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;DOSAGE, LADME-PK;INCREASED-PK;PK;SERUM CONCENTRATION 
LISINOPRIL;MMP3;rs35068180;del/del;EFFICACY;DECREASED-RISK;SIDE_EFFECT;STROKE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED-RISK;DISEASE;INFECTIOUS DISEASE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY;POSITIVE CORRELATION OF PAROXETINE CONCENTRATION WITH IMPROVEMENT IN HAMD SCORES AT WEEK 2 
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE, STROKE 
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*4/*41;LADME-PK;INCREASED-PK;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;TOXICITY;INCREASED-EFFICACY;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED-EFFICACY;EFFICACY;RISK OF RECURRENT CARDIOVASCULAR (CV) EVENTS 1 YEAR AFTER PCI IN CHINESE PATIENTS 
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
DIRECT ACTING ANTIVIRALS, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2;DOSAGE, LADME-PK;INCREASED-PK;PK;SERUM CONCENTRATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
CITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED-PK;PK;DEMETHYLATION CLEARANCE OF DESMETHYLCITALOPRAM 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LONG QT SYNDROME 
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;NEUTROPENIA 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;VOMITING 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
FOLFOX;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME-PK;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
METHOTREXATE;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9 + *1/*9;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DISCONTINUATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;STROKE 
FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
EGFR INHIBITORS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;EXANTHEMA 
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED-RISK;DISEASE;DRUG TOXICITY 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2 + *1/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
EGFR INHIBITORS;HLA-A;HLA-A*03:01;*03:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;EXANTHEMA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-;SIDE_EFFECT;ASTHENIA 
DOCETAXEL;SLCO1B3;rs3834935;A;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;GG;EFFICACY;EFFICACY;EFFICACY;DRUG-RESISTANT PHENOTYPE 
PACLITAXEL;CYP2C8;CYP2C8*2, CYP2C8*3, CYP2C8*4;*2 + *3 + *4;TOXICITY;INCREASED-RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*30:02;*30:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CITALOPRAM, ESCITALOPRAM;;rs1074145;A;OTHER;;OTHER;CONCENTRATIONS OF S-CITALOPRAM AND METABOLIC RATIO OF OF S-DESMETHYLCITALOPRAM/CITALOPRAM 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:03;*06:03;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:03;*15:03;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
IMATINIB;CYP1A2;rs11636419;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIORBITAL EDEMA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ETHANOL;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION INHIBITION 
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;G;EFFICACY;EFFICACY;EFFICACY;DRUG-RESISTANT PHENOTYPE 
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;;OTHER;GREATER HEART RATE (HR) REDUCTION 
BUCILLAMINE;HLA-DRB1;HLA-DRB1*08:02;*08:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PROTEINURIA 
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH 
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
BUCILLAMINE;HLA-DQB1;HLA-DQB1*04:02;*04:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PROTEINURIA 
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;; 
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;;OTHER;HIGH PLATELET REACTIVITY (HPR) 
AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED-RISK;SIDE_EFFECT;URTICARIA 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;URTICARIA 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
CLOZAPINE;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
CLOZAPINE;HLA-DRB5;HLA-DRB5*02:02;*02:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;INFLAMMATION 
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;JAUNDICE 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;OTHER;;OTHER;A CORRELATION OF BRAIN SERT OCCUPANCY WAS ASSOCIATED WITH LARGER PROPORTIONAL HDRS17 DECREASES 
AMOXICILLIN, CLAVULANATE;HLA-DRB5;HLA-DRB5*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATITIS 
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION 
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATITIS 
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA, SEVERE CUTANEOUS ADVERSE REACTIONS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
TICLOPIDINE;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;EFFICACY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;EFFICACY 
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*41;*41;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA NORTRIPTYLINE 
TICLOPIDINE;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ATORVASTATIN;LEPR;rs1805094;GG;OTHER;INCREASED-;OTHER;BONE MARROW DENSITY IN THE LUMBAR SPINE 
TICLOPIDINE;HLA-DQB1;HLA-DQB1*06:04;*06:04;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
TICLOPIDINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
BUSULFAN, CYTARABINE, ETOPOSIDE;ABCC3;rs4148405;G;EFFICACY, TOXICITY;DECREASED-;OTHER;DISEASE-FREE SURVIVAL 
TICLOPIDINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
COCAINE, ETHANOL, NICOTINE;OPRM1;rs1799972;TT;TOXICITY;INCREASED-RISK;DISEASE;SUBSTANCE-RELATED DISORDERS 
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
ANTIPSYCHOTICS;COMT;rs4680;A;OTHER;INCREASED-;OTHER;METHYLATION AT SITES 1 AND 2 IN THE COMT PROMOTER 
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ASPIRIN;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;URTICARIA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ASPIRIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;URTICARIA 
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A, CYP2E1*5B;*1A/*5B;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ASPIRIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;DECREASED-RISK;SIDE_EFFECT;URTICARIA 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;URTICARIA 
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;;SIDE_EFFECT;THROMBOCYTOPENIA 
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED-RISK;SIDE_EFFECT;URTICARIA 
FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA + AG;OTHER;DECREASED-EFFICACY;EFFICACY;FEV1/FVC RATIO 
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;TOXICITY;DECREASED-RISK;DISEASE;DRUG TOXICITY 
EFAVIRENZ, NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED-RISK;OTHER;ALCOHOL ABUSE 
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
ISONIAZID, RIFAMPIN;GSTT1;GSTT1 null;;LADME-PK;DECREASED-PK;PK;SERUM HYDRAZINE CONCENTRATIONS 
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs56038477;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ISONIAZID, RIFAMPIN;GSTM1;GSTM1 null;;LADME-PK;INCREASED-PK;PK;SERUM HYDRAZINE CONCENTRATIONS 
ALLOPURINOL;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTM1;GSTM1 null;;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER 
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA, SEVERE CUTANEOUS ADVERSE REACTIONS 
METHADONE;CYP3A4;rs3735451;C;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;OPIOID WITHDRAWAL SYMPTOMS 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*27;*1/*27;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CLOZAPINE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PHENYTOIN;HLA-B;HLA-B*07:02, HLA-B*13:01;*13:01;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;PK;PK;SIGNIFICANTLY HIGHER (S)-FLUOXETINE AND LOWER AND (S)-NORFLUOXETINE CONCENTRATIONS 
;TRPA1;rs920829;CT + TT;OTHER;INCREASED-LIKELIHOOD;DISEASE;PAIN 
ETHANOL;ALDH2;rs671;A;TOXICITY;DECREASED-RISK;OTHER;ALCOHOL ABUSE 
;NAT2;NAT2 deficiency;;OTHER;;DISEASE;INSULIN RESISTANCE 
FLUOXETINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME-PK;INCREASED-PK;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE AND THE ACTIVE MOIETY IN PATIENTS WITH TWO FUNCTIONAL CYP2D6 ALLELES 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;LADME-PK;DECREASED-PK;PK;CONCENTRATIONS OF 10-OH-NORTRIPTYLINE AND HIGHER NORTRIPTYLINE/10-OH-NORTRIPTYLINE RATIO 
RITODRINE;CACNA1C;rs10774053;AA + AG;OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
SPIRONOLACTONE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;EFFICACY;EFFICACY;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION, END-SYSTOLIC AND END-DIASTOLIC VOLUME 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
WARFARIN;APOE;rs429358;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
WARFARIN;APOE;rs7412;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN D-DIMER LEVELS 
TIMOLOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY, LADME-PK;INCREASED-PK;PK;PLASMA TIMOLOL CONCENTRATION AND EXCERICE HEART RATE REDUCTION 
LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;LADME-PK;DECREASED-;OTHER;GASTRIC PH 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
RABEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;EFFICACY;DECREASED-;OTHER;GASTRIC PH 
;AREG;rs1615111;A;OTHER;DECREASED-;OTHER;OVERALL SURVIVAL 
CISPLATIN, EPIRUBICIN, FLUOROURACIL;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN IL-6 LEVELS 
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN CRP LEVELS 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;DECREASED-;SIDE_EFFECT;AVERAGE CUMULATIVE NEUROTOXICITY GRADE 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
ETHANOL;CYP2E1;rs2031920;T;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
CISPLATIN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;OTHER;INCREASED-LIKELIHOOD;OTHER;BLOOD COAGULATION DISORDERS 
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME-PK;INCREASED-PK;PK;TOLTERODINE EXPOSURE AND INCREASED  ACTIVE METABOLITE (5-HM) CONCENTRATIONS 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ANASTROZOLE;CYP19A1;rs1008805;GG;OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;ARTHRALGIA 
ACE INHIBITORS, PLAIN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs41412545;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CYCLOSPORINE, METHOTREXATE;ATIC;rs2177735;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
LEVETIRACETAM;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
ALLOPURINOL;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs56022120;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;G;DOSAGE, LADME-PK;INCREASED-PK;PK;GLUCURONIDATION 
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;G;DOSAGE, LADME-PK;INCREASED-PK;PK;GLUCURONIDATION 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs138602176;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
CLOPIDOGREL;MED12L, P2RY12;rs5853517;T/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
EXEMESTANE;;rs16964189;TT;TOXICITY;;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs78428806;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;INFLAMMATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ANTIPSYCHOTICS;INSIG2;rs11123469;CC;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;METABOLIC SYNDROME 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS 
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;ABCB1;rs2032582;T;EFFICACY;EFFICACY;EFFICACY;DRUG-RESISTANT PHENOTYPE 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;EFFICACY;EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
ASPIRIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTRITIS 
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;LADME-PK;INCREASED-PK;PK;PLASMA METOPROLOL CONCENTRATIONS 
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
;ACE2;rs2285666;C;OTHER;INCREASED-SEVERITY;OTHER;COVID-19 
"""ACE INHIBITORS, PLAIN"", ""BETA BLOCKING AGENTS"", ""CALCIUM CHANNEL BLOCKERS"", ""DIGOXIN"", ""DIURETICS""";ACE;rs1799752;del;EFFICACY;INCREASED-EFFICACY;EFFICACY;MORTALITY 
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;DECREASED-;SIDE_EFFECT;CYSTIC FIBROSIS PULMONARY EXACERBATION 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE LEUKOPENIA 
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*1;LADME-PK;DECREASED-PK;PK;METABOLIC RATIOS OF DESIPAMINE 
PAMAQUINE;G6PD;G6PD deficiency;;TOXICITY;;DISEASE;HEMOLYSIS 
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;EFFICACY, OTHER;INCREASED-;OTHER;HEART RATE (HR) AND DIASTOLIC BLOOD PRESSURE (DBP) REDUCTIONS DURING EARLY TITRATION 
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;;DISEASE;HEMOLYSIS 
ITRACONAZOLE, KETOCONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;OTHER, LADME-PK;DECREASED-SEVERITY;OTHER;INHIBITION OF CYP3A-CATALYZED METABOLISM OF MIDAZOLAM OR TESTOSTERONE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
HMG COA REDUCTASE INHIBITORS;;rs3764261;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROTECTION AGAINST MYOCARDIAL INFARCTION 
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA, DRUG TOXICITY, HAND-FOOT SYNDROME, 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;ON-TREATMENT PLATELET ACTIVITY 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED-;SIDE_EFFECT;TIME BELOW THERAPEUTIC RANGE 
OSIMERTINIB;CYP2A6;rs28399433;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
AMITRIPTYLINE, FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
PAZOPANIB, PEMETREXED;VEGFA;rs833061;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
PENICILLIN G, PENICILLIN V;HLA-B;HLA-B*55:01;*55:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ETHANOL;GHSR;rs2948694;AG;OTHER;;OTHER;WEIGHT 
OPIOIDS;OPRM1;rs495491;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;;INCREASED-;OTHER;CIGARETTES PER DAY 
OPIOIDS;OPRM1;rs10457090;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;INCREASED-PK;PK;STEADY STATE CONCENTRATION PER DOSAGE 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01/*58:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS, TOXIC OR STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;EFFICACY;EFFICACY;NON-RESPONSE 
WARFARIN;CYP2C9;CYP2C9*2;*2;EFFICACY;EFFICACY;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4 
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR7;rs1935349;T;TOXICITY;INCREASED-RISK;DISEASE;MYALGIA 
METHOTREXATE;TYMS;rs45445694;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*18;TOXICITY, LADME-PK;INCREASED-LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS 
DOCETAXEL, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EFFICACY 
CISPLATIN;ERCC2;rs1799793;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL 
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME 
COCAINE;SLC6A3;rs3836790;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;EFFICACY;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS IN TAIWANESE PATIENTS RECEIVING CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) 
PHENYTOIN;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS, TOXIC OR STEVENS-JOHNSON SYNDROME 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*1/*4;LADME-PK;INCREASED-PK;PK;PAROXETINE SERUM CONCENTRATIONS (CMIN) 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIPHENYLHYDANTOIN-INDUCED SKIN RASH 
IBUPROFEN;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;DURATION OF INHIBITION OF PROSTANOIDS 
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION 
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;INCREASED-PK;PK;THE MAXIMAL ELIMINATION RATE (VMAX) 
ACETAMINOPHEN;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;LADME-PK;INCREASED-PK;PK;ELIMINATION RATE 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED-PK;PK;PLASMA METHYLMERCAPTOPURINE NUCLEOTIDES LEVELS 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS 
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, EFFICACY;EFFICACY;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*4;*1/*3 + *1/*4;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
MERCAPTOPURINE;CYP2A7;rs73032311;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE 
BUPROPION;CYP2B6;CYP2B6*18;*18;LADME-PK;DECREASED-PK;PK;HYDROXYBUPROPION CONCENTRATIONS 
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION 
ANTIEPILEPTICS, CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CUTANEOUS REACTIONS 
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME-PK;INCREASED-PK;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT 
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS, TOXIC OR STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
;NAT1;NAT1*10, NAT1*11A;*10/*11A;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
;NAT1;NAT1*4, NAT1*10;*10/*4;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTT1;GSTT1 null;;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;*5;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME-PK;DECREASED-PK;PK;CLERANCE OF PACLITAXEL 
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED-PK;PK;HYDROXYBUPROPION CONCENTRATIONS AND HYDROXYBUPROPION/BUPROPION RATIO 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;EFFICACY;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION 
IRINOTECAN, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;DECREASED-RISK;DISEASE;ASTHENIA 
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;EFFICACY;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION (MPA) IN CLOPIDOGREL-TREATED PATIENTS UNDERGOING PE RCUTANEOUS CORONARY INTERVENTION 
TEMSIROLIMUS;NR1I2;rs6785049;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
;NAT1;NAT1*3, NAT1*11B;*11B/*3;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
;NAT1;NAT1*10;*10/*10;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALLOGRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS 
DAUNORUBICIN;NRP2;rs10932125;C;DOSAGE, LADME-PK;INCREASED-PK;PK;IC50 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED-RISK;DISEASE;THROMBOCYTOPENIA 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED-RISK;DISEASE;ANEMIA 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME-PK;DECREASED-RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
METOPROLOL;CYP2D6;rs5030655;del/del;OTHER;INCREASED-PK;PK;PLASMA CONCENTRATIONS OF METOPROLOL 
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;;EFFICACY;EFFICACY;LACK OF REMISSION AND LACK OF RESPONSE 
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE DRUG REACTION AFTER THE SECOND SWITCH IN TREATMENT 
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs1105879;C;LADME-PK;INCREASED-PK;PK;GLUCURONIDATION 
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY, LADME-PK;INCREASED-LIKELIHOODPK;PK;ELEVATED PLASMA CONCENTRATIONS 
ISONIAZID, PYRIDOXAL PHOSPHATE;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ATENOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;INCREASED-PK;PK;AMITRIPTYLINE/(E)-10- OH-AT RATIO 
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;INCREASED-PK;PK;NORTRIPTYLINE/(E)-10-OH-NT RATIO 
REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37/*37;LADME-PK;DECREASED-PK;PK;REPAGLINIDE EXPOSURE (DECREASED AUC AND INCREASED  CLEARANCE) 
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EPIDERMAL NECROLYSIS, TOXIC OR STEVENS-JOHNSON SYNDROME 
BENZENE;NQO1;rs1800566;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMATOTOXICITY 
ATAZANAVIR, EFAVIRENZ;TPH2;rs4570625;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DEPRESSION 
METHOTREXATE;DHFR;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED-RISK;DISEASE;THROMBOCYTOPENIA 
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
EFAVIRENZ;CYP2B6;CYP2B6*1;*1;EFFICACY, LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION OF EFAVIRENZ 
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;AGRANULOCYTOSIS 
TEGAFUR;CYP2A6;CYP2A6*1;*1;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA FLUOROURACIL 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED-;SIDE_EFFECT;ADVERSE DRUG REACTIONS 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LIVER INJURY 
ANTIEPILEPTICS;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;DRUG RESISTANCE 
ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2/*2;EFFICACY, LADME-PK;INCREASED-PK;PK;ATORVASTATIN LACTONIZATION 
ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2;EFFICACY, LADME-PK;DECREASED-EFFICACY;EFFICACY;TOTAL AND THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL MAXIMUM PERCENT DECREASES FROM BASELINE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
DOXEPIN;CYP2C9;CYP2C9*3;*3/*3;LADME-PK;DECREASED-PK;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN 
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED-PK;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE AND S-OMEPRAZOLE 
TACROLIMUS;CYP2C19;CYP2C19*2;*2/*2;OTHER;INCREASED-;OTHER;HOSPITAL STAY 
MERCAPTOPURINE;COMT;rs4680;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;MEAN ABSOLUTE DIFFERENCE IN HBA1C 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2xN;*1/*2xN;LADME-PK;INCREASED-PK;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE 
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;LADME-PK;INCREASED-PK;PK;RELATIVE BIOAVAILABILITY OF PRAVASTATIN 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG HYPERSENSITIVITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION 
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;INCREASED-PK;PK;MEAN AMITRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;CLOPIDOGREL RESPONSE IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) 
;CYP2C19;CYP2C19*1, CYP2C19*17;*17;OTHER;RISK-;DISEASE;PEPTIC ULCER DISEASE 
CAFFEINE;ADORA2A;rs5751876;TT;OTHER;INCREASED-;SIDE_EFFECT;ANXIETY 
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED-SEVERITY;DISEASE;RHEUMATOID ARTHRITIS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;COMPOSITE ISCHEMIC EVENTS 
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY, LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;COMPOSITE ISCHEMIC EVENTS 
ATORVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-;SIDE_EFFECT;SERUM CREATINE KINASE LEVELS (INCREASED  RISK OF MYALGIA AND GREATER DEGREE OF MUSCLE DAMAGE) 
NEVIRAPINE;ABCC10;rs2125739;CC;EFFICACY, LADME-PK;INCREASED-LIKELIHOODPK;PK;LOWER NEVIRAPINE PLASMA CONCENTRATIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARBAMAZEPINE-INDUCED STEVENS-JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN) 
METFORMIN;SLC22A1;rs36056065;GTAAGTTG;TOXICITY, LADME-PK;;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;STEVENS-JOHNSON SYNDROME 
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARBAMAZEPINE-INDUCED HYPERSENSITIVITY SYNDROME 
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;EFFICACY;EFFICACY;EFFICACY;ENHANCED RESPONSE TO CLOPIDOGREL (AS MEASURED BY INHIBITION OF ADP-INDUCED PLATELET AGGREGATION) 
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PHENYTOIN TOXICITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;ANTIPLATELET RESPONSE AND REDUCED CLOPIDOGREL ACTIVE METABOLITE FORMATION 
;NAT1;NAT1*10, NAT1*11B;*10/*11B;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED-PK;PK;ORAL CLEARANCE (CL/F) OF OMEPRAZOLE RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE AND S-OMEPRAZOLE 
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
;NAT1;NAT1*4, NAT1*11A;*11A/*4;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
WARFARIN;CYP2C9;CYP2C9*3;*3;EFFICACY;EFFICACY;EFFICACY;SHORTER TIME TO THE FIRST INR OF MORE THAN 4 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED-PK;PK;PLASMA THIOGUANINE NUCLEOTIDES METABOLITES 
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*1/*15;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX 
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY 
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE, TOXICITY;INCREASED-RISK;OTHER;COMPLICATIONS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;ADP-INDUCED MAXIMUM PLATELET AGGREGATION 
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE, TOXICITY;INCREASED-RISK;DISEASE;BRADYCARDIA 
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) 
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;DECREASED-SEVERITY;DISEASE;DRUG TOXICITY 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE AFTER ADJUSTMENT FOR VKORC1*1173 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;LADME-PK;DECREASED-PK;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN 
HALOPERIDOL;COMT;rs4680;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS 
ATORVASTATIN;CYP2D6;CYP2D6*4;*4;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCLE EFFECTS 
DOXEPIN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME-PK;DECREASED-PK;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;EFFICACY;EFFICACY;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, EFFICACY;EFFICACY;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY 
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN INR VALUES IN PATIENTS WITH HEART VALVE REPLACEMENT 
CLOPIDOGREL;CYP2B6;CYP2B6*5;*5;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS 
VENLAFAXINE;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;INCREASED-PK;PK;CMAX AND AUC OF VENLAFAXINE 
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN INR VALUE 
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;LADME-PK;INCREASED-PK;PK;CMAX AND AUC OF VENLAFAXINE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;EFFICACY;EFFICACY;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;EFFICACY;EFFICACY;DELAYED TIME TO REACH STABLE DOSE AND AND TENDED TO HAVE HIGH RISK FOR THE FIRST INR GREATER THAN 3.5 
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ACHIEVING A STABLE DOSE 
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ACHIEVING A STABLE DOSE 
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*10;EFFICACY;INCREASED-EFFICACY;EFFICACY;FREQUENCY OF REMITTERS 
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED-;OTHER;INTRAGASTRIC PH 
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED-;OTHER;INTRAGASTRIC PH 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME-PK;DECREASED-PK;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY, LADME-PK;DECREASED-EFFICACY;EFFICACY;TRAMADOL METABOLISM AND RESPONSE 
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED-;OTHER;MEAL-STIMULATED PLASMA GASTRIN CONCENTRATIONS 
PAROXETINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME-PK;INCREASED-PK;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED-EFFICACY;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3 + *3/*3;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE TO CLOPIDOGREL AND POORER OUTCOMES IN CHINESE PATIENTS WITH ACUTE ISCHEMIC STROKE 
TAMOXIFEN;CYP2D6;CYP2D6*6, CYP2D6*7;*6/*7;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;INCREASED-EFFICACY;EFFICACY;FREQUENCY OF REMITTERS 
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*6;*3/*6;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;DOSAGE, EFFICACY;DECREASED-EFFICACY;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL 
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME-PK;INCREASED-PK;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION 
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME-PK;PK;PK;MEAN PLASMA CONCENTRATION OF OXYMORPHONE AND LOWER MEAN OXYMORPHONE/OXYCODONE RATIO 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*41;*1/*1 + *1/*41;LADME-PK;DECREASED-PK;PK;PAROXETINE PLASMA CONCENTRATIONS INCREASED  DURING THE COURSE OF PREGNANCY 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;LADME-PK;INCREASED-PK;PK;MEAN NORTRIPTYLINE CONCENTRATIONS AND NORTRIPTYLINE CONCENTRATIONS PER UNIT DOSE OF THE MEDICATION 
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*1;LADME-PK;DECREASED-PK;PK;METABOLIC RATIOS OF DESIPAMINE 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*2/*10;LADME-PK;DECREASED-PK;PK;TRAMADOL CLEARANCE IN CHINESE VOLUNTEERS 
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;DOSAGE, EFFICACY;DECREASED-EFFICACY;EFFICACY;METABOLISM AND DECREASED RESPONSE TO TRAMADOL 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5;*5;LADME-PK;INCREASED-PK;PK;NORTRIPTYLINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5;LADME-PK;INCREASED-PK;PK;PAROXETINE PLASMA CONCENTRATION AT AN ADMINISTERED DOSE OF 30MG/DAY 
COTININE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20;*1/*1;LADME-PK;PK;PK;SHORTER CONTININ HALF-LIFE 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;DECREASED-PK;PK;CLEARANCE OF S(+) MIRTAZAPINE 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME-PK;INCREASED-PK;PK;PAROXETINE LEVELS 
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED-PK;PK;ORAL CLEARANCE OF CITALOPRAM 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;LADME-PK;INCREASED-PK;PK; PLASMA PAROXETINE CONCENTRATIONS AT ADMINISTERED DOSE OF 10MG/DAY 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED-PK;PK;TOTAL CLEARANCE OF RACEMIC MIRTAZAPINE 
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME-PK;DECREASED-PK;PK;CODEINE METABOLISM AND MORPHINE AND GLUCURONIDES FORMATION 
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;LADME-PK;INCREASED-PK;PK;PLASMA LEVEL OF MORPHINE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-TREATMENT PLATELET AGGREGATION 
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
;UGT1A1;rs34946978;T;OTHER;INCREASED-LIKELIHOOD;OTHER;GILBERT SYNDROME, CRIGLER-NAJJAR SYNDROME 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
FLURBIPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;INCREASED-PK;PK;AUC, HIGHER HALF-LIFE AND LOWER FLURBIPROFEN CLEARANCE 
DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*4;*1/*4 + *4/*4;LADME-PK;INCREASED-PK;PK;DICLOFENAC/5-HYDROXYDICLOFENAC URINARY CONCENTRATION RATIO 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS 
PYRIMIDINE ANALOGUES;MIR27A;rs895819;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS 
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED-PK;PK;PLASMA RATIO CITALOPRAM (CIT)/N-DESMETHYLCIT (DCIT) 
TIMOLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME-PK;INCREASED-PK;PK;EXPOSURE TO TIMOLOL (HIGHER AREA-UNDER-CURVE, LONGER ELIMINATION HALF-LIVES ) 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;PON1;rs662;C;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOTAL HEMORRHAGE AND MAJOR HEMORRHAGE 
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3;LADME-PK;INCREASED-PK;PK;AUC AND HALF-LIFE TIME (T1/2) 
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;TOXICITY;DECREASED-;SIDE_EFFECT;INOS EXPRESSION AND FEWER ADVERSE EVENTS 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CLOPIDOGREL;P2RY12;rs2046934;A;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ANTIEPILEPTICS;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
ASPIRIN;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASTHMA 
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (REDUCTIONS IN HAEMOGLOBIN A1C (HBA1C) AND FASTING PLASMA GLUCOSE (FPG) LEVELS) 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
LUMACAFTOR;CFTR;rs113993960;del/del;TOXICITY;INCREASED-EFFICACY;EFFICACY;CHANGE IN SWEAT CHLORIDE 
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ABORTION, SPONTANEOUS 
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED-EFFICACY;EFFICACY;ACENOCOUMAROL DOSE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-CLOPIDOGREL PLATELET AGGREGATION (PA) AND HIGHER PLATELET REACTIVITY INDEX (PRI) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) 
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;LADME-PK;DECREASED-PK;PK;PLASMA LEVELS OF MORPHINE, M3G AND M6G LEVELS BUT NOT THOSE OF CODEINE 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;OTHER;INCREASED-;OTHER;OROCECCAL TRANSIT TIME 
;CYP1B1;rs1056836;CC + CG;;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS 
TETRABENAZINE;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;EFFICACY;EFFICACY;LESS ROBUST TREATMENT RESPONSE 
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED-PK;PK;METABOLIC RATIO CIT/DCIT VALUES 
CLOPIDOGREL;PTGS1;rs1330344;T;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CLOMIPRAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED-;SIDE_EFFECT;CLOMIPRAMINE-INDUCED PROLACTIN RELEASE 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED-PK;PK;AUC OF CITALOPRAM 
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED-EFFICACY;EFFICACY;PRESENTATION IN THE NON-REPONDER GROUP 
PHENOBARBITAL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE DRUG REACTIONS 
OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIZZINESS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC STROKE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;PRU 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS 
CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*08:01;*07:02;TOXICITY;DECREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
TRICHLOROETHYLENE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE CLINICAL EVENTS 
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;TOXICITY;SEVERITY-;SIDE_EFFECT;LEUKOPENIA 
ALLOPURINOL;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CARDIOVASCULAR EVENT OCCURRENCE 
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;VOMITING 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
OSIMERTINIB;CYP2C9;rs1057910;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS, EXANTHEMA 
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;CC;TOXICITY;DECREASED-RISK;DISEASE;LEUKOPENIA 
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CLOZAPINE;HLA-DRB3;HLA-DRB3*02:02;*02:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
MERCAPTOPURINE;TPMT;rs1142345;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
MYCOPHENOLATE MOFETIL;UGT2B7;rs7438135;G;TOXICITY;INCREASED-RISK;DISEASE;ANEMIA 
CLOZAPINE;HLA-C;HLA-C*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
CLOZAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;DECREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
AZATHIOPRINE, MERCAPTOPURINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCREATITIS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED-RISK;DISEASE;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
PLATINUM COMPOUNDS, PYRIMIDINE ANALOGUES;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, EXANTHEMA, STEVENS-JOHNSON SYNDROME, 
CAPECITABINE, FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
DOLASETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
CYCLOSPORINE, METHOTREXATE;NFATC2;rs6123048;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*4;*4;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
IFOSFAMIDE;ALDH1A1;rs3764435;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
CLOZAPINE;GSTT1;GSTT1 non-null, GSTT1 null;null/null;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ACHIEVING SVR IN OLDER PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;del;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCYTOPENIA, THROMBOCYTOPENIA 
HMG COA REDUCTASE INHIBITORS;ADAMTS1;rs402007;CC;EFFICACY;EFFICACY;EFFICACY;THE MOST BENEFIT FROM STATIN TREATMENT IN REDUCING THE RISK OF MYOCARDIAL INFARCTION 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*1;TOXICITY;DECREASED-RISK;OTHER;TOBACCO USE DISORDER 
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED-RISK;DISEASE;VIRUS DISEASES 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED-RISK;DISEASE;INFECTIOUS DISEASE 
GEFITINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;ALLOGRAFT REJECTION 
CARBOPLATIN, PACLITAXEL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
LAMOTRIGINE;SCN1A;rs3812718;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;TONIC BLOCK OF NA(V) 1.1 CHANNELS 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED-PK;PK;FORMATION OF METABOLITES 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
PEMETREXED;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
METHOTREXATE;TYMS;rs11280056;del;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
;SLCO1B1;rs4149056;C;OTHER;DECREASED-;OTHER;ERYTHROMYCIN TRANSPORT 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
LEVOFLOXACIN;HLA-B;HLA-B*13:01, HLA-B*13:02;*13:01 + *13:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
PHENYTOIN;HLA-A;HLA-A*03:01;*03:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer;;EFFICACY;INCREASED-RISK;SIDE_EFFECT;THROMBOTIC DISEASE 
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;HLA-DRB1;HLA-DRB1*10:01;*10:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS 
CLOPIDOGREL, PROTON PUMP INHIBITORS;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10  + *1/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4818789;TT;EFFICACY;DECREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
ATENOLOL, METOPROLOL;ADRB2;rs1042714;GG;TOXICITY;INCREASED-RISK;DISEASE;HYPERTRIGLYCERIDEMIA 
ZOLEDRONATE;;rs1152003;CC;TOXICITY;INCREASED-RISK;DISEASE;OSTEONECROSIS 
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
ATORVASTATIN;HMGCR;rs17671591;T;EFFICACY;EFFICACY;EFFICACY;LDL-C RESPONSE 
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DEPRESSION 
TACROLIMUS, VORICONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED-SEVERITY;SIDE_EFFECT;DRUG-DRUG PHARMACOKINETIC INTERACTION 
CARBOPLATIN, PACLITAXEL;LIG3;rs1052536;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH 
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4819128;TT;EFFICACY;DECREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ATORVASTATIN;HMGCR;rs10474433;T;EFFICACY;EFFICACY;EFFICACY;LDL-C RESPONSE 
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, DRUG-INDUCED LIVER INJURY 
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
ATORVASTATIN;PCSK9;rs11591147;T;EFFICACY;EFFICACY;EFFICACY;LDL-C RESPONSE 
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*02:07;*02:07;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ATORVASTATIN;APOE;rs429358;T;EFFICACY;EFFICACY;EFFICACY;LDL-C RESPONSE 
ENALAPRIL;;rs495828;TT;TOXICITY;INCREASED-RISK;DISEASE;COUGH 
RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;AC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ENALAPRIL;;rs495828;TT;TOXICITY;INCREASED-RISK;DISEASE;COUGH 
ATORVASTATIN;APOE;rs7412;T;EFFICACY;EFFICACY;EFFICACY;LDL-C RESPONSE 
;GSTT1;GSTT1 non-null, GSTT1 null;;EFFICACY, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION 
SIMVASTATIN;ABCG2;rs2231142;TT;LADME-PK;INCREASED-PK;PK;EXPOSURE TO DRUG 
CISPLATIN, DOCETAXEL, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPONATREMIA 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, MACULOPAPULAR EXANTHEMA, DRUG HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
CAPECITABINE, FLUOROURACIL;DPYS;rs143004875;(T)7/(T)8;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
FLUVASTATIN;ABCG2;rs2231142;TT;LADME-PK;INCREASED-PK;PK;EXPOSURE TO DRUG 
CAPECITABINE, FLUOROURACIL;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
OSIMERTINIB;CYP2A6;CYP2A6*4;*4;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
OSIMERTINIB;ABCG2;rs2622604;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
L-ASPARAGINE, PREDNISONE, VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN LDL-C 
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN LDL-C 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HIGH ON-TREATMENT PLATELET REACTIVITY 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
TRAMADOL;CYP2B6;CYP2B6 poor metabolizer;;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
TRAMADOL;CYP3A4;CYP3A4 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS, SOMNOLENCE 
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
IRINOTECAN;HLA-B;rs9266271;C;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*34:01;*34:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ATORVASTATIN;HMGCR;rs3846662;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVEL IN BASAL STATE AND POSSIBLY IN RESPONSE TO ATORVASTATIN. 
CLOPIDOGREL;ABCB1;rs1128503;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY, TREMOR, DIABETES MELLITUS, 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6;*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ACUTE CELLULAR REJECTION 
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
BETA BLOCKING AGENTS, METOPROLOL;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING 
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY 
FOLFIRI, FOLFOX, XELOX;TYMS;rs11280056;del/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
IRINOTECAN;ALOX5;rs1051713;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
ETOPOSIDE;;rs6539870;GG;OTHER;INCREASED-;OTHER;SENSITIVITY TO ETOPOSIDE 
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;FREQUENCY OF PATIENTS WHO RECEIVED AT LEAST THE RECOMMENDED 80% OF SCHEDULED RIBAVIRIN 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;STROKE 
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;EFFICACY;EFFICACY;CUMULATIVE REDUCTION OF RIBAVIRIN 
ASPARAGINASE;F5;rs6025;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM 
DABIGATRAN;CES1;rs2244613;GG + GT;LADME-PK;DECREASED-PK;PK;ADJUSTED TROUGH CONCENTRATIONS 
DESIPRAMINE;MC1R;rs2228478;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
;ABCB1;rs1045642;A;;INCREASED-;OTHER;LEVEL OF APOLIPOPROTEIN A1 
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE, EFFICACY, TOXICITY;DECREASED-EFFICACY;EFFICACY;DOSE REQUIREMENT 
DESIPRAMINE;MC1R;rs2228479;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*7, NAT2*16;*16/*7;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CARBAMAZEPINE;LTA, TNF;rs1800629;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SERIOUS HYPERSENSITIVITY 
ASPARAGINASE;IL16;rs11556218;GG + GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOTIC DISEASE 
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER 
GEMCITABINE;SLC29A1;rs9394992;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
DOCETAXEL, THALIDOMIDE;SPG7;rs2292954;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
ANTINEOPLASTIC AGENTS;CTH;rs648743;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
DOCETAXEL, THALIDOMIDE;ABCC6;rs2238472;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
DOCETAXEL, THALIDOMIDE;ATP7A;rs2227291;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMATOLOGIC DISORDER 
ACENOCOUMAROL;CYP4F2;rs2108622;CC;OTHER, LADME-PK;DECREASED-;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS 
ACENOCOUMAROL;CYP4F2;rs2108622;CT;OTHER, LADME-PK;DECREASED-;OTHER;LEVELS OF VITAMIN K-DEPENDENT PROTEINS 
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;BLEEDING EVENTS 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENT 
ACENOCOUMAROL;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY, TOXICITY;DECREASED-EFFICACY;EFFICACY;DOSAGE REQUIREMENT 
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
IRINOTECAN;SLCO1B1;rs4149015;AA + AG;TOXICITY;INCREASED-;DISEASE;NEUTROPENIA 
;CHRM3;rs2165870;AA + AG;;INCREASED-RISK;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*16;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;A MILD INCREASE OF LIVER ENZYMES 
SALBUTAMOL, SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;ASTHMA EXACERBATIONS 
IRINOTECAN;UGT1A9;rs3832043;del/del;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
CISPLATIN;SLC16A5;rs4788863;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE REACTIONS 
IRINOTECAN;ABCC2;rs3740066;CC;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ENALAPRIL, IMIDAPRIL, LISINOPRIL;BDKRB2;rs1799722;CT + TT;TOXICITY;INCREASED-RISK;DISEASE;COUGH 
IRINOTECAN;ABCG2;rs2231137;CT + TT;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
CLOZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;METABOLIC SYNDROME 
HMG COA REDUCTASE INHIBITORS;SREBF1;rs11868035;AA + AG;OTHER;INCREASED-;OTHER;TOTAL CHOLESTEROL 
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED-PK;PK;OXYCODONE CONSUMPTION UP TO THE 12(TH) HOUR IN POSTOPERATIVE PATIENTS 
CISPLATIN;GSTP1;rs1695;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
ACE INHIBITORS, PLAIN;BDKRB2;rs1799722;T;TOXICITY;INCREASED-RISK;DISEASE;COUGH 
ATORVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME-PK;INCREASED-PK;PK;AUC 
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME-PK;DECREASED-;OTHER;GASTRIC PH 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
IRBESARTAN;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;BLOOD PRESSURE RESPONSE 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
DEXMEDETOMIDINE;ADRA2A;rs1800544;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;BISPECTRAL INDEX AND RAMSAY SEDATION SCORES, INDICATING A LONGER PERIOD FOR FALLING ASLEEP 
PACLITAXEL;CYP2C8;rs1113129;G;TOXICITY;DECREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
OPIOIDS;MUC16;rs11882256;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
ISONIAZID, RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ROSUVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME-PK;INCREASED-PK;PK;AUC 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
ROSUVASTATIN;ABCG2;rs2231142;GG;DOSAGE, LADME-PK;DECREASED-PK;PK;AUC 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ISONIAZID, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
SORAFENIB;TNF;rs1800629;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
IRINOTECAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
ALFENTANIL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-RISK;DISEASE;PAIN 
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;TOXICITY;DECREASED-;SIDE_EFFECT;HEMOGLOBIN LEVELS 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ALFENTANIL;OPRM1;rs1799971;AG + GG;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED-RISK;OTHER;ASTHMA EXACERBATIONS 
PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9, ITPA;rs6051702;C;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
CLOPIDOGREL;MIR6076;rs1463411;GG + GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME-PK;DECREASED-;OTHER;GASTRIC PH 
TAMOXIFEN;LRMDA;rs10509373;C;EFFICACY;DECREASED-;OTHER;RECURRENCE-FREE SURVIVAL 
OPIOIDS;CRYBG2;rs36024412;T;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
OPIOIDS;CLCC1;rs168107;T;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
OPIOIDS;POM121L2;rs41269255;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
DIPYRONE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
METHOTREXATE;ABCC2;rs3740065;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
IRINOTECAN;NR3C1;rs61754806;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
IRINOTECAN;VKORC1;rs7294;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
OPIOIDS;ZNF165;rs9393888;C;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
CISPLATIN, CYCLOPHOSPHAMIDE;TPMT;rs1142345;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;SLCO1B1*5;*5;TOXICITY;DECREASED-RISK;SIDE_EFFECT;CATARACT 
GEMCITABINE;RRM1;rs9937;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
OLANZAPINE, RISPERIDONE;DRD2;rs1799978;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME UNTIL RESPONSE 
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BLEEDING EVENTS 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
METHOTREXATE;ABCC4;rs9516519;GG + GT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXICITY 
ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PSYCHOMOTOR AGITATION, HYPERKINESIS, IMPULSE CONTROL DISORDER, 
RISPERIDONE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
PALIPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION, WEIGHT GAIN 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;MAGNITUDE OF PLATELET REACTIVITY 
ISONIAZID;NAT2;NAT2*6, NAT2*7;*6 + *7;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6 + *7;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATOTOXICITY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*16;*16;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;HEPATITIS 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;ON-TREATMENT PLATELET REACTIVITY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*4;TOXICITY, LADME-PK;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
CAPECITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, HAND-FOOT SYNDROME 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATOTOXICITY 
ISONIAZID;NAT2;NAT2*16;*16;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
OLANZAPINE, RISPERIDONE;DRD2;rs1799732;del;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO RESPOND 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
OPIOIDS;CYP2A7P1, CYP2B6;rs3745274;GG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-B;HLA-B*35:03;*35:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
;CHRNA3;rs1051730;A;OTHER;INCREASED-LIKELIHOOD;OTHER;TOBACCO USE DISORDER 
RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA 
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;DECREASED-RISK;SIDE_EFFECT;INFECTIOUS DISEASE 
ANTINEOPLASTIC AGENTS;TYMS;rs2853539;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TARDIVE DYSKINESIA 
OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizers;;LADME-PK;DECREASED-;OTHER;GASTRIC PH 
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;HOT FLASHES 
ANTINEOPLASTIC AGENTS;AKR1C3;rs1937840;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ANTIHYPERTENSIVES;ADIPOQ;rs266729;CG + GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;HYPERTENSION 
MYCOPHENOLIC ACID, TACROLIMUS;IMPDH1;rs2278293;T;EFFICACY;DECREASED-LIKELIHOOD;OTHER;SUBCLINICAL ACUTE REJECTION 
GEMCITABINE;CDA;rs2072671;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*10, CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRY MOUTH, ERECTILE DYSFUNCTION, HYPERHIDROSIS, INSOMNIA
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
NICOTINE;CYP2D6;CYP2D6*2xN, CYP2D6*4, CYP2D6*5;*2xN;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOBACCO USE DISORDER 
GEMCITABINE;DCK;rs4694362;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;RBX1;rs141084494;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1801280;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
PLATINUM COMPOUNDS;SLC31A1;rs4978536;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
OPIOIDS;BDNF-AS;rs11030096;CC + CT;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799930;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY, HEMATOLOGIC DISORDER, LEUKOPENIA, THROMBOCYTOPENIA
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
COCAINE;SYT1;rs2251214;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;COCAINE DEPENDENCE 
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
VALGANCICLOVIR;ABCB1;rs2229109;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;INCREASED-PK;PK;FLUOXETINE PLASMA CONCENTRATION 
TETRABENAZINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;;OTHER;LONGER TITRATION TO ACHIEVE OPTIMAL BENEFIT 
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID 
OLANZAPINE;CYP2C9;CYP2C9 poor metabolizers;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS 
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTRR;rs1801394;AA + AG;EFFICACY;DECREASED-SEVERITY;DISEASE;PAIN 
NICOTINE;HTR3B;rs3758987;TT;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA, DRUG TOXICITY, HAND-FOOT SYNDROME, 
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
ANTIDEPRESSANTS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS 
ENALAPRIL;PCGF3;rs1044147;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED-PK;PK;PAROXETINE PLASMA CONCENTRATION 
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEDATION 
ANTICHOLINERGIC AGENTS;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;INCREASED-PK;PK;SERUM ANTICHOLINERGIC ACTIVITY 
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
ANTINEOPLASTIC AGENTS;ABCG2;rs2231164;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SURVIVAL 
CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED-EFFICACY;EFFICACY;NUMBER OF FAILED MEDICATION TRAILS 
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF MYCOPHENOLIC ACID-7-O-GLUCURONIDE 
MYCOPHENOLATE MOFETIL;ABCC2;rs2273697;AG;LADME-PK;INCREASED-PK;PK; AREA UNDER THE CONCENTRATION VERSUS TIME CURVE (AUC6-12) LEVEL OF THE ACYL GLUCURONIDE OF MYCOPHENOLIC ACID 
CAPECITABINE;DPYD;rs2297595;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;DECREASED-;SIDE_EFFECT;NAUSEA, VOMITING 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ATENOLOL;PAH;rs2245360;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INSULIN RESISTANCE 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*7;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
OPIOIDS;DRD2;rs1125394;CC + CT;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED-;SIDE_EFFECT;ADVERSE EVENTS 
SORAFENIB;VEGFA;rs3025040;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
OPIOIDS;DRD2;rs1079596;CT + TT;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;;OTHER;INCREASED-RISK;SIDE_EFFECT;SUICIDE 
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FEBRILE NEUTROPENIA 
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT intermediate metabolizers;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
FLUOROURACIL;TYMS;rs2847153;AG + GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SURVIVAL 
MORPHINE;ABCC3;rs4148412;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOVENTILATION 
SORAFENIB;UGT1A9;rs7574296;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED-LIKELIHOOD;OTHER;DRUG DOSAGE ALTERED 
TRAMADOL;COMT;rs4680;GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;EFFICACY;EFFICACY;GREATER REDUCTION IN HOMOCYSTEINE 
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED-PK;PK;ANTIDEPRESSANT SERUM LEVELS 
SORAFENIB;SLC15A2;rs2257212;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
FLUOROURACIL;CCND1;rs9344;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME-TO-TUMOR RECURRENCE 
AZATHIOPRINE;TPMT;TPMT intermediate metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS 
CAPECITABINE;UMPS;rs2279199;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
METFORMIN;;rs578427;TT;LADME-PK;INCREASED-PK;PK;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN 
CAPECITABINE;TYMS;rs2853741;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
CLOPIDOGREL;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
CAPECITABINE;SLC22A7;rs4149178;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED PLASMA LEVELS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19 normal metabolizers;;OTHER;DECREASED-RISK;OTHER;MAJOR ADVERSE CARDIAC EVENTS 
METHOTREXATE;SLC19A1;rs1051266;T;TOXICITY;INCREASED-;DISEASE;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ABT-751;UGT1A4;rs6755571;AC;LADME-PK;DECREASED-PK;PK;PLASMA PREDOSE CONCENTRATION (CTROUGH) 
CAPECITABINE;UMPS;rs4678145;CC + CG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASTHENIA 
ABT-751;UGT1A8;rs6431558;CC + CT;LADME-PK;INCREASED-PK;PK;GLUCURONIDATION METABOLIC RATIOS 
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED-PK;PK;MEAN AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC) OF DESIPRAMINE 
ANTINEOPLASTIC AGENTS;DPYD;rs1760217;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
AZATHIOPRINE;TPMT;rs1142345;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTINEOPLASTIC AGENTS;SERPINA3;rs17091162;AC + CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;LADME-PK;DECREASED-PK;PK;MEAN PEAK PLASMA CONCENTRATION OF H4 
VALPROIC ACID;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
ASPIRIN, CLOPIDOGREL;PTGS1;rs10306114;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
METFORMIN;SLC47A2;rs12943590;AA;LADME-PK;INCREASED-PK;PK;RENAL CLEARANCE AND SECRETION CLEARANCE OF METFORMIN 
TAMOXIFEN;NCOA1;rs1804645;CT;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;CHANGE IN LUMBAR BONE MINERAL DENSITY 
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED-RISK;OTHER;CARDIOVASCULAR DEATH,MYOCARDIAL INFARCTION OR STROKE 
CITALOPRAM, ESCITALOPRAM;;rs352428;A;EFFICACY;EFFICACY;EFFICACY;POOR RESPONSE AT 8 WEEK OF TREATMENT 
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
CITALOPRAM;;rs352428;A;EFFICACY;EFFICACY;EFFICACY;POOR RESPONSE AT 6 WEEK OF TREATMENT 
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED-RISK;OTHER;CARDIOVASCULAR DEATH,MYOCARDIAL INFARCTION OR STROKE 
MIDAZOLAM;POR;rs1057868;CT;LADME-PK;DECREASED-PK;PK;MIDAZOLAM METABOLIC RATIOS BY 45% 
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
LENVATINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRY MOUTH, MUCOSITIS 
NICOTINE;CHRNA3;rs578776;G;LADME-PK;INCREASED-PK;PK;PLASMA LEVEL 
GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED PLASMA LEVELS 
TRAZODONE;CYP2D6;CYP2D6 normal metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS 
CAPECITABINE;DPYD;rs17376848;AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;STOMATITIS 
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
LENVATINIB;CYP3A4;rs2242480;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
LENVATINIB;CYP3A5;rs776746;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
CAPECITABINE;ENOSF1, TYMS;rs699517;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
HEROIN;OPRK1;rs6473797;C;TOXICITY;DECREASED-RISK;OTHER;HEROIN DEPENDENCE 
HEROIN;CSNK1E;rs1534891;T;TOXICITY;DECREASED-RISK;OTHER;HEROIN DEPENDENCE 
CAPECITABINE;DPYD;rs12119882;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
ETHANOL;CHRNA5;rs16969968;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ALCOHOL ABUSE 
HEROIN;GAL;rs694066;A;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
HEROIN;OPRD1;rs2236861;A;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CAPECITABINE;SLC22A7;rs2270860;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
METHADONE;CRHBP;rs1500;G;OTHER;DECREASED-;OTHER;RECURRENCE 
METHAMPHETAMINE;FAAH;rs324420;A;OTHER;INCREASED-LIKELIHOOD;OTHER;DEPENDENCE 
ETHANOL;CHRNA3;rs1051730;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ALCOHOL ABUSE 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PEAK CORTISOL RESPONSE 
TAMOXIFEN;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
CAPECITABINE;ENOSF1, TYMS;rs699517;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ASTHENIA 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1 + *1/*10;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEIOMYOMA, LIVER DISORDER, OVARIAN CYSTS, 
HEROIN;HTR3B;rs3758987;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
METOPROLOL;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE 
OSIMERTINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ESCITALOPRAM;HTR2C;rs6318;C;EFFICACY;DECREASED-;DISEASE;PAIN 
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED-PK;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO 
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN PAIN AUC 
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION 
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED-PK;PK;PLASMA OXYMORPHONE/OXYCODONE RATIO 
NICOTINE;CHRNA3;rs1051730;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
PAROXETINE;CYP2D6;CYP2D6 normal metabolizers;;OTHER;INCREASED-;OTHER;METABOLIC RATIO DEM/DOR 
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;INCREASED-PK;PK;MEAN LOGARITHM ESCITALOPRAM CONCENTRATION 
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED-PK;PK;MEDIAN AUC, PLASMA HALF-LIFE AND STEADY-STATE PLASMA CONCENTRATIONS OF PAROXETINE 
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;HAND-FOOT SYNDROME 
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEXUAL DYSFUNCTION 
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;LADME-PK;INCREASED-PK;PK;FLUOXETINE/(S)-NORFLUOXETINE RATIO 
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
ALKYLATING AGENTS, CISPLATIN;ESR1;rs2207396;A;TOXICITY;INCREASED-RISK;DISEASE;OLIGOSPERMIA 
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE 
ANTIDEPRESSANTS;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION IF TOLERANT TO CITALOPRAM TREATMENT 
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;*1/*1;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PARKINSONIAN DISORDER, TARDIVE DYSKINESIA 
OSIMERTINIB;STAT3;rs4796793;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAIL DISORDER 
ESCITALOPRAM;CYP2D6;rs1065852;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE AND REMISSION RATE 
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERTENSION 
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;rs4149014;GG + GT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DOCETAXEL, EPIRUBICIN;;poor metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
;;rs6968865;T;DOSAGE;INCREASED-;OTHER;COFFEE CONSUMPTION 
SULFAMETHOXAZOLE;GCLC;rs761142;AA;TOXICITY;DECREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT intermediate metabolizer genotype;;EFFICACY, TOXICITY, LADME-PK;INCREASED-PK;PK;6-TG LEVELS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH, MYOCARDIAL INFARCTION, STROKE, 
;CYP1A1;rs2472297;T;DOSAGE;INCREASED-;OTHER;COFFEE CONSUMPTION 
SULFAMETHOXAZOLE;GCLC;rs761142;A;TOXICITY;DECREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
TRAMADOL;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs2273697;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
TACROLIMUS;CYP3A4;rs35599367;AG;OTHER;INCREASED-PK;PK;CREATININE CLEARANCE 
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;PON1;rs662;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (PR) AT 1 MONTH AND AT 6 MONTHS AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI) 
ANTIPSYCHOTICS;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TARDIVE DYSKINESIA 
ISONIAZID;ASTN2;rs117491755;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ALECTINIB;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, DIARRHEA, 
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
CISPLATIN;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS 
ETHANOL;CRHBP;rs10055255;TT;TOXICITY;INCREASED-SEVERITY;OTHER;ALCOHOL ABUSE 
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SEXUAL DYSFUNCTION 
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
OXALIPLATIN;HLA-DRB1;HLA-DRB1*12:01;*12:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CEFACLOR;HLA-DRB1;HLA-DRB1*14:54;*14:54;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-SEVERITY;OTHER;ALCOHOL ABUSE 
SULFASALAZINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
SULFASALAZINE;HLA-B;HLA-B*56:03;*56:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*2;*1/*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;HEART RATE 
METHAMPHETAMINE;DAOA;rs778293;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANAPHYLAXIS 
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*20;*20;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, ANGINA PECTORIS 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
SORAFENIB;KDR;rs2071559;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*14;*14;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED-RISK;DISEASE;HYPOKALEMIA 
RISPERIDONE;ADRB2;rs1042713;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEXUAL ADVERSE EVENTS 
BECLOMETHASONE, BUDESONIDE, FLUTICASONE, FLUTICASONE PROPIONATE, MOMETASONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;STATUS ASTHMATICUS 
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*1x2;*1/*1x2;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
CYTARABINE;GLI1;rs2228224;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
CYTARABINE;ARHGAP9, GLI1;rs2229300;GT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL, OVERALL SURVIVAL 
CODEINE;ABCB1;rs1128503;A;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS 
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION 
CODEINE;ABCB1;rs1045642;A;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;CNS DEPRESSION IN BREAST-FEEDING INFANTS 
CLOPIDOGREL, RESPIRATORY SYSTEM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
;CELSR2, PSRC1;rs602633;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL 
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs524731;A;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE, COCAINE DEPENDENCE, OPIOID-RELATED DISORDERS, 
ATAZANAVIR, INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
METHOTREXATE;SLCO1B1;rs4149081;G;OTHER, LADME-PK;INCREASED-PK;PK;CLEARANCE 
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;DEATH 
VALPROIC ACID;SCN1A;rs10167228;AA;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;GRAFT VS HOST DISEASE 
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;LADME-PK;INCREASED-PK;PK;DOSE/WEIGHT ADJUSTED AUC FOR MIRTAZAPINE 
TROGLITAZONE;;rs10811661;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;BETA CELL FUNCTION 
PLATINUM COMPOUNDS;ERCC2;rs1799793;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
NEVIRAPINE;CYP2B6;rs3745274;T;LADME-PK;INCREASED-;OTHER;PLASMA LEVEL 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME-PK;DECREASED-PK;PK;CITALOPRAM ORAL CLEARANCES OF CITALOPRAM 
METHAMPHETAMINE;PICK1;rs713729;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS 
IMATINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;EXANTHEMA 
CAFFEINE;DRD2;rs1110976;GG;OTHER;DECREASED-;SIDE_EFFECT;ANXIETY 
OPIOIDS;;rs4530637;AG + GG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3778156;G;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE, COCAINE DEPENDENCE, OPIOID-RELATED DISORDERS, 
;;rs1111875;C;LADME-PK;DECREASED-PK;PK;INSULIN SECRETION AT BASELINE 
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4 + *6;LADME-PK;INCREASED-PK;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE 
OPIOIDS;TACR3;rs1384401;AG + GG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
FOLFIRI;ABCC2;rs2273697;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED-PK;PK;CITALOPRAM AUC AND TERMINAL ELIMINATION HALF-LIFE 
PLATINUM COMPOUNDS;SLC22A2;rs316003;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
METHOTREXATE;ABCC2;rs717620;T;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
METHAMPHETAMINE;PICK1;rs713729;T;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;RECURRENCE 
OPIOIDS;CYP2D6;rs1065852;AA;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
FOLFIRI;ABCC2;rs1885301;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA 
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;INCREASED-PK;PK;MEDIAN CONCENTRATION/DOSE RATIO AND MEDIAN PARENT DRUG/METABOLITE RATIO 
OPIOIDS;DRD3;rs6280;CC + CT;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
HYDROCHLOROTHIAZIDE;;rs17137967;CC + CT;TOXICITY;INCREASED-;SIDE_EFFECT;FASTING GLUCOSE 
;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
OPIOIDS;DRD3;rs324029;AA + AG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED-SEVERITY;DISEASE;BREAST TENDERNESS, VAGINAL DRYNESS, VOMITING, 
OPIOIDS;EXOC4;rs718656;TT;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs4646244;A;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;HEPATITIS 
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS 
NICOTINE;CHRNB2;rs2072660;T;OTHER;INCREASED-SEVERITY;DISEASE;TOBACCO USE DISORDER 
DIRECT ACTING ANTIVIRALS;IFNL4;rs11322783;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PLATINUM COMPOUNDS;APLF;rs3213239;CCGG/CCGG + CCGG/del;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;EFFICACY;EFFICACY;LACK OF TREATMENT RESPONSE 
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PLATINUM COMPOUNDS;ERCC2;rs50872;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS;ABCG2;rs1448784;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;HEPATITIS 
NICOTINE;CHRNB2;rs2072661;A;OTHER;INCREASED-SEVERITY;DISEASE;TOBACCO USE DISORDER 
CODEINE, HYDROCODONE, OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
HYDROXYCHLOROQUINE;CYP2C8;rs10882526;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs660652;GG;TOXICITY;INCREASED-;DISEASE;TOBACCO USE DISORDER 
METHAMPHETAMINE;;rs1421292;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
ACE INHIBITORS, PLAIN;ABO;rs495828;GT + TT;TOXICITY;;DISEASE;COUGH 
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
GLICLAZIDE;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1 + *17;EFFICACY;DECREASED-;OTHER;PLATELET REACTIVITY 
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR DISEASE 
OPIOIDS;ZNF804A;rs7597593;CC;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;DECREASED-PK;PK;MAXIMUM PLASMA CONCENTRATION OF 10-HYDROXY NORTRIPTYLINE 
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;rs1051730;AA;TOXICITY;INCREASED-SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS 
HYDROXYCHLOROQUINE;CYP3A5;rs776746;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
PLATINUM COMPOUNDS;IL16;rs7170924;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
INDOMETHACIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
;CHRNA3;rs1051730;AA + AG;OTHER;INCREASED-LIKELIHOOD;OTHER;NON-SMALL CELL LUNG CARCINOMA 
NEVIRAPINE;HLA-B;HLA-B*15:10;*15:10;TOXICITY;DECREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;STROKE, MYOCARDIAL INFARCTION, DEATH, 
ASPIRIN;TBXA2R;rs1131882;A;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH 
OPIOIDS;CNR1;rs2023239;TT;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
;NQO1;rs1800566;AA;OTHER;;OTHER;SIGNIFICANTLY SHORTER SURVIVAL 
BUSULFAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO 
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METFORMIN;SLC29A4;rs3889348;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
;NQO1;rs1800566;A;TOXICITY;INCREASED-RISK;DISEASE;LEUKEMIA 
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;GSTT1 null;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
OPIOIDS;CNR1;rs6928499;CC;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
NEVIRAPINE;CYP2B6;rs58425034;CC + CG;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED-;DISEASE;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED-RISK;SIDE_EFFECT;DEATH, MYOCARDIAL INFARCTION 
DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;DECREASED-SEVERITY;DISEASE;PAIN 
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
DOCETAXEL, THALIDOMIDE;SLC10A2;rs2301159;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
AXITINIB, SORAFENIB;HIF1A;rs11549465;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DISEASE PROGRESSION 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
METHOTREXATE;SLC19A1;rs1051266;CC + CT;EFFICACY;INCREASED-SEVERITY;DISEASE;RHEUMATOID ARTHRITIS 
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
NICOTINE;DBH;rs77905;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
METHOTREXATE;ADORA2A;rs2298383;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;OTHER;INCREASED-;OTHER;PLATELET AGGREGATION WITH ADP 
RISPERIDONE;CYP2D6;rs3892097;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS, TREMOR, MUSCLE RIGIDITY, 
;CYP2B6;rs3211371;TT;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
;CYP2B6;rs3211371;CT;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED-RISK;SIDE_EFFECT;PSYCHOMOTOR AGITATION, INSOMNIA 
IRINOTECAN;UGT1A1;rs4124874;G;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
;CYP24A1;rs2762939;C;OTHER;DECREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs16969968;A;TOXICITY;INCREASED-SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE OUTCOME 
MORPHINE;ABCC3;rs739923;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOVENTILATION 
CITALOPRAM;PAPLN;rs11628713;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SUICIDAL IDEATION 
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION 
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EFFICACY AS MEASURED BY DECREASE IN HBA1C AFTER 6-MONTH TREATMENT 
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED-PK;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS OF FLUOXETINE 
IMATINIB;SLC22A1;rs1867351;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIORBITAL EDEMA 
FLUOROURACIL, LEUCOVORIN;ERCC2;rs13181;GG + GT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
VERAPAMIL;KCNIP1, KCNMB1;rs11739136;CT + TT;EFFICACY;EFFICACY;EFFICACY;EARLIER ACHIEVEMENT OF BLOOD PRESSURE CONTROL 
OPIOIDS;DRD3;rs9288993;AG + GG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
OSIMERTINIB;CYP2C9;rs1057910;AC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
OPIOIDS;DRD3;rs2654754;AG + GG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
OPIOIDS;ZNF568;rs10405238;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
ANTIEPILEPTICS;HLA-B;HLA-B*53:01;*53:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, SEVERE CUTANEOUS ADVERSE REACTIONS, 
PENICILLIN G;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, SEVERE CUTANEOUS ADVERSE REACTIONS, 
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CORONARY RESTENOSIS, THROMBOTIC DISEASE 
METFORMIN;AMHR2;rs784892;G;LADME-PK;DECREASED-PK;PK;METFORMIN SECRETORY CLEARANCE 
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA) 
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer;;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*9, CYP2C19*13, CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE), DEATH, MYOCARDIAL INFARCTION, STROKE
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;THROMBOTIC DISEASE 
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;OTHER;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*8;*8;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) 
ATEZOLIZUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;THYROTOXICOSIS, HYPOTHYROIDISM 
CARBOPLATIN, GEMCITABINE;RRM1;rs9937;GG;TOXICITY;RISK-;DISEASE;HEMATOLOGIC DISORDER 
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED-SEVERITY;OTHER;ALCOHOL ABUSE 
METFORMIN;SLC22A1;rs628031;A;TOXICITY, LADME-PK;;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
OPIOIDS;GABRB3;rs4906902;AA;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA NORTRIPTYLINE 
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA NORTRIPTYLINE 
BECLOMETHASONE DIPROPIONATE, FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;STATUS ASTHMATICUS, EMERGENCIES 
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;LADME-PK;INCREASED-PK;PK;AMITRIPTYLINE/NORTRIPTYLINE RATIO CORRECTED FOR DOSE AND WEIGHT 
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;AA;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED AREA UNDER THE CURVE (AUC6-12) OF MYCOPHENOLIC ACID (MPA) 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ISONIAZID, RIFAMPIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ISONIAZID, RIFAMPIN;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ETHANOL;DRD2;rs1799732;GG;TOXICITY;INCREASED-SEVERITY;OTHER;ALCOHOL ABUSE 
SALBUTAMOL;THRB;rs892940;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (BDR) 
OPIOIDS;TACR1;rs735668;AA;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;THROMBOTIC DISEASE 
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH, RECURRENCE 
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
OPIOIDS;OPRM1;rs510769;CC;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
AMOXICILLIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs72552763;GAT/del;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEPATOTOXICITY 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
NICOTINE;CYP2A13;rs72552266;CT;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;CYSTITIS 
;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED-LIKELIHOOD;OTHER;GILBERT SYNDROME, CRIGLER-NAJJAR SYNDROME 
DOXORUBICIN;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BULLOUS PEMPHIGOID 
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA, NEUTROPENIA 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;GRAFT VS HOST DISEASE 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ACUTE CELLULAR REJECTION 
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION, DRUG TOXICITY, NEUTROPENIA, DIARRHEA
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, FEBRILE NEUTROPENIA, LEUKOPENIA, 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
SUNITINIB;KDR;rs1870377;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*28 + *6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, HEADACHE, INSOMNIA, DRUG TOXICITY
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, HEADACHE, INSOMNIA, DRUG TOXICITY
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
METHOTREXATE;MTR;rs3768142;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS 
CARBAMAZEPINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CARBAMAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3C;TOXICITY, LADME-PK;INCREASED-PK;PK;LEVELS OF ERYTHROCYTE 6-THIOGUANINE NUCLEOTIDE METABOLITES 
CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;non-null;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEARING LOSS 
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE REACTIONS 
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION 
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;TRANSIENT ISCHEMIC ATTACK, DEATH, STROKE, MYOCARDIAL INFARCTION
TACROLIMUS;CYP3A4;rs4646437;AG + GG;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HEART FAILURE, MYOCARDIAL INFARCTION, ANGINA PECTORIS, 
;CYP4A11;rs1126742;AG + GG;LADME-PK;DECREASED-PK;PK;HDL-C CONCENTRATION 
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*2, CYP2D6*2x2, CYP2D6*2xN, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41, CYP2D6*41x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
TICAGRELOR;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
PEMETREXED;SLC19A1;rs914232;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
FLUOROURACIL, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FLUOROURACIL, IRINOTECAN;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5);TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED-PK;PK;AUC OF THE S-ENANTIOMER OF CITALOPRAM (NO EFFECT ON R-CT) 
PEMETREXED;SLC19A1;rs1051298;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
RISPERIDONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEADACHE, MUSCLE SPASM, SOMNOLENCE, DIZZINESS
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
AMOXICILLIN, AMPICILLIN, BACAMPICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
METHAMPHETAMINE;DRD3;rs6280;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;COGNITIVE DISORDER 
NICOTINE;CYP2A6;CYP2A6 low activity;;OTHER;DECREASED-RISK;DISEASE;LUNG NEOPLASMS 
VINCRISTINE;ACTN1;rs2268979;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MUCOSITIS 
PEMETREXED;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CAPECITABINE, FLUOROURACIL, FOLFIRI, FOLFIRINOX, FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA, DIARRHEA, STOMATITIS, LEUKOPENIA
VINCRISTINE;PAPPA;rs12235805;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;DECREASED-SEVERITY;DISEASE;DIARRHEA 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
PEMETREXED;SLC19A1;rs3788189;GG + GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;DECREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
CAPECITABINE, FLUOROURACIL, FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH 
AMITRIPTYLINE, ANTIDEPRESSANTS, CLOMIPRAMINE, DESIPRAMINE, FLUOXETINE, IMIPRAMINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;TOTAL CHOLESTEROL 
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*1;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, DIARRHEA 
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
VINCRISTINE;NRG3;rs12253008;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, MYELOSUPPRESSION 
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT intermediate metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
VINCRISTINE;LRRTM3;rs10997459;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
VINCRISTINE;ARHGAP5;rs8006511;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT normal metabolizer;;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
NICOTINE;CYP2A6;rs28399433;CC;TOXICITY;DECREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
VINCRISTINE;METTL8;rs79802223;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DEATH, STROKE, HEART FAILURE, MYOCARDIAL INFARCTION
;UGT1A1;rs4148325;CT;LADME-PK;DECREASED-LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA 
;UGT1A1;rs11888492;G;LADME-PK;DECREASED-LIKELIHOOD;OTHER;NEONATAL HYPERBILIRUBINEMIA 
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;CORTISOL RESPONSE 
CISPLATIN;CERS6;rs13022792;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
CISPLATIN;TLR4;rs10759932;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
VINCRISTINE;NFIB;rs10961381;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE 
VINCRISTINE;MCM3AP;rs1815857;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
VINCRISTINE;SPDYA;rs12474420;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
VINCRISTINE;PDE4D;rs12658429;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
VINCRISTINE;FBN2;rs12656510;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
VINCRISTINE;VTI1A;rs17129858;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
VINCRISTINE;ZFAND3;rs200858088;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*11:01;*11:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANAPHYLAXIS 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED-RISKEFFICACY;EFFICACY;PERIPHERAL VASCULAR DISEASES 
MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;VIRUS DISEASES 
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;LOW-DENSITY LIPOPROTEIN CHOLESTEROL 
ACETAMINOPHEN / CODEINE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;CONSTIPATION 
RASBURICASE;G6PD;G6PD deficiency;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA 
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
SIROLIMUS;ABCB1;rs1128503;AA;TOXICITY;INCREASED-;SIDE_EFFECT;TRIGLYCERIDES 
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ATRIAL FIBRILLATION 
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ISONIAZID;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *5/*6 + *6/*6;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DECREASED GLOMERULAR FILTRATION RATE 
ADALIMUMAB, AMIODARONE, BEVACIZUMAB, BICALUTAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, ERLOTINIB, EVEROLIMUS, FLUOROURACIL, GEFITINIB, GEMCITABINE, IRINOTECAN, LEUCOVORIN, METHOTREXATE, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB, SITAGLIPTIN, TEGAFUR / GIMERACIL / OTERACIL, TRASTUZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED-RISK;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES 
TAMSULOSIN;CYP2D6;CYP2D6 intermediate metabolizer;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INTERSTITIAL LUNG DISEASES 
ANASTROZOLE, EXEMESTANE, LETROZOLE;CCDC148;rs79048288;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN 
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, ERYTHEMA MULTIFORME 
PEMETREXED;DHFR;rs1650697;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;EFFICACY;EFFICACY;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE 
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*1;EFFICACY;EFFICACY;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE 
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, 
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE, DIZZINESS, DRUG TOXICITY, 
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, 
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ASPIRIN;PTGS2;rs12042763;GG;EFFICACY;DECREASED-RISK;DISEASE;PROSTATIC NEOPLASMS 
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*37/*37 + *37/*15;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
;CYP2A6;rs56267346;G;OTHER;DECREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
;DBH;rs6479643;C;OTHER;DECREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
FLURBIPROFEN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*36;*1/*36;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;GRAFT VS HOST DISEASE 
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
;CASP9;rs1052576;T;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;LEUKOCYTOSIS 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;DECREASED-;SIDE_EFFECT;DRUG TOXICITY 
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;DECREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CYCLOSPORINE, METHOTREXATE;ATIC;rs17514110;CC;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CYCLOSPORINE, METHOTREXATE;NFATC2;rs3787186;TT;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CYCLOSPORINE, METHOTREXATE;ABCC2;rs3740065;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CETUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY 
CYCLOSPORINE, METHOTREXATE;ABCC1;rs8058040;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
ATAZANAVIR, EFAVIRENZ;TPH2;rs7305115;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DEPRESSION 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*01:02;*01:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS 
ATAZANAVIR, EFAVIRENZ;TPH2;rs1386493;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DEPRESSION 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
CAPECITABINE;ENOSF1;rs2612091;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*31:03;*31:03;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME 
CARBOPLATIN, PACLITAXEL;OPRM1;rs544093;GG + GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
MYCOPHENOLATE MOFETIL;IMPDH1;rs2228075;T;EFFICACY, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GI INTOLERANCE 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, NEUTROPENIA 
ISONIAZID;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ERLOTINIB, GEFITINIB;USP36;rs3744797;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
OSIMERTINIB;HLA-B;HLA-B*51:02;*51:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS 
DEXMEDETOMIDINE;CACNB2;rs10764319;CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA, HYPOTENSIVE DISORDER 
DEXMEDETOMIDINE;CACNA2D2;rs2236957;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA, HYPOTENSIVE DISORDER 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DEXMEDETOMIDINE;UGT2B10;rs1841042;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA, HYPOTENSIVE DISORDER 
DEXMEDETOMIDINE;ADRA2B;rs3813662;AA + CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA, HYPOTENSIVE DISORDER 
METHYLPHENIDATE;CES1;rs2307227;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
PURINE ANALOGUES;NUDT15;NUDT15*1, NUDT15*3;*1/*3;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
CLOPIDOGREL;THSD7A;rs7807369;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
CLOPIDOGREL;;rs1149515;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY, MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ONDANSETRON;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;POSTOPERATIVE NAUSEA AND VOMITING 
;ERAP2;rs17524572;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
PEMBROLIZUMAB;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PEMBROLIZUMAB;HLA-DPB1;HLA-DPB1*02:02;*02:02;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
MORPHINE;SLC22A1;rs72552763;del/del;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPOVENTILATION 
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
;CASP9;rs4661636;C;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;LEUKOCYTOSIS 
;CASP8;rs6736233;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
CLOZAPINE;LEPR;rs6657868;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PNEUMONIA 
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED-RISK;DISEASE;SEIZURES 
CISPLATIN, PACLITAXEL;GGT1;rs2017869;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA 
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
;UGT1A1;rs4148323;A;OTHER;INCREASED-LIKELIHOOD;OTHER;GILBERT SYNDROME, CRIGLER-NAJJAR SYNDROME 
CLOZAPINE;LEPR, LEPROT;rs1137101;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PNEUMONIA 
DOLUTEGRAVIR;NR1I2;rs2472677;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION, ADVERSE EVENTS 
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
CLOZAPINE;LEPR;rs1805096;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PNEUMONIA 
CLOZAPINE;LEPR;rs9436746;AC + CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PNEUMONIA 
RISPERIDONE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
;UGT1A1;rs35350960;A;OTHER;INCREASED-LIKELIHOOD;OTHER;GILBERT SYNDROME, CRIGLER-NAJJAR SYNDROME 
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
WARFARIN;ASPH;rs4379440;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED-;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL DISTURBANCES IN HCV-HIV COINFECTED PATIENTS 
HMG COA REDUCTASE INHIBITORS;CETP;rs3764261;A;EFFICACY, LADME-PK;INCREASED-;OTHER;HDL CHOLESTEROL 
PYRIMIDINE ANALOGUES;MTHFR;rs1801133;AA + AC;;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
METHOTREXATE;ITPA;rs1127354;A;TOXICITY;;SIDE_EFFECT;GASTROINTESTINAL TOXICITIES 
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) IN HCV-HIV COINFECTED PATIENTS 
CAFFEINE;;rs4410790;T;OTHER;;OTHER;HABITUAL CONSUMPTION 
LIRAGLUTIDE;GLP1R;rs6923761;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;WEIGHT LOSS 
METHAMPHETAMINE;ESR1;rs2234693;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
;ABCG8;rs11887534;CG;OTHER;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SURVIVAL 
PLATINUM;ERCC5;rs17655;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
RISPERIDONE;HTR2C;rs3813929;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
PACLITAXEL;FGD4;rs10771973;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SENSORY PERIPHERAL NEUROPATHY 
CAFFEINE;CYP1A1;rs2470893;T;OTHER;;OTHER;HABITUAL CONSUMPTION 
CITALOPRAM;SLC6A4;rs25531;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SOCS3;rs4969170;AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA IN HCV-HIV COINFECTED PATIENTS 
MIDAZOLAM;POR;rs1057868;TT;OTHER, LADME-PK;INCREASED-PK;PK;METABOLIC RATIO OF MIDAZOLAM 
ENALAPRIL;PNPT1;rs13009649;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
METHOTREXATE;ITPA;rs1127354;A;EFFICACY;EFFICACY;EFFICACY;RESPONSE TO METHOTREXATE 
NICOTINE;HTR3B;rs11606194;CT + TT;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
ASPIRIN;SLC6A12;rs499368;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ASTHMA 
GEFITINIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
WARFARIN;CYP4F2;rs2189784;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
ASPIRIN;SLC6A12;rs557881;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ASTHMA 
PLATINUM COMPOUNDS;WIF1;rs10878232;GG + GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTIEPILEPTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;NON-RESPONSE 
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
PLATINUM COMPOUNDS;WNT5B;rs12819505;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PLATINUM COMPOUNDS;AXIN2;rs4541111;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;T;TOXICITY;INCREASED-;SIDE_EFFECT;GI TOXICITY 
MERCAPTOPURINE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED-;SIDE_EFFECT;GI TOXICITY 
MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
PLATINUM COMPOUNDS;CXXC4;rs4413407;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ENALAPRIL;PNPT1;rs13015243;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;;rs11969064;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (SVR AND RVR) IN HCV-HIV COINFECTED PATIENTS 
PLATINUM COMPOUNDS;ERCC2;rs13181;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PNEUMONITIS 
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PNEUMONITIS 
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
AMPHETAMINE;DRD2;rs12364283;AA;EFFICACY;DECREASED-;OTHER;STOP REACTION TIME 
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG-RESISTANCE 
ANTIEPILEPTICS;ABCB1;rs1045642;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG-RESISTANCE 
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATIONS DUE TO ADVERSE EVENTS AND GREATER SEVERITY OF SIDE EFFECTS 
CLOPIDOGREL;CD80;rs34394661;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
MYCOPHENOLATE MOFETIL;UGT1A9;rs6714486;A;LADME-PK;PK;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY) 
CARBAMAZEPINE;;rs1633021;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
PLATINUM COMPOUNDS;AXIN2;rs11868547;CC + CG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
MYCOPHENOLATE MOFETIL;UGT1A9;rs17868320;T;LADME-PK;PK;PK;CHANGES IN MYCOPHENOLIC ACID EXPOSURE-RELATED PARAMETERS ON DAY 7 AFTER TRANSPLANTATION (TREATMENT WITH 2G PER DAY) 
MORPHINE;ABCB1;rs1045642;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
TACROLIMUS;IL10;rs1800871;AA;LADME-PK;INCREASED-LIKELIHOODPK;PK;ACHIEVING TARGET CONCENTRATIONS 
METHOTREXATE;ARID5B;rs4948496;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
;CYP2B6;rs3760657;AA;OTHER;DECREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
FOLLITROPIN BETA, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;T;EFFICACY, LADME-PK;EFFICACY;EFFICACY;GOOD RESPONSE TO CONTROLLED OVARIAN HYPERSTIMULATION 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, OTHER;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
;UGT2B10;rs11726322;CC;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY, OTHER;DECREASED-RISK;DISEASE;THROMBOTIC DISEASE 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM 
CLOPIDOGREL;ABCB1;rs1045642;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME-PK;INCREASED-PK;PK;PLASMA MK-4 CONCENTRATION 
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;BONE MINERAL DENSITY 
FENOFIBRATE;PPARA;rs135543;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN FASTING LDL-C 
FENOFIBRATE;PPARA;rs9626730;CC + CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN FASTING IL-2 
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;DECREASED-;OTHER;WARFARIN SENSITIVITY INDEX (INR/CPSS) 
;VDR;rs1544410;CC;;DECREASED-EFFICACY;EFFICACY;BONE MINERAL DENSITY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
FENOFIBRATE;PPARA;rs135550;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN FASTING LDL-C 
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;URINARY DPD/CR LEVELS 
EXEMESTANE;CYP19A1;rs7176005;TT;TOXICITY;;SIDE_EFFECT;A SIGNIFICANTLY HIGHER ODDS OF VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER PATIENTS 
TACROLIMUS;PPARA;rs4253728;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ACUTE CELLULAR REJECTION 
VINCRISTINE;SLC5A7;rs1013940;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ETHANOL;ADH1B;rs1229984;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERURICEMIA 
VINCRISTINE;NKAIN3;rs10504361;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES 
ATENOLOL;PROX1;rs340874;C;TOXICITY;INCREASED-;SIDE_EFFECT;GLUCOSE ELEVATION 
TACROLIMUS;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEPSIS, SEIZURES, NEPHROTOXICITY, 
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
SIMVASTATIN;ABCG2;rs2231142;GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
VINCRISTINE;ABCC1;rs3784867;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;SIGNIFICANTLY HIGHER ON-TREATMENT PLATELET REACTIVITY WITH A MAINTENANCE DOSE OF 75 MG DAILY 
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE, NAUSEA, ADVERSE EVENTS, 
OPIOIDS;IL6;rs1800795;CG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE, NAUSEA, ADVERSE EVENTS, 
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
SUNITINIB;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, TREATMENT INTERRUPTION 
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
METOPROLOL;CYP2D6;rs1065852;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;HEART RATE 
CONJUGATED ESTROGENS, MEDROXYPROGESTERONE;VDR;rs1544410;TT;EFFICACY;INCREASED-;OTHER;SPINE BONE MINERAL DENSITY 
VERAPAMIL;CACNB2;rs2357928;GG;EFFICACY, TOXICITY;INCREASED-RISKEFFICACY;EFFICACY;ADVERSE OUTCOME 
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE TO METFORMIN 
TACROLIMUS;CYP3A5;rs4646450;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE TO METFORMIN 
TRAZODONE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PROLONGED QTC INTERVAL 
INTERFERONS, RIBAVIRIN;BCL2;rs1800477;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;FREQUENCY (ABOUT DOUBLE) IN NON-RESPONDER PATIENTS COMPARED WITH RESPONDER PATIENTS (HCV GENOTYPE 4) 
CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN;KRAS;rs112445441;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MSH6;rs3136228;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC3;rs1799794;CC;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
;NR1I2;rs7643645;GG;OTHER;INCREASED-RISK;OTHER;DEATH 
PLATINUM COMPOUNDS;CCND1;rs9344;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
VERAPAMIL;CACNB2;rs11014166;AT + TT;EFFICACY, TOXICITY;INCREASED-RISKEFFICACY;EFFICACY;ADVERSE OUTCOME 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC1;rs2074087;C;TOXICITY;DECREASED-SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES 
FLUOROURACIL;;rs2960436;AA;EFFICACY;;OTHER;BETTER SURVIVAL OUTCOME 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs1885301;AA;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES 
FLUOROURACIL;IGFBP3;rs2854744;TT;EFFICACY;;OTHER;BETTER SURVIVAL OUTCOME 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;TT;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs3740066;TT;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES 
COCAINE;DRD2;rs1125394;C;TOXICITY;INCREASED-RISK;DISEASE;COCAINE DEPENDENCE 
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED-RISK;DISEASE;COCAINE DEPENDENCE 
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED-RISK;DISEASE;COCAINE DEPENDENCE 
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149015;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS 
TACROLIMUS;CYP3A5;rs4646453;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;TT;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;ADVERSE DRUG REACTION 
OPIOIDS;COMT;rs4633;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;C;TOXICITY, LADME-PK;DECREASED-RISK;SIDE_EFFECT;ADVERSE DRUG REACTIONS 
ACETAMINOPHEN / TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CONSTIPATION 
;VDR;rs2228570;AA + AG;;DECREASED-EFFICACY;EFFICACY;BONE MINERAL DENSITY 
OPIOIDS;COMT;rs4633;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS 
CAPECITABINE;ABCB1;rs1128503;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME, NEUTROPENIA 
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS 
CAPECITABINE;ABCB1;rs2032582;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ERECTILE DYSFUNCTION, INSOMNIA, SEDATION, PHYSIOLOGICAL SEXUAL DISORDER
FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;DECREASED-RISK;DISEASE;DIARRHEA 
CAPECITABINE;ABCB1;rs1045642;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
WARFARIN;CYP2C9;rs7900194;A;DOSAGE, LADME-PK;;OTHER;WARFARIN VARIABILITY 
SUNITINIB;NR1I2;rs3814055;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
AMPHETAMINE;OPRM1;rs510769;TT;OTHER;DECREASED-;OTHER;STIMULATION AND EUPHORIA SCORES AFTER AMPHETAMINE 
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;DISEASE;MUSCULAR DISEASES 
SUNITINIB;ABCG2;rs2231137;CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
;LRP5;rs3736228;T;;DECREASED-;OTHER;BONE MINERAL DENSITY 
CISPLATIN;NHLH1;rs11265375;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;;rs4355801;A;;DECREASED-;OTHER;LUMBAR SPINE BONE MINERAL DENSITY 
;;rs4355801;A;;INCREASED-RISK;DISEASE;OSTEOPOROSIS 
;LRP5;rs3736228;T;;INCREASED-RISK;DISEASE;OSTEOPOROSIS 
BORTEZOMIB;CBS;rs915854;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES, PAIN, NEUROPATHIC PAIN, 
;UGT2B15;rs3100;AA;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
AMPHETAMINE;OPRM1;rs2281617;CC;OTHER;INCREASED-;OTHER;EUPHORIC AND ENERGETIC AFTER AMPHETAMINE (10 MG) 
WARFARIN;HNF4A;rs6130615;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CISPLATIN;SEMA6A;rs3806915;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED-RISK;DISEASE;THROMBOTIC DISEASE 
WARFARIN;HNF4A;rs1884613;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ASPIRIN, CLOPIDOGREL;ITGB3;rs5918;CC + CT;EFFICACY, OTHER;DECREASED-RISK;DISEASE;THROMBOTIC DISEASE 
WARFARIN;HNF4A;rs3212191;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ONDANSETRON;SLC6A4;rs1042173;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;TREATMENT RESPONSE AMONG PATIENTS CARRYING THE SLC6A4 PROMOTER LENGTH POLYMORPHISM LONG/LONG GENOTYPE 
WARFARIN;;rs61162043;G;OTHER;INCREASED-LIKELIHOOD;OTHER;HAVING WARFARIN DOSE GREATER THAN 7.5 MG/DAY 
RISPERIDONE;HTR2A;rs6313;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
HEROIN;OPRM1;rs2075572;G;TOXICITY;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
RISPERIDONE;;rs1805054;TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
ANTIHYPERTENSIVES;NEDD4L;rs4149601;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESISTANT HYPERTENSION 
ANTIHYPERTENSIVES;ADRB1;rs1801252;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESISTANT HYPERTENSION 
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
RISPERIDONE;HTR2C;rs3813929;CT + TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
BLEOMYCIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE, VINDESINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA, VOMITING 
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY, LEUKOPENIA 
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;rs776746;CC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;RESISTANT HYPERTENSION 
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
METHADONE;OPRM1;rs1799971;G;OTHER;DECREASED-LIKELIHOOD;DISEASE;RECURRENCE 
;CYP2C9;rs1057910;C;;DECREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
;CYP2C9;rs1057910;C;;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
SUFENTANIL;CYP3A4;rs2242480;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPOVENTILATION 
;ADRA2A;rs3750625;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;DIABETES, GESTATIONAL 
;ADRA2A;rs11195418;G;OTHER;DECREASED-LIKELIHOOD;DISEASE;DIABETES, GESTATIONAL 
MURAGLITAZAR;REN;rs2368564;TT;TOXICITY;DECREASED-RISK;DISEASE;EDEMA 
CHLOROQUINE, PRIMAQUINE;SLCO2B1;rs12422149;GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PARASITEMIA 
ASPIRIN;IL4;rs2243250;TT;OTHER;DECREASED-;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA 
WARFARIN;CYP2C9;rs1057910;AC + CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE TO METHOTREXATE 
METFORMIN;AMHR2;rs784892;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;POST-HBA1C LEVELS 
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLA2G4A;rs12746200;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;URTICARIA 
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED-SEVERITY;DISEASE;TARDIVE DYSKINESIA 
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;EFFICACY;EFFICACY;SHORTER TIME TO FIRST THERAPEUTIC INR AND TIME TO FIRST INR>4 
FLUOROURACIL;DPYD;rs75017182;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
NEVIRAPINE;CYCSP5;rs3099844;A;TOXICITY, OTHER;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLCG1;rs2228246;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA, URTICARIA 
ANTIHYPERTENSIVES;NOS3;rs1799983;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
ANTIHYPERTENSIVES;NOS3;rs2070744;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
;ADRA2A;rs1800038;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;DIABETES, GESTATIONAL 
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
CISPLATIN;SLC22A1;rs683369;CG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
NICOTINE;;rs4887074;G;TOXICITY;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs10937158;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs3749438;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG1;rs225440;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;PON1;rs854552;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;;rs2292997;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CISPLATIN;PPARD;rs2038067;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
TACROLIMUS;CYP3A5;rs6977165;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY, LEUKOPENIA 
WARFARIN;VKORC1;rs9923231;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROPERTION OF THE FIRST 6 MONTHS' TREATMENT TIME SPENT WITHIN THE TARGET INR RANGE (PTIR) 
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-SEVERITY;DISEASE;MYELOSUPPRESSION 
;OPRM1;rs1799971;AA;TOXICITY;INCREASED-SEVERITY;DISEASE;SUBSTANCE-RELATED DISORDERS 
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-SEVERITY;DISEASE;HAND-FOOT SYNDROME 
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
FLUOROURACIL;DPYD;rs17376848;G;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
ACETAMINOPHEN / TRAMADOL;MIR107;rs2296616;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
LITHIUM;GSK3B;rs334558;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE 
CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE;NQO1;rs1800566;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ANEMIA, DRUG TOXICITY 
ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;CG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;NEUROPATHIC PAIN 
OPIOIDS;CYP1A2;rs2069514;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
OPIOIDS;DRD3;rs2654754;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
OPIOIDS;DRD3;rs324029;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
METHAMPHETAMINE;FAAH;rs324420;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;METHAMPHETAMINE DEPENDENCE 
OPIOIDS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
RISPERIDONE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
ASPIRIN;UGT1A6;rs1105879;AC + CC;EFFICACY;INCREASED-RISK;DISEASE;COLONIC NEOPLASMS 
ACETAMINOPHEN / TRAMADOL;OPRM1;rs677830;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CONSTIPATION 
OPIOIDS;CYP3A5;rs15524;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
REGORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DEATH 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AA + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
TAXANES;NR1I3;rs11584174;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ATAZANAVIR, RITONAVIR;UGT1A1;rs8330;G;OTHER;INCREASED-RISK;SIDE_EFFECT;NEPHROLITHIASIS 
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
EFAVIRENZ;CYP2B6;rs28399499;TT;TOXICITY;INCREASED-RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER 
NEVIRAPINE;ABCB1;rs10276036;TT;TOXICITY;INCREASED-RISK;DISEASE;DRUG HYPERSENSITIVITY 
TAXANES;UGT2B7;rs7438284;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ATAZANAVIR, RITONAVIR;UGT1A1;rs10929303;T;OTHER;INCREASED-RISK;SIDE_EFFECT;NEPHROLITHIASIS 
TAXANES;UGT2B7;rs7439366;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ATAZANAVIR, RITONAVIR;UGT1A1;rs1042640;G;OTHER;INCREASED-RISK;SIDE_EFFECT;NEPHROLITHIASIS 
TAXANES;UGT2B7;rs7662029;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
TAXANES;UGT2B7;rs7668258;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED-RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER 
ANTIPSYCHOTICS;GRM3;rs1468412;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MEMORY IMPAIRMENT 
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;NON-RESPONSIVENESS 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
RISPERIDONE;BDNF;rs6265;TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
CORTICOSTEROIDS;FCER2;rs28364072;G;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASTHMA-RELATED ER VISIT OR HOSPITALIZATION 
FLUOROURACIL, RADIOTHERAPY;CXCL8;rs4073;AA;EFFICACY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
FLUOROURACIL, RADIOTHERAPY;KDR;rs1870377;AA;TOXICITY;RISK-;SIDE_EFFECT;MUCOSITIS 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;TOXICITY;DECREASED-RISK;DISEASE;DEPRESSION 
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN PERCENTAGE REDUCTION OF TRIGLYCERIDES LEVEL 
CANGRELOR;P2RY12;rs6787801;G;OTHER;;OTHER;5% LOWER ADP-INDUCED PEAK PLATELET AGGREGATION IN-VITRO 
;APOC1, APOE;rs445925;A;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL 
SUNITINIB;FGFR2;rs2981582;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799931;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE REACTIONS 
SUNITINIB;FLT4;rs307826;CC + CT;EFFICACY;DECREASED-;DISEASE;OVERALL SURVIVAL 
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED-RISK;DISEASE;HEROIN DEPENDENCE 
SUNITINIB;NR1I3;rs2307424;AA + AG;EFFICACY;DECREASED-;DISEASE;OVERALL SURVIVAL 
;FADS1, FEN1, MIR611, TMEM258;rs174541;T;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL 
;;rs258494;C;LADME-PK;PK;PK;BASELINE LDL CHOLESTEROL 
;LDLR;rs6511720;T;OTHER;PK;PK;BASELINE LDL CHOLESTEROL 
;PNMT;rs2934965;T;OTHER;DECREASED-RISK;OTHER;SICKLE CELL PAIN CRISIS 
FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY;GSTP1;rs1695;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DEXAMETHASONE, LENALIDOMIDE;ABCB1;rs2229109;CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
AZATHIOPRINE;DDRGK1, ITPA;rs1127354;AC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;NON-RESPONSE 
;PNMT;rs2941523;GG;OTHER;DECREASED-RISK;OTHER;SICKLE CELL PAIN CRISIS 
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED-RISK;OTHER;CHRONIC LUNG ALLOGRAFT DYSFUNCTION 
;PNMT;rs876493;AA + AG;OTHER;DECREASED-RISK;OTHER;SICKLE CELL PAIN CRISIS 
ATENOLOL, BISOPROLOL;ACY3;rs2514036;C;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE, ELEVATED SYSTOLIC BLOOD PRESSURE 
LOSARTAN;KIRREL2, NPHS1;rs3814995;T;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
ASPIRIN;ADORA1;rs16851030;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA 
ANTINEOPLASTIC AGENTS;FPGS;rs1544105;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
SUNITINIB;NR1I3;rs4073054;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SUNITINIB;FLT4;rs307821;AA + AC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ALPRAZOLAM;CYP3A4;rs35599367;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;INCREASED-RISK;OTHER;TRANSPLANT REJECTION 
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;DECREASED-LIKELIHOOD;OTHER;OVERALL SURVIVAL 
SUNITINIB;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
OLANZAPINE;CYP1A1;rs2472297;T;LADME-PK;PK;PK;25% HIGHER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO 
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED-RISK;OTHER;TRANSPLANT REJECTION 
BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;INCREASED-;DISEASE;PROGRESSION-FREE SURVIVAL 
OPIOIDS;ADGRV1;rs2366929;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
BEVACIZUMAB, CAPECITABINE, OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;DECREASED-;DISEASE;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;FMO3;rs1736557;AA;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;DECREASED-LIKELIHOOD;OTHER;OVERALL SURVIVAL 
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
ASPIRIN, CLOPIDOGREL;PEAR1;rs2644592;G;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN, CLOPIDOGREL;PEAR1;rs11264580;C;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
BUPROPION, NICOTINE;APOE;rs429358;CC + CT;OTHER;INCREASED-LIKELIHOOD;DISEASE;RECURRENCE 
ASPIRIN, CLOPIDOGREL;PEAR1;rs57731889;TT;EFFICACY;EFFICACY;EFFICACY;LOW ON-TREATMENT PLATELET REACTIVITY 
ALENDRONATE, IBANDRONATE, RISEDRONATE, ZOLEDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS OF THE JAW 
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
ANTINEOPLASTIC AGENTS;GSTM5;rs3754446;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ATORVASTATIN, BEZAFIBRATE;APOE;rs449647;AT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;LIPID-LOWERING EFFECT 
HALOPERIDOL;SLC6A5;rs2298826;AA;TOXICITY;;SIDE_EFFECT;MOTOR SIDE EFFECTS 
OLANZAPINE;AHR;rs4410790;T;LADME-PK;PK;PK;29% LOWER MEAN 4'-DESMETHYL OLA/OLANZAPINE (OLA) RATIO 
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
ASPIRIN, CLOPIDOGREL;PEAR1;rs3737224;T;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN, CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EPISTAXIS, GASTROINTESTINAL HEMORRHAGE, HEMATOMA, HEMATURIA
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED-SEVERITY;DISEASE;ALCOHOL ABUSE 
VENLAFAXINE;CYP2D6;rs5030655;del;LADME-PK;PK;PK;IMPAIRED METABOLIC ACTIVITY 
ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EPISTAXIS, GASTROINTESTINAL HEMORRHAGE, HEMATOMA, HEMATURIA
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
CISPLATIN, DOXORUBICIN;CASP3;rs2720376;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs59502379;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
NEVIRAPINE;CCHCR1;rs1265112;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH 
CISPLATIN, DOXORUBICIN;CYP3A4;rs4646437;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
;GLI1;rs2228226;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;INCREASED-SEVERITY;DISEASE;TOBACCO USE DISORDER 
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREMOR 
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED-;DISEASE;FATIGUE 
CLOZAPINE;ACKR1;rs2814778;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
ESCITALOPRAM;;rs2069521;A;TOXICITY;INCREASED-;DISEASE;FATIGUE 
ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED-;DISEASE;FATIGUE 
ESCITALOPRAM;;rs2069521;A;TOXICITY;INCREASED-;SIDE_EFFECT;NAUSEA/VOMITING 
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED-;SIDE_EFFECT;NAUSEA/VOMITING 
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED-;SIDE_EFFECT;NAUSEA/VOMITING 
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, STEVENS-JOHNSON SYNDROME 
CLOPIDOGREL;CYP1A2;rs762551;AA + AC;EFFICACY, LADME-PK;DECREASED-EFFICACY;EFFICACY;ON-TREATMENT PLATELET REACTIVITY 
ETHANOL;OPRK1;rs6473797;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ALCOHOL ABUSE 
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO1;rs1800566;A;EFFICACY;EFFICACY;EFFICACY;WORSE OUTCOME (OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL) 
HEROIN;GRM3;rs274618;T;OTHER;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
THIAZOLIDINEDIONES;AQP2;rs296766;T;TOXICITY;INCREASED-RISK;DISEASE;EDEMA 
ETHANOL;CHRNA3;rs578776;G;TOXICITY, OTHER;DECREASED-LIKELIHOOD;DISEASE;ALCOHOL ABUSE 
CISPLATIN, DOXORUBICIN;ABCC5;rs939338;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CISPLATIN, DOXORUBICIN;FASLG;rs763110;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CISPLATIN, DOXORUBICIN;MSH2;rs4638843;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;rs3087879;C;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PHARMACOLOGICAL RESISTANCE 
COCAINE;CHRNA5;rs684513;G;OTHER;INCREASED-LIKELIHOOD;DISEASE;COCAINE DEPENDENCE 
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
ALLOPURINOL;;rs2734583;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, STEVENS-JOHNSON SYNDROME 
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
ALLOPURINOL;PSORS1C1;rs9263726;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, STEVENS-JOHNSON SYNDROME 
FEXOFENADINE;SLCO2B1;rs2306168;T;LADME-PK;DECREASED-PK;PK; AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE 
ANTINEOPLASTIC AGENTS;SLC28A3;rs17343066;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION (P<0.001) 
CLOZAPINE;TRAT1;rs116982346;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA, NEUTROPENIA, PANCYTOPENIA, THROMBOCYTOPENIA
EFAVIRENZ;CYP2A6;rs8192726;AC + CC;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION (P=0.028) 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
;ADH1B;rs1789891;A;OTHER;INCREASED-;DISEASE;ALCOHOL ABUSE 
ANTINEOPLASTIC AGENTS;DCTD;rs12067645;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
EFAVIRENZ;UGT2B7;rs7439366;CC + CT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA, NEUTROPENIA, PANCYTOPENIA, THROMBOCYTOPENIA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC2;rs13181;G;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CLOZAPINE;TRAC;rs377360;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
NEVIRAPINE;CCHCR1;rs746647;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
;FGFBP1;rs2245964;CC;OTHER;INCREASED-;OTHER;BONE MINERAL DENSITY 
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED-RISK;SIDE_EFFECT;DEATH, GASTROINTESTINAL HEMORRHAGE 
;FGFBP1;rs16892645;TT;OTHER;INCREASED-;OTHER;BONE MINERAL DENSITY 
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN LDL 
;;rs2824292;G;OTHER;INCREASED-RISK;DISEASE;VENTRICULAR FIBRILLATION 
NEVIRAPINE;;rs6545803;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEVIRAPINE-INDUCED RASH 
NICOTINE;FMO1;rs10912675;C;OTHER;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
NEVIRAPINE;POLR3G;rs2562519;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
NICOTINE;FMO1;rs7877;T;OTHER;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
ASPARAGINASE;GRIA1;rs4958381;T;TOXICITY;INCREASED-RISK;; 
PACLITAXEL;CYP17A1;rs743572;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ACENOCOUMAROL;CYP2C9;rs1057910;C;EFFICACY;INCREASED-RISK;SIDE_EFFECT;DEATH, GASTROINTESTINAL HEMORRHAGE 
CISPLATIN, FLUOROURACIL;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER, OSTEOPOROSIS 
CARBOPLATIN, DOCETAXEL, PACLITAXEL;SOX10;rs139887;CG;TOXICITY;INCREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN, ARTHRITIS, PAIN, 
ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;METABOLIC BONE DISORDER, OSTEOPOROSIS 
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
CAPECITABINE;CES2;rs11075646;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
WARFARIN;VKORC1;rs9923231;T;EFFICACY;EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN, ARTHRITIS, PAIN, 
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;rs4880;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
"""ANALGESICS AND ANESTHETICS"", ""ANTIBIOTICS"", ""ANTIEPILEPTICS"", ""ANTIFUNGALS FOR SYSTEMIC USE"", ""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"", ""ANTIMYCOBACTERIALS"", ""ANTITHYROID PREPARATIONS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ANEMIA, THROMBOCYTOPENIA, NEUTROPENIA, 
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED-LIKELIHOOD;OTHER;SHORT AND LONG-TERM WEIGHT LOSS 
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME-PK;PK;PK;BEING A PREDICTOR OF MITOTANE PLASMA CONCENTRATIONS OF AT LEAST 14 G/ML AFTER 3 MONTHS OF TREATMENT 
BORTEZOMIB, MELPHALAN, PREDNISONE;CTLA4;rs4553808;GG;TOXICITY;;SIDE_EFFECT;EARLIER ONSET OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY 
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED-PK;PK;PBMC-ASSOCIATED DRUG CONCENTRATIONS 
;CRHR1;rs1876828;TT;LADME-PK;DECREASED-PK;PK;BASELINE CORTISOL LEVELS 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;INCREASED-PK;PK;INTRACELLULAR PBMC EXPOSURE 
VALPROIC ACID;SOD2;rs4880;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ALOPECIA 
;ABCB1;rs1045642;AA;OTHER;INCREASED-LIKELIHOOD;OTHER;HELICOBACTER PYLORI INFECTION 
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ALOPECIA 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-;OTHER;ADP-STIMULATED PLATELET AGGREGATION 
CAPECITABINE;CDA;rs10916825;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME 
ANTINEOPLASTIC AGENTS;ABCB1;rs4148737;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
CLOPIDOGREL, TICAGRELOR;CYP4F2;rs3093135;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, RECURRENCE 
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME-PK;INCREASED-PK;PK;MINIMUM PLASMA CONCENTRATIONS 
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;IRON OVERLOAD 
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DEFERASIROX;UGT1A1;rs887829;TT;EFFICACY;DECREASED-RISK;DISEASE;IRON OVERLOAD 
METFORMIN;SLC47A2;rs12943590;AA + AG;LADME-PK;INCREASED-PK;PK;RENAL AND SECRETORY CLEARANCE OF METFORMIN 
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE TO METFORMIN 
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME 
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;DECREASED-PK;PK;ORAL CLEARANCE OF ATORVASTATIN 
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
DEFERASIROX;CYP1A2;rs762551;AA;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;IRON OVERLOAD 
ANTINEOPLASTIC AGENTS;CYP3A5;rs776746;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
DEFERASIROX;CYP1A1;rs2606345;CC;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;IRON OVERLOAD 
HEROIN;GRM3;rs274622;C;OTHER;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME-PK;INCREASED-PK;PK;ACCUMULATION OF DRUG IN PBMCS 
ETHANOL;CHRNA4;rs1044394;G;TOXICITY;DECREASED-RISK;OTHER;ALCOHOL ABUSE 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;AG;TOXICITY;INCREASED-RISK;DISEASE;VENOUS THROMBOSIS 
OPIOIDS;ENPP2;rs2249015;AA;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED-RISK;DISEASE;VENOUS THROMBOSIS 
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ASPIRIN;ADORA1;rs2228079;GG + GT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA 
LOVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
METHOTREXATE;MTHFR;rs1801131;GG + GT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;SKIN DISORDER 
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA 
PROPRANOLOL;CYP2D6;rs1065852;AA;LADME-PK;INCREASED-PK;PK;AREA UNDER PLASMA CONCENTRATION OF PROPRANOLOL 
CAPECITABINE, FLUOROURACIL;DPYD;rs6668296;T;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS 
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs1799793;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;APOE;rs7412;CT + TT;OTHER;INCREASED-;OTHER;HYPERURICEMIA 
CAPECITABINE, FLUOROURACIL;DPYD;rs115349832;C;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED-LIKELIHOOD;OTHER;WEIGHT REGAIN AFTER INTENTIONAL WEIGHT LOSS 
;APOE;rs429358;CC + CT;OTHER;INCREASED-;OTHER;HYPERTRIGLYCERIDEMIA 
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
SIMVASTATIN;APOE;rs429358;C;EFFICACY;INCREASED-RISK;OTHER;MORTALITY AFTER MYOCARDIAL INFARCTION, HOWEVER THIS CAN BE ELIMINATED 
CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;G;OTHER;INCREASED-LIKELIHOOD;DISEASE;WEIGHT GAIN 
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, ILOPERIDONE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;HTR2C;rs3813929;C;OTHER;INCREASED-RISK;DISEASE;WEIGHT GAIN 
HEROIN;SOD2;rs5746136;TT;TOXICITY;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
OPIOIDS;ENPP2;rs7832704;A;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
CARBOPLATIN, DOCETAXEL, PACLITAXEL;BCL2;rs2849380;TT;TOXICITY;INCREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
CARBOPLATIN, DOCETAXEL, PACLITAXEL;OPRM1;rs544093;TT;TOXICITY;INCREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
CARBOPLATIN, DOCETAXEL, PACLITAXEL;;rs879207;AG;TOXICITY;INCREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
TOLCAPONE;;rs4680;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REACTION TIME 
DOLASETRON, GRANISETRON;NOS1AP;rs10494366;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;QTC PROLONGATION 
SUNITINIB;ABCB1;rs2032582;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CAPECITABINE, FLUOROURACIL;DPYD;rs56276561;T;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
CLOZAPINE;ELAVL2;rs73482673;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;MID-DOSE PLASMA CONCENTRATIONS 
FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;PLASMA EXPOSURE 
TOLCAPONE;COMT;rs4680;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;REACTION TIME 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;PLASMA EXPOSURE 
HEROIN;SOD2;rs2758339;AC + CC;TOXICITY;DECREASED-RISK;DISEASE;HEROIN DEPENDENCE 
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
IRINOTECAN;TOP1;rs6072262;GG;TOXICITY;DECREASED-SEVERITY;DISEASE;NEUTROPENIA 
WARFARIN;APOB;rs679899;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ERLOTINIB;EGFR;rs712829;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
ERLOTINIB;ABCG2;rs2622604;CC;OTHER, LADME-PK;DECREASED-PK;PK;MEAN AUC 
WARFARIN;APOB;rs1367117;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
MORPHINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN PAIN 
MORPHINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN PAIN 
PHENYTOIN;ABCB1;rs1045642;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG RESISTANCE 
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;;SIDE_EFFECT;ALL STATIN-INDUCED MYOPATHY AND SEVERE MYOPATHY 
ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
LEFLUNOMIDE;CYB5A;rs1790834;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED-RISK;DISEASE;STROKE 
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
NEVIRAPINE;CYP2B6;rs3745274;T;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;C;EFFICACY;EFFICACY;EFFICACY;NONRESPONSE TO ANTI-EGFR-BASED TREATMENT 
EDOXABAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
CYCLOSPORINE;ABCB1;rs1045642;GG;EFFICACY, LADME-PK;DECREASED-PK;PK;INTRACELLULAR AND BLOOD CONCENTRATION 
BLEOMYCIN;BLMH;rs1050565;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
CISPLATIN;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE HEARING IMPAIRMENT 
CITALOPRAM;FKBP5;rs4713916;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
OPIOIDS;TH;rs10770141;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;COCAINE DEPENDENCE 
OPIOIDS;COMT;rs4680;AA;TOXICITY;DECREASED-RISK;OTHER;DEATH 
;VEGFA;rs2010963;CC + CG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
OPIOIDS;TH;rs10770140;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
PHENYTOIN;ABCB1;rs1128503;A;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA DRUG LEVELS 
PHENYTOIN;ABCB1;rs1045642;A;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA DRUG LEVELS 
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;GG;TOXICITY;INCREASED-RISK;DISEASE;CARDIOMYOPATHIES 
DEXMEDETOMIDINE;PRKCB;rs9922316;T;OTHER;INCREASED-;OTHER;DEXMEDETOMIDINE ED50 VALUES FOR DRUG-INDUCED DORSAL HAND VEIN (DHV) CONSTRICTION 
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT 
CYCLOSPORINE;ABCB1;rs2229109;CC;EFFICACY, LADME-PK;INCREASED-PK;PK;INTRACELLULAR AND BLOOD CONCENTRATION 
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED-EFFICACY;EFFICACY; RATE OF HIGH ON-TREATMENT PLATELET REACTIVITY (HTPR) AT 1 MONTH OF TREATMENT 
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CORONARY DISEASE 
EFAVIRENZ;CYP2B6;rs28399499;C;TOXICITY, LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
PRASUGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BLEEDING COMPLICATIONS 
NICOTINE;DRD1;rs686;A;EFFICACY, TOXICITY, OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;INCREASED-EFFICACY;EFFICACY; RATE OF HYPER-RESPONSE AT 1 MONTH OF TREATMENT 
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED-RISK;DISEASE;WEIGHT GAIN 
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED-PK;PK;MITOTANE PLASMA CONCENTRATIONS 
NICOTINE;DRD1;rs4532;T;EFFICACY, TOXICITY, OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
REPAGLINIDE;SLC30A8;rs16889462;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;EFFICACY 
ATAZANAVIR, RITONAVIR;UGT1A7;rs17863778;AA;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
BEVACIZUMAB;EDN1;rs5370;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;G6PD, IKBKG;rs5030868;A;;;OTHER;PROTECTION FROM PLASMODIUM VIVAX MALARIA INFECTION 
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;EFFICACY;DECREASED-RISK;DISEASE;TRANSPLANT REJECTION 
ATAZANAVIR, RITONAVIR;UGT1A3;rs3806596;CC;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA, EXANTHEMA 
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;TOXICITY;INCREASED-RISK;DISEASE;LEUKOPENIA 
ATAZANAVIR, RITONAVIR;UGT1A7;rs7586110;GG;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
OXALIPLATIN;ERCC2, KLC3;rs13181;GG + GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
APREPITANT, OLANZAPINE;HTR3C;rs6766410;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;NAUSEA, VOMITING 
ATAZANAVIR, RITONAVIR;UGT1A7;rs17868323;GG;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
BEVACIZUMAB;VEGFA;rs3025039;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
APREPITANT, OLANZAPINE;MTHFR;rs1801131;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;NAUSEA, VOMITING 
APREPITANT, OLANZAPINE;HTR3B;rs7943062;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;NAUSEA, VOMITING 
TAFENOQUINE;;rs62103056;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
METHOTREXATE;GGH;rs719235;CC;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;BONE MARROW TOXICITY 
TIMOLOL;ADRB1;rs1801252;AA;OTHER;INCREASED-;OTHER;SYSTOLIC (SAP) AND DIASTOLIC (DAP) ARTERIAL PRESSURE RESPONSES TO TIMOLOL 
CISPLATIN;LRP2;rs2228171;G;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
DISULFIRAM;DBH;rs1611115;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
FENTANYL, PROPOFOL, REMIFENTANIL, SEVOFLURANE;ADRB2;rs1042718;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOTENSIVE DISORDER 
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;SEVERITY-EFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
;SLC30A8;rs13266634;C;OTHER;INCREASED-RISK;DISEASE;DIABETES MELLITUS, TYPE 2 
THIAZIDES, PLAIN;SLCO2A1;rs34550074;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPONATREMIA 
ROSUVASTATIN;FMO3;rs1736557;A;EFFICACY;SEVERITY-EFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
WARFARIN;GGCX;rs699664;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) 
CISPLATIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
WARFARIN;GGCX;rs11676382;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
METHYLPHENIDATE;COMT;rs4680;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ANTIEPILEPTICS;SCN2A;rs2304016;A;EFFICACY;EFFICACY;EFFICACY;DRUG RESISTANCE 
WARFARIN;GGCX;rs11676382;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) 
WARFARIN;NQO1;rs1800566;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
;G6PD;rs1050828;T;;INCREASED-;OTHER;PROTECTION AGAINST SEVERE (P=0.006) AND MILD MALARIA (P=0.027) 
ANTITHYROID PREPARATIONS, METHIMAZOLE, PROPYLTHIOURACIL;KLRC4;rs2734565;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;AGRANULOCYTOSIS 
OXALIPLATIN;ERCC1;rs11615;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA, MUCOSITIS, NEUTROPENIA, 
ACE INHIBITORS, PLAIN;;rs4267385;CC + CT;OTHER;;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH 
ACE INHIBITORS, PLAIN;;rs4459610;AA + AT;OTHER;;OTHER;SAME PROTECTIVE PROPERTIES AGAINST ANGIOTENSIN-CONVERTING ENZYME INHIBITORS-INDUCED COUGH 
;G6PD;rs1050828;T;;INCREASED-;OTHER;PROTECTION AGAINST DEVELOPING SEVERE MALARIA 
METHOTREXATE;MTHFR;rs1801133;AG;TOXICITY;INCREASED-RISK;DISEASE;ALOPECIA 
ACE INHIBITORS, PLAIN;BDKRB2;rs8016905;AG;TOXICITY;;DISEASE;COUGH 
;F5;rs6025;C;OTHER;INCREASED-LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS 
CARBOPLATIN, PACLITAXEL;TRIM5;rs7950311;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;MTHFR;rs1801131;G;OTHER;INCREASED-LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS 
ANTINEOPLASTIC AGENTS;;rs6674079;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;MTHFR;rs1801133;G;OTHER;INCREASED-LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS 
CARBOPLATIN, PACLITAXEL;;rs2549714;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;SERPINE1;rs2227631;A;OTHER;INCREASED-LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS 
ANTINEOPLASTIC AGENTS;;rs4910232;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;INTERNATIONAL NORMALIZED RATIO VARIABILITY (INR-VAR) 
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN HYPERSENSITIVITY 
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
ANTINEOPLASTIC AGENTS;ZNF100;rs3795247;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN INR DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT 
ASPIRIN;PTGIR;rs1126510;AG + GG;OTHER;DECREASED-RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA 
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;NUMBER OF EXAMINATIONS ABOVE THE THERAPEUTIC RANGE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT 
ASPIRIN;TBXA2R;rs1131882;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA 
ASPIRIN;PTGER3;rs7551789;A;OTHER;INCREASED-RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA 
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR>=2 
ASPIRIN;PTGER2;rs1353411;GG;OTHER;INCREASED-RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA 
ASPIRIN;PTGER2;rs2075797;G;OTHER;DECREASED-RISK;OTHER;ASPIRIN-INTOLERANT ASTHMA 
DOCETAXEL, PACLITAXEL;CYP3A4;rs2740574;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
DOXORUBICIN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED-;OTHER;STABLE WARFARIN DOSE 
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY; VASP INDEX 
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED-;SIDE_EFFECT;DECLINE IN FEV 1 AFTER ASPIRIN PROVOCATION 
CLOPIDOGREL;CYP2C19;rs4986893;AG + GG;EFFICACY;EFFICACY;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY 
ASPIRIN, CLOPIDOGREL;NECAB1;rs74569896;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;EFFICACY;EFFICACY;HIGH POST-CLOPIDOGREL PLATELET REACTIVITY 
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ATHEROTHROMBOTIC EVENTS DURING THE 6-YEAR FOLLOW UP IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT 
WARFARIN;CYP2C9;rs1799853;T;EFFICACY, TOXICITY;INCREASED-;SIDE_EFFECT;BLOOD COAGULATION DISORDERS 
ASPIRIN, CLOPIDOGREL;EFR3A;rs4736529;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
DOCETAXEL, PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
GEMCITABINE;SLC28A1;rs2242046;GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMATOLOGIC TOXICITY 
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE DURING 3-MONTH DAILY OBSERVATION PERIOD IN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT 
WARFARIN;CYP2C9;rs1057910;C;EFFICACY, TOXICITY;INCREASED-;SIDE_EFFECT;BLOOD COAGULATION DISORDERS 
GEMCITABINE;CDA;rs1048977;CC + CT;OTHER, LADME-PK;INCREASED-PK;PK;ELIMINATION CLEARANCE OF DFDU AND FORMATION CLEARANCE OF DFDCTP 
PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
CYTARABINE;ABCB1;rs1128503;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;EFFICACY;EFFICACY;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC) 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;EFFICACY;EFFICACY;EFFICACY;POORER REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDLC) 
PRAVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PERCENT REDUCTION IN LDL-CHOLESTEROL 
GEMCITABINE;CMPK1;rs1044457;CC;OTHER, LADME-PK;DECREASED-PK;PK;FORMATION CLEARANCE OF DFDCTP 
ASPIRIN, CLOPIDOGREL;WDR24;rs11640115;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
GEMCITABINE;CDA;rs4655226;CC;OTHER, LADME-PK;INCREASED-PK;PK;ELIMINATION CLEARANCE OF DFDU 
CARBOPLATIN, PACLITAXEL;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED-;OTHER;BIOCHEMICAL RESPONSE, OPTIMAL CYTOREDUCTION, AND SENSITIVITY TO THE INDUCTION CHEMOTHERAPY TREATMENT 
VARENICLINE;ICAM5;rs901886;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SLEEP DISORDERS 
METHOTREXATE;ABCC1;rs2238476;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
MITOXANTRONE;ABCB1;rs1128503;AA;OTHER;INCREASED-;OTHER;SENSITIVITY IN VITRO 
MERCAPTOPURINE, METHOTREXATE;FOLH1;rs61886492;A;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CYTARABINE;ABCB1;rs2032582;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STEVENS-JOHNSON SYNDROME/EPIDERMAL NECROLYSIS, TOXIC 
;PPARA;rs135561;AA + AG;OTHER;DECREASED-RISK;OTHER;ALL-CAUSE MORTALITY 
CLOZAPINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS, NEUTROPENIA 
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;TOXICITY;DECREASED-;SIDE_EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ABNORMAL LIVER-FUNCTION TESTS (ALFTS) 
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;DISEASE ACTIVITY 
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;TOXICITY;DECREASED-;SIDE_EFFECT;MEAN CUMULATIVE DOSES OF ISONIAZID BEFORE THE DEVELOPMENT OF ANTITUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY (ATDIH) 
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOC3;rs5128;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS 
FLUTICASONE PROPIONATE;CYP3A4;rs35599367;AA + AG;EFFICACY;EFFICACY;EFFICACY;IMPROVED ASTHMA CONTROL (AS MEASURED BY DECREASE IN AVERAGE ASTHMA CONTROL SCORE) 
ALLOPURINOL;CCHCR1;rs9263745;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
LETROZOLE;;rs74418677;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN, ARTHRITIS, DISCONTINUATION, 
ACE INHIBITORS, PLAIN;AGTR1;rs5186;C;TOXICITY;INCREASED-;SIDE_EFFECT;MAJOR CARDIOVASCULAR EVENTS (MACE) RATE 
CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MITOXANTRONE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;TROUGH BLOOD CONCENTRATION NORMALIZED FOR THE DAILY DOSE (C) PER KILOGRAM BODY WEIGHT (D) (C/D, NG/ML/MG/KG/DAY) RATIO DURING THE FIRST MONTH AFTER TRANSPLANTATION 
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION 
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
METHOTREXATE;FOXP3;rs3761548;GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
;CHAT;rs1880676;G;OTHER;INCREASED-RISK;DISEASE;SCHIZOPHRENIA 
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;SIK3;rs139961185;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS 
OXALIPLATIN;XRCC1;rs25487;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;DECREASED-;SIDE_EFFECT;RENAL FUNCTION (LOWER CREATININE CLEARANCE) AT 3 MONTHS OF FOLLOW-UP 
METFORMIN;SLC22A1;rs622342;AA;LADME-PK;DECREASED-PK;PK;CL RENAL REFERENCE AND LOWER AND CL SEC REFERENCE 
ALLOPURINOL;PSORS1C2;rs9263733;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
CYCLOSPORINE;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DELAYED GRAFT FUNCTION 
METHOTREXATE;ABCG2;rs13120400;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
EXEMESTANE, LETROZOLE;;rs912571;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN, ARTHRITIS, DISCONTINUATION, 
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOA5;rs964184;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERLIPIDEMIAS 
VALPROIC ACID;POLG;rs2307441;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CISPLATIN, CYCLOPHOSPHAMIDE;ADH1C;rs698;CT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;COMPLETE RESPONSE 
EXEMESTANE, LETROZOLE;CCDC148;rs79048288;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN, ARTHRITIS, DISCONTINUATION, 
OXALIPLATIN;GSTP1;rs1695;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;DRD2;rs6277;G;;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A4;rs35599367;AA + AG;DOSAGE, LADME-PK;DECREASED-;OTHER;STATIN DOSES FOR OPTIMAL LIPID CONTROL 
;DRD2;rs1799732;G;;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
VALPROIC ACID;POLG;rs3087374;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
EDOXABAN;SLCO1B1;rs2306283;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
EDOXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
HYDROCHLOROTHIAZIDE;ADD1;rs4961;TT;OTHER;INCREASED-;OTHER;HYDROCHLOROTHIAZIDE INDUCED CALCIUM RETENTION 
EDOXABAN;SLCO1B1;rs999278;AA + AC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
LEVODOPA;DRD3;rs6280;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
LEVODOPA;DRD2;rs1799732;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
BUSULFAN, CYCLOPHOSPHAMIDE;CTH;rs1021737;TT;TOXICITY;INCREASED-RISK;DISEASE;HEPATIC VENO-OCCLUSIVE DISEASE 
FUROSEMIDE, SPIRONOLACTONE;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DIURETIC UNRESPONSIVENESS 
EDOXABAN;SLCO1B1;rs4149057;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
SIMVASTATIN;ABCB1;rs2032582;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL 
SIMVASTATIN;ABCB1;rs2032582;AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL 
FUROSEMIDE, SPIRONOLACTONE;ACE;rs4341;CG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DIURETIC UNRESPONSIVENESS 
SIMVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL 
ATORVASTATIN;NOS3;rs2070744;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;ANTI-INFLAMMATORY EFFECTS 
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;INCREASED-;OTHER;WHOLE BLOOD NITRITE 
PAROXETINE;CYP1A2;rs2472304;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
FUROSEMIDE, SPIRONOLACTONE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DIURETIC UNRESPONSIVENESS 
PAROXETINE;CYP1A2;rs4646425;T;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ATORVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
CISPLATIN, DOXORUBICIN;ERCC1;rs11615;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MUCOSITIS 
METHAMPHETAMINE;ARRB2;rs4790694;C;OTHER;INCREASED-LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS 
METHOTREXATE;ABCG2;rs2231142;GT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PAROXETINE;CYP1A2;rs2470890;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
PEGINTERFERON ALFA-2A, RIBAVIRIN;SCARB1;rs10846744;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1829346;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATITIS 
CISPLATIN, DOXORUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ANEMIA, MUCOSITIS 
ATORVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
CLOZAPINE;CYP2C19;rs4244285;AA;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS 
ATORVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME-PK;INCREASED-PK;PK;AUC 
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
IRINOTECAN;SLCO1B1;rs2306283;GG;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs2027701;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
SIMVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME-PK;INCREASED-PK;PK;AUC SIMVASTATIN ACID 
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY;EFFICACY;HIGHER PLATELET REACTIVITY INDEX (PRI) VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) AT 1 MONTH OF TREATMENT 
ANTIPSYCHOTICS;SLC18A2;rs363341;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1059698;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
ANTIPSYCHOTICS;GRIK3;rs1334802;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs73594404;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, NEUTROPENIA 
PAROXETINE;CYP1A2;rs4646427;TT;EFFICACY;EFFICACY;EFFICACY;SLOWER RESPONSE TIME 
METHOTREXATE;SHMT1;rs1979277;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ABDOMINAL PAIN 
PAROXETINE;CYP1A2;rs762551;A;TOXICITY;INCREASED-RISK;DISEASE;FATIGUE 
ANTIPSYCHOTICS;HTR2A;rs9567733;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs36080650;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATITIS 
METHOTREXATE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
ANTIPSYCHOTICS;DRD2;rs1124491;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS, RADIOTHERAPY;MEG3;rs10132552;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME-PK;INCREASED-PK;PK; SERUM R -WARFARIN CONCENTRATION 
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;;SIDE_EFFECT;DIMINISHED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DURING THE FIRST YEAR AFTER ENGRAFTMENT 
METHOTREXATE;ABCC2;rs17222723;AT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
METHAMPHETAMINE;SLC6A9;rs2486001;T;TOXICITY, OTHER;INCREASED-RISK;DISEASE;SUBSTANCE-RELATED DISORDERS 
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;INCREASED-RISK;DISEASE;PROTEINURIA 
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
;KCNH2;rs1805123;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;ATRIAL FIBRILLATION 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
METHAMPHETAMINE;ARRB2;rs2036657;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS 
METHOTREXATE;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY; ASPIRIN-RESISTANT PHENOTYPE 
ROSUVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
;CRHR1;rs110402;AA;OTHER;INCREASED-RISK;DISEASE;MAJOR DEPRESSIVE DISORDER 
NICOTINE;ARRB2;rs4790694;A;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED-EFFICACY;EFFICACY;MEDIAN WEEKLY WARFARIN DOSE REQUIREMENTS 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMATOLOGICAL TOXICITY 
ATORVASTATIN;ABCB1;rs1045642;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYALGIA 
CAPECITABINE;MTHFR;rs1801133;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION 
CARVEDILOL;ADRB2;rs1042714;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN RESTING BLOOD PRESSURE 
CLOPIDOGREL;PON1;rs662;CC + CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ANTIDEPRESSANTS;NTRK2;rs1439050;G;TOXICITY;INCREASED-RISK;DISEASE;SUICIDE 
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
BEVACIZUMAB;;rs1478947;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ASPIRIN;TBXA2R;rs4523;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN RESISTANCE 
METHAMPHETAMINE;ARRB2;rs1045280;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS 
ASPIRIN;GP1BA;rs6065;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN RESISTANCE 
OLANZAPINE;PMCH;rs7973796;G;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;OBESITY 
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED-;DISEASE;NEUTROPENIA 
WARFARIN;VKORC1;rs9934438;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
ASPIRIN;TGFB1;rs1800469;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT CHRONIC URTICARIA 
WARFARIN;F7;rs6046;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;SEN SITIVITY TO WARFARIN DURING INDUCTION 
WARFARIN;F7;rs6046;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL, VINORELBINE;MTHFR;rs1801133;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE TO CHEMOTHERAPY 
ASPIRIN, CLOPIDOGREL;KRTAP10-4, TSPEAR;rs201441480;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, TREATMENT MODIFICATION 
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
METHOTREXATE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, DRUG TOXICITY 
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;DECREASED-;OTHER;ERYTHROCYTE PLASMA MEMBRANE FLUIDITY 
WARFARIN;CYP2C9;rs7900194;A;LADME-PK;DECREASED-PK;PK;S-WARFARIN CLEARANCE 
ASPIRIN, CLOPIDOGREL;ECHS1;rs140410716;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIGB;rs12050587;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ASPIRIN, CLOPIDOGREL;AGAP3;rs75750968;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
GEMCITABINE;SLC28A2;rs11854484;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMATOLOGIC TOXICITY 
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATION 
ACETAMINOPHEN;TLR4;rs1927911;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASTHMA 
TIMOLOL;;rs16947;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;BRADYCARDIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;;rs11636687;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
GEMCITABINE;SLC28A2;rs1060896;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMATOLOGIC TOXICITY 
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATION 
ASPIRIN, CLOPIDOGREL;ZDHHC3;rs3749187;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
VENLAFAXINE;CYP2D6;rs3892097;CT + TT;LADME-PK;INCREASED-PK;PK;VENLAFAXINE CONCENTRATION PER UNIT DOSE 
;ADORA2A;rs5996696;AC + CC;OTHER;DECREASED-RISK;DISEASE;PARKINSON DISEASE 
;ADORA2A;rs71651683;CT;OTHER;DECREASED-RISK;DISEASE;PARKINSON DISEASE 
;IFITM3;rs12252;GG;OTHER;INCREASED-SEVERITY;OTHER;COVID-19 
METHOTREXATE;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CAFFEINE;CYP1A2;rs762551;CC;OTHER;DECREASED-RISK;DISEASE;PARKINSON DISEASE 
CAFFEINE;CYP1A2;rs2470890;CC;OTHER;DECREASED-RISK;DISEASE;PARKINSON DISEASE 
CLOZAPINE;ABCB1;rs1045642;AA;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
WARFARIN;VKORC1;rs9934438;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN AUC (AREA UNDER CURVE) PROTHROMBIN TIME 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;CC;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA 
;KCNJ11;rs5219;TT;;INCREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS, TYPE 2 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs374113543;A;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs373327528;A;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;HYPERCHOLESTEROLEMIA 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9;rs6051702;AA;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
DEXAMETHASONE;SERPINE1;rs6092;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;OSTEONECROSIS 
GEMCITABINE;CDA;rs2072671;AA + AC;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
NICOTINE;CHRNB2;rs2072661;GG;EFFICACY, TOXICITY, OTHER;INCREASED-;OTHER;ABSTINENCE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CLOZAPINE;CYP1A2;rs2069514;A;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED INSULIN LEVELS 
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
EVEROLIMUS;MTOR;rs2024627;C;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CISPLATIN, DOXORUBICIN, METHOTREXATE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
NICOTINE;CHRM2;rs324650;T;TOXICITY, OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
CETUXIMAB, PANITUMUMAB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SURVIVAL 
;VDR;rs1544410;C;;INCREASED-RISK;DISEASE;ASTHMA 
CLOZAPINE;CYP1A2;rs35694136;del;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED INSULIN LEVELS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;PON1;rs662;CT + TT;OTHER;INCREASED-;OTHER;SMALL-DENSE LDL LEVELS 
PROTON PUMP INHIBITORS;TRPM6;rs3750425;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPOMAGNESEMIA PRIMARY 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
;FKBP5;rs1360780;CC + CT;EFFICACY;INCREASED-LIKELIHOOD;; 
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C, MIR1264, MIR1912;rs12836771;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
HALOTHANE, SUCCINYLCHOLINE;RYR1;rs193922803;T;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
SIMVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME-PK;INCREASED-PK;PK;AUC SIMVASTATIN ACID 
PROTON PUMP INHIBITORS;TRPM6;rs2274924;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPOMAGNESEMIA PRIMARY 
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
DOXORUBICIN;ERCC1;rs3212986;AA + AC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;INFECTIOUS DISEASE, LEUKOPENIA 
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs518147;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
SIMVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME-PK;INCREASED-PK;PK;AUC SIMVASTATIN ACID 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192172;T;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
NEVIRAPINE;CYP2B6;rs2054675;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ASUNAPREVIR, DACLATASVIR, DIRECT ACTING ANTIVIRALS, LEDIPASVIR / SOFOSBUVIR, OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERCHOLESTEROLEMIA 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192176;A;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192177;T;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918593;A;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
NEVIRAPINE;CYP2B6;rs3786547;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE;DPYD;rs1801160;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918592;A;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
CAPECITABINE;DPYD;rs1801159;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
METHYLPHENIDATE;DRD3;rs6280;CT + TT;TOXICITY;INCREASED-;SIDE_EFFECT;INTOLERABILITY 
CISPLATIN;ACYP2;rs1872328;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
CLOPIDOGREL;PON1;rs662;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS (COMPOSITE OF CARDIAC DEATH, MI, STENT THROMBOSIS) IN KOREAN PATIENTS AFTER PCI 
DOXORUBICIN;XPC;rs2228001;GG + GT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;INFECTIOUS DISEASE 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
HEROIN;OPRM1;rs9479757;GG;TOXICITY;INCREASED-SEVERITY;OTHER;HEROIN DEPENDENCE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;BLUNTING OF ALCOHOL CRAVING 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;EFFICACY;EFFICACY;HIGHER RATE OF SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs1125338;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;;rs71542416;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
IRINOTECAN;ABCG1;rs425215;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
XELOX;ABCA2;rs2271862;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
IRINOTECAN;ABCC5;rs562;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
OPIOIDS;TACR1;rs6715729;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OVERDOSE 
OPIOIDS;DRD2;rs4436578;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVERDOSE 
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVERDOSE 
IRINOTECAN;SLCO1B1;rs2306283;AG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
TRAMADOL;ABCB1;rs1045642;AA;TOXICITY;DECREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
;ABCB1;rs2032582;CC + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
METHOTREXATE;FPGS;rs10106;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ALOPECIA, LEUKOPENIA 
;HIF1A;rs11549467;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs12596638;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
COUMARIN, NICOTINE;CYP2A6;rs28399433;C;OTHER, LADME-PK;DECREASED-;OTHER;EXPRESSION OF ENZYME CONTRIBUTING TO THE METABOLISM 
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
;PEMT;rs7946;T;;INCREASED-RISK;DISEASE;FATTY LIVER DISEASE 
ANTIBIOTICS;LGALS3;rs11125;AT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED-RISK;DISEASE;THROMBOCYTOPENIA 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED-RISK;DISEASE;HAND-FOOT SYNDROME 
METHOTREXATE;DHFR;rs1650723;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MUCOSITIS 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
METHOTREXATE;ABCG2;rs2231135;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
NICOTINE;HINT1;rs3852209;CC;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;METASTATIC NEOPLASM 
;VDR;rs1544410;CC;OTHER;DECREASED-LIKELIHOOD;OTHER;PRE-ECLAMPSIA 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
RISPERIDONE;SLC6A4;rs3813034;AA;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ISONIAZID, RIFAMPIN;GSTP1;rs1695;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs3764435;A;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs168351;A;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs117648444;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ETHANOL, NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;INTOXICATION 
ISONIAZID, RIFAMPIN;NAT2;rs1799929;TT;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
OPIOIDS;COMT;rs4680;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERALGESIA 
ISONIAZID, RIFAMPIN;NAT2;rs1799930;AA;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;DHFR;rs1053129;CC;TOXICITY;INCREASED-RISKEFFICACY;EFFICACY;METASTATIC NEOPLASM 
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
TAMOXIFEN;HS6ST3;rs118042719;A;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
PHENYTOIN;ABCB1;rs2229107;A;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA DRUG LEVELS 
"""3,4-METHYLENEDIOXYMETHAMPHETAMINE"", ""COCAINE"", ""ETHANOL"", ""OPIOIDS""";OPRM1;rs1799971;AG;TOXICITY;INCREASED-RISK;OTHER;SUBSTANCE-RELATED DISORDERS 
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
MYCOPHENOLIC ACID, TACROLIMUS;ABCC2;rs717620;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PRIMARY GRAFT FAILURE, KIDNEY TUBULAR NECROSIS, ACUTE 
METHADONE;CYP2B6;rs1038376;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SUCCINYLCHOLINE;BCHE;rs1799807;C;LADME-PK;;SIDE_EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY 
SUCCINYLCHOLINE;BCHE;rs1803274;T;LADME-PK;;SIDE_EFFECT;BUTYRYLCHOLINESTERASE DEFICIENCY 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;THROMBOCYTOPENIA 
CLOPIDOGREL;CYP2C18;rs1042192;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
CLOZAPINE;HNMT;rs2737385;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;SEDATION 
FLUOROURACIL;DPYD;rs1801160;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
METHADONE;CYP2B6;rs2279343;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
CLOPIDOGREL;NOC3L;rs12572897;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
TAMOXIFEN;LPP;rs6790761;A;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
NICOTINE;CHRNA5;rs16969968;A;TOXICITY, OTHER;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
CLOPIDOGREL;CYP2C8;rs1058932;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
SUNITINIB;ABCB1;rs2032582;AA + AC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
NICOTINE;CHRNA3;rs578776;A;TOXICITY, OTHER;DECREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
TAMOXIFEN;LPP;rs77693286;A;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;rs17863783;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
RIFAMPIN;RIPOR2;rs10946739;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
;EGFR;rs763317;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
;GAL;rs948854;C;OTHER;INCREASED-SEVERITY;DISEASE;ANXIETY DISORDERS 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
CARBAMAZEPINE;ZNRD1-AS1;rs3869066;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ATAZANAVIR;ABCB1;rs2032582;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
HMG COA REDUCTASE INHIBITORS;EYS;rs1337512;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;RHABDOMYOLYSIS 
RIFAMPIN;AGBL4;rs393994;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ATAZANAVIR;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs9342288;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;RHABDOMYOLYSIS 
ASPIRIN;SLC30A9;rs1047626;A;TOXICITY, OTHER;DECREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ESCITALOPRAM, NORTRIPTYLINE;BDNF;rs962369;C;EFFICACY, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SUICIDAL IDEATION 
ACE INHIBITORS, PLAIN;KCNMA1;rs2253201;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs3857532;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;RHABDOMYOLYSIS 
ASPIRIN;TSC1;rs7862221;C;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
RIFAMPIN;AGBL4;rs320003;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ASPIRIN;THRA;rs11819745;G;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
RIFAMPIN;CUX2;rs7958375;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
ASPIRIN;CHIA;rs3818822;A;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ATAZANAVIR;ABCB1;rs1128503;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERBILIRUBINEMIA 
ASPIRIN;;rs1074373;C;TOXICITY, OTHER;DECREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY, LADME-PK;INCREASED-PK;PK;PLASMA FREE PHENYTOIN CONCENTRATION 
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY, LADME-PK;INCREASED-PK;PK;PLASMA FREE PHENYTOIN CONCENTRATION 
HEROIN;GRM3;rs1990040;A;OTHER;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
ASPIRIN;ZBTB22;rs3130100;C;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
CYCLOSPORINE, SIROLIMUS, TACROLIMUS;TCF7L2;rs7903146;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;RHABDOMYOLYSIS 
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
ASPIRIN;HLA-DPB1;rs3097671;C;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ASPIRIN;HLA-DPB2;rs3129294;C;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ASPIRIN;HLA-DPB1;rs1042151;G;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ASPIRIN;HLA-DPB1;rs1042136;C;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
RIFAMPIN;RIPOR2;rs10946737;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PREDNISOLONE;GATA3;rs3824662;AA;PD;INCREASED-RISK;SIDE_EFFECT;SEPSIS 
RIFAMPIN;AGBL4;rs319952;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NICOTINE;OPRM1;rs10485057;AA;TOXICITY;INCREASED-RISK;OTHER;TOBACCO USE DISORDER 
ETHANOL;DPP6;rs2533200;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CISPLATIN, CYCLOPHOSPHAMIDE;EPHX1;rs1051740;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY GRADES 1-4 
CARBAMAZEPINE;;rs192543598;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ETHANOL;;rs7900002;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;;rs2582405;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CISPLATIN, CYCLOPHOSPHAMIDE;NAT2;rs1801280;CT;TOXICITY;INCREASED-RISK;DISEASE;ANEMIA 
ETHANOL;;rs56722963;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CISPLATIN, CYCLOPHOSPHAMIDE;MUTYH;rs3219484;CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4 
CARBAMAZEPINE;ALK;rs187926838;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ETHANOL;MED19, TMX2;rs576859;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
METHOTREXATE;ATIC;rs7563206;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ENZYMES;A2M;rs669;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGIC TRANSFORMATION 
METHOTREXATE;ATIC;rs3821353;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CHOP, RITUXIMAB;NCF4;rs1883112;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
ENZYMES;F12;rs1801020;GG;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
SUNITINIB;ABCB1;rs1128503;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
METHOTREXATE;ATIC;rs2372536;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;;rs6589386;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
ETHANOL;ADH1C;rs13125415;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
METHOTREXATE;ATIC;rs12995526;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CISPLATIN, CYCLOPHOSPHAMIDE;RAD52;rs11226;AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4 
ETHANOL;SLC39A8;rs13135092;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CISPLATIN, CYCLOPHOSPHAMIDE;LIG3;rs1052536;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA GRADE 3-4 
ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, DEPRESSION, 
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
INDINAVIR;UGT1A1;rs4148323;AG;TOXICITY;INCREASED-RISK;DISEASE;HYPERBILIRUBINEMIA 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
METHOTREXATE;FPGS;rs10760502;AA;EFFICACY, TOXICITY, OTHER;DECREASED-LIKELIHOOD;OTHER;DISCONTINUATION 
METHOTREXATE;FPGS;rs10106;TT;EFFICACY, TOXICITY, OTHER;DECREASED-LIKELIHOOD;OTHER;DISCONTINUATION 
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs55886062;AC + CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;FPGS;rs10106;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;;rs9679319;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;;rs1402398;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;THSD7B;rs13382553;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
METHOTREXATE;ABCB1;rs868755;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;;rs2673136;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;;rs13129401;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
METHOTREXATE;ABCB1;rs10280623;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;CADM2;rs62250713;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;ADH1B;rs75967634;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, VINCRISTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FEVER, MUCOSITIS 
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-SEVERITY;OTHER;HEROIN DEPENDENCE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
;CYP2A6;rs56113850;T;OTHER;DECREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
ETHANOL;PDE4B;rs6421482;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;;rs61767420;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;GCKR;rs1260326;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;;rs494904;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
;CHRNA5;rs503464;AA + AT;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
METHOTREXATE;SPATA9;rs72783407;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
METHOTREXATE;BIRC5;rs9904341;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS 
PROTEIN KINASE INHIBITORS;STAT6;rs324011;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ADVERSE EVENTS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
OPIOIDS;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;INCREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
TAMOXIFEN;C1QTNF6;rs114557570;C;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
;CHRNA5;rs637137;AA + AT;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
DOCETAXEL;VEGFA;rs833061;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DOCETAXEL;VEGFA;rs13207351;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
DOCETAXEL;VEGFA;rs35864111;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RELAPSE 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;MINIMAL RESIDUAL DISEASE 
DOCETAXEL;VEGFA;rs699947;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
EXEMESTANE;;rs62293499;C;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CT;OTHER;INCREASED-;OTHER;PLATELET AGGREGATION WITH EPINEPHRINE 
FLUOROURACIL;DPYD;rs4294451;AT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
CITALOPRAM;COL26A1;rs17135437;T;TOXICITY;INCREASED-;SIDE_EFFECT;HEARING AND VISION-RELATED SIDE-EFFECTS 
CITALOPRAM;;rs16965962;A;TOXICITY;INCREASED-;SIDE_EFFECT;GENERAL SIDE-EFFECT BURDEN 
ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ASPIRIN;ACE;rs4292;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN INTOLERANCE 
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;EFFICACY;EFFICACY;STRONGER AGGREAGTION 
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;rs4982753;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS 
FLUOROURACIL;DPYD;rs4294451;AT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
;ACE2;rs2074192;T;OTHER;INCREASED-SEVERITY;OTHER;COVID-19 
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CLOPIDOGREL RESISTANCE 
ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;NET DECREASE IN AA-INDUCED PLATELET AGGREGATION AFTER ASPIRIN TREATMENT 
MERCAPTOPURINE;ITPA;rs1127354;AC;LADME-PK;INCREASED-PK;PK;6-MMPN LEVELS 
;FGFR2;rs1219648;G;TOXICITY, OTHER;INCREASED-RISK;DISEASE;BREAST NEOPLASMS 
ANASTROZOLE;;rs6735923;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
ACENOCOUMAROL;CYP2C9;rs1799853;CT + TT;TOXICITY;INCREASED-RISK;DISEASE;GASTROINTESTINAL HEMORRHAGE 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;rs7319981;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
;AGT;rs699;AG;OTHER;INCREASED-LIKELIHOOD;OTHER;COVID-19 
ANASTROZOLE;;rs1877193;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
CAPECITABINE;DPYD;rs2786783;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
;COMT;rs4818;CC + CG;OTHER;INCREASED-SEVERITY;OTHER;PAIN 
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7662029;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7439366;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED-;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CEFACLOR;LIMD1;rs62242178;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
CEFACLOR;LIMD1;rs62242177;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
REPAGLINIDE;SLCO1B1;rs4149056;CC;OTHER, LADME-PK;INCREASED-PK;PK;MEAN PLASMA AUC 
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;rs1048101;AG + GG;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;KIDNEY DISORDER 
THALIDOMIDE;XRCC5;rs1051685;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
THALIDOMIDE;ERCC1;rs735482;AC + CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOZAPINE, OLANZAPINE;GCG;rs13429709;C;OTHER;INCREASED-;DISEASE;WEIGHT GAIN 
CLOZAPINE, OLANZAPINE;GLP1R;rs2268639;T;OTHER;INCREASED-;DISEASE;WEIGHT GAIN 
NICOTINE;OPRM1;rs1799971;AA + AG;DOSAGE;INCREASED-;OTHER;SMOKING 
NICOTINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED-;OTHER;SMOKING 
TOLCAPONE;COMT;rs4680;AA;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;ALCOHOL ABUSE 
NICOTINE;UGT2B10;rs112561475;AG + GG;LADME-PK;INCREASED-PK;PK;GLUCURONIDATION OF NICOTINE 
NICOTINE;UGT2B10;rs61750900;T;LADME-PK;DECREASED-PK;PK;NICOTINE GLUCURONIDATION 
CLOZAPINE, OLANZAPINE;GCG;rs13429709;CC;OTHER;INCREASED-;DISEASE;WEIGHT GAIN 
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;KIDNEY DISORDER 
METHAMPHETAMINE;HTR1A;rs878567;A;TOXICITY, OTHER;;DISEASE;PSYCHOTIC DISORDER 
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CAPTOPRIL;ACE;rs4291;AA;EFFICACY;DECREASED-SEVERITY;DISEASE;KIDNEY FAILURE 
ANTIEPILEPTICS;;rs4471527;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ANTIPSYCHOTICS;LEPR;rs1137101;G;OTHER;INCREASED-LIKELIHOOD;DISEASE;OBESITY 
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
ANTIEPILEPTICS;;rs77542827;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
STAVUDINE;SAMHD1;rs8124728;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE (HEART-RATE LOWERING) 
IRINOTECAN;TGFB1;rs1800469;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
CYTARABINE, DAUNORUBICIN, MITOXANTRONE;DCK;rs4643786;CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTIEPILEPTICS;NIPAL2;rs199755581;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
OXALIPLATIN, PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
AMLODIPINE, CHLORTHALIDONE, LISINOPRIL;ACE;rs4291;AA + AT;OTHER;DECREASED-;SIDE_EFFECT;FASTING GLUCOSE 
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
IRINOTECAN;TGFBR2;rs3087465;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
SUNITINIB;FLT4;rs307826;CT;EFFICACY;EFFICACY;EFFICACY;REDUCED PROGRESSION-FREE SURVIVAL 
SUNITINIB;CYP3A5;rs776746;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DOSE REDUCTIONS DUE TO TOXICITY 
RITODRINE;PDE4B;rs17128809;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;ABCC1;rs246221;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
SUNITINIB;FLT4;rs307821;AC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
BETA BLOCKING AGENTS;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HEART TRANSPLANTATION, DEATH 
SALBUTAMOL;;rs9552679;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;COL22A1;rs6988229;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs17495520;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
ASPIRIN, CLOPIDOGREL;CDH15;rs72819363;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CORONARY RESTENOSIS, DISEASE PROGRESSION 
ANTIEPILEPTICS;DDX12P;rs77491650;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
SALBUTAMOL;;rs1663332;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs1663330;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs17701271;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs518350;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs10511905;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SORAFENIB;ABCC2;rs717620;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
SALBUTAMOL;CLOCK;rs1522113;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs1423515;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs1419555;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SALBUTAMOL;;rs6002674;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
;ACE2;rs2106809;A;OTHER;INCREASED-LIKELIHOOD;OTHER;COVID-19 
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
ASPIRIN, CLOPIDOGREL;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;CORONARY RESTENOSIS, DISEASE PROGRESSION 
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
ALLOPURINOL;;rs1634776;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
PACLITAXEL;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
SALBUTAMOL;;rs11252394;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;BRONCHODILATOR RESPONSE (FEV1) 
SORAFENIB;SLCO1B1;rs4149056;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
COCAINE;GABRA2;rs11503014;G;TOXICITY;INCREASED-SEVERITY;OTHER;COCAINE DEPENDENCE 
COCAINE;OPRM1;rs2236256;C;TOXICITY;DECREASED-SEVERITY;OTHER;COCAINE DEPENDENCE 
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
METHOTREXATE;ABCB1;rs1128503;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
;AGT;rs699;A;OTHER;DECREASED-SEVERITY;OTHER;COVID-19 
CANGRELOR;P2RY12;rs9859552;TT;OTHER;;OTHER;20% AND 17% LESS INHIBITION OF PLATELET AGGREGATION WITH CRANGRELOR (0.05 AND 0.25 MICROM) IN-VITRO 
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
RADIOTHERAPY;TANC1;rs10497203;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-RISK;DISEASE;LEUKOPENIA 
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
GLUCOCORTICOIDS;GLCCI1;rs37973;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;POOR RESPONSE 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;TUMOR RESPONSE RATE 
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;DECREASED-;SIDE_EFFECT;INTERVAL OF THERAPY TO LEUKOPENIA ONSET 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;rs3087243;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PSORIASIS 
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-RISK;DISEASE;LEUKOPENIA 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;rs10782001;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PSORIASIS 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;rs11209026;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PSORIASIS 
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;INCREASED-SEVERITY;DISEASE;LEUKOPENIA 
METHOTREXATE;MTHFR;rs1801133;A;LADME-PK;INCREASED-RISKPK;PK;PROLONGED HIGH CONCENTRATIONS 
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
MORPHINE;ABCB1;rs2032582;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
COLISTIMETHATE;SLC15A2;rs2257212;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY 
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;FOLIC ACID DEFICIENCY ANEMIA 
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL 
WARFARIN;CYP2C9;rs28371685;CT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
CETUXIMAB;CCND1;rs9344;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL 
WARFARIN;F7;rs510335;GT + TT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
TACROLIMUS;IL10;rs1800871;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
ESCITALOPRAM;HTR1B;rs11568817;AC + CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE COGNITIVE EFFECTS 
CETUXIMAB;CCND1;rs9344;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;MDGA2;rs1160351;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEXSUAL DYSFUNCTION 
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOC1, APOE, TOMM40;rs429358;CC + CT;TOXICITY;INCREASED-;SIDE_EFFECT;NON-HDL CHOLESTEROL 
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE COGNITIVE EFFECTS 
TACROLIMUS;IL10;rs1800872;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
;;rs17234657;G;;INCREASED-RISK;DISEASE;CROHN DISEASE 
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED-;OTHER;WARFARIN DOSE 
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED-RISK;DISEASE;DYSKINESIAS 
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;SOD2;rs4880;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED-RISK;DISEASE;HALLUCINATIONS 
;;rs2200733;T;;INCREASED-RISK;DISEASE;ATRIAL FIBRILLATION 
ESTRADIOL;NFE2L2;rs6721961;T;TOXICITY;INCREASED-RISK;DISEASE;VENOUS THROMBOEMBOLISM 
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
WARFARIN;F2;rs5896;CT + TT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
;HLA-DRA;rs3135388;A;;INCREASED-RISK;DISEASE;MULTIPLE SCLEROSIS 
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
;NOD2;rs17221417;G;;INCREASED-RISK;DISEASE;CROHN DISEASE 
CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;ONE YEAR PROGRESSION FREE SURVIVAL 
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FLU-LIKE SYMPTOMS 
CLOPIDOGREL;CES1;rs71647871;CT;PD;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PLATELET REACTIVITY 
;TCF7L2;rs12255372;T;;INCREASED-RISK;DISEASE;DIABETES MELLITUS, TYPE 2 
;IL6;rs1800797;AG + GG;OTHER;INCREASED-SEVERITY;OTHER;PAIN 
;TCF7L2;rs12243326;C;;INCREASED-RISK;DISEASE;DIABETES MELLITUS, TYPE 2 
;TCF7L2;rs4506565;T;;INCREASED-RISK;DISEASE;DIABETES MELLITUS, TYPE 2 
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED-;OTHER;WARFARIN DOSE 
;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED-;OTHER;PLATELET REACTIVITY 
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN DURING PAINFUL PROCEDURE 
ETHANOL;RABGAP1L;rs61826952;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL MEAN NUMERICAL RATING SCALE (NRS) SCORE FOR PAIN 
;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
TRAMADOL;CYP2D6;rs1058172;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVERDOSE 
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
TRAMADOL;CYP2B6;rs4803419;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVERDOSE 
;ACE2;rs4240157;CC;OTHER;INCREASED-RISK;OTHER;DEATH 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS 
;ACE2;rs4240157;C;OTHER;INCREASED-LIKELIHOOD;OTHER;COVID-19 
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION, ELEVATED LIVER ENZYMES 
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;CONCENTRATION-TO-ADJUSTED DOSE RATIO 
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS, NEUTROPENIA, PANCREATITIS, VOMITING
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION, ELEVATED LIVER ENZYMES 
HMG COA REDUCTASE INHIBITORS;COQ5;rs10849757;AA + AG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
ZOLEDRONATE;FDPS;rs2297480;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS 
HMG COA REDUCTASE INHIBITORS;COQ3;rs11548336;TT;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
IMATINIB;CYP2B6;rs3745274;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;CG + GG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3211371;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE DELAY 
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;CLMN;rs8014194;A;EFFICACY;EFFICACY;EFFICACY;CHANGE IN TOTAL CHOLESTEROL 
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs12721655;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
NINTEDANIB;DSP;rs2076295;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO PROGRESSION 
FLUOROURACIL, LEUCOVORIN;MTHFR;rs1801133;GG;TOXICITY;DECREASED-SEVERITY;DISEASE;DRUG TOXICITY 
WARFARIN;F2;rs5896;CT + TT;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
BUSULFAN;CYP2C19;rs12248560;CC;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO 
CAPECITABINE;MTHFR;rs1801131;TT;TOXICITY;DECREASED-;DISEASE;DRUG TOXICITY 
WARFARIN;F7;rs510317;GG;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;rs1135216;CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PSORIASIS 
OLANZAPINE, QUETIAPINE, RISPERIDONE;ANKK1;rs1800497;AA;TOXICITY;INCREASED-RISK;DISEASE;HEADACHE 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;rs651630;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PSORIASIS 
RADIOTHERAPY;TANC1;rs264588;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
RADIOTHERAPY;TANC1;rs264631;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
BUSULFAN;CYP2C9;rs1799853;CT + TT;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO 
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DOSE DELAY 
RADIOTHERAPY;TANC1;rs7582141;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GRADE 3-4 NONHEMATOLOGICAL TOXICITY 
RADIOTHERAPY;TANC1;rs6432512;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
RADIOTHERAPY;TANC1;rs264663;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCB1;rs2032582;CC;EFFICACY;EFFICACY;EFFICACY;OVERALL SURVIVAL 
RADIOTHERAPY;TANC1;rs264651;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3745274;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION 
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE DELAY 
PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY, HEMATOLOGIC DISORDER, LEUKOPENIA, 
SECUKINUMAB;ERAP2;rs2248374;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs12210538;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs723685;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DOSE DELAY 
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs6907567;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DOSE DELAY 
ASPIRIN;LTC4S;rs730012;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;URTICARIA 
ATORVASTATIN, ROSUVASTATIN;COQ2;rs4693075;G;TOXICITY;INCREASED-RISK;DISEASE;MUSCULAR DISEASES 
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
WARFARIN;VKORC1;rs2884737;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
EFAVIRENZ, NELFINAVIR;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED-EFFICACY;EFFICACY;RISE IN CD4-CELL COUNT 
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;FAVORABLE VIROLOGIC RESPONSES 
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATION 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATIONS 
DOXORUBICIN;ABCC2;rs17222723;A;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
AZATHIOPRINE;XDH;rs2295475;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
;ATP8B3;rs10421558;G;TOXICITY;DECREASED-LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA 
;ABCB1;rs1045642;AA;OTHER;INCREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;T;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ANTHRACYCLINES AND RELATED SUBSTANCES, DOXORUBICIN, EPIRUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO PROGRESSION 
RITONAVIR;APOC3;rs2854117;T;TOXICITY;INCREASED-RISK;DISEASE;HYPERTRIGLYCERIDEMIA 
;AGTR1;rs5186;CC;OTHER;INCREASED-RISK;DISEASE;ISCHEMIA 
IMATINIB;ARID5B;rs10821936;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;T;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1801280;C;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
FEXOFENADINE;ABCB1;rs1045642;AA;DOSAGE, LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION 
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;INCREASED-PK;PK;PLASMA CMIN VALUES 
EFAVIRENZ;CYP2B6;rs4803419;T;LADME-PK;INCREASED-PK;PK;PLASMA CMIN VALUES 
IMATINIB;ATIC;rs2372536;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
ATORVASTATIN, SIMVASTATIN;CYP3A4;rs2740574;CC + CT;OTHER;DECREASED-RISK;OTHER;DOSE DECREASE OR DRUG SWITCHING 
FEXOFENADINE;ABCB1;rs2032582;AA;DOSAGE, LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION 
RITODRINE;KCNMB2;rs7625907;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED-PK;PK;PLASMA CMIN VALUES 
DOXORUBICIN;ABCC1;rs45511401;T;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
CAPECITABINE, FOLFOX, TEGAFUR;SMAD7;rs4939827;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DOXORUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
;ATP8B3;rs10403288;A;TOXICITY;DECREASED-LIKELIHOOD;OTHER;ASPIRIN-INDUCED ASTHMA 
SIMVASTATIN;ABCB1;rs1128503;A;EFFICACY;DECREASED-RISK;SIDE_EFFECT;MYALGIA 
;ACE2;rs2074192;T;OTHER;INCREASED-SEVERITY;OTHER;COVID-19 
DOXORUBICIN;CYBA;rs4673;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
SIMVASTATIN;ABCB1;rs1045642;A;EFFICACY;DECREASED-RISK;SIDE_EFFECT;MYALGIA 
DOXORUBICIN;RAC2;rs13058338;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
SIMVASTATIN;ABCB1;rs2032582;C;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MYALGIA 
;ABO;rs8176746;T;;INCREASED-;OTHER;ACE ACTIVITY 
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED-PK;PK;CONCENTRATION-TO-ADJUSTED DOSE RATIO 
ATORVASTATIN, SIMVASTATIN;PON1;rs705379;AA + AG;EFFICACY;EFFICACY;EFFICACY;CHANGE IN HDL-CHOLESTEROL 
ATORVASTATIN, SIMVASTATIN;PON1;rs662;CC + CT;EFFICACY;EFFICACY;EFFICACY;CHANGE IN HDL-CHOLESTEROL 
ATORVASTATIN;PON1;rs705379;GG;OTHER;DECREASED-;OTHER;OXIDATIVE STRESS 
CLOZAPINE;TACR1;rs58933792;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRY MOUTH 
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED-PK;PK;CONCENTRATION/DOSE RATIO 
FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED-PK;PK;TIME TO REACH STABLE DOSE OF TACROLIMUS 
FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED-PK;PK;DOSE OF TACROLIMUS 
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED-PK;PK;TIME TO REACH STABLE DOSE 
TAMOXIFEN;SLCO1A2;rs10841795;AG + GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DIZZINESS 
CLOZAPINE;ERBB4;rs3942465;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRY MOUTH 
DIAZEPAM;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ADVERSE EVENTS 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB2;rs1042713;GG;OTHER;INCREASED-RISK;OTHER;EMERGENCY DEPARTMENT AND HOSPITAL UTLIIZATION 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs1049674;AT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CUSHING SYNDROME 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";NOS3;rs1799983;TT;OTHER;INCREASED-RISK;OTHER;EMERGENCY DEPARTMENT UTLIIZATION 
EFAVIRENZ, LOPINAVIR, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, RITONAVIR;;rs2853826;G;TOXICITY;INCREASED-;SIDE_EFFECT;BASELINE ADIPONECTIN AND WITH GREATER ADIPONECTIN DECLINE 
DIAZEPAM;CYP2C19;rs12248560;CT + TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ADVERSE EVENTS 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB1;rs1801253;GG;OTHER;DECREASED-RISK;OTHER;EMERGENCIES 
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ABCB1;rs9282564;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
OLANZAPINE;UGT1A4;rs2011425;GG + GT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;AUTONOMIC NERVOUS SYSTEM DISORDER 
OLANZAPINE;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRY MOUTH 
CABAZITAXEL;ABCB1;rs17327624;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SIMVASTATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL 
OLANZAPINE;UGT1A4;rs2011425;GG + GT;LADME-PK;INCREASED-PK;PK;GLUCURONIDATED METABOLITES OF OLANZAPINE 
;COL1A1;rs1800012;AA + AC;;INCREASED-RISK;DISEASE;FRACTURES, BONE 
CYCLOSPORINE;ABCB1;rs1045642;AG;TOXICITY;INCREASED-SEVERITY;DISEASE;GINGIVAL HYPERPLASIA 
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;ACUTE REJECTION 
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG RESISTANCE 
CABAZITAXEL;ABCB1;rs2235040;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ASTHENIA 
TACROLIMUS;NOD2;rs2066844;CC;OTHER;INCREASED-;OTHER;HOSPITAL STAY 
TACROLIMUS;CYP3A5;rs776746;TT;EFFICACY;INCREASED-RISK;OTHER;ACUTE REJECTION 
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED-RISK;OTHER;ACUTE REJECTION 
CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION 
WARFARIN;VKORC1;rs2359612;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE 
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
OSELTAMIVIR;CES1;rs121912777;CT + TT;LADME-PK;PK;PK;SIGNIFICANTLY LARGER MEAN AUC OF OSELTAMIVIR, LOWER CMAX OF OSELTAMIVIR CARBOXYLATE, AND A SMALLER OSELTAMIVIR CARBOXYLATE-TO-OSELTAMIVIR AUC RATIO 
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;PBMC CONCENTRATIONS 
CABAZITAXEL;CYP2C8;rs11572093;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASTHENIA 
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE 
CITALOPRAM;CYP2C19;rs4244285;A;TOXICITY;INCREASED-;SIDE_EFFECT;INTOLERANCE 
WARFARIN;VKORC1;rs9934438;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE 
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;;DISEASE;WEIGHT GAIN 
WARFARIN;VKORC1;rs8050894;CG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE 
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SLEEP INITIATION AND MAINTENANCE DISORDERS 
WARFARIN;VKORC1;rs2884737;AC + CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THE FIRST INR WITHIN THE THERAPEUTIC RANGE 
NORTRIPTYLINE;GNB3;rs5443;TT;EFFICACY;EFFICACY;EFFICACY;IMPROVEMENTS IN NEUROVEGETATIVE SYMPTOMS 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATION 
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATION 
;SLC19A1;rs1051266;C;OTHER;INCREASED-LIKELIHOOD;OTHER;DOWN SYNDROME 
DIGOXIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED-PK;PK;DUODENAL ABSORPTION OF DIGOXIN AFTER DIRECT DELIVERY TO THE SURFACE OF THE DUODENUM BY ENDOSCOPE 
OLANZAPINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;T;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
OLANZAPINE;ABCB1;rs1045642;A;EFFICACY;EFFICACY;EFFICACY;POSITIVE RELATIONSHIP BETWEEN OLANZAPINE PLASMA LEVELS AND POSITIVE SYMPTOM REDUCTION COMPARED TO SUBJECTS WITH THE GG GENOTYPE 
OLANZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATIONS 
NICOTINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
OLANZAPINE;DRD2;rs6275;A;OTHER, LADME-PK;INCREASED-;OTHER;PROLACTIN 
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;rs9024;GG;TOXICITY;INCREASED-RISK;DISEASE;CARDIOMYOPATHIES 
OLANZAPINE;DRD2;rs6279;G;OTHER, LADME-PK;INCREASED-;OTHER;PROLACTIN 
CEPHALEXIN;;rs34545984;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
OLANZAPINE;DRD2;rs1124493;T;OTHER, LADME-PK;INCREASED-;OTHER;PROLACTIN 
OLANZAPINE;DRD2;rs2734841;A;OTHER, LADME-PK;INCREASED-;OTHER;PROLACTIN 
ASPIRIN;;rs115346678;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;MTHFD1;rs2236225;A;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EVENT FREE SURVIVAL 
SIMVASTATIN;PPARA;rs4253728;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL 
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
CODEINE;WBP2NL;rs9620007;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE IN KOREAN PATIENTS WITH MECHANICAL HEART VALVE REPLACEMENT SINCE DAY 7 OF WARFARIN THERAPY 
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;OPRM1;rs62436463;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
METFORMIN;SLC22A2;rs316009;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
METFORMIN;SLC22A2;rs316019;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SIMVASTATIN;PPARA;rs4823613;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL AND LDL-CHOLESTEROL 
;ANKK1;rs1800497;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RELAPSE 
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SUICIDAL IDEATION, ADVERSE EVENTS, DELIBERATE SELF-HARM, 
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
AMIODARONE, ANTIBIOTICS, ANTIPSYCHOTICS, DIURETICS, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED-RISK;DISEASE;TORSADES DE POINTES 
NICOTINE;OPRM1;rs1799971;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
NICOTINE;OPRM1;rs1799971;AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
BUPROPION;ANKK1;rs1800497;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
OLANZAPINE;DRD2;rs2734842;G;OTHER, LADME-PK;INCREASED-;OTHER;PROLACTIN 
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
PYRIMIDINE ANALOGUES;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ROSUVASTATIN;ABCG2;rs2231142;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PERCENTAGE CHANGE IN LDL-CHOLESTEROL LEVELS 
AMITRIPTYLINE;CYP2C19;rs4244285;AA;OTHER, LADME-PK;INCREASED-PK;PK;LOG METABOLIC RATIO OF AMITRIPTYLINE/NORTRIPTYLINE 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, OR STROKE 
ROSUVASTATIN;SLCO1B1;rs4149056;TT;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATIONS OF ROSUVASTATIN 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, OR STROKE 
ROSUVASTATIN;ABCG2;rs2231142;TT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS OF ROSUVASTATIN 
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, OR STROKE 
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CORONARY RESTENOSIS 
CISPLATIN, DOCETAXEL, FLUOROURACIL;CCL2;rs1024611;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
;SERPINE1;rs7242;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;MAJOR DEPRESSIVE DISORDER 
;SERPINE1;rs2227684;G;OTHER;INCREASED-LIKELIHOOD;DISEASE;MAJOR DEPRESSIVE DISORDER 
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CLINICAL RESPONSE 
GEMCITABINE;CDA;rs60369023;A;TOXICITY, LADME-PK;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA 
BISPHOSPHONATES;IL1B;rs16944;GG;EFFICACY;INCREASED-LIKELIHOODPK;PK;RESISTANCE 
CLODRONATE;VDR;rs1544410;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESISTANCE 
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER ANTI-COAGULATION 
CLODRONATE;VDR;rs731236;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESISTANCE 
CYTARABINE, IDARUBICIN;NT5C3A;rs3750117;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;INDUCTION FAILURE 
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;APOA5;rs662799;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN LDLC 
CITALOPRAM, SERTRALINE;HTR2A;rs6311;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
CISPLATIN, DOCETAXEL, FLUOROURACIL;IL6;rs1800796;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA, 
BUPRENORPHINE / NALOXONE;OPRM1;rs648893;AG + GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DEPRESSION 
METHOTREXATE;ADORA2A;rs2267076;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;ADORA2A;rs2236624;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;ADORA2A;rs2298383;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
TACROLIMUS;CYP3A5;rs776746;CT + TT;OTHER;INCREASED-PK;PK;BLOOD PRESSURE 
METHOTREXATE;ADORA2A;rs3761422;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
CISPLATIN, DOCETAXEL, FLUOROURACIL;TNF;rs1799964;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG RESISTANCE 
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CISPLATIN, DOCETAXEL, FLUOROURACIL;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
HYDROCHLOROTHIAZIDE;NELL1;rs12279250;C;LADME-PK;INCREASED-;SIDE_EFFECT;PLASMA TRIGLYCERIDES 
BUPRENORPHINE / NALOXONE;OPRD1;rs678849;TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ANXIETY DISORDERS 
ARIPIPRAZOLE;DAOA;rs2391191;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;BRIEF PSYCHIATRIC RATING SCALE SCORES 
BUPRENORPHINE / NALOXONE;OPRD1;rs569356;A;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;CRAVING 
OLANZAPINE;HTR2C;rs6318;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED-RISK;OTHER;TACROLIMUS NEPHROTOXICITY 
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY, TOXICITY;INCREASED-RISK;OTHER;SUBCLINICAL ALLOGRAFT NEPHROPATHY 
SIMVASTATIN;CYBA;rs4673;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN DNA DAMAGE 
BUPROPION;CYP2B6;rs3211371;CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
ASPIRIN;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG RESISTANCE 
OLANZAPINE;DRD3;rs6280;CC;EFFICACY;EFFICACY;EFFICACY;GREATER POSITIVE SYMPTOM IMPROVEMENT AND POSITIVE SYMPTOM REMISSION 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
OLANZAPINE;RGS4;rs951439;CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
CABAZITAXEL;TUBB1;rs151352;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
RISPERIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
OLANZAPINE, PERPHENAZINE;RGS4;rs951439;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;POSITIVE RESPONSE 
CABAZITAXEL;CYP2C8;rs1341164;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
OLANZAPINE;LEP;rs4731426;GG;TOXICITY;INCREASED-RISK;DISEASE;WEIGHT GAIN 
HEROIN;GRM3;rs13242038;T;OTHER;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235015;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
;ACE;rs4343;G;LADME-PK;INCREASED-;OTHER;ACE ACTIVITY 
ANTIDEPRESSANTS;HTR1A;rs6295;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;TREATMENT RESPONSE 
OPIOIDS;ABCB1;rs9282564;CC + CT;TOXICITY;DECREASED-RISK;OTHER;DEATH 
ANTHRACYCLINES AND RELATED SUBSTANCES, TAXANES;ABCB1;rs1045642;AA;EFFICACY, LADME-PK;INCREASED-LIKELIHOODEFFICACY;EFFICACY;COMPLETE RESPONSE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PAROXETINE, SERTRALINE;HTR1A;rs6295;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;NON-RESPONSE 
OPIOIDS;KCNJ6;rs2070995;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;FREQUENCY OF RESCUE ANALGESIC ADMINISTRATION 
WARFARIN;VKORC1;rs8050894;G;DOSAGE, EFFICACY;EFFICACY;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION 
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;EFFICACY;EFFICACY;DECREASED WARFARIN DOSE AND INCREASED  RISK OF OVER-ANTICOAGULATION 
NEVIRAPINE;CYP2B6;rs28399499;CT;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
NEVIRAPINE;CYP3A5;rs776746;CC + CT;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs3849942;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
METHAMPHETAMINE;DTNBP1;rs3213207;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PSYCHOTIC DISORDER 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs2814707;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
METHAMPHETAMINE;PICK1;rs2076369;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;RELAPSE OF PSYCHOSIS 
NEVIRAPINE;CYP2B6;rs12721646;CT + TT;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;rs928655;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OVERALL GASTROINTESTINAL TOXICITY 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs774359;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;rs983332;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs868856;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE BASE ON DISEASE ACTIVITY SCORE IN 44 JOINTS IMPROVEMENT AT 6 MONTHS OF TREATMENT 
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY; DISEASE ACTIVITY AS ASSESSED BY THE PHYSICIAN, LESS PATIENT-ASSESSED DIFFICULTY WITH PHYSICAL TASKS, AND FEWER SWOLLEN JOINTS 
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
ANTIANDROGENS;AKR1C3;rs12529;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;PROSTATE CANCER-SPECIFIC MORTALITY 
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED-;OTHER;MAINTENANCE DOSE OF WARFARIN 
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG;TOXICITY;INCREASED-RISK;DISEASE;NEPHROTOXICITY 
CISPLATIN, CYCLOPHOSPHAMIDE;TP53;rs1042522;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
PACLITAXEL;CYP2C8;rs11572080;TT;TOXICITY;INCREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES 
METHOTREXATE;ABCC1;rs2238476;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6028945;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6071980;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;rs6138150;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA;EFFICACY, LADME-PK;INCREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
ANTIPSYCHOTICS;CLCN6, MTHFR;rs1801133;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;METABOLIC SYNDROME 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854548;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854555;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs7046653;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
BUPRENORPHINE;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED-RISK;OTHER;SUBSTANCE WITHDRAWAL SYNDROME 
WARFARIN;VKORC1;rs9934438;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE OF INR (TTR) 
DOCETAXEL;;rs11185648;CT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE IN JAPANESE PATIENTS 
DOCETAXEL;RXRA;rs11185647;AG;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA, NEUTROPENIA 
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
DOCETAXEL;RXRA;rs2234753;AG;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
DOCETAXEL;RXRA;rs6413517;GT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
DOCETAXEL;RXRA;rs62576288;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
;DRD2;rs1799732;GG;;INCREASED-LIKELIHOOD;DISEASE;SCHIZOPHRENIA 
;SCN1A;rs2298771;CT;OTHER;INCREASED-LIKELIHOOD;DISEASE;EPILEPSY 
METHOTREXATE;;rs9345389;G;TOXICITY;;SIDE_EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE. 
DOCETAXEL;HNF4A;rs6130615;TT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
ANTIPSYCHOTICS;HTR2A;rs7997012;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG RESISTANCE 
SIMVASTATIN;;rs76103438;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
DIAZEPAM;CYP3A4;rs35599367;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ADVERSE EVENTS 
ANTIPSYCHOTICS;HTR2A;rs6314;AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DRUG RESISTANCE 
DOCETAXEL;HNF4A;rs2273618;CT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
DOCETAXEL;HNF4A;rs3746574;CT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
WARFARIN;VKORC1;rs9934438;A;DOSAGE, EFFICACY;;OTHER;A MORE RAPID ATTAINMENT OF TARGET INR AND HIGHER FREQUENCY OF DOSE ADJUSTMENTS 
DOCETAXEL;NR1I2;rs3732360;TT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
;NRXN1;rs985919;C;OTHER;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;rs4149601;AG + GG;EFFICACY;DECREASED-RISK;OTHER;CARDIOVASCULAR EVENTS 
MEPERIDINE;SERINC5;rs185462714;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DOCETAXEL;NR1I2;rs3732359;AA;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
;CHRNA5;rs17408276;C;OTHER;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
BETA BLOCKING AGENTS;;rs139945292;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR EVENTS 
NICOTINE;COMT;rs4680;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;DISEASE;MUSCULAR DISEASES 
PENICILLIN G, PENICILLIN V;;rs115200108;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
NICOTINE;COMT;rs4680;AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RELAPSE 
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
DOCETAXEL;NR1I2;rs3814058;CC + TT;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
;CHRNA5;rs16969968;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
;NRXN1;rs1882296;C;OTHER;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
DOCETAXEL;NR1I3;rs10538494;TT;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;SEPTIN3, WBP2NL;rs739296;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
MEPERIDINE;FIP1L1;rs113100019;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
DOCETAXEL;NR1I3;rs75114882;AG;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
;NRXN1;rs10865246;C;OTHER;INCREASED-SEVERITY;DISEASE;TOBACCO USE DISORDER 
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
DOCETAXEL;NR1I3;rs2501873;CC;TOXICITY;DECREASED-SEVERITY;DISEASE;ANEMIA 
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs3212986;AC;TOXICITY;INCREASED-RISK;DISEASE;NEPHROTOXICITY 
CISPLATIN, CYCLOPHOSPHAMIDE;XRCC1;rs25487;CC;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
MEPERIDINE;;rs11049274;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
DOCETAXEL;RXRA;rs1536475;AG;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
CISPLATIN;XPC;rs2228001;G;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
DOCETAXEL;NR1I3;rs2502815;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
DOCETAXEL;NR1I3;rs9725457;AA;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA 
CISPLATIN;ERCC2, KLC3;rs13181;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
ETHANOL;ACSS2;rs6088638;T;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
CAPECITABINE, FLUOROURACIL;DPYD;rs17376848;AG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1058164;C;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
CISPLATIN;ERCC1;rs11615;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL 
;APOE;rs429358;CC;OTHER;INCREASED-SEVERITY;OTHER;COVID-19 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1985842;T;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
;NAT2;rs1801280;T;OTHER;INCREASED-SEVERITY;DISEASE;INSULIN RESISTANCE 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1135840;G;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371713;G;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
;NAT2;rs1208;A;OTHER;INCREASED-SEVERITY;DISEASE;INSULIN RESISTANCE 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;;rs72631546;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
GEFITINIB;ABCG2;rs2231142;GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs112568578;G;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
CAPECITABINE, FLUOROURACIL;MIR23A, MIR24-2, MIR27A;rs895819;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;;DISEASE;NEUTROPENIA 
AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SLEEP APNEA SYNDROMES 
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED-RISK;DISEASE;COCAINE DEPENDENCE 
;PTGS2;rs20417;G;;INCREASED-RISK;DISEASE;STROKE 
ATENOLOL, BETA BLOCKING AGENTS, CARVEDILOL, METOPROLOL;PPARA;rs4253778;GG;EFFICACY;DECREASED-;OTHER;CARDIAC REHOSPITALIZATION 
DOXORUBICIN;RARG;rs2229774;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
FLUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ASPIRIN;TMEM196;rs9886152;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
PAZOPANIB;HIF1A;rs11549467;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
;CLOCK;rs1801260;AA + AG;OTHER;INCREASED-LIKELIHOOD;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY 
MERCAPTOPURINE, METHOTREXATE;ITPA;rs7270101;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED-RISK;DISEASE;COCAINE DEPENDENCE 
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;COMPLETE RESPONSE RATE 
MERCAPTOPURINE, METHOTREXATE;IMPDH1;rs2278293;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
RITUXIMAB;FCGR3A;rs396991;AA;;DECREASED-;OTHER;LEVELS OF IGG 
COCAINE;CNR1;rs806368;C;OTHER;DECREASED-RISK;DISEASE;COCAINE DEPENDENCE 
MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
ALENDRONATE, RALOXIFENE;VDR;rs1544410;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT IN BONE MINERAL DENSITY 
ASPARAGINASE, DEXAMETHASONE, METHOTREXATE;PYGL;rs7142143;CC + CT;DOSAGE;INCREASED-RISKEFFICACY;EFFICACY;RELAPSE 
INTERFERONS;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PAZOPANIB;CXCL8;rs4073;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ERLOTINIB;EGFR;rs121434569;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
INTERFERONS;IFNL3;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (SVR) TO INTERFERON MONOTHERAPY IN HCV GENOTYPE 1 PATIENTS 
CAPECITABINE, IRINOTECAN, OXALIPLATIN;DPYD;rs17376848;AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;;rs4888024;G;TOXICITY;;SIDE_EFFECT;END-OF-INDUCTION MINIMAL RISIDUAL DISEASE (MRD) IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND IS ALSO ASSOCIATED WITH GREATER METHOTREXATE CLEARANCE 
TACROLIMUS;ABCB1;rs1128503;AG;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATIONS 
TACROLIMUS;ABCB1;rs2032582;AC + CT;LADME-PK;INCREASED-PK;PK;TROUGH CONCENTRATIONS 
METHOTREXATE;ABCC1;rs3784862;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXICITY 
ETHANOL;OPRM1;rs1799971;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CAPECITABINE;DPYD;rs2297595;CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;ABCB1;rs1045642;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs945665113;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (SVR) IN HCV GENOTYPE 1 PATIENTS 
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
SUNITINIB;SLC22A5;rs2631367;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL (OS) TIME 
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;PRIMARY CLINICAL ENDPOINT OF DEATH DUE TO CARDIOVASCULAR CAUSES, NON-FATAL MI OR STENT THROMBOSIS 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
SUNITINIB;SLC22A5;rs2631370;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;PTGS2;rs20417;CG + GG;;DECREASED-RISK;DISEASE;STROKE 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs376695472;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ANTIDEPRESSANTS;HTR2A;rs6311;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
BETA BLOCKING AGENTS;ADRB2;rs1042713;GG;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;DEATH 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
FLUOROURACIL;DPYS;rs2959023;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SUNITINIB;IL4R;rs1805015;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;rs20417;CG + GG;OTHER;INCREASED-RISK;DISEASE;COLONIC NEOPLASMS 
;PTGS2;rs20417;CG + GG;OTHER;DECREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
FLUOROURACIL;DPYS;rs2669429;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
SUNITINIB;SLC22A5;rs2631372;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;GG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
SUNITINIB;IL4R;rs1801275;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
HEROIN;BDNF;rs16917234;TT;TOXICITY;DECREASED-AGE AT ONSET;SIDE_EFFECT;HEROIN DEPENDENCE 
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606619;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
TENOFOVIR;ABCC4;rs1751034;CC + CT;LADME-PK;INCREASED-PK;PK;INTRACELLULAR TENOFOVIR DIPHOSPHATE (TFV-DP) CONCENTRATIONS 
AZITHROMYCIN, ERYTHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PAIN, DIARRHEA 
CORTICOSTEROIDS;DTNBP1;rs35514893;T;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
;CYP1B1;rs1056836;CC + CG;OTHER;INCREASED-RISK;DISEASE;BREAST NEOPLASMS 
THIOTEPA;GSTP1;rs1138272;T;OTHER;INCREASED-PK;PK;NON-INDUCIBLE THIOTEPA CLEARANCE AND DECREASED TEPA CLEARANCE 
TENOFOVIR;ABCC4;rs1751034;TT;OTHER;INCREASED-PK;PK;TENOFOVIR RENAL CLEARANCE, AND LOWER AUC 
FLUOROURACIL;DPYD;rs2786783;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
;G6PD;rs72554664;T;OTHER;INCREASED-LIKELIHOOD;OTHER;DIABETES MELLITUS, TYPE 2 
OPIOIDS;;rs12442183;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS 
CORTICOSTEROIDS;KL;rs450789;G;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
INTERFERON BETA-1A, INTERFERON BETA-1B;IRF6;rs2205986;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
METHOTREXATE;NR1I2;rs3814058;C;TOXICITY;DECREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
METHOTREXATE;ABCC2;rs2273697;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BONE MARROW DISORDER 
FLUOROURACIL;WNT5B;rs2010851;CC;EFFICACY;DECREASED-;OTHER;TIME TO TUMOR RECURRENCE (TTR) 
CORTICOSTEROIDS;ME3;rs2125362;A;EFFICACY;INCREASED-SEVERITY;DISEASE;ASTHMA 
HEROIN;OPRD1;rs508448;GG;TOXICITY;DECREASED-AGE AT ONSET;SIDE_EFFECT;HEROIN DEPENDENCE 
METHOTREXATE;NR1I2;rs6785049;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CORTICOSTEROIDS;LHX2;rs7851998;A;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
FLUOROURACIL;DPYD;rs2811178;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CORTICOSTEROIDS;LHFPL3;rs61585310;G;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
ASPARAGINASE, CORTICOSTEROIDS, CYCLOPHOSPHAMIDE, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE;IL10;rs1800896;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;GSK3B;rs3732361;A;LADME-PK;DECREASED-RISK;SIDE_EFFECT;BONE MARROW DISORDER, TOXIC LIVER DISEASE 
HEROIN;BDNF;rs6265;TT;TOXICITY;DECREASED-AGE AT ONSET;SIDE_EFFECT;HEROIN DEPENDENCE 
MORPHINE;SLC22A1;rs12208357;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
CORTICOSTEROIDS;TRDN;rs4897302;T;EFFICACY;INCREASED-SEVERITY;DISEASE;ASTHMA 
NICOTINE;CHRNA5;rs55781567;G;TOXICITY;INCREASED-;DISEASE;TOBACCO USE DISORDER 
HEROIN;OPRD1;rs4654327;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEROIN DEPENDENCE 
OLANZAPINE;GIPR;rs10423928;AA + AT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED-;DISEASE;TOBACCO USE DISORDER 
NICOTINE;CHRNA5;rs503464;A;TOXICITY;INCREASED-;DISEASE;TOBACCO USE DISORDER 
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
FLUOROURACIL;DPYD;rs1801265;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
DAUNORUBICIN, DOXORUBICIN;SLC22A17;rs4982753;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;CYCSP5;rs9469003;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
NICOTINE;CHRNA5;rs55853698;G;TOXICITY;INCREASED-;DISEASE;TOBACCO USE DISORDER 
AMANTADINE, ANTICHOLINERGICS, DOPAMINE AGONISTS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED-RISK;DISEASE;DEATH 
MELPHALAN;POLR1G;rs967591;A;EFFICACY, TOXICITY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL AND TIME-TO-TREAT FAILURE 
CORTICOSTEROIDS;ACOT7;rs11121611;G;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, COGNITIVE DISORDER, CONSTIPATION
DAUNORUBICIN, DOXORUBICIN;SLC22A7;rs4149178;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
ROSUVASTATIN;SCAP;rs12487736;CC + CT;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;HYPERLIPIDEMIAS 
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CORTICOSTEROIDS;APOBEC3B;rs5995653;A;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C3;rs3094188;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MORPHINE;COMT;rs4680;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, DEPRESSION, 
GEMCITABINE, PACLITAXEL;CDA;rs2072671;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
MONTELUKAST;ABCC1;rs119774;CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;CHANGES IN FEV1 
TRIAMCINOLONE;HCG22;rs2523864;T;TOXICITY;INCREASED-;SIDE_EFFECT;OCULAR HYPERTENSION 
ANTIDEPRESSANTS;CREB1, METTL21A;rs7569963;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
MORPHINE;IL6;rs10499563;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, DEPRESSION, 
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130501;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs184278615;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CITALOPRAM;;rs4675690;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDALITY 
CITALOPRAM;CREB1, METTL21A;rs7569963;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDALITY 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs201469165;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOE;rs7412;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA 
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
TRIAMCINOLONE;HCG22;rs3873352;G;TOXICITY;INCREASED-;SIDE_EFFECT;OCULAR HYPERTENSION 
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C1;rs3815087;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MORPHINE;IL6R;rs2228145;AC + CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, DEPRESSION, 
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130931;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MORPHINE;BDNF;rs6265;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, DEPRESSION, 
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MORPHINE;IL2;rs2069762;AC + CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, FATIGUE, DEPRESSION, 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs1071748;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
METHOTREXATE;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ALLOPURINOL;;rs2844665;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CHLORTHALIDONE;NPPA;rs5065;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CYCLOPHOSPHAMIDE;SOD2;rs4880;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PRIMARY OVARIAN FAILURE 
DOXORUBICIN;SLC22A16;rs714368;CC;TOXICITY, LADME-PK;INCREASED-PK;PK;DOXORUBICINOL AUC 
MERCAPTOPURINE, METHOTREXATE;SLC29A1;rs747199;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;AGRANULOCYTOSIS, LEUKOPENIA 
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;;rs2844665;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;ORAL MUCOSITIS 
CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;CT + TT;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGIC CYSTITIS 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;rs973541788;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRA;rs3129880;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME-PK;DECREASED-RISK;SIDE_EFFECT;VENOOCCLUSIVE DISEASE OF THE LIVER 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371725;C;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SLEEP DISORDERS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CYCLOSPORINE, METHOTREXATE;MTHFR;rs1801133;A;OTHER;;SIDE_EFFECT;GRAFT VS HOST DISEASE 
CARBOPLATIN, CISPLATIN, GEMCITABINE;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs2004511;T;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
DOXORUBICIN;CBR3;rs8133052;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;TUMOR RESPONSE 
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME-PK;DECREASED-SEVERITY;DISEASE;NEUTROPENIA 
DOXORUBICIN;CBR3;rs1056892;A;DOSAGE, LADME-PK;INCREASED-PK;PK;DOXORUBICINOL AUC 
ANTIHYPERTENSIVES;ATP2B1;rs1401982;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESISTANT HYPERTENSION 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371702;A;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE 
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PRURITUS 
MERCAPTOPURINE, METHOTREXATE;SLC28A3;rs10868138;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
HEROIN;GRM3;rs724226;A;OTHER;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
ACENOCOUMAROL;VKORC1;rs7294;T;OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESIDUAL PLATELET REACTIVITY 
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
CORTICOSTEROIDS;CRHR1;rs242941;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PERCENT CHANGE IN FEV 
METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
CORTICOSTEROIDS;FKBP5;rs4713916;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;GLUCOCORTICOID RESPONSIVENESS 
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs242941;AA;EFFICACY;PK;PK;DELAYED CORTISOL RESPONSE TO STRESS 
OPIOIDS;ABCB1;rs1045642;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
CORTICOSTEROIDS;CRHR1;rs1876828;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PERCENT CHANGE IN FEV 
GEMCITABINE;;rs1155463;C;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs1876828;TT;EFFICACY;PK;PK;DELAYED CORTISOL RESPONSE TO STRESS 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;rs955434;AA + AG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;;rs61824877;A;EFFICACY, TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA 
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
TRAMADOL;OPRM1;rs1799971;GG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;NAUSEA 
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;HMGCS2;rs9943291;G;EFFICACY, TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA 
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METHADONE;DAO;rs55944529;TT;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;SUBSTANCE WITHDRAWAL SYNDROME 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
;KCNIP1, KCNMB1;rs11739136;CT + TT;OTHER;DECREASED-RISK;DISEASE;HYPERTENSION 
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA, VOMITING 
ATAZANAVIR;ABCB1;rs2032582;AT;TOXICITY;INCREASED-RISK;DISEASE;HYPERBILIRUBINEMIA 
DABIGATRAN;ABCB1;rs4148738;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
INFLIXIMAB;IL23R;rs10489629;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
INFLIXIMAB;SLCO1C1;rs3794271;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
NICOTINE;CHRNA3;rs578776;A;OTHER;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR FUNCTION (LVEF) 
PEGINTERFERON ALFA-2A;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CRYOGLOBULINEMIA 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;rs16906115;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
IRINOTECAN;ABCC1;rs3743527;CT + TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
IRINOTECAN;ABCB1;rs12720066;AC + CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
NICOTINE;CHRNA3;rs3743078;C;OTHER;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
NICOTINE;CHRNB4;rs3813567;G;OTHER;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
IRINOTECAN;ABCC1;rs17501331;AG + GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;EFFICACY;EFFICACY;SIGNIFICANTLY GREATER IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION (LVEF) 
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CRYOGLOBULINEMIA 
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;CRYOGLOBULINEMIA 
;UGT1A1;rs4148323;AA;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS, CEREBRAL PALSY, HEARING LOSS, 
PEGINTERFERON ALFA-2A;NT5C2;rs10883841;CT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;CRYOGLOBULINEMIA 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
INFLIXIMAB;ADAM17;rs10929587;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
CLOPIDOGREL;MED12L, P2RY12;rs10935838;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
;ago-02;rs4961280;AA + AC;OTHER;DECREASED-;OTHER;PROGRESSION-FREE SURVIVAL 
STAVUDINE;TNF;rs1799964;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROPATHY 
CLOPIDOGREL;MED12L, P2RY12;rs2046934;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CLOPIDOGREL;MED12L, P2RY12;rs6809699;AC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
NICOTINE;CHRNA5;rs684513;G;OTHER;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606618;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
NICOTINE;CHRNA5;rs637137;A;OTHER;DECREASED-RISK;DISEASE;TOBACCO USE DISORDER 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
;IL1A;rs1800587;A;OTHER;INCREASED-SEVERITY;DISEASE;PAIN 
FLUTICASONE / SALMETEROL;CRHR1;rs242941;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN CHANGE IN FEV 
PROPRANOLOL;COMT;rs4680;G;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
PEGINTERFERON ALFA-2A;CYP27B1, METTL1;rs10877012;GT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PROPRANOLOL;COMT;rs4818;G;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
CORTICOSTEROIDS;APOBEC3B;rs6001366;T;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CORTICOSTEROIDS;KCNN1;rs2278992;C;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
PEGINTERFERON ALFA-2A;VDR;rs7975232;AA;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CORTICOSTEROIDS;ANKRD30B;rs12959468;A;EFFICACY;DECREASED-SEVERITY;DISEASE;ASTHMA 
ROSUVASTATIN;CRP;rs1205;CT + TT;EFFICACY, OTHER, LADME-PK;DECREASED-;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN 
PROPRANOLOL;COMT;rs6269;G;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA, LEUKOPENIA, THROMBOCYTOPENIA, ANEMIA
RISPERIDONE;HTR2A;rs6311;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
HEROIN;GRM3;rs2189814;T;OTHER;INCREASED-RISK;DISEASE;HEROIN DEPENDENCE 
ROSUVASTATIN;;rs2808630;CC + CT;EFFICACY, OTHER, LADME-PK;DECREASED-;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN 
METHADONE;OPRD1;rs204076;AT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ROSUVASTATIN;HNF1A;rs1169288;AC + CC;EFFICACY, OTHER, LADME-PK;DECREASED-;OTHER;PLASMA LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN 
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR(LV) REMODELING AND GREATER INCREASE IN LVEF (LEFT VENTRICULAR EJECTION FRACTION) 
PROPRANOLOL;COMT;rs4633;C;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE 
ERYTHROMYCIN;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
;KCNIP1, KCNMB1;rs11739136;CT + TT;OTHER;DECREASED-;OTHER;BLOOD PRESSURE 
TACROLIMUS;ABCB1;rs2032582;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
CAFFEINE, ISOFLURANE;RYR1;rs118192162;AC;TOXICITY;;DISEASE;MALIGNANT HYPERTHERMIA 
RISPERIDONE;NR1I2;rs7643645;GG;LADME-PK;DECREASED-PK;PK;9-HYDROXY-RISPERIDONE LEVELS 
REPAGLINIDE;SLCO1B1;rs2306283;GG;OTHER, LADME-PK;DECREASED-PK;PK;REPAGLINIDE PLASMA CONCENTRATION (AUC) AND CMAX 
HALOTHANE;RYR1;rs118192161;CT;TOXICITY;;DISEASE;MALIGNANT HYPERTHERMIA 
RISPERIDONE;NR1I2;rs7643645;GG;LADME-PK;DECREASED-PK;PK;ACTIVE MOIETY LEVELS 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
TACROLIMUS;ABCB1;rs1045642;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
GEFITINIB;CYP2D6;rs1065852;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
EGFR INHIBITORS;PIK3CA;rs6443624;C;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;EXANTHEMA 
EGFR INHIBITORS;PIK3CA;rs2677760;T;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;EXANTHEMA 
MISOPROSTOL;SLCO1B1;rs4149087;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FEVER 
MISOPROSTOL;ABCC4;rs11568658;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FEVER 
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;COLLAGEN INDUCED PLATELET AGGREGATION AFTER ASPIRIN OR DUAL ANTIPLATELET THERAPY (DAPT) ADMINISTRATION 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;RAF1;rs11710163;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI 
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
OLANZAPINE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PCI 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;ALOX15;rs3892408;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
METHADONE;CCL11;rs1129844;A;TOXICITY;INCREASED-;SIDE_EFFECT;INSOMNIA 
EGFR INHIBITORS;PIK3CA;rs2699905;C;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;EXANTHEMA 
FLUOXETINE;;rs2433320;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;HAMD SCORES 
ANTIPSYCHOTICS;MTHFR;rs1801133;G;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs5789;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
CLOZAPINE, OLANZAPINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;PNPLA3;rs738409;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA, DRUG TOXICITY 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA 
ANTHRACYCLINES AND RELATED SUBSTANCES, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;CYP4X1;rs17102977;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;TPMT;rs1142345;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;MACULOPAPULAR EXANTHEMA 
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ASPIRIN-INDUCED ASTHMA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED-;DISEASE;EVENT-FREE SURVIVAL 
ANTIPSYCHOTICS;GABRG3;rs2061051;A;TOXICITY;INCREASED-SEVERITY;DISEASE;TARDIVE DYSKINESIA 
GEMCITABINE;;rs642990;CT + TT;TOXICITY;DECREASED-RISK;DISEASE;NEUTROPENIA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;LONGER MEDIAN PROGRESSION-FREE SURVIVAL TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
GEMCITABINE;RRM1;rs1042858;A;DOSAGE;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;;rs17661089;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;ACSS2;rs17309872;AT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;ABCC1;rs246240;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ONSET OF TOXICITY 
BUPROPION, NICOTINE;EPB41;rs6702335;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;ABSTINENCE 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;rs62328061;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
;IL17F;rs763780;CC;OTHER;INCREASED-LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS 
DAUNORUBICIN;NOS3;rs1799983;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;IL17A;rs2275913;AA;OTHER;INCREASED-LIKELIHOOD;OTHER;RECURRENT PREGNANCY LOSS 
ACE INHIBITORS, PLAIN;KCNIP4;rs145489027;A;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
PEMETREXED;ATIC;rs12995526;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
OPIOIDS;PDYN;rs910080;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
ACE INHIBITORS, PLAIN;KCNIP4;rs1495509;C;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
FOLFIRI, FOLFOX, XELOX;MTHFR;rs1801131;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
GEMCITABINE;ALG10;rs1705772;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXICITY 
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;UGT1A1;rs887829;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
RITONAVIR;APOC3;rs2854116;C;OTHER;INCREASED-RISK;DISEASE;HYPERTRIGLYCERIDEMIA 
PEMETREXED;GGH;rs16930092;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ANASTROZOLE;UGT1A4;rs3732218;GG;LADME-PK;INCREASED-PK;PK;GLUCURONIDATION 
HALOPERIDOL;CYP2D6;rs3892097;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
FOLFIRI, FOLFOX, XELOX;ABCB1;rs1045642;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ACE INHIBITORS, PLAIN;KCNIP4;rs7675300;A;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
CYCLOPHOSPHAMIDE;VEGFA;rs2010963;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING 
NEVIRAPINE;TRAF3IP2;rs76228616;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
GEMCITABINE;ALOX5AP;rs4769060;AG + GG;LADME-PK;DECREASED-PK;PK;CMAX AND A LOWER MEAN AUC 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
SUFENTANIL;OPRM1;rs1799971;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;IL7;rs16906115;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
GEMTUZUMAB OZOGAMICIN;CD33;rs1803254;CC + CG;TOXICITY;INCREASED-;SIDE_EFFECT;DEATH 
FOLFIRI, FOLFOX, XELOX;BRAF;rs113488022;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA 
OPIOIDS;TH;rs2070762;G;TOXICITY;INCREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
GEMTUZUMAB OZOGAMICIN;CD33;rs35112940;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ISONIAZID, RIFAMPIN;CYP2E1, DUX1;rs6413432;AT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
ANTINEOPLASTIC AGENTS, FLUOROURACIL, LEUCOVORIN;SPARC;rs1059829;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO TUMOR RECURRENCE 
OPIOIDS;DBH;rs1611131;G;TOXICITY;DECREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
ANTIPSYCHOTICS;HSPG2;rs2445142;C;TOXICITY;INCREASED-SEVERITY;DISEASE;TARDIVE DYSKINESIA 
FOLFIRI, FOLFOX, XELOX;DPYD;rs1801265;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTIPSYCHOTICS;HSPG2;rs878949;T;TOXICITY;INCREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
QUETIAPINE;RIMS1;rs502046;CC + CT;EFFICACY, TOXICITY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
ETHANOL;TAS2R16;rs846664;C;OTHER;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
FLUOROURACIL;SCN1A;rs3812718;CC;OTHER;DECREASED-;OTHER;TIME TO TUMOR RECURRENCE (TTR) 
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME IN THERAPEUTIC RANGE 
OPIOIDS;DRD2;rs1076560;A;TOXICITY;INCREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
EFAVIRENZ;NR1I2;rs2472677;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;DISCONTINUATION 
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;VIROLOGICAL RESPONSE 
CETUXIMAB;KRAS;rs112445441;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
SORAFENIB;VEGFA;rs2010963;CG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTR;rs1805087;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
SORAFENIB;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
SORAFENIB;VEGFA;rs1570360;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, MUSCULAR DISEASES, RHABDOMYOLYSIS, TOXIC LIVER DISEASE
COCAINE, HEROIN;OPRM1;rs62638690;T;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;COCAINE DEPENDENCE, HEROIN DEPENDENCE 
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
EFAVIRENZ;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER 
CETUXIMAB, PANITUMUMAB;KRAS;rs112445441;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;rs1799853;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
;MTR;rs1805087;GG;OTHER;INCREASED-LIKELIHOOD;DISEASE;RHEUMATOID ARTHRITIS 
METHOTREXATE;MTR;rs1805087;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METHOTREXATE-INDUCED NODULOSIS 
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED-PK;PK;AUC0-12 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DISCONTINUATION 
FLUOROURACIL;SCN1A;rs3812718;TT;OTHER;DECREASED-;OTHER;TIME TO TUMOR RECURRENCE (TTR) 
ATAZANAVIR;UGT1A1;rs887829;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
SIMVASTATIN;SLCO1B1;rs4363657;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES 
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
TACROLIMUS;CYP3A5;rs776746;CT;TOXICITY;INCREASED-RISK;DISEASE;NEPHROTOXICITY 
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;MUSCULAR DISEASES 
EFAVIRENZ;CYP2B6;rs4803419;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CENTRAL NERVOUS SYSTEM DISORDER 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
FLUOROURACIL;DPYD;rs1801160;CT;LADME-PK;DECREASED-PK;PK;DPD ACTIVITY 
ALLOPURINOL;PSORS1C1;rs3131003;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
FLUOROURACIL;MTHFR;rs1801133;GG;EFFICACY;INCREASED-;DISEASE;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
OPIOIDS;PDYN;rs1997794;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS 
ONDANSETRON;ABCB1;rs1045642;GG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
DEXMEDETOMIDINE;CYP2A6;rs8192733;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA, HYPOTENSIVE DISORDER 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs1799971;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PAIN 
OPIOIDS;PDYN;rs1022563;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;OPIOID-RELATED DISORDERS 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
RISPERIDONE;LEP;rs7799039;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OBESITY 
PERINDOPRIL;AGTR1;rs5182;TT;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;CARDIAC EVENTS 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) AND CHANGES IN VIRAL LOAD AFTER 4 WEEKS OF TREATMENT 
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE NEUTROPENIA 
CYTARABINE;CDA;rs602950;GG;EFFICACY, LADME-PK;INCREASED-EFFICACY;EFFICACY;CYTOTOXICITY 
HALOPERIDOL;CYP2D6;rs3892097;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
CYTARABINE;CDA;rs532545;TT;EFFICACY, LADME-PK;INCREASED-EFFICACY;EFFICACY;CYTOTOXICITY 
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
BISPHOSPHONATES;RBMS3;rs17024608;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;OSTEONECROSIS 
;NEDD4L;rs4149601;AG;OTHER;INCREASED-RISK;DISEASE;CARDIOVASCULAR DISEASE 
FLUOROURACIL;DPYD;rs55886062;AC;LADME-PK;DECREASED-PK;PK;DPD ACTIVITY 
ANTIPSYCHOTICS;INSIG2;rs17587100;C;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
ONDANSETRON;ABCB1;rs2032582;CC;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
;CTLA4;rs3087243;A;OTHER;DECREASED-RISK;DISEASE;RHEUMATOID ARTHRITIS 
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780094;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
FLUOROURACIL;DPYD;rs115232898;CT;LADME-PK;DECREASED-PK;PK;DPD ACTIVITY 
RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
TENOFOVIR;ABCC4;rs1059751;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;KIDNEY DISORDER 
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs6769511;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;DISEASE PROGRESSION 
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
CYTARABINE;CDA;rs2072671;CC;EFFICACY, LADME-PK;INCREASED-EFFICACY;EFFICACY;CYTOTOXICITY 
WARFARIN;VKORC1;rs9934438;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
ALLOPURINOL;NOTCH4;rs367398;AA + AG;TOXICITY;DECREASED-RISK;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS 
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;KCNQ1;rs163182;CC + GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;DISEASE PROGRESSION 
;NQO1;rs1800566;AA;OTHER;DECREASED-LIKELIHOOD;OTHER;SURVIVAL 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;EFFICACY;EFFICACY;RAPID VIRAL RESPONSE (RVR) TO PEG-IFN/RIBAVIRIN THERAPY AT 4 WEEKS IN HCV GENOTYPE 3 PATIENTS 
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs4402960;G;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;DISEASE PROGRESSION 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
EFAVIRENZ;CYP2B6;rs3745274;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;IMMUNOLOGICAL FAILURE 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NQO1;rs1800566;AA;TOXICITY;DECREASED-LIKELIHOOD;OTHER;SURVIVAL 
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, GASTROINTESTINAL TOXICITY, TOXIC LIVER DISEASE, 
EFAVIRENZ;CYP2B6;rs3745274;GT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;SLEEP DISORDERS 
SUNITINIB;ABCB1;rs1045642;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
VERAPAMIL;CACNA1C;rs1051375;AA;EFFICACY;DECREASED-RISK;OTHER;PRIMARY OUTCOME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEDIAN SURVIVAL TIME (MST) 
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED-SEVERITY;DISEASE;THROMBOCYTOPENIA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL (OS) TIME 
SUNITINIB;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;INCREASED-PK;PK;PLASMA LEVEL 
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL (OS) TIME 
EFAVIRENZ;CYP2A6;rs28399433;AC + CC;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DEATH 
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
VERAPAMIL;CACNA1C;rs1051375;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;PRIMARY OUTCOME 
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780093;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG 
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DOSE DECREASE OR SWITCH TO ANOTHER CHOLESTEROL-LOWERING DRUG IN USERS WITH A STARTING DOSE OF MORE THAN 20 MG 
CARBOPLATIN, CISPLATIN, GEMCITABINE;;rs12118636;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;TOXICITY;;SIDE_EFFECT;ALOPECIA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
ANTINEOPLASTIC AGENTS;ABCB1;rs1045642;AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEDIAN SURVIAL TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL (OS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
CARBOPLATIN, CISPLATIN, GEMCITABINE;NRAS;rs1065634;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
CARBOPLATIN, CISPLATIN, GEMCITABINE;GPX5;rs451774;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
VINCRISTINE;ACTG1;rs1135989;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
METHADONE;CYP2B6;rs3745274;GG;TOXICITY;INCREASED-SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME 
CARBOPLATIN, TAXANES;ATP7B;rs1801249;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
VINCRISTINE;CAPG;rs3770102;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
VALPROIC ACID;COL1A1;rs1800012;AA + AC;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
VINCRISTINE;ABCB1;rs4728709;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
DOXORUBICIN;AKR1C3;rs1937840;GG;OTHER;DECREASED-;OTHER;ABSOLUTE LEUCOCYTE AND NEUTROPHIL COUNTS ON DAY 15 
METHADONE;CYP2B6;rs2279343;AA;TOXICITY;INCREASED-SEVERITY;OTHER;NEONATAL ABSTINENCE SYNDROME 
KETOPROFEN;CYP2C9;rs1799853;CC;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DYSPEPSIA 
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED-;OTHER;TIME TO THERAPEUTIC INR 
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
REMIFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
MERCAPTOPURINE;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
CARBOPLATIN, TAXANES;GSR;rs3594;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ACENOCOUMAROL, WARFARIN;APOE;rs429358;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
ETHANOL;SLC6A4;rs4251417;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CARBOPLATIN, TAXANES;VEGFA;rs6900017;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
METHYLPHENIDATE;COMT;rs4680;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
NALOXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;CORTISOL RESPONSE 
ETHANOL;SLC6A4;rs25531;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
INTERFERONS, RIBAVIRIN;VDR;rs2228570;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;CRYOGLOBULINEMIA 
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
EGFR INHIBITORS;PIK3CA;rs2677760;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIARRHEA 
CETUXIMAB;EGFR;rs2227983;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
EGFR INHIBITORS;PIK3CA;rs2459693;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIARRHEA 
IRINOTECAN;CES1;rs7187684;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
METHOTREXATE;ATIC;rs2372536;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;SLC6A4;rs2066713;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CORTICOSTEROIDS, SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;EXACERBATIONS 
ANTIPSYCHOTICS;IL1B;rs4849127;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
BETA BLOCKING AGENTS;CYP2D6;rs1065852;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA 
FLUOROURACIL;DPYD;rs1801265;GG;LADME-PK;INCREASED-PK;PK;DPD ACTIVITY 
EGFR INHIBITORS;PIK3CA;rs6443624;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTIPSYCHOTICS;IL1B;rs16944;AG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs885004;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;CARDIOTOXICITY 
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GINGIVAL OVERGROWTH 
EGFR INHIBITORS;PIK3CA;rs2677760;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CORTICOSTEROIDS;ADRB2;rs1042713;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;UNCONTROLLED ASTHMA 
IRINOTECAN;CES1;rs2244614;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
ANTIPSYCHOTICS;IL1B;rs1143634;AA;TOXICITY;DECREASED-;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;TOXICITY;DECREASED-;SIDE_EFFECT;WEIGHT GAIN 
METHYLPHENIDATE;ADGRL3;rs2345039;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs7853758;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;CARDIOTOXICITY 
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
WARFARIN;CYP2C9;rs1799853;T;EFFICACY;EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
CARBOPLATIN, TAXANES;ATP7B;rs1061472;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;rs4379368;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
;FMO3;rs2266780;AG + GG;OTHER;DECREASED-SEVERITY;DISEASE;TOBACCO USE DISORDER 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;rs710446;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
IRINOTECAN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
ASPIRIN;LPA;rs3798220;CT;EFFICACY;DECREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
WARFARIN;CYP2C19;rs3814637;T;TOXICITY;RISK-;SIDE_EFFECT;OVER-ANTICOAGULATION 
FLUOROURACIL;DPYD;rs72728438;CT;LADME-PK;DECREASED-PK;PK;DPD ACTIVITY 
FLUOROURACIL;ABCC11;rs7194667;GG + GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
EGFR INHIBITORS;PIK3CA;rs2699905;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
FLUOROURACIL;DPYD;rs115632870;CT;LADME-PK;DECREASED-PK;PK;DPD ACTIVITY 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs56392308;del;TOXICITY;DECREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
ETHANOL;SLC6A3;rs6350;AG;TOXICITY;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs8176719;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;rs9574;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;rs2289252;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOSIS 
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-;SIDE_EFFECT;INFECTIOUS DISEASE, TOXIC LIVER DISEASE 
DEXMEDETOMIDINE;NR1I2;rs3814057;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;BRADYCARDIA, HYPOTENSIVE DISORDER 
;MAOA;rs1137070;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOBACCO USE DISORDER 
;MAOB;rs1799836;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOBACCO USE DISORDER 
CAPECITABINE;;rs9936750;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED-;SIDE_EFFECT;INFECTIOUS DISEASE, NEPHROTOXICITY, TOXIC LIVER DISEASE, 
DOXORUBICIN;ABCB1;rs1045642;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DOXORUBICIN;CBR3;rs1056892;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
CAPECITABINE;DPYD;rs3918290;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
FOLFIRI;UGT1A1;rs4124874;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MYELOSUPPRESSION 
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CETUXIMAB;EGF;rs4444903;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;COMPLETE PATHOLOGIC RESPONSE 
AFATINIB, ERLOTINIB, GEFITINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
;HAVCR2;rs10515746;AA + AC;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE 
;HAVCR2;rs1036199;AC + CC;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE 
AFATINIB, ERLOTINIB, GEFITINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
GLATIRAMER ACETATE;;rs12459996;T;TOXICITY;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
FLUOROURACIL;OR10AE3P, PSMB3P;rs10876844;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIARRHEA 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
HEROIN;BDNF;rs6265;TT;OTHER;INCREASED-RISK;OTHER;ADDICTION 
METHAMPHETAMINE;BDNF;rs6265;T;OTHER;INCREASED-RISK;OTHER;ADDICTION 
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;ABCB1;rs2235047;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;CBR3;rs1056892;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
FENTANYL;OPRM1;rs540825;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
CLOPIDOGREL;ABCB1;rs2032582;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
AFATINIB, ERLOTINIB, GEFITINIB;NUP62;rs9523;CC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
;;rs2207418;GG;OTHER;INCREASED-RISK;DISEASE;DEATH 
ALFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY 
WARFARIN;CYP2C9;rs9332197;C;EFFICACY;EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
WARFARIN;CYP2C9;rs1057910;C;TOXICITY;RISK-;SIDE_EFFECT;OVER-ANTICOAGULATION 
WARFARIN;CYP2C18;rs2901783;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
WARFARIN;F5;rs6018;G;TOXICITY;RISK-;SIDE_EFFECT;HEMORRHAGE 
WARFARIN;PROS1;rs8178607;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
;CHRM3;rs2165870;GG;TOXICITY;INCREASED-RISK;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING 
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
CAPECITABINE;DPYD;rs1801265;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
DOXORUBICIN;GSTP1;rs1695;GG;TOXICITY;INCREASED-;SIDE_EFFECT;MICRONUCLEATED BINUCLEATED CELLS 
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
METHOTREXATE;MTHFR;rs1801133;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE ACTIVITY SCORE 28 IN RHEUMATOID ARTHRITIS 
;SCN5A;rs7626962;GT + TT;OTHER;INCREASED-LIKELIHOOD;DISEASE;CARDIAC RHYTHM DISEASE 
CARBOPLATIN, TAXANES;VEGFA;rs879825;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
EXEMESTANE, LETROZOLE;ESR1;rs4870061;CT + TT;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME-PK;DECREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
CARBOPLATIN, TAXANES;SCN10A;rs9825762;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
LETROZOLE;ESR1;rs4870061;TT;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
METHOTREXATE;ABCC2;rs2273697;AA + AG;LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
EXEMESTANE, LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
CISPLATIN, ETOPOSIDE;NQO1;rs1800566;AA;OTHER;DECREASED-;OTHER;OVERALL SURVIVAL 
CISPLATIN;SLC22A2;rs316019;AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEPHROTOXICITY 
LETROZOLE;ESR2;rs10140457;CC;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
EXEMESTANE;ESR1;rs2813543;AA;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
EXEMESTANE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
BISPHOSPHONATES;;rs2736308;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS OF THE JAW 
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
BISPHOSPHONATES;;rs2736308;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS OF THE JAW 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;DPYD;rs67376798;AT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
CARBOPLATIN, GEMCITABINE;TNF;rs1800629;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
SORAFENIB;KDR;rs2305948;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
;COMT;rs4680;AG + GG;OTHER;DECREASED-;OTHER;LENGTH OF HOSPITAL STAY 
CARBOPLATIN, GEMCITABINE;PRRC2A;rs11229;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBOPLATIN, GEMCITABINE;PRRC2A;rs10885;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
METHADONE, MORPHINE;COMT;rs4680;AG + GG;OTHER;DECREASED-LIKELIHOOD;OTHER;TREATMENT 
SORAFENIB;FLT1;rs664393;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CARBOPLATIN, GEMCITABINE;MSH5;rs3115672;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA 
HMG COA REDUCTASE INHIBITORS;ATP2B1;rs17381194;T;TOXICITY;INCREASED-RISK;DISEASE;MYALGIA 
CARBOPLATIN, GEMCITABINE;DOCK8;rs10491684;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
HMG COA REDUCTASE INHIBITORS;;rs4693570;C;TOXICITY;INCREASED-RISK;DISEASE;MYALGIA 
;EPO;rs1617640;A;OTHER;INCREASED-;OTHER;ENDOGENOUS LEVELS OF EPO 
HMG COA REDUCTASE INHIBITORS;DMPK;rs672348;G;TOXICITY;INCREASED-RISK;DISEASE;MYALGIA 
ASPIRIN;EYA1;rs12678747;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PEPTIC ULCER DISEASE 
CARBOPLATIN, GEMCITABINE;CYP2C8;rs1058932;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBOPLATIN, GEMCITABINE;CYP2C8;rs11572078;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
AZITHROMYCIN, CHLORPROMAZINE, CILOSTAZOL, CIPROFLOXACIN, CITALOPRAM, CLARITHROMYCIN, DOFETILIDE, DONEPEZIL, DRONEDARONE, ERYTHROMYCIN, ESCITALOPRAM, FLECAINIDE, FLUCONAZOLE, HALOPERIDOL, HYDROXYCHLOROQUINE, LEVOFLOXACIN, METHADONE, MOXIFLOXACIN, ONDANSETRON, OXALIPLATIN, PAPAVERINE, PENTAMIDINE, PROCAINAMIDE, PROPOFOL, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
CARBOPLATIN, GEMCITABINE;C6orf15;rs2233980;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBOPLATIN, GEMCITABINE;CDSN;rs3130985;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
ETOPOSIDE, PLATINUM COMPOUNDS;DYNC2H1;rs716274;AG + GG;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
METHADONE, MORPHINE;OPRM1;rs1799971;AG + GG;OTHER;DECREASED-LIKELIHOOD;OTHER;TREATMENT 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA, NEUTROPENIA, GASTROINTESTINAL TOXICITY, 
ETOPOSIDE, PLATINUM COMPOUNDS;YAP1;rs10895256;GT + TT;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
HMG COA REDUCTASE INHIBITORS;COQ2;rs6535454;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN INTOLERANCE, DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY 
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN INTOLERANCE, DEFINED PRIMARILY THROUGH MUSCLE SYMPTOMATOLOGY 
CARBOPLATIN, GEMCITABINE;HLA-C;rs1049709;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
CARBOPLATIN, GEMCITABINE;HCP5;rs3130907;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
LENALIDOMIDE;CTNNB1;rs4135385;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBOPLATIN, ERLOTINIB, PACLITAXEL;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CARBOPLATIN, GEMCITABINE;SERPINC1;rs5877;C;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
IBRUTINIB;KCNQ1;rs2237895;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIAC RHYTHM DISEASE, CARDIOTOXICITY 
TAMOXIFEN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MUCOSITIS 
;SCN5A;rs7626962;GG;OTHER;INCREASED-LIKELIHOOD;DISEASE;SUDDEN INFANT DEATH 
LENALIDOMIDE;CTNNB1;rs4533622;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CARBOPLATIN, GEMCITABINE;;rs886423;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBOPLATIN, GEMCITABINE;;rs886424;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
BETA BLOCKING AGENTS;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
CARBOPLATIN, GEMCITABINE;ATAT1;rs9262132;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
;ABO;rs495828;GG;LADME-PK;INCREASED-;OTHER;ACE ACTIVITY 
CARBOPLATIN, GEMCITABINE;PPP1R18;rs9262143;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
;OPRM1;rs1799971;AG + GG;OTHER;DECREASED-;OTHER;LENGTH OF HOSPITAL STAY 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE 
SORAFENIB;;rs4604006;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
IBRUTINIB;KCNQ1;rs163182;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIAC RHYTHM DISEASE, CARDIOTOXICITY 
CARBOPLATIN, GEMCITABINE;MUCL3;rs3094086;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
OLANZAPINE;GIPR;rs10423928;AA;TOXICITY;INCREASED-;SIDE_EFFECT;PLASMA INSULIN LEVELS 
SORAFENIB;;rs4604006;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ANTHRACYCLINES AND RELATED SUBSTANCES;;rs28714259;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
CYCLOSPORINE;CTLA4;rs231775;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GINGIVAL OVERGROWTH 
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SORAFENIB;VEGFA;rs699947;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
FENTANYL;OPRM1;rs9397685;AG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NAUSEA, VOMITING 
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;EFFICACY;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE 
;ABCC4;rs2274407;AA + AC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PHYSICAL AND LIFE WELL-BEING QUALITY OF LIFE (QOL) SCALES 
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL (OS) TIME 
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY, TOXICITY;INCREASED-RISKEFFICACY;EFFICACY;OVER-ANTICOAGULATION 
PAZOPANIB;HFE;rs2858996;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
;;rs2207418;GG;OTHER;INCREASED-RISK;DISEASE;HEART FAILURE 
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;DECREASED-PK;PK;TROUGH CONCENTRATIONS 
GLATIRAMER ACETATE;;rs75041078;A;TOXICITY;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
GLATIRAMER ACETATE;;rs1056854;A;TOXICITY;INCREASED-RISK;DISEASE;CORONARY ARTERY DISEASE 
METHAMPHETAMINE;GAD2;rs2236418;AG + GG;OTHER;INCREASED-LIKELIHOOD;DISEASE;METHAMPHETAMINE DEPENDENCE, PSYCHOTIC DISORDER, SUBSTANCE-RELATED DISORDERS, 
GLICLAZIDE, GLYBURIDE;ABCC8, KCNJ11;rs757110;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;AA + AC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
TACROLIMUS;ABCB1;rs2229109;CT + TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RENAL TRANSPLANT FAILURE 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TRANSPLANT REJECTION 
FENTANYL;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPOVENTILATION 
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;DECREASED-PK;PK;TROUGH LEVELS 
AFATINIB, ERLOTINIB, GEFITINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;rs2031920;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
OSELTAMIVIR;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEPRESSION, GASTRITIS, HYPERSENSITIVITY, 
METHOTREXATE;ABCC3;rs9895420;AA + AT;TOXICITY, LADME-PK;INCREASED-;SIDE_EFFECT;PLASMA LEVELS 
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
COCAINE;OPRD1;rs678849;T;TOXICITY;DECREASED-RISK;OTHER;COCAINE DEPENDENCE 
CERIVASTATIN;RYR2;rs2819742;AA;TOXICITY;DECREASED-RISK;DISEASE;RHABDOMYOLYSIS 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs1891059;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
ANTIEPILEPTICS;ABCC2;rs2273697;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROBABILITY OF ANTIEPILEPTIC DRUG RESPONSE 
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RELAPSE IN THE CENTRAL NERVOUS SYSTEM 
;CYP1A2;rs35694136;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
ANTITHYMOCYTE GLOBULIN;FCGR3A;rs396991;AC + CC;OTHER;INCREASED-;OTHER;SENSITIVE TO ANTILYMPHOCYTE SERUM 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;LINC00251;rs141059755;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs17021408;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
PEGASPARGASE;ARHGAP28;rs9958628;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;DOK5;rs117532069;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs80223967;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCG2;rs3114020;CT + TT;EFFICACY;INCREASED-RISK;SIDE_EFFECT;DEATH 
THEOPHYLLINE;CYP1A2;rs35694136;T/del + TT;EFFICACY;INCREASED-SEVERITY;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
THEOPHYLLINE;CYP1A2;rs35694136;T;EFFICACY, LADME-PK;DECREASED-PK;PK;PLASMA DRUG LEVELS 
;CYP1A2;rs762551;C;OTHER;INCREASED-LIKELIHOOD;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;rs1061472;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
VERAPAMIL;NR1H3;rs2279238;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE 
VERAPAMIL;NR1H3;rs12221497;A;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE 
;DDC;rs921451;T;;SEVERITY-;DISEASE;TOBACCO USE DISORDER 
ATENOLOL, VERAPAMIL;NR1H3;rs11039149;G;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE 
;DDC;rs3735273;C;;SEVERITY-;DISEASE;TOBACCO USE DISORDER 
SEVOFLURANE;KCNK2;rs6686529;CC + CG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SEDATION 
;DDC;rs1451371;T;;SEVERITY-;DISEASE;TOBACCO USE DISORDER 
CHOP, RITUXIMAB;SLC35F4;rs74832512;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PROTEASE INHIBITORS;APOC3;rs2854116;CC + CT;EFFICACY;DECREASED-SEVERITY;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA 
VARENICLINE;CHRNB1, ZBTB4;rs2302764;C;TOXICITY;INCREASED-SEVERITY;DISEASE;NAUSEA 
PROTEASE INHIBITORS;APOC3;rs2854117;CT + TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA 
VARENICLINE;CHRNB2;rs2072661;A;TOXICITY;INCREASED-SEVERITY;DISEASE;NAUSEA 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;BMP7;rs79085477;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
VARENICLINE;CHRNB2;rs4292956;T;TOXICITY;INCREASED-SEVERITY;DISEASE;NAUSEA 
VARENICLINE;CHRNB2;rs2072660;C;TOXICITY;INCREASED-SEVERITY;DISEASE;NAUSEA 
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED-RISK;SIDE_EFFECT;DEATH 
AZATHIOPRINE;DDRGK1, ITPA;rs1127354;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
MORPHINE;FAAH;rs324420;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;RESPIRATORY INSUFFICIENCY 
CHOP, RITUXIMAB;OXNAD1;rs11721010;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
MORPHINE;FAAH;rs11576941;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
PROTEASE INHIBITORS;APOC3;rs5128;CG + GG;TOXICITY;DECREASED-;SIDE_EFFECT;HYPERTRIGLYCERIDEMIA 
SUNITINIB;ABCB1;rs2032582;AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
DOCETAXEL;SLCO1B3;rs11045585;G;TOXICITY;INCREASED-RISK;DISEASE;LEUKOPENIA 
APIXABAN;ABCB1;rs4148738;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
DOCETAXEL;ABCC2;rs12762549;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
;DTNBP1;rs3213207;T;;DECREASED-RISK;DISEASE;BIPOLAR DISORDER 
ASPIRIN;ITGB3;rs5918;CT;OTHER;INCREASED-;OTHER;SENSITIVITY TO ASPIRIN 
CHOP, RITUXIMAB;CIDEA;rs75614943;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CYTARABINE;CDA;rs3215400;C/del + del/del;TOXICITY;INCREASED-;DISEASE;DRUG TOXICITY 
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;INCREASED-LIKELIHOOD;DISEASE;SUBSTANCE-RELATED DISORDERS 
CHOP, RITUXIMAB;NOS1;rs77241831;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;PSYCHOTIC DISORDER 
CYTARABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED-;DISEASE;DRUG TOXICITY 
ANTIPSYCHOTICS;;rs9346455;GG + GT;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
;DTNBP1;rs3213207;T;;DECREASED-SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS 
SUFENTANIL;ABCB1;rs1045642;GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
;DTNBP1;rs2619539;C;;DECREASED-SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS 
CYTARABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED-;DISEASE;DRUG TOXICITY 
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CYTARABINE;CDA;rs532545;CT + TT;TOXICITY;INCREASED-;DISEASE;DRUG TOXICITY 
HEROIN;OPRD1;rs2236855;A;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
SUNITINIB;ABCB1;rs1128503;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;THROMBOEMBOLISM 
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
NICOTINE;NRXN1;rs2193225;C;OTHER;;OTHER;SMOKING QUANTITY 
HEROIN;OPRD1;rs2298897;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
NICOTINE;NRXN1;rs2193225;C;OTHER;;OTHER;SMOKING QUANTITY, HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE 
NICOTINE;NRXN1;rs6721498;A;OTHER;;OTHER;SMOKING QUANTITY, HEAVINESS OF SMOKING INDEX AND FAGERSTROM TEST FOR NICOTINE DEPENDENCE 
SUNITINIB;ABCB1;rs1045642;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CHOP, RITUXIMAB;;rs1607795;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SUFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
;DTNBP1;rs2619538;T;;DECREASED-SEVERITY;OTHER;MANIC SYMPTOMS IN PSYCHOSIS 
ETHANOL;FUT2;rs492602;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;FTO;rs9937709;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
PLATINUM;RICTOR;rs6878291;GG;TOXICITY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ANTIDEPRESSANTS;NR3C1;rs852977;G;EFFICACY;INCREASED-PK;PK;ANTIDEPRESSANT RESPONSE 
CERIVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-RISK;DISEASE;RHABDOMYOLYSIS 
PAROXETINE;HTR3B;rs1176744;AA;TOXICITY;INCREASED-RISK;DISEASE;NAUSEA 
ETHANOL;;rs1783835;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
CHOP, RITUXIMAB;TNIP3;rs116665727;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;APEX1;rs1760944;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
CHOP, RITUXIMAB;IL10;rs1800871;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
SUNITINIB;ABCB1;rs2032582;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;MUTYH;rs3219489;CG + GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ETHANOL;SLC4A8;rs12296477;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ASPIRIN;ITGB3;rs5918;CC + CT;OTHER;;OTHER;SHORTER BLEEDING TIME 
;NR3C1;rs10482633;G;;INCREASED-EFFICACY;EFFICACY;ANTIDEPRESSANT RESPONSE 
ESCITALOPRAM;HTR2A;rs9316233;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;ANTIDEPRESSANT RESPONSE 
ETHANOL;ARID4A;rs61974485;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
ETHANOL;;rs8008020;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
NICOTINE;OPRM1;rs1799971;AG;TOXICITY;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
ETHANOL;TNRC6A;rs72768626;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;NOS1AP;rs10494366;T;TOXICITY;INCREASED-RISK;OTHER;HYPOGLYCEMIA 
KETOROLAC;;rs2562456;CC;EFFICACY;EFFICACY;EFFICACY;SLOWER ANALGESIC ONSET IN EUROPEAN AMERICANS UNDERGOING ORAL SURGERY 
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
AZATHIOPRINE;ABCC1;rs2074087;CC + CG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA 
FLUVASTATIN;SREBF1;rs60282872;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;APOLIPOPROTEIN A1 AND C3 
BEVACIZUMAB, PEMETREXED;SLC19A1;rs1051298;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CISPLATIN, RADIOTHERAPY;TP53;rs1042522;CG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;SLC30A8;rs13266634;C;OTHER, LADME-PK;INCREASED-;OTHER;BASELINE PROINSULIN LEVELS AFTER ADJUSTING FOR INSULIN LEVELS 
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED-LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs943580;GG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs2071230;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
LEVONORGESTREL;ADAMTS10;rs7255721;CG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs7945189;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEART PALPITATIONS 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs12353214;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;KL;rs211247;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CRP;rs1205;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
NICOTINE;CHRNA4;rs1044396;AG;OTHER;INCREASED-LIKELIHOOD;OTHER;SMOKING INITIATION 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CDKN2B-AS1;rs10757274;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
NICOTINE;CHRNA4;rs1044396;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs699;GG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
NICOTINE;CHRNA4;rs1044397;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOBACCO USE DISORDER 
COXIBS;PTGS2;rs20417;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
COXIBS;PTGS2;rs4648276;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ACUTE CORONARY SYNDROME 
SEVOFLURANE;FASTKD3, MTRR;rs3733784;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION 
HEROIN;OPRM1;rs524731;A;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
HEROIN;OPRM1;rs511435;T;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
HEROIN;OPRM1;rs495491;G;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
AZATHIOPRINE;ADK;rs10824095;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CISPLATIN;ACYP2;rs1872328;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
AZATHIOPRINE;SLC29A1;rs747199;CG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-TREATMENT PLATELET AGGREGATION 
AZATHIOPRINE;IMPDH2;rs11706052;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA 
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
AZATHIOPRINE;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA 
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs2228622;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS 
HEROIN;OPRM1;rs3823010;A;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780413;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS 
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780412;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OBSESSIVE-COMPULSIVE SYMPTOMS 
HEROIN;;rs9478495;A;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
;;rs9424490;G;;INCREASED-RISK;OTHER;CURRENT SMOKING 
;USH2A;rs12126638;C;;INCREASED-RISK;OTHER;CURRENT SMOKING 
;AK4;rs1109374;C;;INCREASED-RISK;OTHER;CURRENT SMOKING 
ASPIRIN, CLOPIDOGREL;ITGA2;rs1062535;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESIDUAL PLATELET REACTIVITY 
;ITGB1;rs1187075;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
HEROIN;OPRM1;rs562859;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
LETROZOLE;;rs1324052;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL PAIN, ARTHRITIS, DISCONTINUATION, 
PLATINUM, VINORELBINE;STMN1;rs182455;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
TEGAFUR;DPYD;rs1801159;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;ITGB1;rs2230395;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
HEROIN;OPRM1;rs3778150;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
BEVACIZUMAB, PEMETREXED;GGH;rs3780126;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;TPH2;rs1843809;TT;OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;AGGRESSION, DEPRESSION 
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESIDUAL PLATELET REACTIVITY 
HEROIN;;rs9384169;C;TOXICITY;INCREASED-RISK;OTHER;HEROIN DEPENDENCE 
ANTIPSYCHOTICS;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED-;SIDE_EFFECT;QT INTERVAL 
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTIDEPRESSANTS, ANTIPSYCHOTICS, BENZODIAZEPINE DERIVATIVES, OPIOIDS, SYMPATHOMIMETICS;OPRM1;rs1799971;G;TOXICITY;INCREASED-RISK;OTHER;CARDIAC ARREST, RESPIRATORY INSUFFICIENCY 
BEVACIZUMAB, PEMETREXED;GGH;rs11545077;CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DIGOXIN;NOS1AP;rs10494366;GG;TOXICITY;INCREASED-;SIDE_EFFECT;SHORTENED QT INTERVAL 
SUNITINIB;ABCB1;rs2032582;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS, HAND-FOOT SYNDROME, HYPERTENSION, 
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION AFTER STIMULI WITH ADENOSINE DIPHOSPHATE, COLLAGEN, AND EPINEPHRINE 
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;EFFICACY;EFFICACY;HIGHER FENTANYL DOSE REQUIREMENT TO ACHIEVE ADEQUATE PAIN RELIEF IN CHINESE WOMEN UNDERGOING GYNECOLOGIC SURGERY 
CANNABINOIDS, COCAINE, ETHANOL, NICOTINE, OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED-RISK;OTHER;SUBSTANCE-RELATED DISORDERS 
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SUNITINIB;FLT1;rs7993418;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CISPLATIN;NFE2L2;rs6721961;GG + GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OTOTOXICITY 
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;EFFICACY;EFFICACY;HIGHER RESPONSIVENESS TO OPIOIDS AND REQUIRED LESS ANALGESIC DRUGS IN LABORING WOMEN 
FLUVOXAMINE;HTR2A;rs6311;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL SIDE EFFECTS 
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;EFFICACY;EFFICACY;LESS PAIN CONTROL IN JAPANESE PATIENTS UNDERGOING PAINFUL OROFACIAL COSMETIC SURGERY 
OLANZAPINE;FMO3;rs2266780;GG;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED SERUM OLANZAPINE N-OXIDE CONCENTRATIONS 
METOPROLOL;CYP2D6;rs3892097;T;EFFICACY, LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS OF METOPROLOL AND GREATER REDUCTIONS IN HEART RATE, DIASTOLIC BLOOD PRESSURE, AND MEAN ARTERIAL PRESSURE IN PMS THAN IN NON-PMS. 
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESIDUAL PLATELET REACTIVITY 
PLATINUM COMPOUNDS;CCN4;rs10956697;AA + AC;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
ASPIRIN;ITGB3;rs5918;CC + CT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;THE LACK OF ASPIRIN EFFECT 
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
OLANZAPINE;FMO1;rs12720462;AA + AC;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ARIPIPRAZOLE;DRD2;rs2514218;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PSYCHOMOTOR AGITATION 
PLATINUM COMPOUNDS, TAXANES;GSTP1;rs1695;AA;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;HEMATOLOGICAL TOXICITY 
PLATINUM, TAXANES;ABCB1;rs2032582;CC;TOXICITY, LADME-PK;DECREASED-RISK;SIDE_EFFECT;GRADE 3 OR 4 GASTROINTESTINAL TOXICITY 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
OLANZAPINE;FMO1;rs7877;CT + TT;LADME-PK;INCREASED-PK;PK;DOSE-ADJUSTED SERUM OLANZAPINE CONCENTRATIONS 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESIDUAL PLATELET REACTIVITY 
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;rs1529927;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;24-H EXCRETION OF CHLORIDE AND POTASSIUM 
AMPHETAMINE, CANNABINOIDS, COCAINE, OPIOIDS;KAT2B;rs9829896;C;TOXICITY;DECREASED-RISK;OTHER;SUBSTANCE-RELATED DISORDERS 
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
IMATINIB;ABCG2;rs2231142;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ASPIRIN;NAT2;rs4271002;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;INTOLERANCE 
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT 
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5723;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME 
PLATINUM COMPOUNDS;CCN4;rs2929973;GG + GT;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ENALAPRIL;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
ANTIPSYCHOTICS;HTR2A;rs6311;TT;TOXICITY;INCREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT 
METHADONE;MYOCD;rs1714984;AA + AG;EFFICACY;EFFICACY;EFFICACY;INCREASED  RISK OF BEING NONRESPONDERS 
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NONRESPONSE TO METHADONE MAINTENANCE TREATMENT 
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5729;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;24-H EXCRETION OF CALCIUM AND DECREASED URINARY VOLUME 
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
ANTIPSYCHOTICS;CYP2D6;rs1065852;A;TOXICITY;INCREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
OLANZAPINE;HTR2C;rs518147;C;TOXICITY;DECREASED-RISK;DISEASE;WEIGHT GAIN 
PRAVASTATIN;CETP;rs708272;AG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;CORONARY ARTERY DISEASE 
ATORVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;BENEFIT 
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;EFFICACY;EFFICACY;ASPIRIN-DEPRESSED THROMBIN GENERATION AND PROLONGED BLEEDING TIME AFTER ASPIRIN 
ASPIRIN;F13A1;rs5985;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;INHIBITION OF FXIII ACTIVATION BY ASPIRIN 
VERAPAMIL;ADRB1;rs1801253;CC + CG;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
AZATHIOPRINE;ITPA;rs1127354;C;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
CHOP, RITUXIMAB;NCF4;rs1883112;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;DECREASED-SEVERITY;SIDE_EFFECT;BONE DENSITY 
CHOP, RITUXIMAB;ABCG2;rs2231137;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PRAVASTATIN;CETP;rs708272;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN LUMINAL DIAMETER 
AMIODARONE, DIURETICS, SOTALOL;NOS1AP;rs10800397;T;TOXICITY;;SIDE_EFFECT;DRUG-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION 
ANTIPSYCHOTICS;;rs6977820;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA 
AMIODARONE;NOS1AP;rs10800397;T;TOXICITY;;SIDE_EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION 
WARFARIN;VKORC1;rs17880887;T;DOSAGE;EFFICACY;EFFICACY;LOWER LEVELS OF TRANSTHYRETIN PRECUROR 
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;;SIDE_EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION 
ASPIRIN;HNMT;rs1050891;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ACETYLSALICYLIC ACID-INTOLERANT CHRONIC URTICARIA 
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;;SIDE_EFFECT;AMIODARONE-INDUCED VENTRICULAR ARRHYTHMIA AND QT PROLONGATION 
ASPIRIN;LTC4S;rs730012;AC + CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SENSITIVITY TO ASPIRIN 
ANTIPSYCHOTICS;SMYD3;rs2485914;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TARDIVE DYSKINESIA 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATOTOXICTY 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEPATOTOXICTY 
CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;COMPLETE REMISSION 
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 
LEVONORGESTREL;TP53;rs1042522;CG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ASPIRIN;GP6;rs1613662;AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE TO ASPIRIN 
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;3-YEAR EVENT FREE SURVIVAL 
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2, KLC3;rs13181;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
ACENOCOUMAROL, PHENPROCOUMON, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;EFFICACY;EFFICACY;8.3% HIGHER MEAN DAILY COUMARIN DOSE TO REACH A STABLE INTERNATIONAL NORMALIZED RATIO (INR) 
ASPIRIN;ITGB3;rs5918;CT;TOXICITY;INCREASED-;SIDE_EFFECT;BLOOD LOSS 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, THROMBOCYTOPENIA 
SUNITINIB;KDR;rs2305948;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE, EPIRUBICIN, PLATINUM;GSTP1;rs1695;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-CLOPIDOGREL PLATELET REACTIVITY (HPR) 
;ITGB3;rs5918;CC + CT;OTHER;;OTHER;SHORTER BLEEDING TIME 
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;OTHER;INCREASED-RISK;OTHER;DEATH 
FENTANYL, HYDROMORPHONE, OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PAIN 
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;ADP-INDUCED PLATELET AGGREGATION 
BEVACIZUMAB;CXCR4;rs2228014;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
BETA BLOCKING AGENTS;ADRB1;rs1801253;CC;OTHER;DECREASED-RISK;OTHER;DEATH 
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;PPCDC;rs147451859;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;AMENORRHEA 
SUNITINIB;FLT4;rs6877011;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;DISEASE PROGRESSION 
HALOPERIDOL;ABCB5;rs17143212;CT;TOXICITY;INCREASED-;SIDE_EFFECT;DRUG TOXICITY 
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;;rs17587029;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;AMENORRHEA 
SUNITINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
OPIOIDS;CNIH3;rs10799590;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
SUNITINIB;VEGFA;rs3025039;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED-SEVERITY;DISEASE;TARDIVE DYSKINESIA 
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
SUNITINIB;CYP3A4;rs4646437;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERTENSION 
ATORVASTATIN;ABCB1;rs2032582;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs6025;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
CISPLATIN;NFE2L2;rs6721961;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
CARVEDILOL;ADRB2;rs1042714;CC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;IMPROVED LEFT VENTRICULAR EJECTION FRACTION 
TACROLIMUS;FOXP3;rs3761548;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
TACROLIMUS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIABETES MELLITUS 
METHOTREXATE;RAVER2;rs72675408;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED-RISK;SIDE_EFFECT;ATAXIA, DIPLOPIA, DIZZINESS, DYSARTHRIA
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED-RISK;SIDE_EFFECT;ATAXIA, DIPLOPIA, DIZZINESS, DYSARTHRIA
CAPECITABINE, FLUOROURACIL;PPARD;rs2016520;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
EFAVIRENZ;CYP2B6;rs8192719;CT + TT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
;SULT1A1, SULT1A2;rs1801030;CC + CT;OTHER;INCREASED-LIKELIHOOD;DISEASE;HOT FLASHES 
OPIOIDS;MCOLN1;rs116181528;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;OVERDOSE 
CERIVASTATIN, HMG COA REDUCTASE INHIBITORS, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
;AKT1;rs2494732;CC;OTHER;INCREASED-LIKELIHOOD;DISEASE;PSYCHOTIC DISORDER 
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 
BEVACIZUMAB;KCNAB1;rs6770663;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;TOXICITY 
ASPIRIN;CEP68;rs7572857;AA;TOXICITY;INCREASED-;SIDE_EFFECT;DECLINE OF FORCED EXPIRATORY VOLUME IN 1S (FEV(1)) BY ASPIRIN PROVOCATION 
OPIOIDS;MCOLN1;rs114077267;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;OVERDOSE 
ACENOCOUMAROL;VKORC1;rs9923231;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
PLATINUM COMPOUNDS;MDM2;rs2279744;GT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
ASPIRIN;ITGB3;rs5918;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET INHIBITION BY ASPIRIN 
;SLC2A9;rs62293298;AG;OTHER;DECREASED-LIKELIHOOD;OTHER;HYPERURICEMIA 
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATION 
ASPIRIN;TLR3;rs3775291;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-EXACERBATED RESPIRATORY DISEASE 
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATION 
OPIOIDS;MCOLN1;rs115208233;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;OVERDOSE 
TACROLIMUS;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;ACUTE CELLULAR REJECTION 
NICOTINE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;CRAVING 
NICOTINE;DRD2;rs1800497;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;CRAVING 
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
;ABCG2;rs2231142;GT + TT;OTHER;INCREASED-LIKELIHOOD;OTHER;HYPERURICEMIA 
ACENOCOUMAROL, WARFARIN;CYP2C9;rs72558189;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
TELBIVUDINE;TK2;rs3826160;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENTS ON DAY 14 
;SLC22A12;rs3825017;CT;OTHER;INCREASED-LIKELIHOOD;OTHER;HYPERURICEMIA 
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
SUNITINIB;CYP1A1;rs1048943;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, MUCOSITIS 
OLANZAPINE;DRD2;rs2440390;T;TOXICITY;INCREASED-;DISEASE;WEIGHT GAIN 
PRAVASTATIN;ADAMTS1;rs428785;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;FATAL CORONARY DISEASE OR NONFATAL MYOCARDIAL INFARCTION 
OLANZAPINE;HTR2C;rs6318;G;TOXICITY;INCREASED-;DISEASE;WEIGHT GAIN 
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;NEURAL TUBE DEFECTS 
OLANZAPINE;HTR2C;rs2497538;C;TOXICITY;INCREASED-;DISEASE;WEIGHT GAIN 
OLANZAPINE;HTR2C;rs1414334;G;TOXICITY;INCREASED-;DISEASE;WEIGHT GAIN 
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
PIOGLITAZONE;LPL;rs328;CG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE RATE AFTER 10 WEEKS OF PIOGLITAZONE TREATMENT 
PACLITAXEL;EPHA5;rs7349683;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
;SCN1A;rs3812718;T;OTHER;INCREASED-RISK;DISEASE;SEIZURES, FEBRILE 
;UGT1A1;rs4148323;AA + AG;OTHER;INCREASED-SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA, HYPERBILIRUBINEMIA 
;CHRNA5;rs16969968;A;OTHER;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
PACLITAXEL;ABCB1;rs3213619;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
VERAPAMIL;NOS1AP;rs10494366;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;QTC PROLONGATION 
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
;;rs1051730;A;OTHER;INCREASED-SEVERITY;OTHER;TOBACCO USE DISORDER 
;CYP2R1;rs12794714;A;OTHER;INCREASED-LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY 
OLANZAPINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;SOCIAL AND CLINICAL NEEDS 
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
;CYP2R1;rs10741657;A;OTHER;DECREASED-LIKELIHOOD;OTHER;VITAMIN D DEFICIENCY 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE AT 4 WEEKS AFTER THE INITIATION OF TREATMENT 
TAMOXIFEN;E2F7;rs310786;CC;TOXICITY;INCREASED-;SIDE_EFFECT;LUMBAR BONE LOSS 
ALENDRONATE;DKK1;rs2241529;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;BONE DENSITY 
CLOPIDOGREL;CES1;rs8192950;G;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;TRANSIENT ISCHEMIC ATTACK, STROKE 
ANTIPSYCHOTICS;DRD2;rs1799732;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SIDE EFFECTS 
SUNITINIB;KDR;rs2305948;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
WARFARIN;CYP2C9;rs4918758;C;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS 
SUNITINIB;VEGFA;rs3025039;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED-PK;PK;AREA UNDER THE CURVE FROM BASELINE TO THE LAST MEASURED CONCENTRATION 
EXEMESTANE;ESR1;rs9322336;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULOSKELETAL TOXICITY 
WARFARIN;CYP2C9;rs9332096;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE REQUIREMENT IN MECHANICAL HEART VALVE REPLACEMENT PATIENTS 
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED-;OTHER;PEAK PLASMA CONCENTRATION OF INCREASED  PROLACTIN 
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERTENSION 
SUNITINIB;FLT4;rs6877011;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
OLANZAPINE;GSTP1;rs1695;AA;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;SYNCOPE 
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED-;OTHER;WARFARIN DOSE 
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;AA;TOXICITY;INCREASED-RISK;DISEASE;CARDIOMYOPATHIES 
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
NORTRIPTYLINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ORTHOSTATIC HYPOTENSION 
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
MORPHINE, OXYCODONE;OPRM1;rs1799971;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
MORPHINE, OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
CARBAMAZEPINE;HNF4A;rs2071197;GG;EFFICACY;INCREASED-PK;PK;CONCENTRATION-TO-DOSE RATIOS 
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED-;OTHER;WARFARIN DOSE 
PRAVASTATIN;MTHFR;rs1801133;GG;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;CORONARY ARTERY DISEASE, MYOCARDIAL INFARCTION 
SUNITINIB;ABCB1;rs1128503;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG + GG;EFFICACY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;TNF;rs1800629;AA + AG;EFFICACY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IL10;rs1800872;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
SUNITINIB;ABCB1;rs2032582;AA + AT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSIENT ISCHEMIC ATTACK, STROKE 
SUNITINIB;VEGFA;rs2010963;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED-SEVERITY;OTHER;SMOKING 
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED-SEVERITY;OTHER;SMOKING 
;CHRNA5;rs16969968;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;SCHIZOPHRENIA 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
CLOPIDOGREL;N6AMT1;rs2254638;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA, TOXIC LIVER DISEASE 
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED-SEVERITY;OTHER;CRAVING 
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
ERYTHROMYCIN;SLCO1B1;rs4149056;C;LADME-PK;DECREASED-PK;PK;ERYTHROMYCIN METABOLISM 
PAZOPANIB, SIMVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
GENTAMICIN;MT-RNR1;rs267606617;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
CYCLOSPORINE, TACROLIMUS;LEP;rs2167270;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS 
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
MERCAPTOPURINE;NUDT15;rs73189762;GT;DOSAGE;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
ETHANOL;HTR3B;rs1176744;C;OTHER;INCREASED-LIKELIHOOD;DISEASE;ALCOHOL ABUSE 
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED-;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MUCOSITIS 
METHOTREXATE;ADORA2A, SPECC1L;rs5760410;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
CALCIUM CHANNEL BLOCKERS, NITRENDIPINE;KCNH2;rs1137617;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
CLOPIDOGREL;KDR;rs7667298;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ANGINA PECTORIS 
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED-RISK;DISEASE;GRAFT VS HOST DISEASE 
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED-RISK;DISEASE;GRAFT VS HOST DISEASE 
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED-SEVERITY;OTHER;CRAVING 
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;rs1801133;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
;MTHFR;rs1801131;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
BUSULFAN, CYCLOPHOSPHAMIDE, METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RELAPSE 
CLOPIDOGREL;KDR;rs2305948;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGINA PECTORIS, MYOCARDIAL INFARCTION 
METHOTREXATE;ABCB1;rs1128503;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;MUCOSITIS 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ORAL MUCOSITIS 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
;FKBP5;rs1360780;CC + CT;;INCREASED-RISK;OTHER;POST-TRAUMATIC STRESS DISORDER (PTSD) 
;FKBP5;rs3800373;AA + AC;OTHER;INCREASED-RISK;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY 
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
;TBX21;rs17244587;A;;INCREASED-RISK;DISEASE;MAJOR DEPRESSIVE DISORDER 
;PSMB4;rs2296840;T;OTHER;INCREASED-RISK;DISEASE;MAJOR DEPRESSIVE DISORDER 
METFORMIN;SLC22A1;rs34059508;A;DOSAGE, LADME-PK;INCREASED-PK;PK;BIOAVAILABILITY 
METFORMIN;SLC22A1;rs12208357;C;DOSAGE, LADME-PK;INCREASED-PK;PK;BIOAVAILABILITY (AUC, CL & AUC/CL RATIO) 
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BLEEDING EVENTS 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DEATH 
;CHRNA5;rs680244;C;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
METHOTREXATE;PTPN22;rs2476601;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
;CHRNA3;rs1051730;G;;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
METHOTREXATE;TNFAIP3;rs6920220;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
;CHRNA3, CHRNA5;rs578776;G;;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
;CHRNA5;rs16969968;A;;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
RISPERIDONE;ABCB1;rs1045642;AA;LADME-PK;INCREASED-SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA 
;CHRNA5;rs569207;C;;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;CYP1A1;rs2606345;A;EFFICACY, LADME-PK;INCREASED-RISK;DISEASE;SEIZURES 
;SLCO1B3;rs2417940;C;OTHER;INCREASED-SEVERITY;OTHER;NEONATAL HYPERBILIRUBINEMIA, HYPERBILIRUBINEMIA 
SERTRALINE;;rs13432159;G;TOXICITY;INCREASED-;SIDE_EFFECT;GENERAL SIDE-EFFECTS 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;RELAPSE FREE TIME 
;KIF6;rs20455;AG + GG;OTHER;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED-;SIDE_EFFECT;ANEMIA 
ROSUVASTATIN;GATM;rs9806699;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
TAMOXIFEN;CYP2D6;rs3892097;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED-;SIDE_EFFECT;ANEMIA 
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
FLUOROURACIL, IRINOTECAN, OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUROTOXICITY SYNDROMES, NEUTROPENIA 
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED-;OTHER;CORONARY FLOW RESERVE 
HMG COA REDUCTASE INHIBITORS;;rs116561224;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
;KCNH2;rs3815459;T;OTHER;INCREASED-;OTHER;QT INTERVAL 
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;;rs114577328;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ANTIDEPRESSANTS;HTR2A;rs17288723;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
;KCNH2;rs3807375;CT + TT;OTHER;INCREASED-;OTHER;QT INTERVAL 
CITALOPRAM;GRIK4;rs1954787;C;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;NON-RESPONSE 
;KCNH2;rs1805123;GT + TT;OTHER;INCREASED-;OTHER;QT INTERVAL 
CYCLOSPORINE;NR1I2;rs2276707;C;DOSAGE, LADME-PK;DECREASED-PK;PK;BIOAVAILABILITY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799930;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
PLATINUM COMPOUNDS;GSTP1;rs1695;G;TOXICITY, LADME-PK;DECREASED-RISK;DISEASE;NEUTROPENIA 
CLOZAPINE;;rs149104283;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
;KCNH2;rs1805123;G;OTHER;DECREASED-;OTHER;QT INTERVAL 
ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
;KCNH2;rs3807375;T;OTHER;INCREASED-;OTHER;QT INTERVAL 
OXALIPLATIN;GSTP1;rs1695;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUROTOXICITY SYNDROMES 
;KCNQ1;rs757092;G;OTHER;INCREASED-;OTHER;QT INTERVAL 
;KCNH2;rs3815459;T;OTHER;INCREASED-;OTHER;QT INTERVAL 
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED-;OTHER;ADENOSINE-STIMULATED MYOCARDIAL FLOW 
;VEGFA;rs2010963;CG + GG;OTHER;INCREASED-RISK;OTHER;PREMATURE BIRTH 
;KCNH2;rs1805123;GG;OTHER;DECREASED-;OTHER;QT INTERVAL 
;KCNQ1;rs757092;G;OTHER;INCREASED-;OTHER;QT INTERVAL 
OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY, LADME-PK;INCREASED-SEVERITY;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;INFECTIOUS DISEASE 
CYCLOSPORINE;NR1I2;rs2276707;T;DOSAGE, LADME-PK;INCREASED-PK;PK;BIOAVAILABILITY 
RIFAMPIN;NR1I2;rs3814055;TT;OTHER;INCREASED-PK;PK;ERYTHROMYCIN BREATH TEST 
PLATINUM COMPOUNDS;CCN4;rs2977549;CC + CT;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CITALOPRAM;HTR2A;rs7997012;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
TACROLIMUS;CYP3A4;rs2740574;CC + TT;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
CYCLOSPORINE;NR1I2;rs3814055;C;DOSAGE, LADME-PK;DECREASED-PK;PK;BIOAVAILABILTY 
ASPIRIN, CLOPIDOGREL;MYOM2;rs17064642;CC + CT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
ANTIDEPRESSANTS;HTR2A;rs7997012;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
SUFENTANIL;COMT;rs4680;AA + AG;DOSAGE;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
ANTIDEPRESSANTS;GRIK4;rs12800734;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
;KIF6;rs20455;AG + GG;OTHER;INCREASED-RISK;DISEASE;CORONARY DISEASE 
PRAVASTATIN;SLCO1B1;rs2306283;G;LADME-PK;DECREASED-PK;PK;PLASMA AUC 
PRAVASTATIN;SLCO1B1;rs4149015;AG;OTHER, LADME-PK;INCREASED-PK;PK;AUC0-12 
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
PLATINUM COMPOUNDS;CCN4;rs2977551;CC + CT;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
FLUOROURACIL;TP53;rs1042522;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PEGINTERFERON ALFA-2A, RIBAVIRIN;ITPA;rs6051702;AC + CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ANEMIA 
NICOTINE;CHRNA3, CHRNA5;rs578776;GG;TOXICITY;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
NICOTINE;CHRNA4;rs1044396;AA;TOXICITY;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
NICOTINE;CHRNA4;rs2229959;CC;TOXICITY;INCREASED-LIKELIHOOD;OTHER;SMOKING CESSATION 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;rs13306278;T;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
PRAVASTATIN;TLR4;rs4986790;AG + GG;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;CARDIOVASCULAR EVENTS 
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606617;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
PEGINTERFERON ALFA-2A, RIBAVIRIN;VDR;rs1544410;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED-;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
FLUOROURACIL;IGFBP3;rs2854746;CC;EFFICACY;;OTHER;BETTER SURVIVAL OUTCOME 
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO ACHIEVE STABLE DOSE 
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DYING 
PLATINUM COMPOUNDS;ERCC2, KLC3;rs13181;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DYING 
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED-;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DYING 
CLOPIDOGREL;ABCB1;rs2032582;AA;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DISEASE PROGRESSION 
CARBOPLATIN, PACLITAXEL;NR1I2;rs1523130;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;SURVIVAL 
CARBOPLATIN, PACLITAXEL;NR1I2;rs1523127;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
IRINOTECAN;UGT1A1;rs10929302;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;THROMBOCYTOPENIA 
NICOTINE;CHRNA4;rs1044396;G;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
CISPLATIN;LRP2;rs2075252;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CAPECITABINE;CDA;rs3215400;C/del + CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CLOPIDOGREL;POR;rs2286823;GG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
SUNITINIB;POR;rs1057868;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SUNITINIB;SLCO1B3;rs4149117;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED-;SIDE_EFFECT;TIME ABOVE THERAPEUTIC RANGE 
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;HAND-FOOT SYNDROME 
CLOPIDOGREL;CES1P1;rs3785161;AC + CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-TREATMENT PLATELET ACTIVITY 
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
METHOTREXATE;ATIC;rs2372536;G;;SEVERITY-;DISEASE;RHEUMATOID ARTHRITIS 
LEUCOVORIN, TEGAFUR;FASTKD3, MTRR;rs1801394;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;STOMATITIS 
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANY GRADE 3 ADVERSE EVENT 
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
PAZOPANIB;CXCL8;rs1126647;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
NICOTINE;CHRNA4;rs2236196;G;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs111564371;CT;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED DIASTOLIC BLOOD PRESSURE, ELEVATED SYSTOLIC BLOOD PRESSURE 
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MUCOSITIS 
NICOTINE;CHRNA3;rs1051730;AA + AG;TOXICITY;DECREASED-;SIDE_EFFECT;LUNG FUNCTION 
CYCLOPHOSPHAMIDE, FLUOROURACIL;MTHFR;rs1801133;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
CARBAMAZEPINE;HSPA1A;rs1043620;T;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;HYPERSENSITIVITY 
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CARBAMAZEPINE;HSPA1A;rs506770;G;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;HYPERSENSITIVITY 
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;FIBRIN CLOT FORMATION TIME 
CYCLOPHOSPHAMIDE, FLUOROURACIL;TP53;rs1042522;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
CARBAMAZEPINE;HSPA1L;rs2227956;G;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;HYPERSENSITIVITY 
CLOPIDOGREL;P2RY12;rs6787801;AG + GG;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY IN CYP2C19*1/*1 CARRIERS 
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED-;SIDE_EFFECT;HYPERTENSION 
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION, TREATMENT INTERRUPTION 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;EXPOSURE 
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED-;SIDE_EFFECT;HYPERTENSION 
CARBAMAZEPINE;MLN;rs2894342;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY SYNDROME 
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;INCREASED-PK;PK;EXPOSURE 
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED-;SIDE_EFFECT;ANXIETY 
CAFFEINE;ADORA2A;rs2298383;CC;TOXICITY;INCREASED-;SIDE_EFFECT;ANXIETY 
CAFFEINE;;rs4822492;CC;TOXICITY;INCREASED-;SIDE_EFFECT;ANXIETY 
;MT-RNR1;rs267606617;G;OTHER;INCREASED-LIKELIHOOD;OTHER;HEARING LOSS, SENSORINEURAL 
CARBAMAZEPINE;;rs3130690;T;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
CAFFEINE;ADORA2A;rs5751876;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;BEING SENSITIVE TO CAFFEINE 
CAFFEINE;ADORA2A;rs5751876;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INSOMNIA 
ETHANOL, HEROIN, METHAMPHETAMINE;ANKS1B;rs2133896;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE, HEROIN DEPENDENCE, METHAMPHETAMINE DEPENDENCE, 
CARBAMAZEPINE;MICA;rs2848716;C;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs2965667;TT;OTHER;DECREASED-RISK;DISEASE;COLORECTAL NEOPLASMS 
CAFFEINE;ADORA2A;rs5751876;TT;DOSAGE;DECREASED-;OTHER;HABITUAL CONSUMPTION 
CARBAMAZEPINE;BAG6, PRRC2A;rs750332;C;TOXICITY;INCREASED-RISK;DISEASE;STEVENS-JOHNSON SYNDROME 
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs16973225;AA;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
;CHRNA5;rs588765;T;EFFICACY;EFFICACY;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP 
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED-;OTHER;WARFARIN DOSE 
RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA 
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PERCENTAGE CHANGE IN HDL-C LEVELS 
ALENDRONATE;SOST;rs1234612;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;BONE DENSITY 
CYTARABINE, DAUNORUBICIN;ABCB1;rs1128503;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
CYTARABINE, DAUNORUBICIN;CDA;rs532545;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;COLITIS 
CYTARABINE, DAUNORUBICIN;ABCB1;rs1045642;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
ALENDRONATE;SOST;rs865429;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;BONE DENSITY 
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMOLYTIC ANEMIA 
CYTARABINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;MED12L, P2RY12;rs6801273;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY 
CYTARABINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;MED12L;rs6798347;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY 
ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL (PFS) TIME 
CYTARABINE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SEVOFLURANE;ABCB1;rs1128503;GG;OTHER;DECREASED-LIKELIHOOD;OTHER;ADVERSE EVENTS 
TACROLIMUS;KCNJ11;rs5219;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIABETES MELLITUS, TYPE 2 
ACE INHIBITORS, PLAIN;ETV6;rs2724635;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
SUNITINIB;ABCB1;rs1128503;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ASPIRIN;TAPBP;rs2071888;CC + CG;TOXICITY;INCREASED-;SIDE_EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE 
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;rs3740065;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;COMPOSITE OUTCOME OF NON-FATAL MI, ALL CAUSE DEATH AND STENT THROMBOSIS 
HYDROCHLOROTHIAZIDE;KCNJ1;rs12795437;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS 
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
VALPROIC ACID;LEPR;rs1137101;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
PHENYTOIN;CFHR4;rs78239784;G;TOXICITY;INCREASED-RISK;DISEASE;MACULOPAPULAR EXANTHEMA 
HYDROCHLOROTHIAZIDE;KCNJ1;rs11600347;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS 
CABAZITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
VALPROIC ACID;ANKK1;rs1800497;AG + GG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
HYDROCHLOROTHIAZIDE;KCNJ1;rs658903;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS 
CABAZITAXEL;ABCB1;rs1045642;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
CLOPIDOGREL;P2RY12;rs6787801;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY 
CABAZITAXEL;CYP3A5;rs776746;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ACE INHIBITORS, PLAIN;PRKCQ;rs500766;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
HYDROCHLOROTHIAZIDE;KCNJ1;rs675388;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DIABETES MELLITUS 
DOXORUBICIN;GSTP1;rs1695;GG;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;CHEMORESISTANCE 
CABAZITAXEL;ABCB1;rs1128503;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
PROPOFOL;DRD2;rs2283265;AA + AC;OTHER;DECREASED-;OTHER;HEART RATE 
NICOTINE;CHRNA4;rs2236196;A;OTHER;INCREASED-LIKELIHOOD;OTHER;NICOTINE DEPENDENCE 
ACETAMINOPHEN;UGT1A;rs1042640;CG + GG;TOXICITY;DECREASED-RISK;DISEASE;LIVER FAILURE, ACUTE 
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;DECREASED-;SIDE_EFFECT;BLEEDING EVENTS 
ACETAMINOPHEN;UGT1A;rs8330;CG + GG;TOXICITY;DECREASED-RISK;DISEASE;LIVER FAILURE, ACUTE 
GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;RESPONSE RATE (RR) 
HYDROCHLOROTHIAZIDE;KCNJ1;rs59172778;AG;TOXICITY;INCREASED-;SIDE_EFFECT;SERUM POTASSIUM 
ETHANOL;CACNA1C;rs1034936;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALCOHOL ABUSE 
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, THROMBOCYTOPENIA 
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
WARFARIN;EPHA7;rs114504854;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ACETAMINOPHEN;UGT1A;rs10929303;CT + TT;TOXICITY;DECREASED-RISK;DISEASE;LIVER FAILURE, ACUTE 
ACE INHIBITORS, PLAIN;XPNPEP2;rs2050011;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;TNF;rs1800629;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
NICOTINE;ADGRL3;rs2271339;AG;TOXICITY;INCREASED-RISK;OTHER;TOBACCO USE DISORDER 
NICOTINE;ADGRL3;rs1456862;AT;TOXICITY;INCREASED-RISK;OTHER;TOBACCO USE DISORDER 
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE (RR) 
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
ETHANOL;MAP2K4;rs2159140;CT;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
SUNITINIB;ABCB1;rs1045642;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA, MUCOSITIS 
SORAFENIB;UGT1A9;rs17868320;T;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL (OS) TIME 
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE (RR) 
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPOVENTILATION 
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) (MORE THAN ONE YEAR) WHEN RECEIVING A LOADING DOSE OF 300 MG 
DOCETAXEL;ABCC10;rs2125739;CT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
;ARNT;rs2228099;CG + GG;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs3813867;GG;TOXICITY;INCREASED-SEVERITY;DISEASE;TOXIC LIVER DISEASE 
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) 
;DEPTOR;rs4871827;AA + AG;OTHER;INCREASED-;OTHER;HDL CHOLESTEROL 
CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;DEPTOR;rs4871827;AG;OTHER;DECREASED-LIKELIHOOD;OTHER;BRAIN ISCHEMIA, MYOCARDIAL INFARCTION, PERIPHERAL VASCULAR DISEASES, 
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;rs3745274;TT;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
;DEPTOR;rs4871827;AG;OTHER;DECREASED-LIKELIHOOD;OTHER;DIABETIC RETINOPATHY, CHRONIC KIDNEY FAILURE 
LOSARTAN;STK39;rs6749447;GG + GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN AMBULATORY BLOOD PRESSURE 
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EARLY MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) 
;AHR;rs2066853;AA + AG;OTHER;INCREASED-RISK;OTHER;ADENOMATOUS AND HYPERPLASTIC POLYPS 
RISPERIDONE;HTR6;rs9659997;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA 
CISPLATIN, IRINOTECAN;DCBLD1;rs17574269;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CISPLATIN, IRINOTECAN;;rs7186128;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
RISPERIDONE;TYMS;rs3786362;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERPROLACTINEMIA 
;TNF;rs1800630;C;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;LEUKOCYTOSIS 
CISPLATIN, IRINOTECAN;;rs2166219;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
RISPERIDONE;HTR2A;rs6311;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA 
CISPLATIN, IRINOTECAN;;rs4655567;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY, NEUROTOXICITY SYNDROMES 
CISPLATIN, IRINOTECAN;;rs2018683;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
RISPERIDONE;BDNF;rs6265;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA 
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ADORA2A;rs2236624;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
LEUCOVORIN, METHOTREXATE;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED-PK;PK;DISTRIBUTION VOLUME 
CISPLATIN, IRINOTECAN;;rs2018683;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESISTANT RELAPSE 
;OPRM1;rs1799971;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;HEROIN DEPENDENCE 
CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESISTANT RELAPSE 
CISPLATIN, IRINOTECAN;;rs4655567;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESISTANT RELAPSE 
METHOTREXATE;ABCC4;rs7317112;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
RISPERIDONE;UGT1A1;rs1976391;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERPROLACTINEMIA 
RISPERIDONE;HTR2C;rs6318;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERPROLACTINEMIA 
CYCLOSPORINE;;rs2275913;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
LENALIDOMIDE;ABCB1;rs2032582;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
HEROIN;DBH;rs1611114;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MEMORY IMPAIRMENT 
DILTIAZEM;PLCD3;rs12946454;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
CAPECITABINE, FLUOROURACIL, OXALIPLATIN;MTHFR;rs1801131;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
DOCETAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
"""BETA BLOCKING AGENTS"", ""THIAZIDES, PLAIN""";;rs11191548;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE 
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;WITHDRAWAL 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;MINIMUM PLASMA CONCENTRATIONS 
MORPHINE;ABCB1;rs9282564;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPOVENTILATION 
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ABCC1;rs246240;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
LENALIDOMIDE;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED-;OTHER;BLOOD PRESSURE 
LENALIDOMIDE;GSTP1;rs1695;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
CISPLATIN, IRINOTECAN;ABCC4;rs16950650;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;OTHER;INCREASED-;OTHER;COLLAGEN-INDUCED PLATELET AGGREGATION 
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;ABCB1;rs1045642;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA 
GEMCITABINE;SLC29A3;rs780668;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED-RISK;DISEASE;DIARRHEA 
ATORVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
CAFFEINE;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ALBUMINURIA, HYPERTENSION 
GEMCITABINE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;LADME-PK;DECREASED-PK;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE 
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, MUSCULAR DISEASES, RHABDOMYOLYSIS, TOXIC LIVER DISEASE
ALLOPURINOL;CFLAR;rs1594;A;TOXICITY;;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
OXYCODONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
CAPECITABINE;CES2;rs11075646;CG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;TIME TO PROGRESSION 
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE OF DISEASE 
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS 
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;DECREASED-;OTHER;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS 
ASPIRIN;AGT;rs5050;GG;TOXICITY;INCREASED-RISK;DISEASE;PEPTIC ULCER HEMORRHAGE 
SUNITINIB;NR1I2;rs6785049;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
BUPROPION;SACM1L;rs2251954;C;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
ROSUVASTATIN;GATM;rs9806699;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME-PK;DECREASED-PK;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE 
BUPROPION;SACM1L;rs2742421;G;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;rs28371759;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ROSUVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;LDL-C REDUCTION 
BUPROPION;SACM1L;rs2742423;G;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;;SIDE_EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY 
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;LADME-PK;DECREASED-PK;PK;EXPOSURE TO CLOPIDOGREL ACTIVE METABOLITE 
BUPROPION;SACM1L;rs1969624;T;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
EFAVIRENZ;NR1I3;rs2307424;GG;TOXICITY;;SIDE_EFFECT;EARLY (< 3 MONTHS) TERMINATION OF EFAVIRENZ THERAPY 
BUPROPION;SACM1L;rs2245705;C;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
BUPROPION;SACM1L;rs2742435;G;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;INHIBITION OF PLATELET AGGREGATION AND POOR-RESPONDER STATUS 
BUPROPION;SACM1L;rs2742390;A;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
SIMVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;LDL-C REDUCTION 
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED-LIKELIHOOD;OTHER;EARLY RELAPSE 
SIMVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;LDL-C REDUCTION 
PEMETREXED;DHFR;rs442767;GG;TOXICITY;INCREASED-RISK;DISEASE;FATIGUE 
FLUOROURACIL;MTHFR;rs1801131;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
BUPROPION;SACM1L;rs2742417;T;TOXICITY;DECREASED-;SIDE_EFFECT;SEXUAL SIDE-EFFECTS 
TEMSIROLIMUS;NR1I2;rs3814055;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
SUNITINIB;FLT3;rs1933437;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
CAPECITABINE;CES1;rs71647871;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HAND-FOOT SYNDROME, DRUG TOXICITY 
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
GEMCITABINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
ROSUVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;LDL-C REDUCTION 
NALTREXONE;OPRD1;rs4654327;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;NALTREXONE-INDUCED BLUNTING OF ALCOHOL STIMULATION AND ALCOHOL CRAVING 
IRINOTECAN;UGT1A;rs11563250;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ATORVASTATIN, SIMVASTATIN;RYR2;rs2819742;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;MUSCULAR DISEASES, MYALGIA 
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs2347128;GG;EFFICACY;INCREASED-;OTHER;PROGRESSION-FREE SURVIVAL 
;MET;rs40239;AG + GG;OTHER;INCREASED-;OTHER;OVERALL SURVIVAL 
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION, DRUG TOXICITY, ADVERSE EVENTS, 
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs17718347;TT;EFFICACY;INCREASED-;OTHER;PROGRESSION-FREE SURVIVAL 
;MET;rs40239;AG + GG;OTHER;INCREASED-;OTHER;OVERALL SURVIVAL 
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;rs1045642;AA;TOXICITY, LADME-PK;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
EFAVIRENZ;CYP2B6;rs3745274;T;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA EFAVIRENZ EXPOSURE (AUC) DURING THE FIRST 24 WEEKS OF ANTIRETROVIRAL THERAPY 
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED-RISK;DISEASE;CENTRAL NERVOUS SYSTEM DISORDER 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs112563513;A;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
EFAVIRENZ;CYP3A4;rs2740574;C;OTHER, LADME-PK;INCREASED-PK;PK;PLASMA EFAVIRENZ EXPOSURE 
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DISCONTINUATION 
EFAVIRENZ;CYP3A5;rs776746;C;LADME-PK;DECREASED-PK;PK;PLASMA EFAVIRENZ EXPOSURE 
CLOPIDOGREL;ABCB1;rs1045642;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT; CARDIOVASCULAR EVENTS 
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
ACE INHIBITORS, PLAIN;MME;rs989692;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANGIOEDEMA 
HMG COA REDUCTASE INHIBITORS;LILRB5;rs12975366;TT;DOSAGE, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE;HTR2A;rs6311;TT;TOXICITY;INCREASED-LIKELIHOOD;OTHER;PHYSIOLOGICAL SEXUAL DISORDER 
CABAZITAXEL;CYP3A5;rs776746;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs6311;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
CABAZITAXEL;TUBB1;rs463312;AC;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ISCHAEMIC EVENTS 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4986893;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
NEVIRAPINE;CYP2B6;rs28399499;C;LADME-PK;INCREASED-;OTHER;PLASMA LEVEL 
;SLC2A9;rs16890979;T;LADME-PK;DECREASED-PK;PK;SERUM URIC ACID 
CYCLOPHOSPHAMIDE;IKZF3;rs9908694;CC;EFFICACY;INCREASED-;DISEASE;EVENT-FREE SURVIVAL 
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;DECREASED-RISK;DISEASE;DRUG TOXICITY 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192122;A;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922816;T;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
METHAMPHETAMINE;DRD4;rs1800955;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG PSYCHOSIS 
BEVACIZUMAB;GC;rs4588;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CETUXIMAB;GC;rs4588;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs28933397;T;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
ASPIRIN;TAPBP;rs1059288;AG + GG;TOXICITY;INCREASED-;SIDE_EFFECT;FEV1 DECREASE AFTER ASPIRIN CHALLENGE 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs140530655;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
GEFITINIB;IKBKB;rs2272733;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;EXANTHEMA 
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922772;T;OTHER;INCREASED-RISK;DISEASE;MALIGNANT HYPERTHERMIA 
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
FENOTEROL;SLC22A1;rs12208357;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
FENOTEROL;SLC22A1;rs34130495;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
ACE INHIBITORS, PLAIN;AGT;rs699;GG;EFFICACY;DECREASED-RISK;DISEASE;STROKE 
;P2RY12;rs2046934;G;OTHER;INCREASED-RISK;DISEASE;PERIPHERAL VASCULAR DISEASES 
GEFITINIB;RELA;rs11227247;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
FENOTEROL;SLC22A1;rs55918055;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
IRINOTECAN;KCNQ5;rs9351963;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
FENOTEROL;SLC22A1;rs34059508;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
;P2RY12;rs2046934;G;OTHER;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION 
GEFITINIB;IKBKE;rs2151222;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
ISONIAZID, PHENYTOIN;NAT2;rs1801280;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ISONIAZID, PHENYTOIN;NAT2;rs1799931;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
TAMOXIFEN;CYP2D6;rs28371725;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
TAMOXIFEN;CYP2D6;rs3892097;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
TAMOXIFEN;CYP2D6;rs1065852;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;EFFICACY;EFFICACY;IMPROVED RESPONSE 
GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE EVENTS 
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCR2;rs2230054;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
GEMCITABINE;SLCO1B1;rs4149086;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE DRUG REACTION 
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;rs5443;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;OTHER;DECREASED-RISK;DISEASE;DEATH 
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
;CHRNA3;rs1051730;A;OTHER;INCREASED-RISK;DISEASE;LUNG NEOPLASMS 
CITALOPRAM;GRIK2;rs2518224;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION 
ACENOCOUMAROL, WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
IRINOTECAN;UGT1A9;rs7586110;G;TOXICITY;INCREASED-RISK;DISEASE;ANEMIA 
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
;HYKK;rs8034191;C;OTHER;INCREASED-RISK;DISEASE;LUNG NEOPLASMS 
ISONIAZID, PHENYTOIN;NAT2;rs1041983;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
TACROLIMUS;TCF7L2;rs290487;CC + CT;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
ACE INHIBITORS, PLAIN;AGT;rs699;GG;EFFICACY;DECREASED-RISK;DISEASE;STROKE 
GEMCITABINE;POLR2A;rs2228130;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
VALPROIC ACID;CYP2C9;rs1057910;AC;OTHER, LADME-PK;INCREASED-PK;PK;MEAN PLASMA DRUG CONCENTRATIONS 
CITALOPRAM;GRIA3;rs4825476;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TREATMENT-EMERGENT SUICIDAL IDEATION 
IMATINIB;SLC22A5;rs274558;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, EYE DISEASES 
ISONIAZID, PHENYTOIN;NAT2;rs1208;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ANTIPSYCHOTICS;COMT;rs4818;CC + CG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;TARDIVE DYSKINESIA 
;CHRNA3;rs1051730;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL VASCULAR DISEASES 
;CHRNA3;rs1051730;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;LUNG NEOPLASMS 
DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
ISONIAZID, PHENYTOIN;NAT2;rs1799930;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
;CHRNA3;rs1051730;A;OTHER;INCREASED-;OTHER;NUMBER OF CIGARETTES SMOKED PER DAY 
ISONIAZID, PHENYTOIN;NAT2;rs1799929;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
IMATINIB;ABCB1;rs2235040;CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, EYE DISEASES 
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) 
IMATINIB;EGFR;rs10258429;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, EYE DISEASES 
ANTIPSYCHOTICS;COMT;rs165599;AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;TARDIVE DYSKINESIA 
IMATINIB;SLC22A1;rs683369;CG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, EYE DISEASES 
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OBESITY 
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";HTR2A;rs6305;A;OTHER;INCREASED-LIKELIHOOD;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME 
ASPIRIN;TBXA2R;rs4523;AA;EFFICACY;INCREASED-RISK;OTHER;HIGH ON-ASPIRIN RESIDUAL PLATELET REACTIVITY 
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DBH;rs1611115;T;OTHER;DECREASED-LIKELIHOOD;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME 
RISPERIDONE;DRD2;rs1799978;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INSULIN RESISTANCE 
PACLITAXEL;ABCB1;rs2032582;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";OPRM1;rs1799971;G;OTHER;INCREASED-LIKELIHOOD;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";BDNF;rs6265;T;OTHER;DECREASED-LIKELIHOOD;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME 
ANTIPSYCHOTICS;COMT;rs4680;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;TARDIVE DYSKINESIA 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";COMT;rs4680;AA;OTHER;DECREASED-LIKELIHOOD;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME 
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERTENSION 
TACROLIMUS;CAPN10;rs5030952;CT;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
WARFARIN;CYP2C18;rs2901783;G;DOSAGE;;OTHER;OUTCOME TIME TO STABLE DOSE 
IDARUBICIN;RAC2;rs13058338;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DRD2;rs6275;AA;OTHER;DECREASED-LIKELIHOOD;DISEASE;HEADACHE DISORDERS, SUBSTANCE WITHDRAWAL SYNDROME 
IDARUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOTOXICITY 
OPIOIDS;OPRM1;rs9479757;AG;OTHER;DECREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;ITPA;rs1127354;AA + AC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ANEMIA 
OPIOIDS;GAL;rs948854;CC;OTHER;INCREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
OPIOIDS;ABCB1;rs1045642;GG;OTHER;DECREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
OPIOIDS;OPRD1;rs2236861;A;OTHER;DECREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
IDARUBICIN;CYBA;rs4673;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
HYDROCHLOROTHIAZIDE;NOS3;rs1799983;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN DIASTOLIC BLOOD PRESSURE 
IDARUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PRAVASTATIN;CETP;rs708272;A;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;SLC28A2;rs11854484;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
DIURETICS;PDE4D;rs702553;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;BASELINE MEAN ARTERIAL BLOOD PRESSURE 
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2235040;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS 
ESCITALOPRAM;KCNE1;rs1805127;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET INHIBITION 
ESCITALOPRAM;KCNE1;rs4817668;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISK;OTHER;HIGH PLATELET REACTIVITY 
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs588765;T;EFFICACY;EFFICACY;EFFICACY;INCREASED  CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY) 
;CHRNA3;rs1051730;A;EFFICACY;EFFICACY;EFFICACY;DECREASED CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IN THE PLACEBO GROUP 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCYTOPENIA, THROMBOCYTOPENIA 
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;rs1051730;A;EFFICACY;EFFICACY;EFFICACY;INCREASED  CHANCE OF ACHIEVING 6 MONTH ABSTINENCE IF PRESCRIBED NRT (NICOTIENE REPLACEMENT THERAPY) 
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2032583;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EFFECTS 
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs4148737;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCC3;rs4148416;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
;FOXO3;rs4946936;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
;FOXO3;rs17069665;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;ARNT;rs3215133;T/del + del/del;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
ETHANOL;GHSR;rs2232165;AG;OTHER;;OTHER;HEAVY CONSUMPTION 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs1045642;G;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs10276036;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTIPSYCHOTICS;NEFM;rs1379357;G;EFFICACY;EFFICACY;EFFICACY;RESPONSE TIME 
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs1128503;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DEATH 
ANTIPSYCHOTICS;NEFM;rs1457266;G;EFFICACY;EFFICACY;EFFICACY;RESPONSE TIME 
;ARNT;rs12410394;AA + AG;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
CELECOXIB;IL23R;rs7518660;A;TOXICITY;INCREASED-RISK;DISEASE;ADENOMA 
CELECOXIB;ALOX12;rs11078659;A;TOXICITY;INCREASED-RISK;DISEASE;ADENOMA 
;CYP1A2;rs2470890;CT + TT;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
;;rs11072508;CT + TT;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
CELECOXIB;PTGES;rs2302821;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR TOXICITY AND SYMPTOMS 
;CSK;rs4886410;CG + GG;OTHER;DECREASED-LIKELIHOOD;DISEASE;COLORECTAL NEOPLASMS 
CELECOXIB;PTGER4;rs4133101;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITIES 
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH3A1;rs2228100;CC + CG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;CYSTITIS 
TAMOXIFEN;ABCC2;rs3740065;AA;EFFICACY, LADME-PK;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE OF BREAST CANCER 
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INSOMNIA 
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs1045642;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
FARGLITAZAR, INSULINS AND ANALOGUES;SCNN1B;rs34241435;A;TOXICITY;;SIDE_EFFECT;OEDEMA 
HYDROCHLOROTHIAZIDE;SCNN1G;rs5723;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE 
FARGLITAZAR, GLYBURIDE;SCNN1B;rs889299;A;TOXICITY;;SIDE_EFFECT;OEDEMA 
HYDROCHLOROTHIAZIDE;SCNN1G;rs5729;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN OFFICE DIASTOLIC BLOOD PRESSURE 
GEFITINIB;IKBKE;rs12142086;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
NICOTINE;CHRNA5;rs680244;C;OTHER;DECREASED-LIKELIHOOD;OTHER;ABSTINENCE 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS, ORAL ULCER 
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATION 
LORAZEPAM;UGT2B15;rs1902023;AA;LADME-PK;INCREASED-PK;PK;AREA UNDER THE VISUAL ANALOG SCALE-TIME CURVE DURING THE INDUCED STATE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs3213619;G;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;TUBB2A;rs9501929;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
NALOXONE, OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ERYTHEMA 
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;DECREASED-PK;PK;DOSE-ADJUSTED TACROLIMUS BLOOD CONCENTRATIONS 
NICOTINE;CHRNA5;rs16969968;A;OTHER;DECREASED-LIKELIHOOD;OTHER;ABSTINENCE 
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED LIVER ENZYMES 
BISOPROLOL;CYP3A5;rs776746;TT;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE, ELEVATED DIASTOLIC BLOOD PRESSURE 
NALOXONE, OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ERYTHEMA 
PAZOPANIB;VEGFA;rs2010963;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE 
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
;SLC22A3;rs2504938;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
NALOXONE, OXYCODONE;COMT;rs4680;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC + CG;TOXICITY, LADME-PK;;DISEASE;DIARRHEA 
FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY, LADME-PK;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
BUPRENORPHINE, METHADONE;COMT;rs4680;AG + GG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
;SLC22A3;rs512077;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
BUPRENORPHINE, METHADONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN 
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
GLUCARPIDASE;ABCC4;rs7317112;AG + GG;TOXICITY;INCREASED-RISK;OTHER;NEPHROTOXICITY 
HYDROCHLOROTHIAZIDE;ADRB2;rs2400707;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE 
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
NICOTINE;CHRNA5;rs16969968;GG;OTHER;INCREASED-;OTHER;FUNCTIONAL MRI REACTIVITY TO SMOKING IMAGES 
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;CC;OTHER;INCREASED-;SIDE_EFFECT;URINARY POTASSIUM EXCRETION 
HEROIN;DRD2;rs1076560;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;HEROIN DEPENDENCE 
SUFENTANIL;ABCB1;rs1128503;GG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
HYDROCHLOROTHIAZIDE;WNK1;rs2107614;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE 
HYDROCHLOROTHIAZIDE;RAD52, WNK1;rs2277869;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN WHOLE DAY AMBULATORY BLOOD PRESSURE 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MERCAPTOPURINE, PREDNISONE, VINCRISTINE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MYELOSUPPRESSION 
METFORMIN;SLC47A2;rs34399035;T;LADME-PK;DECREASED-PK;PK;METFORMIN UPTAKE IN HEK-293 CELLS AND REDUCTION IN PROTEIN EXPRESSION LEVELS 
OXALIPLATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERTENSION, HAND-FOOT SYNDROME 
CYTARABINE, IDARUBICIN;CBR3;rs8133052;GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
WARFARIN;;rs16871327;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
WARFARIN;EPHA7;rs78132896;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
FENOFIBRATE;FABP1;rs2241883;CC + CT;TOXICITY;INCREASED-RISK;DISEASE;HYPERTRIGLYCERIDEMIA 
ANTIPSYCHOTICS;SNAP25;rs1051312;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
GEFITINIB;TAB2;rs577001;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFIT1;rs304478;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SVR (SUSTAINED VIROLOGICAL RESPONSE) 
PEGINTERFERON ALFA-2B, RIBAVIRIN;OASL;rs12819210;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
OXALIPLATIN;ABCB1;rs1045642;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;RECURRENCE-FREE SURVIVAL 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PAZOPANIB;VEGFA;rs833061;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
COCAINE;SLC6A3;rs6347;TT;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE (RR) 
ATORVASTATIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs8187710;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL (PFS) TIME 
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs17222723;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP1B1;rs1056836;C;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE (RR) 
GEFITINIB;NFKBIA;rs2233407;AA + AT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SPIDR;rs6473187;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
GEFITINIB;NR1H2;rs2695121;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SLCO1B1;rs3829306;T;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
SUNITINIB;VEGFA;rs2010963;CG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
WARFARIN;;rs115112393;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
ANTIPSYCHOTICS;HTR2C;rs6318;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;HTR2C;rs3813929;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;HTR2C;rs518147;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ATORVASTATIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
ANTIPSYCHOTICS;DRD2;rs6275;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;DRD2;rs7131056;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;INSIG2;rs17047764;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;GNB3;rs5443;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;MC4R;rs489693;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
TIANEPTINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-RISK;OTHER;SUICIDAL IDEATION 
ATORVASTATIN;ABCB1;rs1128503;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
ANTIPSYCHOTICS;BDNF, BDNF-AS;rs6265;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANTIPSYCHOTICS;ADRA2A;rs1800544;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2071559;G;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
THEOPHYLLINE;CYP1A2;rs2069514;GG;LADME-PK;INCREASED-PK;PK;RATIO OF 1,3 DMU/THEOPHYLLINE 
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
GEFITINIB;NFKBIA;rs2233409;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
GEFITINIB;NFKBIA;rs8904;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CLOPIDOGREL RESISTANCE 
GEFITINIB;NFKBIB;rs2053071;CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
LEVODOPA;DRD3;rs6280;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HALLUCINATIONS 
GEFITINIB;NFKBIA;rs2233406;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
CLOPIDOGREL;ITGB3;rs5918;C;EFFICACY;EFFICACY;EFFICACY;LESS DECREASE IN THE PLATELET REACTIVITY AFTER 600 MG OF CLOPIDOGREL 
CLOPIDOGREL;ITGB3;rs5918;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;ANTIPLATELET EFFECT TO A 300 MG CLOPIDOGREL LOADING-DOSE UP TO 24 H FOLLOWING INTERVENTION 
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2070673;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2515641;T;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
PERINDOPRIL;AGTR1;rs275651;TT;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;CARDIAC EVENTS 
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SULT2B1;rs2302948;T;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;FEVER 
ESCITALOPRAM;KCNH2;rs3807372;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ACQUIRED LONG QT SYNDROME (ALQTS) 
HEROIN;OPRM1;rs1799971;AA + AG;OTHER;DECREASED-LIKELIHOOD;OTHER;ADDICTION 
GEFITINIB;IKBKB;rs9694958;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLC22A12;rs11231825;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;FEVER 
GEFITINIB;IKBKE;rs3748022;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXANTHEMA 
ASPIRIN;FSIP1;rs7179742;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA 
ASPIRIN;PTGS1;rs10306114;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE TO ASPIRIN 
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;rs4430924;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ASPIRIN;CEP68;rs7572857;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN-INTOLERANT ASTHMA 
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;ABCB1;rs2032582;A;EFFICACY;INCREASED-RISK;DISEASE;TRANSPLANT REJECTION 
PAROXETINE;HTR2A;rs6311;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NAUSEA 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs10945919;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS 
DAUNORUBICIN, DOXORUBICIN, EPIRUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEFT VENTRICULAR DYSFUNCTION 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;AG;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;AC + CC;EFFICACY;INCREASED-;DISEASE;PROGRESSION-FREE SURVIVAL 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
CYCLOPHOSPHAMIDE, FLUOROURACIL, METHOTREXATE;FGFR4;rs351855;GG;EFFICACY;INCREASED-LIKELIHOOD;OTHER;DISEASE FREE SURVIVAL 
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE 
CLOPIDOGREL;CES1;rs71647871;CT;LADME-PK;INCREASED-PK;PK;LEVELS OF CLOPIDOGREL ACTIVE METABOLITE 
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY; ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION 
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;ON-TREATMENT ADP-INDUCED PLATELET AGGREGATION 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED-PK;PK;CMAX OF THE ACTIVE METABOLITE 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-PK;PK;CMAX OF THE ACTIVE METABOLITE 
CARBOPLATIN, PEMETREXED;MTHFR;rs1801133;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
VEMURAFENIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARCINOMA, SQUAMOUS CELL, HYPERBILIRUBINEMIA, NAUSEA, 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING 
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY INDEX (PRI) AT 4 H AFTER THE DOSING 
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;KLC1, XRCC3;rs861539;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;PK;PK;RISK OF BEING UNDERDOSED 
OPIOIDS;SLC18A2;rs363332;A;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
OPIOIDS;SLC18A2;rs363334;G;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
OPIOIDS;SLC18A2;rs363338;C;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;OPIOID-RELATED DISORDERS 
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;MISP;rs8110536;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;EFFICACY;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION 
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE TO CLOPIDOGREL 
SUNITINIB;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PAZOPANIB;VEGFA;rs699947;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CYTARABINE, IDARUBICIN;NQO2;rs1143684;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED-RISK;DISEASE;HYPERLIPIDEMIAS 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;NON-RESPONSE TO CLOPIDOGREL 
WARFARIN;VEGFA;rs35410204;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
PACLITAXEL;EPHA8;rs209709;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
GLUCOCORTICOIDS, METHOTREXATE, RADIOTHERAPY;CDH2;rs1944294;AT + TT;TOXICITY;DECREASED-;SIDE_EFFECT;BONE DENSITY 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG;TOXICITY;DECREASED-RISK;DISEASE;LYMPHOPENIA 
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;EFFICACY;EFFICACY;HIGHER P2Y12 REACTION UNITS (PRU) AND LOWER PERCENT INHIBITION 
CYTARABINE, IDARUBICIN;NQO1;rs1800566;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
WARFARIN;VEGFA;rs866236;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
PACLITAXEL;ABCG1;rs492338;AA;TOXICITY;INCREASED-RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
OXALIPLATIN;ABCB1;rs1128503;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PACLITAXEL;EPHA6;rs301927;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
;SULT1A1;rs1042028;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
;SULT1A1;rs1042028;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;LUNG NEOPLASMS 
;SULT1A1;rs1042028;T;OTHER;INCREASED-LIKELIHOOD;OTHER;LYMPH NODE METASTASIS 
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET RESPONSIVENESS TO CLOPIDOGREL 
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
CALCIUM;VDR;rs731236;G;EFFICACY;INCREASED-RISK;DISEASE;FRACTURES, BONE 
;SULT1A1;rs1042028;T;OTHER;DECREASED-LIKELIHOOD;DISEASE;UROLOGIC NEOPLASMS 
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET RESPONSIVENESS TO CLOPIDOGREL 
;SULT1A1;rs1042028;T;OTHER;INCREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235040;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs12720067;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ASPIRIN, CLOPIDOGREL;IRS1;rs13431554;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
DOCETAXEL;VAC14;rs875858;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CLOPIDOGREL;CYP3A4;rs2242480;CT + TT;EFFICACY;EFFICACY;EFFICACY;REDUCED GP IIB/IIIA ACTIVATION AND LOWER PLATELET ACTIVATION 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10280101;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;FGG;rs1800792;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs7787082;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
OPIOIDS;COMT;rs6269;AG + GG;OTHER;INCREASED-LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION 
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE 
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;THE TIME TO ACHIEVE A FIRST INR WITHIN THE THERAPEUTIC RANGE 
OSIMERTINIB;EGFR;rs121434569;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL, OVERALL SURVIVAL 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148739;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;EFFICACY;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK 
OPIOIDS;COMT;rs4680;AG + GG;OTHER;INCREASED-LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION 
ETHANOL;ADH1B;rs1229984;TT;LADME-PK;INCREASED-PK;PK;VMAX 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs11983225;C;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;EFFICACY;EFFICACY;SHORTER TIME TO HAVE OVER-ANTICOAGULATION (INR >4) RISK 
OPIOIDS;COMT;rs4818;CG + GG;OTHER;INCREASED-LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION 
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;AVERAGE DAILY DOSE DURING THE FIRST PERIOD OF STABILITY 
OPIOIDS;COMT;rs4633;CC + CT;OTHER;INCREASED-LIKELIHOOD;OTHER;REQUIRING POSTOPERATIVE INTERVENTION 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10248420;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;A;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;F2;rs5896;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
BORTEZOMIB;PKNOX1;rs2839629;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERBILIRUBINEMIA 
SUNITINIB;VEGFA;rs699947;A;TOXICITY;INCREASED-;SIDE_EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED  RISK OF DEVELOPING GRADE 3 HYPERTENSION 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235067;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ATENOLOL;FTO;rs9940629;G;OTHER;;DISEASE;HYPERCHOLESTEROLEMIA 
SUNITINIB;VEGFA;rs833061;C;TOXICITY;INCREASED-;SIDE_EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED  RISK OF DEVELOPING GRADE 3 HYPERTENSION 
ALFENTANIL, FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;PAIN, POSTOPERATIVE 
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED-;SIDE_EFFECT;SYSTOLIC BLOOD PRESSURE AND INCREASED  RISK OF DEVELOPING GRADE 3 HYPERTENSION 
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148740;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
ATENOLOL;ABCB1;rs10267099;G;OTHER;INCREASED-RISK;DISEASE;HYPERCHOLESTEROLEMIA 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;OTHER;DECREASED-;OTHER;PLATELET FUNCTION 
ATENOLOL;ABCB1;rs3213619;G;OTHER;INCREASED-RISK;DISEASE;HYPERCHOLESTEROLEMIA 
CORTICOSTEROIDS;DCAF4;rs7160796;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;CHANGE IN FORCED EXPIRATORY VOLUME IN 1 S (FEV1) 
SUNITINIB;NOS3;rs2070744;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GRADE 3 HYPERTENSION 
ATENOLOL;PRKCB;rs11649514;GT + TT;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERGLYCEMIA 
ATENOLOL;FTO;rs12595985;AA;OTHER;INCREASED-RISK;DISEASE;HYPERCHOLESTEROLEMIA 
CYCLOPHOSPHAMIDE;ALDH1A1;rs8187996;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, TREATMENT MODIFICATION 
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;OTHER;DECREASED-;OTHER;PLATELET FUNCTION 
ATENOLOL;GALNT2;rs2144297;T;OTHER;;DISEASE;HYPERCHOLESTEROLEMIA 
ATENOLOL;GALNT2;rs2144300;C;OTHER;;DISEASE;HYPERCHOLESTEROLEMIA 
ETHANOL;ANKK1, DRD2;rs1800497;A;TOXICITY;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE, LADME-PK;DECREASED-PK;PK;IN VIVO METABOLISM OF (S)-WARFARIN BUT NOT (R)-WARFARIN 
ATENOLOL;PLA2G4A;rs10157410;C;OTHER;INCREASED-RISK;DISEASE;HYPERCHOLESTEROLEMIA 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION VALUES 
ATENOLOL;PTGS2;rs4648287;G;OTHER;INCREASED-LIKELIHOOD;DISEASE;HYPERCHOLESTEROLEMIA 
ISONIAZID, RIFAMPIN;NOS2;rs11080344;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ENALAPRIL;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;COUGH 
ISONIAZID, RIFAMPIN;BACH1;rs2070401;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET AGGREGATION VALUES 
ISONIAZID, RIFAMPIN;MAFK;rs4720833;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
ISONIAZID, RIFAMPIN;XPO1;rs11125883;AC + CC;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CLOPIDOGREL;CYP2C19;rs12248560;CC;EFFICACY;EFFICACY;EFFICACY;GREATER PLATELET INHIBITION 2 H AFTER A 600-MG DOSE 
ISONIAZID;NAT2;rs1041983;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
ISONIAZID;NAT2;rs1495741;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CLOPIDOGREL;CYP2C9;rs1057910;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET INHIBITION 7H AFTER A CLOPIDOGREL 600-MG LOADING DOSE 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PLATELET AGGREGATION INHIBITION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
ANASTROZOLE, LETROZOLE;ESR1;rs9340799;A;OTHER;INCREASED-RISK;DISEASE;MUSCULOSKELETAL PAIN 
CLOPIDOGREL;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;PLATELET AGGREGATION INHIBITION 
ANASTROZOLE, LETROZOLE;ESR1;rs2234693;C;OTHER;INCREASED-RISK;DISEASE;MUSCULOSKELETAL PAIN 
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PLATELET AGGREGATION INHIBITION 
;CYP3A4;rs2740574;CC;OTHER;INCREASED-LIKELIHOOD;OTHER;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
OPIOIDS;OPRM1;rs1799971;AA + AG;OTHER;DECREASED-LIKELIHOOD;OTHER;ADDICTION 
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;C;DOSAGE, TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) 
REPAGLINIDE;PAX4;rs114202595;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;DIFFERENCE IN POSTPRANDIAL PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) 
;CYP3A4;rs2740574;CT;OTHER;INCREASED-RISK;DISEASE;ENDOMETRIAL NEOPLASMS 
VINCRISTINE;COCH;rs1045644;CG + GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CETUXIMAB, IRINOTECAN, LEUCOVORIN, TEGAFUR;EGFR;rs712830;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
TAMOXIFEN;CYP3A4;rs2740574;CT;OTHER;INCREASED-RISK;DISEASE;ENDOMETRIAL NEOPLASMS 
VINCRISTINE;;rs7963521;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;DIFFERENCE IN FASTING PLASMA GLUCOSE (BEFORE AND AFTER DRUG TREATMENT) 
;VDR;rs3782905;G;OTHER;INCREASED-RISK;DISEASE;ASTHMA 
OPIOIDS;OPRL1;rs6090043;C;TOXICITY;INCREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH-ON CLOPIDOGREL PLATELET REACTIVITY 
CLOPIDOGREL;P2RY12;rs6785930;A;EFFICACY;INCREASED-RISK;SIDE_EFFECT;NEUROLOGICAL EVENTS 
OPIOIDS;COMT;rs165599;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
DOCETAXEL, PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
;VDR;rs2239185;G;;INCREASED-RISK;DISEASE;ASTHMA 
;VDR;rs1540339;T;;INCREASED-RISK;DISEASE;ASTHMA 
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALOPECIA 
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;ANTIPLATELET EFFECT 
CALCITRIOL;VDR;rs2228570;A;EFFICACY;INCREASED-RISK;DISEASE;FRACTURES, BONE 
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ANEMIA 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY 
PERINDOPRIL;BDKRB1;rs12050217;AA;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;CARDIAC EVENTS 
CISPLATIN;AQP1;rs1049305;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA 
ATENOLOL, VERAPAMIL;GRK4;rs1801058;TT;EFFICACY, TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;ADVERSE CARDIOVASCULAR OUTCOMES 
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;BIOPSY-PROVEN ACUTE REJECTION 
PLATINUM COMPOUNDS;HLA-DOB;rs2071554;CT + TT;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
PLATINUM COMPOUNDS;;rs2900420;AA + AG;EFFICACY;DECREASED-RISK;DISEASE;DEATH 
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;DROSHA;rs639174;T;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
OPIOIDS;DRD2;rs6275;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs6413432;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CISPLATIN;;rs3746444;AG + GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE, ADVERSE EVENTS 
ASPIRIN;PTGS2;rs20417;G;OTHER;DECREASED-RISK;DISEASE;CORONARY DISEASE 
CISPLATIN;AQP1;rs28362731;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ASPIRIN;PTGS2;rs20417;G;OTHER;INCREASED-RISK;DISEASE;CORONARY DISEASE 
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
FOLFIRI;ABCC1;rs17501011;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
OPIOIDS;OPRL1;rs6090041;G;TOXICITY;INCREASED-RISK;DISEASE;OPIOID-RELATED DISORDERS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;ANTIPLATELET EFFECT 
ANTIDEPRESSANTS;CUX1;rs365836;G;EFFICACY;LIKELIHOOD-EFFICACY;EFFICACY;NON-RESPONSE 
;SULT1A1;rs1042028;CC + CT;;INCREASED-RISK;DISEASE;PROSTATIC NEOPLASMS 
;SULT1A1;rs1042028;CT + TT;OTHER;INCREASED-RISK;DISEASE;BREAST NEOPLASMS 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;CLOPIDOGREL INHIBITION OF ADP-INDUCED PLATELET AGGREGATION 
;SULT1A1;rs1042028;CT + TT;OTHER;DECREASED-LIKELIHOOD;DISEASE;BREAST NEOPLASMS 
CLOZAPINE;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE, ADVERSE EVENTS 
ANTIDEPRESSANTS;CUX1;rs201522;A;EFFICACY;LIKELIHOOD-EFFICACY;EFFICACY;NON-RESPONSE 
BORTEZOMIB;PKNOX1;rs2839629;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES, PAIN, NEUROPATHIC PAIN, 
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED-RISK;DISEASE;HAND-FOOT SYNDROME 
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED-RISK;DISEASE;HAND-FOOT SYNDROME 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-;DISEASE;DRUG TOXICITY 
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
FOLFIRI;CES1;rs9921399;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
DEXTROAMPHETAMINE, METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED-SEVERITY;OTHER;SOCIAL WITHDRAWAL 
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
METHAMPHETAMINE;GRIN1;rs1126442;GG;TOXICITY;INCREASED-RISK;DISEASE;PSYCHOTIC DISORDER 
FOLFIRI;UGT1A10, UGT1A8;rs1113193;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED-RISK;DISEASE;OTOTOXICITY 
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE RATE TO PEGIFN-ALPHA/RBV TREATMENT AT WEEK 20/24 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SIALOADENITIS 
NICOTINE;CHRNA5;rs588765;CT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT FAILURE 
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED-SEVERITY;DISEASE;HAND-FOOT SYNDROME 
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED-SEVERITY;DISEASE;HAND-FOOT SYNDROME 
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
ATENOLOL;DPYS;rs2669429;AG + GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPERGLYCEMIA 
LENALIDOMIDE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ADVERSE EVENTS 
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
;IFNL3, IFNL4;rs12979860;CC;OTHER;INCREASED-;OTHER;SPONTANEOUS HCV CLEARANCE 
RISPERIDONE;LEP;rs7799039;G;OTHER;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
WARFARIN;VKORC1;rs9923231;T;EFFICACY, TOXICITY;INCREASED-;SIDE_EFFECT;BLOOD COAGULATION DISORDERS 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;FATIGUE 
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CARBOPLATIN, PACLITAXEL;EIF4E2, TIGD1;rs1656402;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;FATIGUE 
NICOTINE;;rs2056527;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
NICOTINE;;rs2056527;CT + TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING CESSATION 
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
PIRFENIDONE;TOLLIP;rs5743890;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;TIME TO THERAPEUTIC INR 
IMATINIB;ABCB1;rs1045642;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM COMPOUNDS;XBP1;rs2269577;GG;TOXICITY;INCREASED-RISK;DISEASE;NAUSEA 
IMATINIB;SLC22A1;rs683369;CC;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
CARBOPLATIN, PACLITAXEL;DSCAM;rs9981861;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
CARBOPLATIN, PACLITAXEL;ETS2;rs1209950;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS, HEADACHE 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS, HEADACHE 
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs1864183;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
MERCAPTOPURINE;NUDT15;rs186364861;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs17782313;CC;OTHER;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;A;OTHER;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;AA;OTHER;INCREASED-LIKELIHOOD;DISEASE;HYPERTRIGLYCERIDEMIA, WEIGHT GAIN 
ATENOLOL, VERAPAMIL;PLEKHH2;rs11124945;G;TOXICITY;DECREASED-RISK;DISEASE;DIABETES MELLITUS 
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED-;DISEASE;PLATELET AGGREGATION 
REGADENOSON;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED-SEVERITY;SIDE_EFFECT;ELEVATED SYSTOLIC BLOOD PRESSURE 
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SOMNOLENCE 
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
;;rs2952768;CC;EFFICACY;DECREASED-SEVERITY;OTHER;SUBSTANCE-RELATED DISORDERS 
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE, STROKE 
NICOTINE;DBH;rs1541333;CC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;END OF TREATMENT ABSTINENCE 
REGADENOSON;AMPD1;rs17602729;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
RISPERIDONE;CNR1;rs806378;T;OTHER;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
RISPERIDONE;CNR1;rs1049353;C;OTHER;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
MERCAPTOPURINE;ABCC4;rs3765534;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
ASPARAGINASE;NFATC2;rs6021191;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
ASPARAGINASE;HLA-DRB1;rs17885382;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERSENSITIVITY 
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;CYSTIC FIBROSIS PULMONARY EXACERBATION 
VANCOMYCIN;;rs2789047;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
LISINOPRIL;MMP3;rs35068180;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;STROKE 
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6113;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY;EFFICACY;SUBOPTIMAL REPERFUSION (POST-PCI TIMI FLOW <3) 
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6118;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBOPLATIN, GEMCITABINE;XYLT2;rs6504649;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6119;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
CARBOPLATIN, GEMCITABINE;ETS2;rs73450548;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;ANTI-VEGF INJECTIONS 
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED-;OTHER;PLATELET REACTIVITY 
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED-LIKELIHOOD;DISEASE;RECURRENCE 
DOXORUBICIN;GSTA1;rs3957357;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs489693;AA;OTHER;INCREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED-SEVERITY;DISEASE;ALCOHOL ABUSE 
;ERCC1;rs3212986;AC;OTHER;DECREASED-;OTHER;DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL 
DEXMEDETOMIDINE;GABRA2;rs279847;GG;TOXICITY;DECREASED-;SIDE_EFFECT;HEART RATE 
TAMOXIFEN;ESR1;rs9340799;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VENOUS THROMBOEMBOLISM 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs149389480;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
MORPHINE;FAAH;rs3766246;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
CLOZAPINE, OLANZAPINE;TBC1D1;rs9852;CC;TOXICITY;INCREASED-;DISEASE;WEIGHT GAIN 
FLUOROURACIL;DPYD;rs67376798;AT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
MORPHINE;FAAH;rs4141964;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
;ABCB11;rs2287622;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEPATOCELLULAR INJURY 
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPOVENTILATION 
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SIDE EFFECTS 
;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ALCOHOL ABUSE, SUBSTANCE-RELATED DISORDERS 
OPIOIDS;GNB3;rs5443;CT + TT;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;INCREASED  PULSE RATE 
ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;FAAH;rs324420;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;WEIGHT GAIN 
MORPHINE;FAAH;rs2295632;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
CAFFEINE;CYP1A2;rs762551;AC + CC;OTHER;DECREASED-RISK;DISEASE;BREAST NEOPLASMS 
MORPHINE;FAAH;rs324420;AA + AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
;ABCB11;rs2287622;GG;TOXICITY;INCREASED-RISK;DISEASE;DRUG-INDUCED LIVER INJURY 
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
DOCETAXEL;NR1I3;rs3003593;AA;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
ANTITHYROID PREPARATIONS;EHMT2;rs652888;G;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;AGRANULOCYTOSIS 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TNF;rs1800629;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PAIN 
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;CONSTIPATION 
HMG COA REDUCTASE INHIBITORS;HLA-G;rs1063320;G;OTHER;DECREASED-LIKELIHOOD;DISEASE;ASTHMA 
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-RISK;DISEASE;DRY MOUTH 
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;SEDATION 
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
ANTITHYROID PREPARATIONS;;rs111618861;del;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;AGRANULOCYTOSIS 
ANTITHYROID PREPARATIONS;HLA-B;rs1071816;C;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;AGRANULOCYTOSIS 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PAIN 
EFAVIRENZ;IL10;rs1800896;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
ETHANOL;ANKK1, DRD2;rs1800497;A;OTHER;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;NFKB1;rs230493;AT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PAIN 
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED-RISK;OTHER;OPIOID-RELATED DISORDERS 
ETHANOL;DRD2;rs1800497;A;OTHER;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs2241716;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PAIN 
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PAIN 
ANTITHYROID PREPARATIONS;FOXF2;rs199564443;del;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;AGRANULOCYTOSIS 
CAPECITABINE;CES1P1;rs7187684;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;;rs6977967;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
CAPECITABINE;CES1P1;rs11861118;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM;XRCC1;rs25487;TT;EFFICACY;;OTHER;WORSE OVERALL SURVIVAL OUTCOME 
PLATINUM;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RESPONSE 
CAPECITABINE;CES1;rs2244613;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PLATINUM;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOZAPINE, ETHANOL;CYP1A2;rs2069514;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;CT + TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RECURRENCE 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
CAPECITABINE;CES1;rs2244614;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CITALOPRAM;CYP2C19;rs4244285;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs620815;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TREATMENT FAILURE TO PEGYLATED INTERFERON-ALPHA/RIBAVIRIN THERAPY IN HCV/HIV-1 COINFECTED PATIENTS 
TENOFOVIR;ABCC2;rs17222723;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;RENAL PROXIMAL TUBULOPATHY 
TENOFOVIR;ABCC2;rs2273697;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;RENAL PROXIMAL TUBULOPATHY 
FLUOROURACIL;DPYD;rs1801160;CT;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CYTARABINE, IDARUBICIN;;rs12036333;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
NEVIRAPINE;CYP2B6;rs28399499;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP2R1;rs10741657;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;rs2248359;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEPHROTOXICITY 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;rs4646536;GG;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;NEPHROTOXICITY 
NICOTINE;DDC;rs2060761;C;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;rs10946737;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
NICOTINE;DDC;rs12718541;A;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE (RAPID AND SUSTAINED VIROLOGICAL RESPONSE) FOR PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 
IMIPRAMINE;CYP2C19;rs12248560;CT + TT;LADME-PK;DECREASED-PK;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS 
IMIPRAMINE;CYP2C19;rs11188072;CT + TT;LADME-PK;DECREASED-PK;PK;DOSE-CORRECTED PLASMA CONCENTRATIONS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
;CXCL5;rs352046;GG;OTHER;INCREASED-RISK;DISEASE;DEATH 
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OVER-ANTICOAGULATION 
CAPECITABINE;CDA;rs602950;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;rs717620;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEPHROTOXICITY 
CAPECITABINE;CDA;rs6690069;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HAND-FOOT SYNDROME 
TENOFOVIR;ABCC2;rs717620;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;KIDNEY TUBULAR DYSFUNCTION 
METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED-SEVERITY;OTHER;SOCIAL WITHDRAWAL 
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;SUBCLINICAL INTRA-STENT THROMBUS 
CAPECITABINE;CES1;rs3217164;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE;CDA;rs10916825;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;rs11854484;CT + TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEPHROTOXICITY 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DIZZINESS 
CAPECITABINE;NSUN3;rs144470777;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;PHC1;rs187805828;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;SERUM OSTEOCALCIN 
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;INADEQUATE INHIBITION OF PLATELET ACTIVITY 
CAPECITABINE;FAT1;rs116134453;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
CAPECITABINE;TENM4;rs141531882;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
TICAGRELOR;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DYSPNEA 
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;EFFICACY;EFFICACY;A 22% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT AFTER ADJUSTMENT FOR CLINICAL AND GENETIC COVARIATES IN HISPANIC-AMERICANS 
AMOXICILLIN, CLAVULANATE;HLA-DQB1;rs9274407;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG INDUCED LIVER INJURY 
CAPECITABINE;CD96;rs77475703;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, GOSERELIN;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AMENORRHEA 
WARFARIN;NQO1;rs1800566;A;DOSAGE;EFFICACY;EFFICACY;A 34% INCREASE IN THERAPEUTIC WARFARIN DOSE REQUIREMENT WHILE HOLDING CLINICAL AND GENETIC PREDICTORS CONSTANT IN HISPANIC-AMERICANS 
CAPECITABINE;ZMIZ1;rs117484357;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;VPS13D;rs138385713;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CETUXIMAB;RASSF1;rs2236947;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SLOWER RESPONSE TIME 
CAPECITABINE;CCDC77;rs141213385;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
ANTIPSYCHOTICS;RGS2;rs4606;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;EXTRAPYRAMIDAL SYMPTOMS, PARKINSONIAN DISORDER 
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) 
DEXMEDETOMIDINE;WBP2NL;rs5758550;AA;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;SEDATION 
CAPECITABINE;ADGRG7;rs117308378;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CARBOPLATIN, CISPLATIN;AKT1;rs1130214;AA + AC;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;DISEASE PROGRESSION 
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs2280055;CC;EFFICACY;EFFICACY;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE 
ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE, DEATH, 
CARBOPLATIN, CISPLATIN;;rs2498804;AA + AC;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;DISEASE PROGRESSION 
CLOZAPINE, OLANZAPINE, RISPERIDONE;DRD2;rs4436578;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BODY WEIGHT GAIN 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
VINCRISTINE;ABCC2;rs12826;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED-PK;PK;PLASMA EXPOSURE 
NICOTINE;GRIN3A;rs10121600;C;OTHER;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
ASPIRIN, CLOPIDOGREL;CYP1A2;rs762551;C;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE, DEATH, 
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN PEAK INR DURING WEEK 1 OF WARFARIN THERAPY 
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE, DEATH, 
CITALOPRAM;HTR1B;rs6296;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;AGITATION 
PRAVASTATIN;ABCA1;rs2230806;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;HDL-CHOLESTEROL 
ASPIRIN, CLOPIDOGREL;PON1;rs662;T;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE, DEATH, 
DEXMEDETOMIDINE;ABCG2;rs2231142;GG;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;SEDATION 
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC"", ""IBUPROFEN"", ""NAPROXEN"", ""PIROXICAM""";CYP2C9;rs1057910;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL BLEEDING 
CAPECITABINE;DPYD;rs75267292;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
NICOTINE;GRIN3A;rs11788456;G;OTHER;RISK-;DISEASE;TOBACCO USE DISORDER 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;FATIGUE 
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC""";CYP2C9;rs1057910;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ACUTE GASTROINTESTINAL BLEEDING 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;SLEEP DISORDERS 
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED-RISK;DISEASE;CORONARY DISEASE 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs368967198;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
CAPECITABINE;SSU72;rs146898897;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, STROKE, DEATH, 
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED-;OTHER;HEART RATE 
CARBOPLATIN, CISPLATIN;PIK3CA;rs2699887;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED-;OTHER;HEART RATE 
CARBOPLATIN, CISPLATIN;PTEN;rs2299939;AC + CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CAPECITABINE;MAN1A1;rs185346775;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CARBOPLATIN, CISPLATIN;AKT1;rs3803304;C;EFFICACY;RISK-EFFICACY;EFFICACY;DISEASE PROGRESSION 
COCAINE;BCHE;rs1803274;TT;OTHER;;DISEASE;COCAINE DEPENDENCE 
PRAVASTATIN;SLCO1B1;rs4149056;CC;LADME-PK;INCREASED-PK;PK;MEAN PEAK CONCENTRATION IN PLASMA AND AREA UNDER THE PLASMA CONCENTRATION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;EGFR;rs11506105;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;SURVIVAL RATE 
ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET REACTIVITY 
HMG COA REDUCTASE INHIBITORS;STAT4;rs7574865;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;LYMPH NODE METASTASES 
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
HEROIN;ALDH2;rs671;AA + AG;OTHER;INCREASED-;DISEASE;HEROIN DEPENDENCE 
FENTANYL;CALCA;rs145837941;GG;DOSAGE;DECREASED-SEVERITY;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING 
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";KCNJ11;rs5219;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TREATMENT FAILURE 
ANTIHYPERTENSIVES, BETA BLOCKING AGENTS, DIURETICS;ADRB1;rs1801253;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;STROKE 
NICOTINE;GRIN3A;rs17189632;T;OTHER;RISK-;DISEASE;TOBACCO USE DISORDER 
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
HMG COA REDUCTASE INHIBITORS;SLCO1A2;rs4149000;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;POOR-RESPONSE TO CLOPIDOGREL 
TRAMADOL;SLC22A1;rs35167514;del;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL 
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION 
ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA, MUCOSITIS, 
TRAMADOL;SLC22A1;rs34130495;A;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL 
TRAMADOL;SLC22A1;rs12208357;T;LADME-PK;PK;PK;HIGHER PLASMA CONCENTRATIONS OF O-DESMETHYLTRAMADOL 
METHADONE;KCNJ6;rs2070995;TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;WITHDRAWAL EFFECTS 
IMATINIB;SLCO1A2;rs3764043;CC;LADME-PK;DECREASED-PK;PK;IMATINIB CLEARANCE 
IMATINIB;SLCO1A2;rs4148978;CC;LADME-PK;INCREASED-PK;PK;IMATINIB CLEARANCE 
VINCRISTINE;ABCC2;rs3740066;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
IMATINIB;SLCO1A2;rs4148977;CC;LADME-PK;INCREASED-PK;PK;IMATINIB CLEARANCE 
FLUOROURACIL;DPYD;rs55886062;AC;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
FLUCLOXACILLIN;NR1I2;rs3814055;CC;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs3894049;CC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;VOL% END-TIDAL SEVOFLURANE CONCENTRATION 
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
EFAVIRENZ;CYP2B6;rs28399499;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs143509841;GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;G;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs200157005;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANGIOEDEMA 
PAROXETINE;CYP1A2;rs4646427;TT;EFFICACY;EFFICACY;EFFICACY;SLOWER RESPONSE TIME 
CARBAMAZEPINE;SCN1A;rs3812718;CC;OTHER;INCREASED-;OTHER;CORTICAL SILENT PERIOD DURATION 
METHOTREXATE;MIR1206;rs2114358;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SLOWER RESPONSE TIME 
ATORVASTATIN;SLCO1B1;rs2306283;G;LADME-PK;DECREASED-PK;PK;PLASMA CONCENTRATIONS 
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS 
FOLIC ACID, METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE DRUG EVENT 
CYTARABINE, IDARUBICIN;BRD10;rs10758713;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUSCULAR DISEASES 
SORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
SORAFENIB;PIK3R5;rs444904;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA WITHIN 24 HOURS AND THROMBOCYTOPENIA 
CYTARABINE, IDARUBICIN;;rs2897047;AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;ABCC2;rs2273697;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CYTARABINE, IDARUBICIN;;rs6550826;GG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
METHOTREXATE;ABCB1;rs1128503;AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
AZATHIOPRINE, MERCAPTOPURINE;ABCC4;rs3765534;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;LEUKOPENIA 
METHOTREXATE;ABCC2;rs4148396;CC + CT;TOXICITY;INCREASED-;SIDE_EFFECT;TIME TO DISCONTINUATION OR DOSE REDUCTION 
METHOTREXATE;ABCC2;rs4148396;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ALOPECIA 
CYTARABINE, IDARUBICIN;;rs9883101;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
FOLIC ACID, METHOTREXATE;TLR4;rs4986790;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ADVERSE DRUG EVENTS 
ROSUVASTATIN;ABCG2;rs2231142;T;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS 
ROSUVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS 
FLUOROURACIL, LEUCOVORIN;DPYD;rs67376798;AT;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR), SUSTAINED VIROLOGICAL RESPONSE (SVR) 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
HYDROCHLOROTHIAZIDE;;rs10792367;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;BLOOD PRESSURE (BP) REDUCTION 
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;DOSAGE;INCREASED-LIKELIHOOD;SIDE_EFFECT;NECESSITY TO REDUCE IRINOTECAN DOSAGE 
;HMGCR;rs12654264;AT + TT;OTHER;INCREASED-;OTHER;SERUM TOTAL CHOLESTEROL 
DOXORUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1045642;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
NICOTINE;CHRNA3;rs3743075;T;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;TOBACCO USE DISORDER 
NICOTINE;CHRNB4;rs7178270;G;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;TOBACCO USE DISORDER 
VINCRISTINE;NDRG1;rs2272653;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
NICOTINE;CHRNB4;rs1948;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;TOBACCO USE DISORDER 
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1719247;T;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;MUSCULAR DISEASES 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1346268;C;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;MUSCULAR DISEASES 
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED-PK;PK;PRAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
IMATINIB;UGT2A1;rs11249454;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;rs11155012;A;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1128503;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED CIRCULATING CREATINE KINASE CONCENTRATION 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VOMITING 
GEMCITABINE;SLC28A1;rs3825876;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
ATORVASTATIN;SLCO1B1;rs4149056;CC;LADME-PK;INCREASED-PK;PK;AUC 
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
RISPERIDONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;PROLONGED QTC INTERVAL 
PITAVASTATIN;SLCO1B1;rs2306283;AG + GG;LADME-PK;INCREASED-PK;PK;PITAVASTATIN PLASMA CONCENTRATIONS (AUC) AND CMAX 
SORAFENIB;EGFR;rs2330951;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
ROSUVASTATIN;SLCO1B1;rs4149056;CC;LADME-PK;INCREASED-PK;PK;AUC (P=0.002) AND CMAX (P=0.003) 
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;MUSCULAR DISEASES 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-RISK;OTHER;MAJOR ADVERSE CARDIOVASCULAR EVENTS 
EVEROLIMUS;ABCB1;rs2032582;A;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;LYMPHOPENIA 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
AZATHIOPRINE, MERCAPTOPURINE;;rs2647087;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCREATITIS 
EVEROLIMUS;RPTOR;rs9906827;T;TOXICITY, OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS 
RADIOTHERAPY;XPC;rs2228001;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA 
EVEROLIMUS;ABCB1;rs1045642;A;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, MYOCARDIAL ISCHEMIA, STROKE, 
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
AZACITIDINE;MTHFR;rs1801133;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY 
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;MYOCARDIAL INFARCTION, MYOCARDIAL ISCHEMIA, STROKE, 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs3212986;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
IMATINIB;SLC22A1;rs628031;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs6500265;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
IMATINIB;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;rs1994862;CC;OTHER;DECREASED-RISK;SIDE_EFFECT;AROUSAL DYSFUNCTION 
EVEROLIMUS;RPTOR;rs9906827;CT + TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
IMATINIB;CHST1;rs9787901;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
IMATINIB;CYP2F1;rs305968;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs9933632;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CBR1;rs20572;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VOMITING 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TP53;rs1042522;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VOMITING 
SORAFENIB;PRKCE;rs11125039;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs714368;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;IL10;rs1800896;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;XRCC1;rs25487;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CTLA4;rs231775;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
;ADH7;rs971074;CT + TT;OTHER;INCREASED-SEVERITY;OTHER;PAIN 
SORAFENIB;ADAMTS18;rs1346563;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERTENSION 
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
CISPLATIN;SLC31A1;rs10981694;GG + GT;TOXICITY;INCREASED-SEVERITY;DISEASE;OTOTOXICITY 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs12248560;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
DEXMEDETOMIDINE;ABCC9;rs11046209;AA;EFFICACY;INCREASED-SEVERITYEFFICACY;EFFICACY;SEDATION 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
VINCRISTINE;CEP72;rs12522955;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CAPECITABINE;;rs72765700;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCG2;rs2231142;GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;TOXICITY;INCREASED-SEVERITY;DISEASE;THROMBOCYTOPENIA 
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs79206939;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, LEUKOPENIA 
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
PRAVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH POST-TREATMENT PLATELET REACTIVITY 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs2273697;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs6907567;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
EVEROLIMUS;FGFR4;rs351855;A;TOXICITY, OTHER;DECREASED-LIKELIHOOD;OTHER;DISCONTINUATION 
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
AZATHIOPRINE, MERCAPTOPURINE;;rs2834826;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
IMATINIB;SLC19A1;rs12659;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
AZACITIDINE;XRCC1;rs25487;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
IMATINIB;NQO1;rs10517;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;DECREASED-LIKELIHOOD;SIDE_EFFECT;HYPERGLYCEMIA 
DESLORATADINE;HRH1;rs901865;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;SEDATION 
IMATINIB;ABCC2;rs2273697;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CYTARABINE, DOXORUBICIN, LEUCOVORIN, METHOTREXATE, PREDNISONE, VINCRISTINE;NOS3;rs1799983;TT;TOXICITY;DECREASED-;SIDE_EFFECT;IQ 
IMATINIB;ABCB4;rs1202283;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
CAPECITABINE;MIR2054;rs10024471;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
METHOTREXATE;DHFR;rs1105525;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAB2;rs3766522;TT;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
METHADONE;NECTIN4;rs11265549;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PRURITUS 
CAPECITABINE;SPRY2;rs117876855;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
CAPECITABINE;SPRY2;rs139544515;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED-RISK;DISEASE;COLONIC NEOPLASMS 
RIVAROXABAN;CYP3A4;rs2246709;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
METHOTREXATE;GGH;rs11545078;A;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;THROMBOCYTOPENIA 
CAPECITABINE;NCOA7;rs185217050;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
CAPECITABINE;CCDC70;rs139368788;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
;HMGCR;rs12654264;AT + TT;OTHER;INCREASED-;OTHER;SERUM LDL 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, NEPHROTOXICITY 
CAPECITABINE;TMEM131L;rs117412990;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
PRAVASTATIN;HMGCR;rs17244841;AT;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN TOTAL CHOLESTEROL 
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;TT;EFFICACY;DECREASED-RISK;DISEASE;COLONIC NEOPLASMS 
CAPECITABINE;SIRPA;rs191934521;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAA2;rs10789038;AA;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
RIVAROXABAN;CYP3A4;rs3735451;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
CAPECITABINE;LMNTD1;rs146644707;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME 
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ANTINEOPLASTIC AGENTS;RBFOX1;rs6500843;G;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED-RISK;DISEASE;COLONIC NEOPLASMS 
PLATINUM;XRCC5;rs1051685;G;TOXICITY;DECREASED-SEVERITY;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA
CLOZAPINE, OLANZAPINE, RISPERIDONE;LEP;rs7799039;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
IRINOTECAN;ABCC1;rs17287570;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION 
SORAFENIB;EPAS1;rs1868089;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY 
PLATINUM;XRCC5;rs6941;A;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;CYP2A6;rs143731390;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DEATH 
IRINOTECAN;ABCG2;rs2622604;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION 
FOLIC ACID;MTHFD1;rs2236225;AA;OTHER;DECREASED-LIKELIHOOD;OTHER;DIABETES, GESTATIONAL 
METHOTREXATE;DHFR;rs442767;GG;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs11692021;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION 
PLATINUM;AQP2;rs10875989;T;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA
APIXABAN, RIVAROXABAN;ABCG2;rs3114018;AA + AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
IRINOTECAN;SLCO1B3;rs7977213;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION 
METHOTREXATE;DHFR;rs408626;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;T;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE 
PLATINUM;AQP2;rs3759125;AA + AC;TOXICITY;INCREASED-SEVERITY;DISEASE;ANEMIA, LEUKOPENIA, NEUTROPENIA, THROMBOCYTOPENIA
IRINOTECAN;SLCO1B3;rs10841661;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE MYELOSUPPRESSION 
METHOTREXATE;DHFR;rs1650697;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
APIXABAN, RIVAROXABAN;ABCG2;rs2622604;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
PLATINUM;AQP2;rs461872;A;TOXICITY;DECREASED-SEVERITY;DISEASE;DIARRHEA, NAUSEA, VOMITING, 
PLATINUM;AQP2;rs7305534;CC + CT;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA, NAUSEA, VOMITING, 
MEPHENYTOIN, TOLBUTAMIDE;CYP2C19;rs41291556;C;LADME-PK;PK;PK;DRAMATIC (APPROXIMATELY 90% AND 70%) REDUCTION IN THE METABOLISM OF S-MEPHENYTOIN AND TOLBUTAMIDE 
PLATINUM;CD74;rs2748249;A;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
ASPIRIN;TBXAS1;rs6962291;AA;OTHER;DECREASED-RISK;SIDE_EFFECT;INTOLERANCE 
PLATINUM;CD74;rs1560661;C;TOXICITY;DECREASED-SEVERITY;DISEASE;DRUG TOXICITY 
CYTARABINE;CDA;rs2072671;AA;TOXICITY, LADME-PK;DECREASED-RISK;SIDE_EFFECT;GRADE III/IV LIVER TOXICITY 
WARFARIN;;rs12777823;A;DOSAGE;EFFICACY;EFFICACY;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS, INDEPENDENT OF CYP2C9*2 AND CYP2C9*3. 
WARFARIN;;rs12777823;A;DOSAGE;EFFICACY;EFFICACY;REDUCED WARFARIN DOSE IN AFRICAN AMERICANS, INDEPENDENT OF CYP2C9*2 AND CYP2C9*3. 
;ALDH1A2;rs12915901;A;OTHER;INCREASED-LIKELIHOOD;OTHER;OSTEOARTHRITIS 
RALOXIFENE, TAMOXIFEN;;rs10030044;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY 
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME, MUCOSITIS, PERIPHERAL NERVOUS SYSTEM DISEASES, 
;SLC2A1;rs841844;CG + GG;TOXICITY;INCREASED-SEVERITY;DISEASE;DRUG TOXICITY 
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;TT;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DIARRHEA 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;INSUFFICIENT ANTIPLATELET RESPONSE TO CLOPIDOGREL 
DASATINIB;ABL1;rs121913459;CT;OTHER, LADME-PK;DECREASED-PK;PK;AUC 0-4 HOURS 
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;DECREASED-SEVERITY;DISEASE;HEPATITIS C VIRUS INFECTION 
HYDROCHLOROTHIAZIDE;AGT;rs5051;T;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
HYDROCHLOROTHIAZIDE;AGTR1;rs5186;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
TAMOXIFEN;ESR2;rs4986938;CC;OTHER;INCREASED-;SIDE_EFFECT;TRIGLYCERIDES IN POSTMENOPAUSAL WOMAN 
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;LEUKOPENIA, NEUTROPENIA 
ONDANSETRON;ABCB1;rs1045642;AA;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING 
TAMOXIFEN;ESR1;rs9340799;GG;OTHER;DECREASED-;SIDE_EFFECT;IN TOTAL CHOLESTEROL IN POSTMENOPAUSAL WOMAN AND INCREASE IN TRIGLYCERIDES AND DECREASE IN HIGH DENSITY LIPOPROTEIN IN PREMENOPAUSAL WOMEN 
TALINOLOL;ABCC2;rs2273697;A;OTHER;INCREASED-PK;PK;RESIDUAL CLEARANCE OF INTRAVENOUS TALINOLOL AND LOWER BIOAVAILABLILTY OF ORALLY ADMINISTERED TALINOLOL 
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME-PK;INCREASED-PK;PK;DOXORUBICINOL AUC 
ONDANSETRON;ABCB1;rs2032582;AA;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING 
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;METABOLIC SYNDROME 
BEVACIZUMAB, CYANOCOBALAMIN, FOLIC ACID, PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MODERATE ANEMIA 
RALOXIFENE, TAMOXIFEN;ZNF423;rs8060157;A;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;OCCURRENCE OF BREAST CANCER DURING SERM (SELECTIVE ESTROGEN RECEPTOR MODULATORS) THERAPY 
TACROLIMUS;ABCB1;rs1045642;AA + AG;EFFICACY;EFFICACY;EFFICACY;DECREASED GLOMERULAR FILTRATION RATE 
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;TOXICITY, LADME-PK;INCREASED-RISK;SIDE_EFFECT;NEUROLOGICAL ADR 
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;TT;OTHER;INCREASED-RISK;SIDE_EFFECT;MODERATE ANEMIA 
SORAFENIB;VEGFB;rs12366035;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY 
CYTARABINE;CDA;rs532545;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;5 YEAR SURVIVAL 
CYTARABINE;CDA;rs532545;TT;EFFICACY;INCREASED-RISK;DISEASE;DEATH 
VINCRISTINE;CEP72;rs71585289;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED-RISK;DISEASE;INFECTIOUS DISEASE 
CLOPIDOGREL;P2RY12;rs2046934;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ACUTE CORONARY SYNDROME 
VINCRISTINE;MIR6076;rs35650931;CC + CG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
SORAFENIB;WWOX;rs9927200;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
DOXEPIN;CYP2C19;rs4244285;AA;LADME-PK;DECREASED-PK;PK;MEDIAN ORAL CLEARANCE OF DOXEPIN 
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED-RISK;DISEASE;CARDIOTOXICITY 
VINCRISTINE;MIR4481;rs7896283;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
CLOMIPRAMINE;CYP2C19;rs4244285;AG;LADME-PK;INCREASED-PK;PK;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE 
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;INCREASED-RISK;OTHER;TOXIC LIVER DISEASE 
CORTICOSTEROIDS;ACP1;rs11553746;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS 
SORAFENIB;MAP2K6;rs11651488;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED-RISK;OTHER;TOXIC LIVER DISEASE 
SORAFENIB;CDH13;rs17682789;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DIARRHEA 
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
CLOMIPRAMINE;CYP2C19;rs4244285;AA;LADME-PK;INCREASED-PK;PK;MEAN CLOMIPRAMINE CONCENTRATIONS CORRECTED FOR DOSE AND WEIGHT AND HIGHER METABOLIC RATIO OF CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE 
PAROXETINE;FKBP5;rs1360780;T;OTHER;INCREASED-RISK;SIDE_EFFECT;SUICIDAL IDEATION 
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;FKBP5;rs1360780;T;OTHER;INCREASED-RISK;SIDE_EFFECT;SUICIDAL IDEATION 
ILOPERIDONE;CYP2D6;rs1065852;GG;OTHER;INCREASED-;SIDE_EFFECT;QTC INTERVAL 
GEMCITABINE;SLC28A1;rs12148896;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED-RISK;SIDE_EFFECT;MYELOSUPPRESSION 
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, VENLAFAXINE;HTR1B;rs130058;A;EFFICACY;DECREASED-RISK;SIDE_EFFECT;SUICIDAL IDEATION 
PAROXETINE;HTR1B;rs130058;A;OTHER;INCREASED-RISK;SIDE_EFFECT;SUICIDAL IDEATION 
GEMCITABINE;CDA;rs471760;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CANNABIDIOL;ABCC5;rs3749442;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEDATION 
CISPLATIN;ACYP2;rs1872328;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;ABCB1;rs2032582;A;OTHER;INCREASED-RISK;SIDE_EFFECT;SUICIDAL IDEATION 
MELPHALAN;SLC7A5;rs4240803;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
ANTIPSYCHOTICS;MC4R;rs17782313;CC + CT;OTHER;INCREASED-RISK;DISEASE;WEIGHT GAIN 
PLATINUM;SLC2A1;rs3738514;T;TOXICITY;DECREASED-SEVERITY;DISEASE;DRUG TOXICITY 
DOXORUBICIN;RARG;rs2229774;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
VINCRISTINE;GARS1;rs1049402;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
SORAFENIB;EGFR;rs917881;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIARRHEA 
VINCRISTINE;FGD4;rs12823621;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
CARBOPLATIN, CISPLATIN;SLC31A1;rs7851395;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
FLUOROURACIL, OXALIPLATIN;ERCC2, KLC3;rs13181;GT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PLATINUM;SLC2A1;rs4658;CC;TOXICITY;DECREASED-SEVERITY;DISEASE;DRUG TOXICITY 
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;ADD1;rs4961;GT + TT;OTHER;INCREASED-;OTHER;AMBULATORY BLOOD PRESSURE 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs238406;GT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
;RAD52, WNK1;rs2277869;CC;OTHER;INCREASED-;OTHER;AMBULATORY BLOOD PRESSURE 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs13422094;C;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs12211463;G;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7757130;A;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
FENTANYL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2473967;G;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
THIAZIDES, PLAIN;ADD1;rs4961;GG;EFFICACY;DECREASED-RISK;DISEASE;MYOCARDIAL INFARCTION 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs1799793;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
FENTANYL;COMT;rs4680;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SOMNOLENCE 
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STATIN-RELATED MYOPATHY 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;EFFICACT AS MEASURED BY LOWER PAIN RELIEF TO OPIOIDS 
ACE INHIBITORS, PLAIN;SH2B1;rs192613545;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
RADIOTHERAPY;OSMR;rs1239344;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ESOPHAGITIS 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PAIN 
RADIOTHERAPY;CDK1;rs10711;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PNEUMONITIS 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALOPECIA 
CELECOXIB;CYP2C9;rs1799853;CT;LADME-PK;PK;PK;HIGHER PLASMA CONCENTRATIONS OF CELECOXIB 
HYDROCHLOROTHIAZIDE;REN;rs11240688;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN SBP 
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;C;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
ACE INHIBITORS, PLAIN;RBFOX3;rs62063838;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN BLOOD PRESSURE 
RADIOTHERAPY;PRKCE;rs940052;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ESOPHAGITIS 
ACE INHIBITORS, PLAIN;MBOAT1;rs10946364;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
RADIOTHERAPY;PRKCE;rs11125035;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ESOPHAGITIS 
ROFECOXIB;PTGS1;rs3842787;T;EFFICACY;EFFICACY;EFFICACY;REDUCTION IN COX-1 INHIBITION AND DEPRESSION OF THE URINARY THROMBOXANE METABOLITE 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs11615;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;FEBRILE NEUTROPENIA 
RADIOTHERAPY;RIGI;rs11795343;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PNEUMONITIS 
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
ACE INHIBITORS, PLAIN;RBFOX3;rs56044629;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
HYDROCHLOROTHIAZIDE;WNK1;rs880054;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;REDUCTION IN SBP 
RADIOTHERAPY;;rs7259857;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;ESOPHAGITIS 
CELECOXIB;PTGS1;rs3842787;T;EFFICACY;EFFICACY;EFFICACY;REDUCTION IN COX-1 INHIBITION 
;COL1A1;rs1800012;AA + AC;;INCREASED-RISK;DISEASE;FRACTURES, BONE 
HYDROCHLOROTHIAZIDE;ADD1;rs4961;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;ABSOLUTE MEAN BLOOD PRESSURE 
ACE INHIBITORS, PLAIN;GABRG2;rs77370934;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
;COL1A1;rs1800012;AA + AC;;DECREASED-;OTHER;BONE MINERAL DENSITY (BMD) 
VINCRISTINE;BAHD1;rs3803357;AA + AC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
ACE INHIBITORS, PLAIN;RBFOX3;rs56209714;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
METHYLPREDNISOLONE, PREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;INFECTIOUS DISEASE 
ANASTROZOLE, LETROZOLE, TAMOXIFEN;ZNF613;rs8113308;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
PIRFENIDONE;CYP1A2;rs762551;AA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALOPECIA 
CISPLATIN;OTOS;rs2291767;CC + CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;OTOTOXICITY 
ACE INHIBITORS, PLAIN;RBFOX3;rs2061538;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DISCONTINUATION 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIMINISHED ABILITY TO CONCENTRATE 
CITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA, VOMITING 
TACROLIMUS;CYP3A5;rs776746;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEPHROTOXICITY 
MERCAPTOPURINE, METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED-RISK;DISEASE;MYELOSUPPRESSION 
SUNITINIB;CXCL8;rs1126647;TT;OTHER;INCREASED-LIKELIHOOD;SIDE_EFFECT;HYPERTENSION 
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
ETHANOL;PNPLA3;rs738409;GG;TOXICITY;INCREASED-RISK;OTHER;ALCOHOL ABUSE 
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
SORAFENIB;EPAS1;rs9973653;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
;WT1;rs16754;CC + CT;OTHER;INCREASED-LIKELIHOOD;DISEASE;EVENT-FREE SURVIVAL 
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;TRANSPLANT REJECTION 
MERCAPTOPURINE;ITPA;rs1127354;A;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
CANNABINOIDS;FAAH;rs324420;AA;TOXICITY;DECREASED-RISK;DISEASE;SUBSTANCE-RELATED DISORDERS 
SORAFENIB;;rs315498;C;TOXICITY;DECREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DEATH 
VINCRISTINE;MRPL47;rs10513762;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
VINCRISTINE;SYNE2;rs2781377;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
SORAFENIB;EPAS1;rs4035887;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED DIASTOLIC BLOOD PRESSURE, ELEVATED SYSTOLIC BLOOD PRESSURE 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED-EFFICACY;EFFICACY;ON-TREATMENT PLATELET REACTIVITY 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;DHFR;rs408626;CC;EFFICACY;DECREASED-;OTHER;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ELEVATED TRANSAMINASES 
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DEATH 
EFAVIRENZ;ABCB1;rs1045642;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXICITY-RELATED TREATMENT FAILURE 
DOXORUBICIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
ASPIRIN;CYP2D6;rs28360521;CC;TOXICITY, OTHER;INCREASED-RISK;SIDE_EFFECT;GASTROINTESTINAL HEMORRHAGE 
DESFLURANE, PROPOFOL;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;POSTOPERATIVE NAUSEA AND VOMITING, VOMITING 
LOSARTAN;CAMK1D;rs10752271;AG + GG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE 
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;DISEASE;TOXIC LIVER DISEASE 
METHOTREXATE;DHFR;rs408626;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
LOSARTAN;CAMK1D;rs10737062;AG + GG;EFFICACY;DECREASED-SEVERITYEFFICACY;EFFICACY;ELEVATED SYSTOLIC BLOOD PRESSURE 
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE 
METHOTREXATE;MTHFR;rs1801131;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;DHFR;rs442767;GT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;LEUKOPENIA 
CELECOXIB;CYP2C9;rs1057910;C;EFFICACY;DECREASED-RISK;DISEASE;ADENOMA 
MERCAPTOPURINE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTIONS 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;CYP3A4;rs2740574;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ALOPECIA 
MERCAPTOPURINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT INTERRUPTION 
EFAVIRENZ;ABCB1;rs1045642;A;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EMERGING VIRAL DRUG RESISTANCE 
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;CSPG4;rs1127648;AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SORAFENIB;;rs10958704;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY 
METHOTREXATE;SHMT1;rs1979277;AG;TOXICITY;DECREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG;TOXICITY;INCREASED-;SIDE_EFFECT;SPEED OF PLATELET RECOVERY 
SORAFENIB;EPAS1;rs7557402;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY 
METHOTREXATE;MTHFR;rs1801131;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;RED BLOOD CELL TRANSFUSIONS 
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GRAFT VS HOST DISEASE 
APIXABAN, RIVAROXABAN;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
EFAVIRENZ;ABCB1;rs2032582;A;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EMERGING VIRAL DRUG RESISTANCE 
CYCLOPHOSPHAMIDE, DOCETAXEL;VEGFA;rs1570360;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
CARBOPLATIN, GEMCITABINE;OR4D6;rs1453542;CC;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;NEUTROPENIA 
SORAFENIB;MAP2K6;rs12948059;G;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DERMATOLOGIC TOXICITY 
CARBOPLATIN, GEMCITABINE;DDX53;rs5925720;T;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;THROMBOCYTOPENIA 
METHOTREXATE;MTHFD1;rs2236225;AA;OTHER;INCREASED-PK;PK;RED BLOOD CELL FOLATE 
METHOTREXATE;FASTKD3, MTRR;rs1801394;AA;OTHER;INCREASED-PK;PK;RED BLOOD CELL FOLATE 
IRINOTECAN;SEMA3C;rs11979430;T;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
ANTIPSYCHOTICS;DRD2;rs1800497;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;DECREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
IRINOTECAN;SEMA3C;rs7779029;C;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY;EFFICACY;PROTECTION FROM DRUG RESISTANCE 
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY;EFFICACY;PROTECTION FROM DRUG RESISTANCE 
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED-RISK;DISEASE;TARDIVE DYSKINESIA 
IRINOTECAN;;rs1661167;G;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY;EFFICACY;PROTECTION FROM DRUG RESISTANCE 
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs498207;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs6413432;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
BUDESONIDE;FCER2;rs28364072;G;OTHER;;OTHER;SEVERE EXACERBATIONS WITH ASTHMA 
CYCLOPHOSPHAMIDE;NOS3;rs1799983;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813928;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
MYCOPHENOLATE MOFETIL;IL12A;rs568408;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT 
IRINOTECAN;PLCB1;rs2745761;C;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
CYCLOPHOSPHAMIDE;NOS3;rs2070744;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813929;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;WEIGHT GAIN 
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, METHOTREXATE;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED-EFFICACY;EFFICACY;DISEASE FREE SURVIVAL 
IRINOTECAN;PDZRN3;rs11128347;C;TOXICITY;INCREASED-SEVERITY;DISEASE;NEUTROPENIA 
METHADONE;UGT2B7;rs4554144;TT;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
DAPSONE;HLA-DRB1;rs201929247;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
OLANZAPINE;PPARG;rs1801282;CG;OTHER;INCREASED-;DISEASE;WEIGHT GAIN 
METHADONE;UGT2B7;rs11940316;CC;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
CORTICOSTEROIDS;BCL2L11;rs2241843;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
METHADONE;UGT2B7;rs7438135;AA;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
METHADONE;UGT2B7;rs7662029;GG;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;ANEMIA 
OXALIPLATIN;PIN1;rs2233678;CC + CG;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL 
METHADONE;UGT2B7;rs7668258;CC;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
METHOTREXATE;ABCG2;rs2231142;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
METHOTREXATE;AMPD1;rs17602729;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CNS ADVERSE EVENTS 
ANTIEPILEPTICS;ABCB1;rs1045642;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DRUG RESISTANCE 
METHADONE;UGT2B7;rs7439366;CC;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
ANTIEPILEPTICS;ABCB1;rs1128503;A;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DRUG RESISTANCE 
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DRUG RESISTANCE 
METHADONE;UGT2B7;rs4292394;GG;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;MACULOPAPULAR EXANTHEMA 
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs2070676;CG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;SEVERE EMESIS 
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;DRUG RESISTANCE 
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY, LEUKOPENIA, MUCOSITIS, 
THIAZIDES, PLAIN;GNB3;rs5443;CC;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
AMLODIPINE;RYR3;rs877087;TT;EFFICACY;INCREASED-RISK;DISEASE;HEART FAILURE 
FLUOROURACIL;GSTP1;rs1695;GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HAEMATOLOGICAL TOXICITY 
;COL1A1;rs1800012;AA;;DECREASED-;OTHER;BONE MINERAL DENSITY AT FEMORAL NECK AND LUMBAR SPINE 
METHADONE;UGT2B7;rs6600879;GG;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
;COL1A1;rs1800012;AA + AC;;DECREASED-;OTHER;BMD VALUES AT THE LUMBAR SPINE AND FEMORAL NECK 
METHADONE;UGT2B7;rs6600880;AA;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
PLATINUM COMPOUNDS;EIF3A;rs10510050;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;THROMBOCYTOPENIA, TOXIC LIVER DISEASE, VOMITING, 
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
THIAZIDES, PLAIN;AGTR1;rs5186;AA + AC;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
THIAZIDES, PLAIN;ACE;rs4341;GG;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
ATORVASTATIN, RIFAMPIN;SLCO1B1;rs4149056;TT;LADME-PK;PK;PK;A NEARLY TRIPLED INCREASED  PERCENTAGE OF ATORVASTATIN AUC(0 - 48) VALUES AFTER A SINGLE ORAL DOSE OF RIFAMPICIN 
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;C;TOXICITY;RISK-;SIDE_EFFECT;DRUG TOXICITY 
ATORVASTATIN;FDPS;rs2297480;TT;TOXICITY;INCREASED-;SIDE_EFFECT;BONE DENSITY 
ETHANOL;OPRM1;rs1799971;G;;INCREASED-;OTHER;SUBJECTIVE FEELINGS OF INTOXICATION, STIMULATION, SEDATION, AND HAPPINESS 
;ABCC2;rs3740066;C;LADME-PK;;OTHER;ALLELIC IMBALENCE 
CISPLATIN;GSTM4;rs560018;CC;EFFICACY, TOXICITY;INCREASED-EFFICACY;EFFICACY;IC-50 
ATORVASTATIN;FDPS;rs11264359;AA;TOXICITY;INCREASED-;SIDE_EFFECT;BONE DENSITY 
IRINOTECAN;C8orf34;rs1517114;C;TOXICITY;INCREASED-SEVERITY;DISEASE;DIARRHEA 
DICLOXACILLIN, PROBENECID;ABCB1;rs1045642;GG;OTHER, LADME-PK;INCREASED-PK;PK;CLEARANCE OF DICLOXACILLIN 
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OBESITY 
ETHANOL;OPRM1;rs1799971;G;OTHER;RISK-;DISEASE;ALCOHOL ABUSE 
CYCLOSPORINE, DICLOXACILLIN;ABCB1;rs2032582;CC;OTHER, LADME-PK;INCREASED-PK;PK;CLEARANCE OF DICLOXACILLIN 
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
ATORVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC;;INCREASED-;OTHER;CHOLESTEROL SYNTHESIS RATE 
PLATINUM COMPOUNDS;MDM2;rs1690924;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;INCREASED-PK;PK;PLASMA DRUG LEVELS 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE 
SEVOFLURANE;GRIN2B;rs1806201;AA + AG;OTHER;INCREASED-;OTHER;MEAN ARTERIAL PRESSURE 
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;PLATELET INHIBITION AFTER A CLOPIDOGREL 600-MG LOADING DOSE 
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;rs1042714;GG;EFFICACY;INCREASED-;OTHER;STATUS ASTHMATICUS 
METHOTREXATE;CCND1;rs9344;AA;TOXICITY;DECREASED-SEVERITY;DISEASE;DRUG TOXICITY 
RISPERIDONE;ABCB1;rs1045642;A;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED-SEVERITY;DISEASE;LEUKOPENIA 
PACLITAXEL;SOD2;rs4880;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
METHYLPHENIDATE;ABCB1;rs2032582;AA;TOXICITY;INCREASED-;SIDE_EFFECT;ADVERSE EVENTS 
DOCETAXEL;ERCC2;rs13181;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NEUTROPENIA 
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERLIPIDEMIAS 
DOCETAXEL;ERCC1;rs11615;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;RATES OF TARGET LESION REVASCULARIZATION AND MAJOR ADVERSE CARDIOVASCULAR EVENTS 
METFORMIN;SP1;rs2683511;C;LADME-PK;DECREASED-PK;PK;METFORMIN SECRETORY CLEARANCE 
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
NICOTINE;CHRNA3, CHRNA5;rs16969968;A;TOXICITY;INCREASED-RISK;DISEASE;TOBACCO USE DISORDER 
METFORMIN;;rs10747673;G;EFFICACY;DECREASED-EFFICACY;EFFICACY;POST-HBA1C LEVELS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;TO BE CLASSIFIED AS CLOPIDOGREL POOR RESPONDERS 
METFORMIN;;rs10747673;G;LADME-PK;DECREASED-PK;PK;METFORMIN SECRETORY CLEARANCE 
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HEMORRHAGE 
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
CLOPIDOGREL;ATP10A;rs12913988;AA + AG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MAJOR ADVERSE CARDIAC EVENTS (MACE) 
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, LEUKOPENIA, THROMBOCYTOPENIA, TOXIC LIVER DISEASE
CHOP, RITUXIMAB;NCF4;rs1883112;AG + GG;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TOXICITY 
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;CLOPIDOGREL POOR RESPONSE 
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, LEUKOPENIA, THROMBOCYTOPENIA, TOXIC LIVER DISEASE
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, LEUKOPENIA, THROMBOCYTOPENIA, TOXIC LIVER DISEASE
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;HIGH ON-TREATMENT PLATELET REACTIVITY 
MERCAPTOPURINE, METHOTREXATE;GSTP1;rs1695;GG;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;DRUG TOXICITY 
CLOZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;WEIGHT GAIN 
ACENOCOUMAROL;ABCB1;rs1045642;GG + GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
RISPERIDONE;ABCB1;rs2032582;A;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;INCREASED-PK;PK;PLASMA DRUG LEVELS 
SEVOFLURANE;KCNK3;rs1275988;CT + TT;OTHER;INCREASED-;OTHER;MEAN ARTERIAL PRESSURE 
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;TOXIC LIVER DISEASE 
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-LIKELIHOOD;DISEASE;MYELOSUPPRESSION 
DOCETAXEL;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;INFUSION RELATED REACTION 
METFORMIN;SP1;rs784888;G;EFFICACY;DECREASED-SEVERITY;DISEASE;HYPERGLYCEMIA 
PLATINUM COMPOUNDS;MTR;rs1805087;AA + AG;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SEVOFLURANE;GABRA2;rs279858;CC + CT;OTHER;DECREASED-;OTHER;MEAN ARTERIAL PRESSURE 
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;STAYING IN REMISSION 
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA, LEUKOPENIA, THROMBOCYTOPENIA, TOXIC LIVER DISEASE
PACLITAXEL;CYP2C8;rs1113129;CG + GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
METFORMIN;PPARA;rs149711321;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;POST-HBA1C LEVELS 
;COL1A1;rs1800012;AA;;INCREASED-RISK;DISEASE;FRACTURES, BONE 
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
PLATINUM COMPOUNDS;SLC19A1;rs1051266;TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PACLITAXEL;CYP2C8;rs1934951;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ANEMIA 
LENALIDOMIDE;VEGFA;rs699947;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
METFORMIN;SP1;rs2683511;C;EFFICACY;DECREASED-EFFICACY;EFFICACY;POST-HBA1C LEVELS 
SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;OTHER;DECREASED-;OTHER;MEAN ARTERIAL PRESSURE 
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
BUPROPION, NICOTINE;DRD1;rs2168631;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS 
SIMVASTATIN;HMGCR;rs17238540;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION OF LDL CHOLESTEROL 
;NR3C1;rs9324918;C;OTHER;INCREASED-;DISEASE;SICKLE CELL PAIN CRISIS 
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED-RISK;DISEASE;DEATH 
SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;OTHER;DECREASED-;OTHER;MEAN ARTERIAL PRESSURE 
PACLITAXEL;ERCC1;rs3212986;AA + AC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
MORPHINE;ABCC3;rs1978153;C;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOVENTILATION 
;P2RY12;rs2046934;G;;INCREASED-RISK;SIDE_EFFECT;CORONARY ARTERY DISEASE 
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;BLEEDING 
BUPROPION, NICOTINE;DRD1;rs11749035;T;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS 
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;ADP-INDUCED PLATELET AGGREGATION 
PAZOPANIB, SUNITINIB;CXCL8;rs1126647;T;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
;NR3C1;rs2963155;G;OTHER;INCREASED-;DISEASE;SICKLE CELL PAIN CRISIS 
MORPHINE;ABCC3;rs733392;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOVENTILATION 
METHADONE;UGT2B7;rs6600893;CC;EFFICACY, LADME-PK;INCREASED-SEVERITY;OTHER;OPIATE WITHDRAWAL SYMPTOMS 
FENTANYL;MYD88;rs6853;G;TOXICITY;DECREASED-RISK;SIDE_EFFECT;COGNITIVE DISORDER 
METHOTREXATE, PREDNISONE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;REMISSION 
BUPROPION, NICOTINE;DRD1;rs11746641;G;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SMOKING ABSTINENCE WITHIN SLOW NICOTINE METABOLIZERS 
;NR3C1;rs33389;T;OTHER;INCREASED-;DISEASE;SICKLE CELL PAIN CRISIS 
SPIRONOLACTONE;ACE;rs4343;AA + AG;EFFICACY;EFFICACY;EFFICACY;IMPROVEMENT IN LEFT VENTRICULAR EJECTION FRACTION, END-SYSTOLIC AND END-DIASTOLIC VOLUME 
SIMVASTATIN;HMGCR;rs17244841;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION OF LDL CHOLESTEROL 
DOCETAXEL;ERCC1;rs3212986;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;MUCOSITIS 
SEVOFLURANE;CYP2E1;rs3813867;CC + CG;OTHER;DECREASED-;OTHER;MEAN ARTERIAL PRESSURE 
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
SEVOFLURANE;CYP2E1, DUX1;rs2031920;CT + TT;OTHER;DECREASED-;OTHER;MEAN ARTERIAL PRESSURE 
ANTIHYPERTENSIVES, DIURETICS;NOS3;rs2070744;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESISTANT HYPERTENSION 
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;CYBA;rs4673;AA;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
IBUPROFEN;PTGS2;rs20417;CG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PAIN RELIEF 
DIFLOMOTECAN;ABCG2;rs2231142;T;LADME-PK;INCREASED-PK;PK;PLASMA CONCENTRATIONS OF DIFLOMOTECAN 
CYCLOSPORINE;ABCB1;rs2032582;AA;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESISTANCE 
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIABETES MELLITUS 
ROFECOXIB;PTGS2;rs20417;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;PAIN RELIEF 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2884129;G;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
HMG COA REDUCTASE INHIBITORS;;rs13210472;C;TOXICITY;INCREASED-RISK;OTHER;NEOPLASMS 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7104613;T;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
PAZOPANIB, SUNITINIB;CXCL8;rs4073;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;NAUSEA 
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs10413396;T;EFFICACY;EFFICACY;EFFICACY;OPIOIDS RESPONSE 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED-EFFICACY;EFFICACY;PHARMACODYNAMIC RESPONSE 
METHOTREXATE;CCND1;rs9344;AA;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT FREE SURVIVAL 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs3212986;AC + CC;TOXICITY;DECREASED-RISK;SIDE_EFFECT;VOMITING 
ASPIRIN;PTGS1;rs10306114;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;DRUG TOXICITY 
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs2032582;CC;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;RESISTANCE 
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED-;SIDE_EFFECT;WEIGHT GAIN 
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME-PK;DECREASED-PK;PK;PLASMA EXPOSURE TO THE ACTIVE METABOLITE OF CLOPIDOGREL 
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED-EFFICACY;EFFICACY;ACENOCOUMAROL DOSE 
FLUOROURACIL;DPYD;rs1801160;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;STENT THROMBOSIS 
MORPHINE;ABCC3;rs886493;G;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOVENTILATION 
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ABCB1;rs1045642;AA;TOXICITY;INCREASED-RISK;SIDE_EFFECT;VOMITING 
MORPHINE;ABCC3;rs7216383;T;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;HYPOVENTILATION 
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
ETHANOL;;rs10516440;A;TOXICITY;DECREASED-RISK;OTHER;ALCOHOL ABUSE 
TRAMADOL;ABCB1;rs1045642;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS 
CITALOPRAM;CYP2C19;rs12248560;TT;LADME-PK;DECREASED-PK;PK;METABOLIC RATIO CIT/DCIT VALUES 
TRAMADOL;ABCB1;rs2032582;A;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;A DECREASE IN VISUAL ANALOG SCALE >30MM WITHIN 6 HOURS 
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED-SEVERITY;SIDE_EFFECT;ANEMIA 
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED-RISK;SIDE_EFFECT;CARDIOVASCULAR EVENTS 
METHOTREXATE;ABCC2;rs17222723;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUROTOXICITY SYNDROMES 
RISPERIDONE;UGT1A1;rs887829;CT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERPROLACTINEMIA 
FLUOXETINE;CRHR1;rs242941;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RESPONSE 
RISPERIDONE;UGT1A1;rs10929302;AG;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HYPERPROLACTINEMIA 
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
CISPLATIN;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL 
CISPLATIN;GSTP1;rs1138272;CT + TT;EFFICACY;DECREASED-EFFICACY;EFFICACY;EVENT-FREE SURVIVAL, OVERALL SURVIVAL 
SARILUMAB;IL6R;rs4845625;TT;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
VITAMIN K ANTAGONISTS;CYP4F2;rs2108622;TT;EFFICACY;INCREASED-RISKEFFICACY;EFFICACY;STROKE 
RISPERIDONE;HTR2C;rs6318;GG;TOXICITY;INCREASED-SEVERITY;SIDE_EFFECT;WEIGHT GAIN 
WARFARIN;CRP;rs1205;CT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
HYDROCHLOROTHIAZIDE;TCF7L2;rs4132670;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DIABETES 
HYDROCHLOROTHIAZIDE;TCF7L2;rs7917983;T;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
ATORVASTATIN, CERIVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;REACHING TARGET CHOLESTEROL LEVELS 
HYDROCHLOROTHIAZIDE;TCF7L2;rs4506565;T;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
CITALOPRAM;CYP2C19;rs4244285;AA;LADME-PK;INCREASED-PK;PK;METABOLIC RATIO CIT/DCIT VALUES AND MEAN CITALOPRAM DOSE 
LENALIDOMIDE;ABCB1;rs2032582;CC;EFFICACY;DECREASED-EFFICACY;EFFICACY;OVERALL SURVIVAL 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;OTHER;;OTHER;LATER ONSET OF SENSORY NEUROPATHY 
DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXICITY 
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;VOMITING 
SARILUMAB;IL6R;rs4537545;CC;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DYSLIPIDAEMIA 
CALCIUM, ETIDRONIC ACID;VDR;rs1544410;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;MEAN SPINAL BONE MINERAL DENSITY CHANGES 
SARILUMAB;IL6R;rs2228145;AA;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DYSLIPIDAEMIA 
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRD1;rs2234918;CT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PHYSIOLOGICAL SEXUAL DISORDER 
VALPROIC ACID;SOD2;rs4880;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE 
BUPRENORPHINE, FENTANYL, TRAMADOL;ARRB2;rs1045280;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE 
BISPHOSPHONATES;CYP2C8;rs1934951;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS OF THE JAW 
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS, PHYSIOLOGICAL SEXUAL DISORDER 
;IFNL3, IFNL4;rs12979860;CC;OTHER;INCREASED-LIKELIHOOD;DISEASE;JAUNDICE 
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NAUSEA 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;CC;TOXICITY;INCREASED-RISK;DISEASE;DRUG TOXICITY 
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
LENALIDOMIDE;CRBN;rs1705814;CC;DOSAGE, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DOSE REDUCTION, DISCONTINUATION 
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;TOXICITY;DECREASED-RISK;DISEASE;PERIPHERAL NERVOUS SYSTEM DISEASES 
RIFAMPIN;NR1I2;rs2472677;T;OTHER, LADME-PK;DECREASED-PK;PK;CYP3A4 ACITVITY 
CARBAMAZEPINE, LAMOTRIGINE, OXCARBAZEPINE, PHENYTOIN, TOPIRAMATE;SCN2A;rs2304016;A;EFFICACY;EFFICACY;EFFICACY;DRUG RESISTANCE 
CAPECITABINE, OXALIPLATIN;PTGS2;rs5275;AA;EFFICACY;INCREASED-;OTHER;PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL 
;CETP;rs708272;A;;;OTHER;VARIANCE IN LDL, HDL AND LDL/HDL 
HMG COA REDUCTASE INHIBITORS;CETP;rs708272;A;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;CARDIOVASCULAR EVENTS 
DIURETICS;ADD1;rs4961;GT + TT;EFFICACY;DECREASED-LIKELIHOOD;DISEASE;MYOCARDIAL INFARCTION 
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;EFFICACY;EFFICACY;LOWER WARFARIN DOSE REQUIREMENT 
ETHANOL;DRD2;rs1076560;A;OTHER;INCREASED-RISK;DISEASE;ALCOHOL ABUSE 
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PLATELET ACTIVATION RESPONSE TO ADP 
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY 
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE 
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED-RISK;DISEASE;NEUTROPENIA 
BROMPERIDOL, NEMONAPRIDE;DRD2;rs1799732;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;IMPROVEMENT IN ANXIETY-DEPRESSION SYMPTOMS 
THIAZIDES, PLAIN;SLC12A3;rs13306673;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE 
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;DECREASED-LIKELIHOOD;SIDE_EFFECT;GASTROINTESTINAL TOXICITY 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED-EFFICACY;EFFICACY;RAPID VIROLOGICAL RESPONSE (RVR) 
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED-RISK;DISEASE;LEUKOPENIA 
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;INCREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA, ALOPECIA, HYPERSENSITIVITY, 
ATORVASTATIN, ROSUVASTATIN;CYP3A5;rs776746;CC;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUSCULAR DISEASES 
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE 
THIAZIDES, PLAIN;ADRB3;rs4994;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE 
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION FREE SURVIVAL 
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DIARRHEA 
ASPARAGINASE;CPA2;rs199695765;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;PANCREATITIS 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED-EFFICACY;EFFICACY;COMPLETE EARLY VIROLOGICAL RESPONSE 
DAPSONE;HLA-DRB1;rs701829;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
TACROLIMUS;POR;rs1057868;CT + TT;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
WARFARIN;THBD;rs1042580;CC + CT;TOXICITY;DECREASED-RISK;SIDE_EFFECT;HEMORRHAGE 
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
METHYLPHENIDATE;CES1;rs3815583;AC + CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;APPETITE SUPPRESSION 
ACE INHIBITORS, PLAIN;BDKRB2;rs8012552;C;TOXICITY;INCREASED-RISK;DISEASE;COUGH 
CORTICOSTEROIDS;BCL2L11;rs724710;CC;TOXICITY;INCREASED-RISK;SIDE_EFFECT;OSTEONECROSIS 
ACE INHIBITORS, PLAIN;MME;rs2016848;A;TOXICITY;INCREASED-RISK;DISEASE;COUGH 
IRINOTECAN;PIN1;rs2233678;CC + CG;EFFICACY;INCREASED-EFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED-EFFICACY;EFFICACY;SUSTAINED VIROLOGICAL RESPONSE (SVR) 
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN MEAN ARTERIAL PRESSURE 
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OVER-ANTICOAGULATION 
ASPIRIN;ACE;rs4291;AT + TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;ASPIRIN INTOLERANCE 
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572103;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT 
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED-EFFICACY;EFFICACY;REDUCTION IN MEAN BLOOD PRESSURE 
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;T;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT 
ACE INHIBITORS, PLAIN;PTGER3;rs11209716;C;TOXICITY;DECREASED-RISK;DISEASE;COUGH 
MYCOPHENOLATE MOFETIL;HUS1;rs1056663;T;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT 
DAPSONE;HLA-DRB1;rs17211071;A;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG HYPERSENSITIVITY 
TACROLIMUS;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED-RISK;DISEASE;DIABETES MELLITUS 
MYCOPHENOLATE MOFETIL;HUS1;rs2037483;A;TOXICITY;DECREASED-RISK;SIDE_EFFECT;TIME TO ANEMIA IN PATIENTS UNDERGOING LIVING OR DECEASED DONOR KIDNEY TRANSPLANT 
;ADD1;rs4961;GT + TT;OTHER;INCREASED-LIKELIHOOD;DISEASE;HYPERTENSION 
FLUOROURACIL;ABCB1;rs2032582;C;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;EXANTHEMA 
FLUOROURACIL;SLCO1B1;rs2306283;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
;ARG1;rs2781666;TT;OTHER;INCREASED-SEVERITY;OTHER;ASTHMA 
TACROLIMUS;CYP3A4;rs2740574;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
EPIRUBICIN;ABCC1;rs246221;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEFT VENTRICULAR DYSFUNCTION 
LEVODOPA;COMT;rs4680;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DYSKINESIA, DRUG-INDUCED 
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED-RISK;SIDE_EFFECT;TOXIC LIVER DISEASE 
DAUNORUBICIN, DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;RECURRENCE FREE SURVIVAL 
DAUNORUBICIN, DOXORUBICIN;HFE;rs1799945;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DAUNORUBICIN, DOXORUBICIN;GPR35;rs12468485;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DAUNORUBICIN, DOXORUBICIN;UGT1A6;rs17863783;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DAUNORUBICIN, DOXORUBICIN;GSTA2;rs2180314;G;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DAUNORUBICIN, DOXORUBICIN;ETFB;rs79338777;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DAUNORUBICIN, DOXORUBICIN;HNMT;rs17583889;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
DAUNORUBICIN, DOXORUBICIN;ABCC5;rs7627754;AA + AT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;CARDIOTOXICITY 
CEFAZOLIN, CEFDINIR, CEFTRIAXONE, CEFUROXIME, CEPHALEXIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG-INDUCED LIVER INJURY 
TACROLIMUS;CYP2B6;rs3745274;GT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
CORTICOSTEROIDS;WNT7B;rs73175102;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS 
CORTICOSTEROIDS;POGK;rs115587273;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS 
CORTICOSTEROIDS;FAM240C;rs78233573;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS 
CORTICOSTEROIDS;ZNF37A;rs376867011;A;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;OSTEONECROSIS 
CODEINE, HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;EMERGENCIES, PAIN 
GANCICLOVIR, VALGANCICLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*2 + *3 + *4;;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEUTROPENIA 
VALPROIC ACID;ACOT1;rs758109;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
TACROLIMUS;SLCO1B1;rs2306283;AA + AG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY 
AZATHIOPRINE;MOCOS;rs73430958;GT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
VALPROIC ACID;GABPA;rs59288687;CC;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
VALPROIC ACID;NQO1;rs10517;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
VALPROIC ACID;PPARA;rs881740;G;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TOXIC LIVER DISEASE 
METHOTREXATE;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA 
METHOTREXATE;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA 
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ANEMIA 
APIXABAN;APOE;rs7412;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INTRACRANIAL HEMORRHAGES 
APIXABAN;APOE;rs429358;C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;INTRACRANIAL HEMORRHAGES 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs8099917;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12980275;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS 
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12979860;TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PNEUMONITIS 
TACROLIMUS;ABCB1;rs9282564;TT;EFFICACY;DECREASED-RISKEFFICACY;EFFICACY;DEATH 
TACROLIMUS;ABCC2;rs2273697;GG;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL 
TACROLIMUS;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;TRANSPLANT REJECTION 
TACROLIMUS;CYP2C19;rs4244285;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY 
AZATHIOPRINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
AZATHIOPRINE;RRM1;rs1735053;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
AZATHIOPRINE;TPMT;rs9465102;GT + TT;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
CISPLATIN;TRPA1;rs920829;TT;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;NEPHROTOXICITY 
FOLFOX, XELOX;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES 
FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY, TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;TREATMENT MODIFICATION 
CYCLOSPORINE;SLC29A1;rs693955;AA;EFFICACY;DECREASED-LIKELIHOODEFFICACY;EFFICACY;OVERALL SURVIVAL, RECURRENCE FREE SURVIVAL 
AFATINIB, ERLOTINIB, GEFITINIB;AKT1;rs2494750;CC;EFFICACY;INCREASED-LIKELIHOODEFFICACY;EFFICACY;PROGRESSION-FREE SURVIVAL 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;SEVERE CUTANEOUS ADVERSE REACTIONS 
FOLFOX, XELOX;GSTP1;rs1695;GG;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES, MYELOSUPPRESSION 
FOLFOX, XELOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED-LIKELIHOOD;SIDE_EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES, MYELOSUPPRESSION 
FOLFOX, XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;HAND-FOOT SYNDROME, EXANTHEMA, DRUG TOXICITY, 
FOLFOX, XELOX;GSTP1;rs1695;GG;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;MUCOSITIS 
AZATHIOPRINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PANCREATITIS 
AZATHIOPRINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;PANCREATITIS 
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;T;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;DRUG TOXICITY, TOXIC LIVER DISEASE 
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED-RISK;SIDE_EFFECT;DRUG TOXICITY 
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;LEUKOPENIA 
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;ADVERSE EVENTS 
CODEINE, MORPHINE, OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED-LIKELIHOOD;SIDE_EFFECT;URINARY RETENTION, CONSTIPATION, NAUSEA, VOMITING
